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SUMMARY 
 
TDP2, a DNA phosphodiesterase that removes trapped topoisomerase 2 (TOP2) from 5’-DNA 
termini, is required for efficient repair of TOP2-induced DNA double-strand breaks (DSBs). 
Cellular depletion of TDP2 was shown to result in a substantially increased sensitivity to TOP2-
induced DSBs and TOP2 poisons, such as etoposide, in various types of human cancer cell lines. 
In addition, over-expression of TDP2 has been shown to increase resistance to etoposide. 
Recent data suggest that expression levels of TDP2 vary greatly in different cancer cell lines. 
However, there are no reported studies addressing the possible role of TDP2 as a clinical 
predictor of anti-cancer therapy outcome, or wider studies correlating TDP2 over-expression 
with resistance to TOP2 poisons. TDP2 has the potential to be a good target for 
pharmacological inhibition potentially increasing tumour sensitivity to TOP2 poisons, 
particularly those that develop resistance during the course of treatment. There is already a lot 
of interest in the development of TDP2 inhibitors and the in vitro results are very promising 
with many possible small molecule inhibitors showing selectiveness in their target. In my thesis 
I aim to further establish the range of TDP2 and TOP2 mRNA and protein levels in a panel of 
lung and breast cancer cell lines. In addition, I will explore the possibility of a correlation 
between TDP2 protein levels or TOP2/TDP2 protein ratios and sensitivity to the TOP2 poison 
etoposide. This likely complex relationship will be further defined by possible mutation effects 
based on available literature and studies for the cancer cell lines accessible for this project. 
Furthermore, as etoposide has been tested in clinical trials not only alone but also in 
combination with other treatments, I aim to include other accessible drugs, either currently in 
use for cancer treatment or at a promising clinical trial stage, such as estradiol and PARP1 
inhibitors. 
There is a recent model, which suggests that induction of transcriptional programs by 
stimulating breast cancer cells with estrogens, or prostate cancer cells with androgens, can 
involve the formation of TOP2B mediated DSBs and the recruitment of DSB repair proteins. 
TOP2B is believed to be recruited with the estrogen/androgen receptor to regulatory sites on 
target genes. It is hypothesized that the formation of these DSBs by TOP2B could also be 
exploited therapeutically. In my thesis I aim to utilise a combination treatment that will first 
induce transcription with estradiol in breast cancer cells, which will cause transient TOP2B-
mediated DSBs, and then transform those breaks into abortive breaks with etoposide. Cells will 
then be overwhelmed with DSBs and apoptosis will be promoted. This will also be explored in 
TDP2-depleted MCF7 breast cancer cells. Such a strategy could possibly find particular use in 
hormone dependent cancers, where other types of treatment have failed.  
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1. CHAPTER ONE - Introduction 
1.1 DNA Damage 
DNA is the repository of genetic information. Genomic integrity and stability are fundamental 
to the survival of every cell. The human genome is fragile and under a lot of pressure to 
maintain its integrity during exposure to both internal and external (environmental) sources of 
damage (Lindahl, 1993, Jackson and Bartek, 2009). Not repairing this damage can lead to 
harmful mutations and even disease. As the consequences of unrepaired DNA lesions are 
generally detrimental, the cells have a number of DNA repair responses and pathways to 
prevent accumulation of lethal DNA damage and ensure genome integrity and stability. Figure 
1.1 shows in short the types of DNA damage and the repair process responsible for repairing 
them. 
 
  
Figure 1.1: From top to bottom: Sources of DNA damage, examples of DNA lesions induced by these sources 
and most relevant DNA repair mechanisms for removing these lesions. (Adapted from (Hoeijmakers, 2001). 
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The external sources of damage fall under three main categories: ultraviolet radiation, ionising 
radiation and exogenous genotoxic agents. Ultraviolet radiation (commonly known as UV) is an 
electromagnetic radiation present in sunlight with a wavelength from 10nm to 400nm. It can 
potentially cause DNA lesions, such as cyclobutane pyrimidine dimers and 6-4 photoproducts 
that distort the DNA structure (Hoeijmakers, 2001).  Ionising radiation, which can be in the 
form of gamma rays, X-rays or the higher ultraviolet part of the electromagnetic spectrum, can 
induce both single- and double-strand breaks to the DNA double helix, as well as base damage 
by producing hydroxyl (OH) radicals (Ward, 1975, Ward et al., 1987). In addition to radiation, 
DNA damage can result from exogenous genotoxic agents such as the polycyclic aromatic 
hydrocarbons in tobacco smoke (Clansy, 2008, Hoeijmakers, 2001). 
Despite the multitude of external sources of DNA damage, there are many more internal 
sources. By-products of the cell’s own metabolism can lead to oxidative DNA lesions (Beckman 
and Ames, 1997, Cadet et al., 2003, Azzam et al., 2012, Maynard et al., 2009). For example, 
endogenous reactive oxygen species (ROS) can be generated during the immune response, 
lipid peroxidation in peroxisomes and during the electron transfer chain (Cooke et al., 2003). 
Furthermore, certain chemical bonds in the DNA can disintegrate spontaneously under 
physiological conditions; for example nucleotide residues can hydrolyse leading to abasic sites 
and cytosine, adenine, guanine or 5-methylcytosine can de-aminate and result in uracil, 
hypoxanthine, xanthine and thymidine, respectively (Lindahl, 1993).  Even the very process of 
DNA replication is prone to errors and damage, such as A-G and T-C mismatch, as well as 
insertions and deletions during a process called strand slippage (Pray, 2008).  
Unrepaired DNA can lead to multiple problems of different severity for the cell. DNA 
replication or transcription can be halted, because polymerases cannot bypass DNA lesions. 
This can lead to cell-cycle arrest and/or cell death. There are links between bulky DNA adducts 
in smokers and increased lung and bladder cancer risk (Veglia et al., 2003). Accumulation of 
16 
 
point mutations contribute greatly to oncogenesis and can result to the loss of tumour-
suppressor genes or the untimely activation of oncogenes (Hoeijmakers, 2001, Kastan and 
Bartek, 2004, Stratton et al., 2009). p53 point mutation is a well studied example (Goh et al., 
1995). Another example is oxidative 8-hydroxyguanine that results from reactive oxygen 
species, a particularly mutagenic lesion that binds with cytosine or adenine with equal affinity, 
that can lead to G to T and C to A substitutions in the genome (Cheng et al., 1992).  
There is a diverse spectrum of DNA damage categories. These include interstrand crosslink, 
intrastrand crosslink, DNA-protein crosslink, base mismatch, base modification, single-strand 
break (SSB) and double-strand break (DSB). Figure 1.2 depicts that spectrum and highlights the 
corresponding DNA repair pathway that cells use to cope with the damage. 
 
 
DNA SSBs are discontinuities in one of the DNA strands of the double helix and are the most 
common types of DNA lesions in the cell. In fact, they are so common that it is estimated that 
as many as 10,000 SSBs can arise in a single cell per day (Beckman and Ames, 1997, Caldecott, 
Figure 1.2: Overview of the wide spectrum of types of DNA damage, the major DNA damage response 
mechanisms and their key proteins (Hosoya and Miyagawa, 2014). 
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2001, Lindahl and Nyberg, 1972, Lindahl, 1993). They usually co-occur with loss of a single 
nucleotide and damaged 5′- and/or 3′-termini at the site of the break (Caldecott, 2008). If not 
repaired rapidly, they pose a serious threat to genetic integrity. Even though they are not 
regarded as genotoxic themselves, they can be converted to DSBs by collision with the 
machinery of a replication or transcription fork (Caldecott, 2008, Hoeijmakers, 2001, 
Kouzminova and Kuzminov, 2006, Kuzminov, 2001). The cell has a mechanism to respond to 
such breaks, but an acute increase of SSB levels can saturate this pathway, leading to cell 
death (Caldecott, 2001). Under certain physiological conditions, high levels of SSBs can cause 
excessive activation of the SSB sensor protein poly (ADP-ribose) polymerase 1 (PARP1) 
(Caldecott, 2008, Heeres and Hergenrother, 2007, Moroni, 2008). This continuous activation 
can cause a deficiency in cellular NAD+ and ATP and/or release of apoptosis-inducing factor 
(AIF) from mitochondria (Moroni, 2008, Heeres and Hergenrother, 2007, Caldecott, 2008). A 
common source of SSBs is oxidative attack by endogenous reactive oxygen species (ROS). They 
can occur directly, by disintegration of the oxidized sugar or indirectly, during the DNA base-
excision repair of oxidized bases at damaged, altered or abasic sites (Caldecott, 2008, Demple 
and DeMott, 2002, Hegde et al., 2008, Pogozelski and Tullius, 1998). Another internal source of 
SSBs is the abortive activity of DNA topoisomerase 1 (TOP1) (Caldecott, 2008). 
DSBs are discontinuities in both DNA strands of the double helix and can arise from both 
internal and external DNA damage sources. They do not occur as often as SSBs, as it is 
estimated that only  10  spontaneous  DSBs  arise  per  cell  per  day, as seen in early passage  
primary  human  fibroblasts  (Martin et al., 1985, Lieber et al., 2003, Lieber and Karanjawala, 
2004). They are considered very serious and a single one can be responsible for the induction 
of apoptosis (Rich et al., 2000). In addition, they can lead to chromosomal rearrangements, 
such as translocations, deletions and mis-segregation of chromosomes during mitosis 
(Hoeijmakers, 2001). Ionising radiation (IR) is a major source of DSBs. The IR particles create 
localised clusters of ROS (Azzam et al., 2012). Similar to SSBs, they can be generated directly if 
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the attack of free radicals on the sugar-phosphate backbone of the DNA molecule results in the 
dissolution of two oxidised sugars in close proximity from one another on anti-parallel strands 
of the DNA (Ward et al., 1987, Azzam et al., 2012).  Endogenous DSBs can be a result of various 
processes. As previously mentioned, they can be caused by the collision of unrepaired SSBs 
with the replication machinery, but also due to the mechanical stress on chromosomes during 
chromosomal segregation in mitosis and more importantly for the subject of this thesis, by the 
abortive activity of DNA topoisomerase 2 (TOP2), which transiently nicks both strands of the 
DNA during processes such as replication and transcription as a response to topological stress 
(Adachi et al., 2003, Kouzminova and Kuzminov, 2006, Kuzminov, 2001, Hoeijmakers, 2001).  
1.2 DNA Repair Mechanisms 
As seen in Figure 1.2, there is a variety of DNA repair mechanisms. The more prevalent 
pathways for the repair of interstrand crosslink, intrastrand crosslink, DNA-protein crosslink, 
base mismatch and base modification are base excision repair (BER), mismatch repair (MMR) 
and nucleotide excision repair (NER). These can be used in cases of damage to one of the 
single strands, where the other strand can be used as a template to guide the correction of the 
damaged one. Single-strand break repair (SSBR) is important in its own merit and the same is 
the case for the double-strand break repair (DSBR) response, which consists of homologous 
recombination (HR) and non-homologous end joining (NHEJ). 
1.2.1 Base Excision Repair 
Base excision repair (BER) is a DNA damage response mechanism that can repair DNA 
throughout the cell cycle. It is primarily responsible for removing small base lesions that do not 
distort the double helix, such as SSBs (Dianov and Hübscher, 2013, Hosoya and Miyagawa, 
2014). This is important, because these damaged bases could otherwise lead to mutations by 
mis-pairing or DNA breaks during replication. BER works by deploying glycosylases, which 
recognize and remove specific damaged or inappropriate bases, forming apurinic–apyrimidinic 
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(AP) sites. These AP sites are cleaved by AP endonuclease I (APE1), which results in a SSB that 
can be processed by either short-patch (where a single nucleotide is replaced) or long-patch 
(where 2-10 new nucleotides are synthesized) BER (Liu et al., 2007). 
1.2.2 Mismatch Repair 
Mismatch repair (MMR) is a system that recognises and repairs inaccurate insertion, deletion 
and mis-incorporation of bases and has a ubiquitous presence (Hsieh and Yamane, 2008). 
These problems can occur during DNA replication, recombination and during the repair of 
other forms of DNA damage. In the example of DNA replication, newly synthesised daughter 
DNA strands will commonly include errors. MMR is strand-specific and can distinguish the 
daughter strand from the parental one (Hsieh and Yamane, 2008). MMR is initiated when 
mismatches are recognized by the highly conserved MutS protein. MutS and a second 
conserved protein, MutL, activate the endonucleolytic cleavage of the newly synthesised 
strand close to the region of the damage by a third protein, MutH (Hsieh and Yamane, 2008). 
This can result in removal of a few or up to several thousand base pairs from the newly 
synthesized DNA strand. DNA polymerase re-synthesises the missing part and DNA ligase seals 
the nick. 
1.2.3 Nucleotide Excision Repair 
Nucleotide excision repair (NER) is a very conserved DNA repair pathway. It is the major 
pathway for removal of bulky lesions generated by chemical and physical agents (Kamileri et 
al., 2012). For example, the common UV-generated cyclobutane pyrimidine dimers (CPDs) can 
only be repaired by NER in humans. NER operates in three distinct steps. Firstly, DNA damage 
is recognised and the six NER repair factors are assembled at the damage site in a random 
order, but in a co-operative manner. They form the so-called “closed complex”, which is an 
unstable one. Subsequently, the damage-containing oligomer is removed after nicks have been 
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created on both of its sides. Finally, using the complementary strand as a template, the missing 
oligomer is re-synthesised and ligated (For this paragraph: (Reardon and Sancar, 2006). 
1.2.4 Single-Strand Break Repair 
As mentioned previously, SSBs can arise in different ways. Depending on the cause of the 
damage, the exact variation of the repair pathway that will be followed differs.  
SSBs can arise in an indirect manner during BER by the APE1-led incision of an AP site or the 
lyase activity of a bi-functional DNA glycosylase, as mentioned previously. When that is the 
case, the SSBs are recognized by damage-specific proteins such as APE1, which then recruit 
Polb, XRCC1 and DNA Ligase IIIa, with the latter two forming a stable complex in order to 
complete the repair process (Hosoya and Miyagawa, 2014). After detection and end 
processing, the SSBs can be repaired by either short patch or long patch BER as discussed 
previously (Caldecott, 2008). PARP1 is not thought to play the same role in repair of such 
breaks, even though it has been shown to accumulate at sites of base damage (Durkacz et al., 
1980).    
When SSBs arise directly, the detection and end processing pathway is different. Direct SSBs 
can be the result of ROS-induced disintegration of oxidized deoxyribose, and during abortive 
TOP1 activity that creates a TOP1-linked SSB (Caldecott, 2008). The major proteins that play a 
role in repairing direct SSBs are PARP1, XRCC1, DNA Ligase IIIa, and APE1 (Hosoya and 
Miyagawa, 2014). PARP1 detects and binds to the SSBs and ensures rapid accumulation of 
downstream repair factors at the breaks (D'Amours et al., 1999, Kim et al., 2005). There is an 
abundance of published evidence that show that PARP1 interacts with, and is required for the 
rapid accumulation of the core SSBR protein X-ray cross complementing protein 1 (XRCC1) at 
sites of oxidative damage (Caldecott et al., 1996, El-Khamisy et al., 2003, Masson et al., 1998). 
PARP1 has high affinity for DNA breaks and following binding on the break, it catalyses the 
polymerisation of long branched chains and other target molecules (Benjamin and Gill, 1980, 
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Bramson et al., 1993, Weinfeld et al., 1997). It then autoribosylates and disassociates itself 
from the break (Zahradka and Ebisuzaki, 1982, Ferro and Olivera, 1982). It is then targeted by 
the enzyme poly(ADP-ribose)  glycohydrolase  (PARG) , which  catalyses  the  degradation  of  
the  poly(ADP-ribose) polymers, leading to PARP1 molecule recycling (Cortes et al., 2004, 
Fisher et al., 2007). Inhibition, depletion or deletion of PARP1 has been shown to decrease the 
rate of SSBR (Fisher et al., 2007, Godon et al., 2008, Le Page et al., 2003). 
1.2.5 Double-Strand Break Repair 
Double-strand breaks (DSBs) are one of the most hazardous types of DNA damage, as 
mentioned previously. A single unrepaired DSB can lead to apoptosis, and inaccurate repair to 
deletions, chromosomal aberrations or even cancer (Khanna and Jackson, 2001). The accurate 
repair of these breaks is of vital importance to maintain genomic stability, which is why the cell 
has multiple pathways of dealing with these events (van Gent et al., 2001). There are two 
major pathways for repairing DSBs. These are homologous recombination (HR) and non-
homologous end joining (NHEJ). They not only differ in their fidelity of DSB repair, but also in 
their requirement for a homologous template DNA (Mehta and Haber, 2014). 
1.2.5.1 Homologous Recombination 
Homologous recombination (HR) comprises a series of related pathways, responsible for 
repairing DSBs (Pâques and Haber, 1999, Hartlerode and Scully, 2009). It is an error-free 
pathway that is functional mainly during the late-S and G2 cell cycle phases due to the 
proximity of the sister chromatids, as well as during meiosis to produce new combinations of 
DNA sequences (Delacôte and Lopez, 2008, Sonoda et al., 2006). It is generally error-free, 
because it utilizes as a template for repair, the genetic information contained in the 
undamaged sister chromatid (Cannan and Pederson, 2016).  
HR varies among different cell types, but it can be summed up into three steps: presynapsis, 
synapsis and postsynapsis. When a DSB occurs, the DNA ends around the break are recognised 
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by the heterotrimeric MRN complex, which consists of Mre11, Rad50 and Nbs1. The MRN 
complex resects the ends in a 5’-3’ direction, which generates short 3’ single-stranded 
overhangs with a 3’OH (Uziel et al., 2003). CtIP has also been shown to be required for the 
resection step (Huertas and Jackson, 2009). This resection is followed by the recruitment of 
additional proteins such as RPA, BRCA1, BRCA2, Rad51, Rad52, and Rad54 (Renodon-Cornière   
Axelle, 2013). RPA quickly binds the single-stranded overhang and Rad51 and Rad52 are 
recruited to the DSB; RPA and Rad52 help Rad51 to load onto the single-stranded end to form 
nucleoprotein filaments (van Attikum and Gasser, 2005). This is followed by strand invasion, 
where the filaments "invade" similar or identical DNA molecules that are intact, once they 
have identified a homologous DNA sequence (Forget and Kowalczykowski, 2010). This 
procedure involves the assistance of BRCA1, BRCA2 and the Rad51-like proteins XRCC2, XRCC3, 
RAD51B, RAD51C and RAD51D (Sy et al., 2009, San Filippo et al., 2006, Pellegrini et al., 2002, 
Zhang et al., 2009, Wong et al., 1997, Forget and Kowalczykowski, 2010). DNA polymerase η 
synthesises new DNA using the homologous region as a template and DNA Ligase I carries out 
the ligation to yield the Holliday junction, a four-way junction structure of intermediate nature 
(McIlwraith et al., 2005). There are three ways of resolving this structure and all of them result 
in the error-free repair of the DSB. Figure 1.3 depicts a schematic overview of HR. 
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1.2.5.2 Non-Homologous End Joining 
Non-homologous end joining (NHEJ) is an error-prone pathway which functions at all stages of 
the cell cycle, with an increase in activity in G1 (Hartlerode and Scully, 2009, Lieber, 2010, 
Mahaney et al., 2009). Unlike HR it is error-prone, because it involves elimination of DSBs by 
direct ligation of the broken ends. NHEJ does not require a homologous sequence for accurate 
repair, which is why its existence is so important during G0, G1 and early-S phase, when sister 
chromatids are not available to be used as templates (Delacôte and Lopez, 2008). The main 
protein factors involved in NHEJ are XRCC4-like factor (XLF), XRCC4/DNA Ligase IV and DNA 
proteinkinase (DNA–PK), with the latter being comprised of a protein kinase catalytic subunit 
(DNA–PKcs) and a Ku70/80 heterodimer (Davis et al., 2014, Grundy et al., 2016). Figure 1.4 
depicts a schematic overview of NHEJ. 
 
Figure 1.3: Schematic overview of how DNA double strand breaks are repaired by homologous 
recombination. The key factors involved are also depicted (Adapted from (Renodon-Cornière   Axelle, 2013). 
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NHEJ is initiated by the binding of Ku70/80 heterodimers to both ends of the DSB (Mimori and 
Hardin, 1986). Once bound, the Ku70/80 heterodimer forms a ring-like structure that encircles 
Figure 1.4: Schematic overview of the repair of double strand breaks by non-homologous end joining.  
Ku70/80 recognizes the break and recruits other proteins of this pathway, including DNA-PKcs, XRCC4, XLF and 
PAXX. These proteins form a stable complex that preserves the end alignment, and promotes end-processing 
and ligation likely by ‘trial-and-error’ (Yang et al., 2016). 
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3-4bp of DNA and translocates inwards, making the DSB ends more accessible to other repair 
proteins, such as DNA dependent protein kinase (DNA-PK), which is then recruited to the site 
and forms a stable complex in the presence of the DNA ends (Walker et al., 2001, Yoo and 
Dynan, 1999, Menon and Povirk, 2016). This results in the interaction of Ku70/80 with DNA 
polymerases μ and λ, the XRCC4/DNA Ligase IV complex, and the XRCC4 paralogs XLF and PAXX 
(Chen et al., 2000, Ochi et al., 2015, Menon and Povirk, 2016). If the DNA ends are 
complementary and undamaged, they can be re-joined by the XRCC4/DNA Ligase IV (Reynolds 
et al., 2012).  
In the case of non-complementary or damaged ends, ligation cannot progress without end 
processing to restore conventional ligatable 3’OH and 5’P. When that is the case, a group of 
enzymes including PNKP, APLF, Artemis and APTX are recruited for the process of the 
structures surrounding the DSB, before ligation (Riballo et al., 2004). Artemis, an 
endonuclease, is phosphorylated by DNA-PKcs at the C-terminal motif of residues 399–404 and 
is recruited to the DSB by the same factor (Soubeyrand et al., 2006, Ma et al., 2002). Ku70/80 
does not bind directly to Artemis but there is evidence that Artemis’ function, once recruited, 
is Ku70/80 dependent, further establishing Ku70/80’s importance in NHEJ (Chang et al., 2015, 
Yang et al., 2016). Many publications have shown that Artemis is involved in multiple aspects 
of NHEJ, including performing endonucleolytic nicks of damaged overhangs, but also 
interacting with DNA Ligase IV in facilitating NHEJ (Malu et al., 2012, De Ioannes et al., 2012) 
Once end processing and the gap filling are completed, the DNA gets ligated by DNA Ligase IV 
in a complex with XRCC4 (Critchlow et al., 1997, Grawunder et al., 1997, Grawunder et al., 
1998). XRCC4 has no enzymatic activity itself, but acts as a scaffolding protein to facilitate the 
recruitment of repair factors to the DSB (Mari et al., 2006). Further interactions with Ku70/80, 
DNA-PK, APTX (aprataxin) and APLF (PNK-like factor) mediate the recruitment and stability of 
XRCC4/DNA Ligase IV (Rulten et al., 2011, Rulten et al., 2008, Mari et al., 2006, Mehrotra et al., 
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2011, Macrae et al., 2008, Iles et al., 2007). XLF (XRCC4–like factor) is also recruited to the DSB 
by Ku70/80 and stimulates the DNA ligation by promoting the re-adenylation of DNA Ligase IV 
following end joining (Yang et al., 2016, Ahnesorg et al., 2006, Hammel et al., 2011, Gu et al., 
2007). 
1.3 DNA Topoisomerases 
The DNA is a very large molecule that is usually packed very densely in the nucleus of the cell. 
It is negatively supercoiled in all species, both prokaryotes and eukaryotes (McClendon and 
Osheroff, 2007, Baranello et al., 2012, Wang, 1996, Schvartzman and Stasiak, 2004). This 
makes the complementary DNA strands more accessible during cell processes such as 
replication and transcription. But once replication or transcription has been initiated, helicases 
are only able to separate the two DNA strands and not unwind them. Therefore, once the 
different components of the replication or transcription machinery start to move along the 
DNA strand, it causes topological changes, such as positive supercoiling and tangles. This 
makes it very difficult for the two DNA strands to be separated, something that could 
potentially interfere with essential cell processes (For this paragraph: (McClendon and 
Osheroff, 2007, Wang, 1996, Schvartzman and Stasiak, 2004).  
There are two types of topoisomerases, TOP1 (topoisomerase 1) and TOP2 (topoisomerase 2) 
with two subclasses of TOP2, TOP2A and TOP2B, which have been found to be crucial to 
chromosome metabolism in processes such as transcription and replication (Champoux, 2001, 
Wang, 2002). Both have also been found to be involved in the transient cleavage of DNA 
(Salerno et al., 2010). TOP1 is a ubiquitous nuclear enzyme, which is responsible for catalysing 
the relaxation of superhelical DNA, while generating a transient SSB in the DNA via cycles of 
cleavage and re-ligation (Salerno et al., 2010). TOP2 is also ubiquitous and is involved in the 
ATP-dependent induction of DSBs (Salerno et al., 2010).  
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When these breaks occur near sites of endogenous DNA damage or while topoisomerase 
poisons are present, the result can be abortive topoisomerase-induced DNA strand breaks, 
which feature covalent linkage of the enzyme to the DNA termini by a 3’- or 5’-phosphotyrosyl 
bond (Li and Liu, 2001, Pourquier and Pommier, 2001). These have been implicated in several 
human diseases, such as hereditary and neurodegenerative disease (El-Khamisy et al., 2005, 
Takashima et al., 2002, Yang et al., 1996), cancer and chromosomal instability (Deweese and 
Osheroff, 2009, Nitiss, 2009b), as well as having an impact on the clinical efficacy of anti-
tumour poisons (Li and Liu, 2001, Nitiss, 2009b, Pommier, 2006). Therefore, the importance of 
liberating DNA termini from trapped topoisomerases and repairing the single- or double-strand 
breaks is apparent. 
1.3.1 The role of type 2 topoisomerases in DNA double-strand break repair 
For the purpose of this thesis, this part of the introduction will focus on TOP2. As previously 
mentioned, eukaryotic cells express two types of topoisomerase 2, TOP2A and TOP2B, which 
are encoded by different genes, share about 70% of sequence similarity and have molecular 
weights of 170kDa and 180kDa respectively (Wang, 2002, McClendon and Osheroff, 2007). 
Their function is to alter the topological properties of DNA, by introducing transient DNA DSBs 
and allow another DNA strand (also known as transport or T-segment) to pass through the gap 
(known as gate or G-segment), in order to relieve supercoiling and tangled DNA tension. TOP2 
is also critical for recombination, proper chromosome structure and the separation of 
daughter chromosomes (Wang, 1996, Schvartzman and Stasiak, 2004, Wang, 2002, McClendon 
and Osheroff, 2007). TOP2 is formed of homodimers, which is crucial as it allows the enzymes 
to form the gate, which the T-segment can use to pass through the TOP2-DNA complex. Once 
the T-segment has passed through the gate, the DNA is re-ligated by TOP2 (Deweese and 
Osheroff, 2009, Pendleton et al., 2014). The central domain of TOP2 contains the active site 
tyrosine, which is critical for both the cleavage of the DNA and re-ligation. The N-terminal 
domain of TOP2 contains the site of ATP binding and hydrolysis, which is required for the 
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quicker translocation of the T-segment through the gate (Champoux, 2001, Baird et al., 1999). 
The C-terminal domain is different between the two types of TOP2 and it is the least studied 
part of the enzyme (Pendleton et al., 2014). TOP2 also requires a bivalent cation, Mg2+, to 
complete the chemistry of its enzymatic activity, in addition to binding the DNA (Deweese and 
Osheroff, 2010). A covalent phosphotyrosine bond is generated between the 5’-terminus and 
TOP2, in order to maintain genomic integrity (Sander and Hsieh, 1983); (Pendleton et al., 
2014). The resulting structure is known as the ‘’cleavage complex’’. TOP2A and TOP2B 
enzymatic activity is very similar, but they have different physiological functions.  
 
 
 
 
TOP2A presence is crucial for actively proliferating cells, where it is found in abundance and is 
upregulated (Heck and Earnshaw, 1986, Hsiang et al., 1988). Its concentration increases during 
the cell cycle and peaks during G2/M (Heck et al., 1988, Kimura et al., 1994). TOP2A has been 
associated with replication forks and during the duration of mitosis, it can be found tightly 
Figure 1.5: TOP2 catalytic cycle. The TOP2 homodimer (light blue semi-circles) binds the gate DNA. It then 
changes the spatial arrangement on ATP binding, while introducing a transient DSB in the gate DNA. TOP2 
remains bound on the DSB and it transports the T-segment through it. This represents the ‘cleavage 
complex’. The transient covalent bonds between the 5′ phosphates on either side of the DSB and the tyr835 
of each TOP2 subunit are depicted as pink squares. The DSB is then resealed. Hydrolysis and release of ATP is 
necessary for clamp re-opening (Germe et al., 2009). 
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bound on the chromosomes (Deweese and Osheroff, 2009, Pendleton et al., 2014). In addition, 
TOP2A is less frequently found in non-proliferating and differentiated cells (Pendleton et al., 
2014). 
In contrast, TOP2B concentration does not depend on proliferation and it can be found in high 
levels in most types of cells. Unlike TOP2A, during mitosis TOP2B dissociates from the 
chromosomes (McClendon and Osheroff, 2007, Deweese and Osheroff, 2009, Pendleton et al., 
2014). Even though TOP2B is not as essential as TOP2A and it cannot compensate for the loss 
of TOP2A in mammalian cells (Grue et al., 1998), it is still required for proper neural 
development and function in mammals (Gómez-Herreros et al., 2014, Grue et al., 1998). Most 
importantly, there is emerging data that has linked TOP2B to the transcription of hormonally 
regulated genes (Ju et al., 2006, Cowell et al., 2012), something that will be discussed in more 
detail later. 
1.4 The role of tyrosyl-DNA phosphodiesterase 2 in the restoration of 5’-
phosphate termini at DNA double-strand breaks 
The enzyme that cleaves 3’-phosphotyrosyl bonds had previously been identified as tyrosyl-
DNA-phosphodiesterase 1 (TDP1) (Nitiss et al., 2006). On the other hand, the complementary 
enzyme that cleaved 5’-phosphotyrosyl bonds was not identified until a few years later, even 
though the effect of DNA DSBs containing such termini had been implicated in chromosome 
instability and cancer for some time. 
In 2009, Cortes-Ledesma et al. identified an enzyme in human cells that efficiently restores 5’-
phosphate termini at DNA DSBs in preparation for DNA ligation (Cortes Ledesma et al., 2009). 
This enzyme has been previously reported as TTRAP and EAPII and is a member of the 
Mg2+/Mn2+-dependent family of phosphodiesterases (Cortes Ledesma et al., 2009). As TTRAP 
(TRAF and TNF receptor-associated protein), it was identified through association with the 
cytoplasmic domain of CD40, TNF (tumor necrosis factor) receptor-75 and TRAFs (TNF 
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receptor-associated factors) (Pype et al., 2000). Through this role, it inhibits NFκB activation 
(Pype et al., 2000). It has also been linked to cancer cell proliferation (Xu et al., 2008). In 
addition, as EAPII (ETS1-associated protein II), it was identified as a transcription factor 
involved in tumorigenesis and metastasis (Hahne et al., 2008, Seth and Watson, 2005, Pei et 
al., 2005), through its involvement in the transcription activity of ETS1 (Pei et al., 2003). On the 
other hand, Cortes-Ledesma et al. showed that cellular depletion of this enzyme resulted in 
increased susceptibility and sensitivity to TOP2-induced DNA DSBs (Cortes Ledesma et al., 
2009). Therefore, it was appropriately named tyrosyl-DNA-phospodiesterase 2 (TDP2) (Cortes 
Ledesma et al., 2009). 
Sensitivity to TOP2 targeting agents, such as doxorubicin and etoposide (also known as VP16), 
as well as the catalytic inhibitor ICRF-193 in cells lacking TDP2 has also been shown (Cortes 
Ledesma et al., 2009, Zeng et al., 2011, Gómez-Herreros et al., 2014). More recent work from 
the same group has also revealed that TDP2 knock-out mice demonstrate lymphoid toxicity, 
severe intestinal damage and increased genome instability in the bone marrow, when treated 
with the TOP2 targeting agent etoposide (Gomez-Herreros et al., 2013). Furthermore, in a 
study published recently, it was shown that cells from affected individuals demonstrating 
intellectual disability, seizures and ataxia were very sensitive to TOP2-induced DSBs (Gómez-
Herreros et al., 2014). The same study demonstrated that depleting human cells of TDP2 leads 
to inhibition of TOP2-dependent gene transcription, something the authors also observed in 
mouse post-mitotic neurons following abortive TOP2 activity (Gómez-Herreros et al., 2014). 
Finally, in was also demonstrated that TDP2 is crucial for maintaining regular levels of many 
gene transcripts in the developing mouse brain (Gómez-Herreros et al., 2014).  
TDP2 is an enzyme that demonstrates specificity for phosphotyrosyl bonds (Cortes Ledesma et 
al., 2009, Gao et al., 2012). It is able to remove the tyrosine moiety from the 5′-end of the 
DNA, leaving a phosphate group ready for re-ligation (Cortes Ledesma et al., 2009). 
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Furthermore, it has been found to hydrolyze 5′-tyrosine-DNA adducts that mimic abortive 
TOP2 cleavage complexes, while its preferred substrate was shown to be single-stranded or 
double-stranded DNA with a four-base pair overhang, consistent with the known structure of 
TOP2 cleavage complex (Gao et al., 2012). The specificity constant kcat/Km of TDP2 for single-
stranded 5′-tyrosyl-DNA has been measured as 4 × 105 s−1m−1 (Gao et al., 2012). In addition to 
Mg2+ and Mn2+, TDP2 has been found to be weakly active with Ca2+ or Zn2+ (Gao et al., 2012). 
Furthermore, TDP2 appears as up-regulated in p53 mutant tumour cells (Do et al., 2012). 
Crystal structures of TDP2 for mouse, Caenorhabditis elegans and zebra fish have been 
published (Schellenberg et al., 2012, Shi et al., 2012). These structures show a catalytic site 
formed of four residues chelating a magnesium ion (Schellenberg et al., 2012, Shi et al., 2012). 
In addition, the mouse and the zebra fish structures explain that a minimum of two single-
stranded, unpaired nucleotides are necessary to access the catalytic site (Schellenberg et al., 
2012, Shi et al., 2012, Pommier et al., 2014). In Figure 1.6 the structure of the human TDP2 
catalytic domain can be seen (Hornyak et al., 2016). 
 
 
As mentioned previously, DSBs can be repaired either by NHEJ or HR (Shrivastav et al., 2008). 
TDP2 appears to ‘function in a NHEJ-mediated and HR-independent pathway for the repair of 
TOP2-induced DSBs’ (Gomez-Herreros et al., 2013). It has been previously shown that TDP2 
Figure 1.6: X-ray crystal structure of hTDP2CAT. The molecular representation is coloured from blue to red, 
from the visible N- to C-terminus. Also featured is the position of the M7-motif (Hornyak et al., 2016). 
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liberates DSB termini of the TOP2 cleavage complex by generating 5’phosphate and 3’-
hydroxyl termini ‘clean’ DSBs with 4-bp overhangs that serve as direct substrate for end-joining 
by Ku70/80 and DNA Ligase IV, two of the most important NHEJ components, suggesting an 
error-free NHEJ mechanism (Fig.1.6) (Gomez-Herreros et al., 2013, Hoa et al., 2016).  
Furthermore, it has been shown that deleting TDP2, Ku70 or TDP2 and Ku70 simultaneously in 
DT40 cells increased sensitivity to etoposide, but the TDP2-/-/-/Ku70-/- double mutant 
demonstrated the same sensitivity as the Ku70-/- single mutant (Zeng et al., 2011). If cleavage 
complexes repaired by TDP2 were preferentially repaired by NHEJ, then loss of TDP2 would be 
followed by enhanced repair by HR (Nitiss and Nitiss, 2013). A recent study showed this in the 
form of increased Rad51 foci in TDP2-deficient cells treated with etoposide compared to wild 
type cells, as well as an increase in etoposide-induced sister chromatid exchanges, a molecular 
hallmark of HR (Gomez-Herreros et al., 2013). 
Another interesting observation about TDP2 is that overexpression significantly reverses 
genome instability and mortality of Mre11 mutant TK6 human lymphoblastoid cells (Hoa et al., 
2016). The same paper also suggests that Mre11 and TDP2 operate in separate pathways for 
the repair of etoposide-induced breaks. Moreover, it was also shown that the heterozygous 
mutant MRE11+/-, but not the heterozygous TDP2+/- cells were more sensitive to etoposide 
than wild type cells (Hoa et al., 2016). Interestingly, TDP2-/- cells showed no significant genome 
instability unlike MRE11-/H129N/TDP2-/-cells, suggesting a functional redundancy between the 
nuclease activity of Mre11 and TDP2 in terms of genome stability (Hoa et al., 2016). 
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1.5 Targeting DNA repair proteins in cancer therapy 
Chemotherapy is one of the main strategies used to combat cancer. It is so named because it 
utilises one or more anti-cancer drugs or chemotherapeutic agents. Most of these agents are 
designed to kill cancer cells by inducing DNA damage. As discussed earlier, DNA damage is 
recognised and repaired by a variety of DNA damage response mechanisms. If the DNA 
damage response is successful, the cancer cell will survive. The increasing understanding of the 
DNA repair mechanisms has allowed the use of target-specific drugs that take advantage of 
certain aspects of cancer cells. For example, in cancer cells there are usually specific DNA 
repair factors that are upregulated and those can serve as biomarkers of therapeutic outcome. 
Inhibition of the DNA repair factors is a logical strategy to increase the effect of anti-cancer 
drugs, which is why it has been the subject of a lot of research groups and pharmaceutical 
Figure 1.7: TDP2 pathway for removal of abortive TOP2 cleavage complexes. TDP2 hydrolyzes the tyrosyl-DNA 
links following proteolysis and/or denaturation of TOP2. Non-homologous end joining enzymes Ku and Ligase IV 
are essential downstream of TDP2 to complete DNA repair (Pommier et al., 2014). 
34 
 
companies for several decades. There is a large number of inhibitors that target a variety of 
DNA damage response proteins at different stages of clinical trials at this moment or in the 
past (Hosoya and Miyagawa, 2014). These include drugs targeting PARP1 and TOP2. 
1.5.1 Topoisomerase 2 inhibitors 
There are several classes of drugs that target TOP2. Some of those drugs work by increasing 
the levels of cleavable complexes, while other drugs inhibit the catalytic site of the protein, 
obstructing the re-ligation of the DNA; this has led to the categorisation of TOP2 drugs as TOP2 
poisons or catalytic inhibitors (Rocha et al., 2016, Pommier, 2013, Nitiss, 2009b, Nitiss, 2009a). 
The TOP2 anticancer agents that are used more commonly are anthracyclines (doxorubicin and 
daunorubicin), mitoxantrone and etoposide (Pommier et al., 2010). These drugs are 
considered TOP2 poisons as their effect is to increase levels of TOP2/DNA cleavage complexes 
(Rocha et al., 2016). 
Etoposide is a semi-synthetic derivative of podophyllotoxin, a product of extraction from the 
mandrake root Podophyllum peltatum. It binds to the TOP2/DNA complex preventing the re-
ligation of the DNA strands and causes an abortive break (Fleming et al., 1989). Depending on 
the molar ratio between etoposide and TOP2, the formation of both SSBs and DSBs is possible 
(Bromberg et al., 2003). This leads to accumulation of DSBs, which in turn inhibits DNA 
replication and/or transcription, leading to apoptosis.  It acts primarily in G2 and S phases of 
the cell cycle. It has been used in cancer treatment for over 20 years for a variety of cancers. 
TOP2 poisons are used frequently for lymphomas and lung, ovarian, breasts and colorectal 
cancers (Pommier, 2013). It is not uncommon for patients to develop resistance to etoposide 
and there is data that shows a link between that resistance and TDP2 (Li et al., 2011b, Rocha et 
al., 2016). 
There is evidence that high etoposide concentrations can trigger the process of apotosis, which 
involves caspases (a family of cysteine-dependent proteases) and progresses via the 
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cytocrome c/caspase 9 pathway (Riedl and Shi, 2004). The pathway in short involves the 
release of cytocrome c into the cytoplasm from the mitochondria. It then binds to the 
apoptotic protease activating factor 1 (apaf1) forming the apoptosome. The apoptosome binds 
and cleaves procaspase 9 leading to its activation. The activated caspase 9 is then able to in 
turn activate other regulatory caspases, such as caspase 7 and caspase 3 triggering further 
apoptotic processes (Fig.1.8) (Montecucco et al., 2015). In addition, etoposide has been shown 
to have a similar effect in non-replicating human T-lymphocytes, therefore interfering with 
transcription. It activates DNA damage response and induces phosphorylation of ATM and its 
substrates, H2AX and p53. The pro-apoptotic PUMA protein, a p53 upregulated modulator of 
apoptosis and the caspases are also then activated, leading to apoptosis (Korwek et al., 2012, 
Montecucco et al., 2015). It is also interesting to mention that PARP1 is cleaved in two 
fragments during apoptosis, something that has become a useful hallmark of topoisomerase 
inhibitor-induced apoptosis, and data shows that caspases 3 and 7 are responsible (Germain et 
al., 1999, Curtin, 2005). 
  
 Figure 1.8: Schematic overview of the genotoxic stress-induced apoptotic pathway, showing the key factors 
involved. (Adapted from (Montecucco et al., 2015) 
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1.5.2 PARP1 inhibitors 
It has already been discussed how important the maintenance of genomic integrity is and what 
a big part PARP1 plays in it. It is unsurprising then that for over 30 years, PARP1 inhibitors have 
been the most promising drugs that target DNA repair (Purnell and Whish, 1980, Rouleau et 
al., 2010). As mentioned Poly(ADP-ribose) polymerase 1 (PARP1) is a protein that  has been 
implicated in the repair of SSBs, but it has also been shown to be recruited to sites of DSBs 
(Rouleau et al., 2010). Furthermore, if such SSBs persist unrepaired until the DNA is replicated, 
then DSBs can form (Rouleau et al., 2010). Drugs that work as PARP1 inhibitors can induce the 
formation of such DSBs by interfering with the repair of SSBs, but that is not the only proposed 
explanation (Haffner et al., 2011, Bareschino et al., 2011). 
In 2005, two groups independently showed the ability of PARP inhibitors to selectively inhibit 
the growth of cells with defects in either the BRCA1 or the BRCA2 genes, suggesting a synthetic 
lethality use (Bryant et al., 2005, Farmer et al., 2005). There have been a number of studies 
investigating the use of PARP1 inhibitors as single agents, especially in BRCA-mutated breast, 
ovarian and prostate tumours, with the first two showing the most favourable response (Fong 
et al., 2009, Audeh et al., 2010). In December 2014, the FDA and the EMA approved Olaparib, a 
PARP1 inhibitor as monotherapy for the treatment of recurrent ovarian cancer in women with 
a BRCA1 or BRCA2 mutation (Frampton, 2015). "BRCAness" is a profile of tumours that have 
common traits with BRCA-mutated tumours and is also of interest for PARP1 inhibition (Weil 
and Chen, 2011). 
There have also been studies looking into combination therapies, where a PARP1 inhibitor 
along with one or more other factors of the DNA damage response system, are inhibited 
(Hosoya and Miyagawa, 2014). There is currently a trial (NCT01642251) that is testing a 
combination of the PARP1 inhibitor veliparib, cisplatin and etoposide for extensive stage small-
cell lung cancer, metastatic large cell neuroendocrine NSCLC and small-cell carcinoma of 
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unknown primary or extrapulmonary origin. This trial is at Phase II and due to conclude in 
January 2018, demonstrating that combination therapy targeting both PARP1 and TOP2 
simultaneously has merits after progression from its first phase (Hosoya and Miyagawa, 2014). 
The exact mechanism of action of PARP1 inhibitors with regard to their effects in cancer cells is 
not fully understood, but there is evidence that PARP1 inhibitors trap PARP1 enzymes at the 
locations of damaged DNA; those PARP1-DNA complexes were more cytotoxic than unrepaired 
SSBs caused by PARP1 inactivation, and if we were to draw a parallel with TOP2 poisons, we 
could say that such PARP1 inhibitors act in a PARP1-poison manner (Murai et al., 2012) 
1.6 TDP2 as a biomarker to sensitivity and as a novel therapeutic target 
As mentioned previously, both types of topoisomerase 2 are the targets of several anticancer 
drugs for the treatment of both early and advanced cancers. Cellular depletion of TDP2 has 
been shown to result in increased sensitivity to TOP2-induced DNA breaks and TOP2 poisons 
(Cortes Ledesma et al., 2009, Zeng et al., 2011). On the other hand, over-expression of TDP2 
increases resistance to TOP2 poisons (Do et al., 2012).  
There are recent data which suggest that expression levels of TDP2 vary greatly in different 
types of cancer cell lines, such as breast and lung, ranging from almost no expression to very 
high levels of expression (Li et al., 2011a). However, there are no reported studies addressing 
the possible roles of TDP2 as determinants of outcome or clinical predictors, or studies 
correlating over-expression with resistance to TOP2 poisons. In addition to variations in TDP2 
expression across different tumour types, chemoresistance frequently occurs  (Li et al., 2011b). 
One possible contributing factor to this is increased repair of the DNA, and TDP2 has been 
reported to contribute to such resistance directly (Li et al., 2011b). 
Given TDP2’s role in repairing TOP2-mediated DSBs, TDP2 protein levels could be influential for 
cancer cell resistance to TOP2 poisons, which are widely used in cancer treatment. There are 
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recent studies that reinforce this hypothesis. TDP2 depletion by RNAi in the lung cancer cell 
line A549 resulted in increased sensitivity to etoposide (Cortes Ledesma et al., 2009). Similar 
observations were made in chicken DT40 cells, in which deletion of TDP2 led to increased 
sensitivity to etoposide (Zeng et al., 2011). It has also been observed in both H460 and A549 
lung cancer cell lines that knocking down TDP2 sensitises these cells to etoposide-induced cell 
growth inhibition (Bian et al., 2016). This suggests that types of cancer with high levels of TDP2 
might be relatively resistant to TOP2 poisons, while types of cancers with low levels of TDP2 
might be sensitive to such treatment. Consistent with this idea, increased levels of TDP2 have 
been observed in several non-small cell lung cancer cell lines, and a possible oncogenic role of 
TDP2 in such cancers has been suggested (Li et al., 2011a).  
Two groups of cancer cell lines that could serve as a focus group for studies correlating over-
expression with resistance to TOP2 poisons, or to further explore the potential of TDP2 as 
determinants of outcome or clinical predictors would be a panel of lung cancer and breast 
cancer cell lines. Non-small cell lung cancers in particular, represent 80-85% of all lung cancer 
cases, something that makes them clinically important (Breathnach et al., 2001, Bareschino et 
al., 2011). Breast cancer is the most common type of cancer in women worldwide (Siegel et al., 
2015). Around 20-30% of breast cancer cases will become metastatic (O'Shaughnessy, 2005). 
In addition, about 6% of non pre-existing breast cancer cases begin as metastatic, also known 
as Stage 4 (Program, 2015). Etoposide is a commonly used drug that has been increasingly 
used over the past few years for patients that suffer from metastatic breast cancer and have 
received previous treatment (Yuan et al., 2015, Valabrega et al., 2015).  
TDP2 has the potential to be a good target for pharmacological inhibition to potentially 
increase tumour sensitivity to TOP2 poisons, particularly those that develop resistance during 
the course of treatment. Recently, there has been an increase of information about studies 
looking into the possibility of a TDP2 inhibitor. One group reported that toxoflavin derivatives 
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and deazaflavins were identified as sub-micromolar and selective inhibitors of TDP2 via a high-
throughput screening, however, even though they both demonstrated a structure-activity 
relationship, unfortunately both of them posed challenges (Raoof et al., 2013). Toxoflavins 
demonstrated a key redox liability, early in vitro metabolism and pharmacokinetic issues and 
deazaflavins low cell permeability (Raoof et al., 2013). A different group reported isoquinoline-
1,3-dione compounds as selective TDP2 inhibitors, which were identified by a screening of in-
house collection of synthetic compounds, followed by a structure-activity relationship study 
(Kankanala et al., 2016). Another publication also presented data about deazaflavin being a 
good candidate for TDP2 inhibition, but also went one step further and included data that 
showed potent synergy in combination with etoposide in human prostate cancer cells DU145 
and TDP2-dependent synergy in TK6 human lymphoblast and avian DT40 cells, also showing 
that TDP2 knock out cells did not show significant synergy (Marchand et al., 2016). Another 
paper identified a selective inhibitor via a high-throughput screening and subsequent 
validation studies (Kont et al., 2016). NSC111041 was shown to inhibit TDP2’s binding to DNA 
without intercalating into DNA and also demonstrated a synergistic effect with etoposide in 
TDP2 expressing cells but not cells with depleted TDP2. In addition, the inhibitor increased the 
number of etoposide-dependent γ-H2AX foci, a biomarker for DSBs (Kont et al., 2016). A 
different group reported another collective of TDP2 inhibitors that emerged from 
experimentally verifying the selective inhibitory activity of relevant molecules from the NCI 
diversity small molecule database (Kossmann et al., 2016). This group also reported on the 
binding mode of these inhibitors by molecular dynamics simulations, which showed 
association to the TDP2 DNA-binding cleft (Kossmann et al., 2016). Finally, another group 
confirmed that deazaflavin inhibits TDP2; a fluorescence-based assay was used, which is 
suitable for high-throughput screening, but it was taken one step further and the crystal 
structures of these compounds bound to a ‘humanized’ form of murine TDP2 were 
determined. Interestingly, these structures demonstrated that the compounds act as 
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competitive ligands for the binding site of an incoming DNA substrate, something that could 
potentially point the way towards generating new and effective TDP2 inhibitors (Hornyak et 
al., 2016). 
There is a recent model, which suggests that induction of transcriptional programs, for 
example by stimulating breast or prostate cells with estrogens or androgens respectively, can 
involve the formation of TOP2B-mediated DNA DSBs and the recruitment of DSBR proteins 
(Haffner et al., 2011). It has been previously shown that for successful signal-dependent 
activation of transcription by transcription factors such as the estrogen receptor (ER), 
formation of transient TOP2B-mediated DSBs is required at regulatory elements (Ju et al., 
2006). Ju et. al. showed that rapid increase of TOP2B and PARP1 levels were detected after 
treatment with estradiol (also known as E2) and were also co-purified with Ku80, Ku70 and 
DNA-dependent protein kinase (DNA-PK), all of which are components of the DNA damage and 
repair machinery (Ju et al., 2006). Furthermore, following estradiol treatment, TOP2B and the 
components of the repair machinery were all stably recruited to the pS2 gene promoter but 
not the coding region of the gene (Ju et al., 2006). The pS2 gene encodes the pS2 estrogen 
response element (specific to the breast cancer cell line MCF7) that encompasses structural 
features similar to some growth factors and whose transcription is stimulated by estrogen 
(Stack et al., 1988, Kim et al., 2000). Similar findings have been demonstrated for the androgen 
receptor (Haffner et al., 2010). TOP2B is believed to be recruited with the estrogen or 
androgen receptor to regulatory sites on target genes for efficient activation of those genes 
(Fig.1.9) (Haffner et al., 2011). 
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It has been shown that tumours experiencing acute or chronic hypoxia (such as solid or fast 
growing tumours) are sensitive to PARP1 inhibitors (Chan et al., 2010). Furthermore, there is 
data which suggests that certain types of breast cancer might be sensitive to PARP1 inhibitors 
(Weil and Chen, 2011). Whilst the generation of a transient SSB is central to the activity of 
TOP1, the two subunits of TOP2 introduce DNA breaks in an independent but coordinated 
Figure 1.9: Activation of transcription by the androgen receptor AR is followed by association with TOP2B. 
Together they bind AR target sites. Recruitment of the DNA repair proteins Ku70, Ku80, PARP1, ATM and DNA-
PK follows. TOP2B introduces a DSB, which can be rendered abortive by reactive oxygen species (ROS), dietary 
carcinogens, fork collisions or repair infidelity. Non-repaired abortive DSBs can lead to serious complications 
for the cell, including apoptosis and genomic instability (Haffner et al., 2011). 
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process and therefore can be trapped as a SSB if TOP2 activity on both strands is not 
coordinated, which normally would be a target for PARP1 (Zechiedrich et al., 1989, Nitiss, 
2009b). 
Estradiol is one of the most common estrogen hormones and is sometimes used as part of 
hormone cancer therapy in both women and men, especially breast cancer (Ingle, 2002). In 
addition, it has been involved in higher breast and ovarian cancer risk in women that have 
been prescribed estradiol for menopause (Beral, 2003, Beral et al., 2007).  
Breast cancers are usually hormone dependent and they typically respond well to hormone 
therapies. Even so, a large percentage of those tumours will develop resistance to this type of 
treatment, while still expressing ER, implying that they still depend on the ER pathway 
(Risbridger et al., 2010). It is hypothesised that this could be exploited therapeutically. A 
combination treatment could be established that will first induce transcription (for example 
with estradiol), which will cause transient TOP2B-mediated DNA DSBs, and then transform 
those breaks into abortive breaks using a TOP2 poison. Failure to repair these DSBs due to the 
TOP2B-targeting drug, could lead to the cells being overwhelmed with DSBs, thus promoting 
apoptosis. Such a strategy could possibly find particular use in slow proliferating hormone-
dependent cancers such as breast tumours, where resistance has developed or other types of 
treatment have failed. More specifically, this could potentially be more effective in breast 
cancer cell lines with low levels of TDP2 and higher levels of TOP2B, as this would mean there 
would not be enough TDP2 to remove the stalled TOP2B, increasing the chance of success of 
such a treatment. Furthermore, to increase the success of a cycle treatment as the one 
proposed, the addition of a PARP1 inhibitor could also be utilised to further expand on the 
observation that it is recruited with TOP2B after treatment with estradiol. 
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1.7 Lung and breast cancer cell lines as tools for investigating novel 
therapeutic targets 
Non-small cell lung cancer cell lines are widely used in scientific research. Most of them are 
easy to obtain and maintain. A549 is an epithelial carcinoma cell line (American Type Culture 
Collection - ATCC). It grows in an adherent manner and it was established in 1972 through 
explant culture of lung carcinomatous tissue from a 58-year-old Caucasian male (Giard et al., 
1973). NCI-H292 (H292) is an epithelia mucoepidermoid pulmonary carcinoma cell line (ATCC). 
It grows in an adherent manner and has been previously been identified as Hut 292 (Lechner 
et al., 1983). It was deposited by A. Gazdar (National Cancer Institute-Navy Medical Oncology 
Branch, Bethesda, MD) and it was derived from a 32-year-old Black female (Carney et al., 
1985). NCI-H1650 (H1650) is an epithelial stage 3B adenocarcinoma and specifically 
bronchoalveolar carcinoma derived from a metastatic site (pleural effusion) that grows in an 
adherent manner (ATCC). It was deposited by A. Gazdar and J. Minna in May of 1987 and was 
established from a 27-year-old Caucasian male (Gazdar, 1996). NCI-H460 (H460) is an epithelial 
carcinoma derived from a male patient that grows in an adherent manner (ATCC). It was 
deposited by A. Gazdar and J. Minna in 1982 (Banks-Schlegel et al., 1985). NCI-H226 (H226) is 
an epithelial squamous cell carcinoma, specifically mesothelioma, and was isolated from a 
metastatic site (pleural effusion) (ATCC). It grows in an adherent manner (ATCC). It was 
deposited by A. Gazdar and J. Minna in March of 1980 and was established from a male 
patient (Gazdar, 1996). MOR is an epithelial-like adenocarcinoma cell line that grows in an 
adherent manner in colonies (Public Health England Culture Collections). It was deposited by 
Dr. P. Twentyman and Dr. K. Wright (UKCCR, PO Box 123, Lincolns Inn Fields, London WC2A 
3PX) (Twentyman et al., 1986). Hop92 is an epithelial carcinoma cell line, which was 
contributed by M. Liu. (US National Cancer Institute). It was derived from a 62-year old male 
patient (US National Cancer Institute). HCC95 (prefix HCC for Hamon Cancer Center) is an 
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epithelial squamous cell line derived from a metastatic site (pleural effusion) of a 65-year old 
male patient in 1992 (Wistuba et al., 1999). 
Similar to non-small cell lung cancer, breast cancer lines are also very common in scientific 
research. As previously mentioned, breast cancer is one of the most common types of cancer. 
T47D is an epithelial ductal carcinoma derived from a metastatic site (pleural effusion) of 
mammary gland tissue (ATCC). It was isolated from a 54-year old female and deposited by I. 
Keydar (Keydar et al., 1979). MDA-MB-361 (MM361) is an epithelial adenocarcinoma cell line 
derived from a metastatic site (brain) originating in mammary gland and breast tissue, from a 
40-year old Caucasian female (ATCC). It was deposited by R. Cailleau (Cailleau et al., 1978). 
MDA-MB-453 (MM453) is an epithelial metastatic cancinoma cell line, derived from a 
metastatic site (pericardial effusion) originally from mammary gland and breast tissue (ATCC). 
It was isolated from a 48-year-old Caucasian female and was deposited by R. Cailleau (Cailleau 
et al., 1978). BT-474 (BT474) is an epithelial ductal carcinoma cell line from mammary gland 
tissue (ATCC). It was isolated from a 60-year-old Caucasian female and was deposited by E. 
Lasfargues (Lasfargues et al., 1978).  ZR-75-1 (ZR751) is an epithelial ductal carcinoma derived 
from a metastatic site (ascites) originally from mammary gland tissue (ATCC). It was isolated 
from a 63-year-old Caucasian female and was deposited by L. Engel (Engel et al., 1978). MCF7 
(Michigan Cancer Foundation-7) is an epithelial adenocarcinoma cell line derived from a 
metastatic site (pleural effusion) originating from mammary gland tissue (ATCC). It was 
isolated by a 69-year old Caucasian female by H. Soule and co-workers in 1973 and was 
deposited by C. McGrath (Soule et al., 1973). It is also ERα positive and grows in an estrogen-
dependent manner. That means that types of cancer with the MCF7 profile usually respond 
well to inhibitors of ERα activity or drugs that block estrogen synthesis. MLET5 is an MCF7 
derivative, which whilst ERα positive, it grows in an estrogen-independent manner. It was 
established by over-expressing ERα in MCF7 cells using adenovirus gene transduction, which 
resulted in ligand-independent expression of pS2 and PR (estrogen-regulated genes), and the 
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cell line to be able to grow in an estrogen-independent manner (Tolhurst et al., 2011). 
Similarly, LCC9 is an MCF7 derivative that grows in an estrogen-independent manner, but it 
was acquired in a different way. Brünner et al., had previously established an MCF7 derivative, 
LCC1 that is able to grow in vivo and in vitro independent of estrogen, but still remain sensitive 
to antiestrogens, by cultural selection for resistance (Brunner et al., 1993a). The same group 
was also able to grow an MCF7/LCC1 derivative, LCC2, which in addition to estrogen-
independent growth, it is also resistant to 4OH-TAM, again via cultural selection for resistance, 
but was not cross-resistant to the steroidal entiestrogens ICI 182,780 and ICI 164,384 (Brunner 
et al., 1993b). ICI 182,780 and ICI 164,384 are C7-acyl-substituted analogues of estradiol and 
have a higher affinity for ER than TAM (Wakeling et al., 1991, Thompson et al., 1989). 
Therefore, a few years later, Brunner et al. published a paper in which they reveal another 
MCF7/LCC1 derivative, LCC9, which was selected against ICI 182,780, but through that it also 
acquired cross-selection for TAM (Brünner et al., 1997). 
T47D, Hop92, A549, H460, MCF7, H226 are part of the NCI-60 cell line panel. In the late 1980s, 
the US National Cancer Institute (NCI) created and developed an anticancer drug discovery and 
screen project containing 60 human tumour cell lines (Shoemaker, 2006). The intention of the 
project was to screen in vitro thousands of pharmacological compounds for anticancer activity, 
replacing earlier in vivo models. These cell lines included nine types of cancer: lung, breast, 
prostate, ovary, colon, central nervous system, kidney, leukemia and melanoma, which formed 
a panel referred to as NCI-60 (Abaan et al., 2013).  
1.8 Aims of the thesis 
This thesis aims to initially establish the mRNA and protein levels of TDP2, TOP2A and TOP2B in 
a panel of non-small cell lung cancer cell lines and a panel of breast cancer cell lines and 
explore whether these levels exhibit a large variation. Following that, the project will 
investigate the possibility of a correlation between the levels of TDP2, TOP2A and TOP2B and 
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resistance to the TOP2-targeting agent etoposide. It is hypothesised that cell lines exhibiting 
low levels of TDP2 and high levels of TOP2A and TOP2B will be more sensitive to etoposide, 
compared to cell lines that have showcased high levels of TDP2 and low levels of TOP2A and 
TOP2B. This is based on previous observations where depriving cells of TDP2 has lead to 
increased etoposide sensitivity compared to wild type cells (Cortes Ledesma et al., 2009, Zeng 
et al., 2011). This will serve to establish TDP2 as a biomarker for sensitivity to etoposide and a 
clinical predictor of treatment outcome.  
In addition, the emerging model of TOP2B-mediated DSBs during transcription will be utilised 
to explore the possibility of TDP2 as a novel therapeutic target for inhibition. As previously 
mentioned, this is based on the hypothesis that inducing transcription in selected breast 
cancer cell lines by the estrogen estradiol, thus inducing TOP2B-mediated DSBs, and treating 
them with etoposide to shift the transient DSBs to abortive would overwhelm the cell’s TDP2 
and render it unable to cope with the high number of abortive DSBs, leading to apoptosis. 
Furthermore, it would be interesting to investigate whether the introduction of TOP2B-
mediated DSBs by treatment with estradiol, could be severe enough in itself to affect cell 
survival in cancer cells with low levels of TDP2 or TDP2-depleted cell lines. If the results are 
promising, then perhaps the next step would be a compound that is able to inhibit TDP2 
directly without the need of a knock-out.  
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2. CHAPTER TWO - Materials and Methods 
2.1 General Chemicals and Equipment 
All chemicals were obtained from Fisher Scientific or Sigma unless otherwise stated.  All 
enzymes were obtained from Roche or New England Biolabs unless otherwise stated.   All cell 
culture media was obtained from Gibco® by Life Technologies. All cell culture flasks, dishes and 
cryovials from Corning® Sigma. 
All centrifugation steps, with the exception of cell culture, were carried out using a Thermo 
Scientific Heraeus Pico 21 centrifuge, a Thermo Scientific Heraeus Fresco 21 centrifuge or a 
Beckman Coulter Allegra X-22R centrifuge using S4180, F0630 and F24020H rotors. 
All  cell  culture  centrifugation  steps  were  carried  out  using  a  Denley  B5400  centrifuge  or  
a Hettich® Rotina 38R refrigerated centrifuge. 
The thermal cyclers that were used were Techne TC-5000, MWG-Biotech Primus 25 and 
PeqLab Advanced Primus 25. 
Microscopy was carried out with a Nikon E400 or a Zeiss Axioplan 2. 
The colony counter was a Stuart SC6. 
2.2 Mammalian Cell Culture 
The following cell lines were used: 
• Lung cancer cell lines: A549, H292, H1650, H460, H226, HCC95, Hop92, and MOR 
• Breast cancer cell lines: MDA-MB-453 (MM453), MDA-MB-361 (MM361), T47D, MCF7, 
ZR-75-1 (ZR751), BT474, LCC9 and MLET5. 
The cell lines were maintained in the appropriate media. RPMI was used for H292, H1650, 
H460, H226, Hop92, MOR, T47D, ZR751 and BT474, Leibovitz’s was used for MM361, DMEM 
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was used for A549, HCC95, MM453 and MCF7, and phenol-red-free DMEM + 1% pyruvate was 
used for MLET5 and LCC9. RPMI and DMEM media was supplemented with 2mM L-glutamine, 
50μg/ml streptomycin, 0.5 units/ml penicillin (all from Gibco® by Life Technologies) and 10% 
heat-inactivated foetal bovine serum (FBS – from Pan-Biotech).  Leibovitz’s media was 
supplemented with 2mM L-glutamine, 50μg/ml streptomycin, 0.5 units/ml penicillin and 20% 
heat-inactivated FBS. Phenol-red-free DMEM media was supplemented with 2mM L-
glutamine, 50μg/ml streptomycin, 0.5 units/ml penicillin, 1% pyruvate and 10% charcoal-
stripped FBS (from Sigma). They were all grown in a 37oC humidified incubator with 5% CO2. 
Cells were regularly tested for mycoplasma contamination. A Lonza MycoAlert Mycoplasma 
Detection Kit was used, according to manufacturer’s instructions. 
2.3 Analysis of cellular extracts by gene expression and SDS-PAGE 
immunoblotting 
2.3.1 Whole cell extracts 
Cells were washed with phosphate buffered saline (PBS) and 0.25% Trypsin powder in PBS was 
added for cell dissociation. Cell pellets were obtained at different time points of cell culture 
and were immediately frozen in LN2 and kept at -20
oC after that. 
2.3.2 RNA Extraction 
RNA was extracted for the above cell lines using an optimised protocol. The cells were 
homogenised with 1ml TRI reagent and incubated at room temperature for 5 minutes (min). 
Then, the samples were centrifuged at 4oC for 5 min at 12000g. The supernatant was 
transferred to a new eppendorf tube and 100μl of 1-bromo-3-chloro-propane (BCP) was 
added. The samples were vortexed for 15 seconds (sec) to get a homogenous mixture. They 
were then incubated for 15 min at room temperature. Subsequently, they were centrifuged at 
4oC for 10 min at 12000g. The aqueous phase was rescued and precipitated with 500ml 100% 
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isopropanol. The samples were then vortexed for 10 sec and incubated for 10 min at room 
temperature, followed by a 5 min spin at 12000g at 4oC. The supernatant was discarded and 
1ml of 75% ethanol was added. The samples were once again centrifuged at 4oC for 5 min at 
7500g. The ethanol was removed and the pellet was left to air dry for 5 to 10 min. Finally, the 
RNA was re-suspended in 100μl RNAse-free water. It was quantified with a spectrophotometer 
(Nanodrop, Thermo Scientific). 
2.3.3 Gene expression analysis 
High-capacity cDNA reverse transcription kit without RNAse inhibitor by Applied Biosystems 
was used and the provided protocol was followed. 100ng of RNA were retrotransformed into 
cDNA for each cell line. Cycling conditions were as follows: 25oC for 10 min, 37oC for 120 min 
and 85oC for 5 min on one of the thermal cyclers mentioned in section 2.1. qPCR was run in 
triplicate using 1ng of cDNA for each reaction and TaqMan® gene expression assay by Life 
Technologies was used for each gene (Table 2.1). The volumes used for each single reaction 
were 5μl of 2x master mix, 0.5μl primer & probe, 3.5μl RNAse free water and 1μl sample. A 
two-step cycling program was used: 95oC for 10 min and 40 cycles of 95oC for 15 sec followed 
by 60oC for 1 min. The qPCR machine that was used was an MX3005P Stratagen, with the 
accompanying MxPro QPCR Software. 
Table 2.1: TaqMan® gene expression assay genes 
Gene Catalogue Number Company 
TDP2 Hs01099017_m1 Life Technologies 
TOP2A Hs00172214_m1 Life Technologies 
TOP2B Hs00172259_m1 Life Technologies 
RPLP0 Hs99999902_m1 Life Technologies 
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2.3.4 SDS-Polyacrylamide gel electrophoresis 
10% sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) separating gels 
were used. These were prepared by mixing 4ml of distilled water, 3.3ml of 30% acrylamide, 
2.5ml 1.5M Tris-HCl pH 8.8, 100μl 10% SDS, 100μl 10% APS and 4μl TEMED (Sambrook and 
Russell, 2006). The stacking gels were prepared by mixing 3.4ml distilled water (dH20), 830μl 
30% acrylamide, 630μl 1M Tris-HCl pH 6.8, 50μl 10% SDS, 50μl 10% APS and 5μl TEMED. 
Samples were prepared with the addition of 1x SDS-PAGE loading buffer (50mM  Tris pH 8.0, 
2% w/v SDS, 10%  w/v glycerol,  0.1% w/v  bromophenol  blue  200mM DTT). In order to avoid 
degradation, SDS-PAGE loading buffer heated to 100oC was used on samples that were 
removed from -20oC and kept on ice shortly before the preparation for the western blot. Then, 
the samples were incubated at 100oC for 5 min, vortexed for 20 sec, incubated at 100oC for 5 
min again, vortexed again and centrifuged at 30000rpm for 1 min. The samples were separated 
on SDS-PAGE using Precision Plus Protein standards, dual colour (BioRad) as markers. 
Electrophoresis was carried out using a power pack and a Mini Protean III Cell obtained from 
BioRad, in 1x running buffer (25mM Tris, 250mM glycine, 0.01% w/v SDS) at 200V for 70 min. 
The first time SDS-PAGE was done for a group of replicates, 5μl, 10μl and 20μl of each cell line 
extract were run on the same gel and total protein was  visualised  by  staining  in  Coomassie 
brilliant blue  solution  (0.25%  w/v  coomassie  brilliant blue G-250 BioRad, 50% v/v methanol, 
10% v/v acetic acid) for 30 min, destaining (10% v/v methanol, 10% v/v acetic acid) as required 
and dried. Based on the subsequent strength of the bands, approximate volumes that would 
give the same band strength among all cell lines were picked. These volumes were then 
doubled and doubled again, in order to obtain concentrations with the following correlation: 
4C1=2C2=C3. 
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2.3.5 Immunoblotting of proteins 
Total protein was transferred from polyacrylamide gels to nitrocellulose membrane (Hybond-C 
Extra Membrane from GE Healthcare) by wet transfer using Mini Protean III Trans-Blot Cell 
(BioRad), in 1x Towbin buffer (20mM Tris, 150mM glycine, 10% v/v methanol) at 80V for 1.5h 
or 10V for 999 min.  Successful transfer was determined by non-permanent staining of total 
protein on the membrane with 0.1% w/v Ponceau S in 5% acetic acid.  The stain was removed 
by washing in 1x TBST  (10mM  Tris,  140mM  sodium  chloride,  0.1%  v/v  Tween  20,  pH  7.9). 
Membranes were blocked by incubation with 5% (w/v) milk powder in 1x TBST for 1h at room 
temperature, shaking. The rocker that was used was a Stuart See-saw SSL4. The membranes 
were then incubated in primary antibody under the appropriate conditions (Table 2.2). Actin 
was used as a loading control. TDP2, TOP2A and TOP2B were immunostained on different 
blots, to reduce the likelihood of shared technical artefacts between the different 
immunoblots. Primary antibodies were diluted in 5% (w/v) milk powder in 1x TBST. Following 
that, they were washed in 1x TBST (3x 10 min) at room temperature, shaking. Finally, they 
were incubated in the appropriate secondary antibody at room temperature, shaking (Table 
2.3). Secondary antibodies were diluted in 1x TBST. The membranes were washed again as  
described  for  the  primary  antibody  and  incubated  in  enhanced  chemiluminescence (ECL)  
western  blotting  detection  reagent  (GE  Healthcare)  for  1 min.   To visualise the desired 
proteins, ImageQuant LAS 4000 system was used. To quantify the data obtained, its 
accompanying software ImageQuant TL was used. The software allows for background 
elimination for each individual band. 
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Table 2.2: Primary antibodies for western blotting 
Primary Antibodies Type Organism Company Catalog No. 
Actin Monoclonal Mouse Sigma A4700 
TDP2 Polyclonal Rabbit Biogenes Custom (Thomson et 
al., 2013) 
TOP2A Polyclonal Goat Santa Cruz S-20 
TOP2B Polyclonal Rabbit Santa Cruz H-286 
 
Table 2.3: Secondary antibodies for western blotting 
Secondary Antibodies Company Catalog No. 
Rabbit anti-mouse HRP Dako P0260 
Goat anti-rabbit HRP Dako P0448 
Rabbit anti-goat HRP Dako P0449 
 
2.3.6 Stripping for reprobing western blots 
Stripping is the procedure that allows the removal of primary and secondary antibodies from a 
western blot membrane, in order to be able to reprobe the same western blot with a different 
antibody. This is particularly useful when one wants to use a loading control that has a similar 
size to the protein of interest, such as TDP2 and Actin. This procedure was also followed for 
TOP2A and TOP2B. A protocol for mild stripping by abcam was used. The blots were incubated 
for 10 min at room temperature, shaking, in stripping buffer (for 100ml total volume, 1.5g 
glycine, 1ml of 10% SDS and 1ml Tween 20 was used), which was then discarded. The blot was 
incubated for another 10 min at the same conditions. The buffer was discarded again. That 
was followed by two 10 min incubations with PBS at room temperature, shaking and 
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subsequently 2x 5 min incubation with TBST at room temperature, shaking. At this stage, the 
blots were ready for the immunoblotting protocol to resume from the blocking stage onwards. 
2.4 Analysis of relationship of TDP2, TOP2A and TOP2B protein levels in lung 
and breast cancer cell lines and sensitivity to TOP2 poisons 
2.4.1 Alamar Blue Assay 
In order to explore the effect of different TDP2 levels to etoposide sensitivity in breast cancer 
cell lines, Alamar Blue assays (Invitrogen) were performed. This assay is used to determine 
whether cells are still metabolically active. The protocol was provided by Invitrogen, which is 
as follows: On the first day, the appropriate amount of cells was seeded (which depended on 
cell line growth curves) for each cell line in triplicates in a 96-well plate (flat bottom Corning® 
Costar® cell culture plates) with a final volume of 150μl per well, and on the next day they 
were treated with different concentrations of etoposide (0μM, 5μΜ, 10μΜ, 20μΜ, 30μΜ). 
These concentrations were chosen, because it was determined that after 30μM cell survival 
was very low and therefore not relevant to the objective of the assay, which was to observe 
any differences in cell survival among the selected cell lines. After 3h of treatment, the cells 
were washed twice with 100μl of PBS, and 150μl of appropriate media was added. On the third 
day, the media was changed, but this time the volume was 100μl, and 30μl of Alamar Blue 
reagent was added. The cells were then incubated at 37oC for 4 hours protected from direct 
light, which was followed by measurement of fluorescence (excitation wavelength 540-570nm 
and fluorescence emission 580-610nm) with a BioTek Synergy Multi-Mode Reader. The 
protocol for the third day was done every other day, until there were five fluorescence 
measurements. For each triplicate, the average was calculated. Then for each biological 
replicate, the average was calculated. From these averaged fluorescence values, the standard 
error of the mean was calculated and the results were plotted with Microsoft Excel.  
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The same assay was utilised for three lung cancer cell lines, MOR, HCC95 and H292 and was 
carried out in pairs: MOR-HCC95 and MOR-H292. For these cell lines the same protocol was 
used, although there was an additional concentration of etoposide that was used, which was 
2μM. Finally, for two lung cancer cell lines, LCC9 and ZR751, a continuous treatment was 
utilised, during which the etoposide concentrations were 0nM, 250nM, 500nM, 750nM and 
1μM. Also, the etoposide was not washed until it was time for the Alamar Blue reagent to be 
added.   
2.4.2 Clonogenic Cell Survival Assay 
In order to explore the effect of different TDP2 levels to etoposide sensitivity in lung cancer 
cell lines, clonogenic cell survival assays were utilised. This kind of assay is used to evaluate the 
ability of a cell to proliferate after treatment, in this instance with etoposide, by forming a 
viable colony. The subsequent cell survival curve is therefore defined as the relationship 
between the doses of etoposide and the percentage of cells retaining their ability to 
proliferate after treatment compared to untreated cells. The following optimised protocol was 
followed: On the first day, the appropriate amount of cells was seeded (which was determined 
by trying different numbers of cells, until the appropriate number that produced enough viable 
colonies after two weeks was calculated) and on the next day, they were treated with different 
concentrations of etoposide (0μM, 5μΜ, 15μΜ, 30μΜ). After 3h, the cells were washed twice 
with PBS, appropriate media was added and the cells were left to grow for 14 days. On the 
14th day, the colonies were fixed with 100% ethanol, washed with PBS and stained with 1% 
methylene blue in 70% ethanol.  
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2.5 Selection process and statistical analysis for mutational profiles of breast 
and lung cancer cell lines 
2.5.1 Selection of Databases 
In order to explore the effect of various mutations on the relationship between etoposide 
sensitivity and TDP2 protein levels, TOP2A/TDP2 protein level ratios or TOP2B/TDP2 protein 
level ratios in the previously used panels of lung and breast cancer cell lines, databases that 
provided information on mutations found in those cancer cell lines were required. The 
selection of the appropriate databases was done through review of the relevant literature and 
consultation with people familiar with the field (Futreal et al., 2004, Pavlopoulou et al., 2015, 
Abaan et al., 2013, Yang et al., 2015b). This resulted in the selection of Cancer Cell Line 
Encyclopedia v2.17 (CCLE), IARC TP53 Database R18, Cell Lines Project v78 and COSMIC 
Database v78 (Barretina et al., 2012, Bouaoun et al., 2016, Forbes et al., 2015). 
These databases are expert-curated. For the COSMIC Database, the primary source is papers in 
scientific journals. It was verified that the samples listed were of the same type as the cell lines 
previously used, as multiple instances of the same sample name exist as separate entries, 
indicating that it was not clear for the curator whether these samples were the same. Samples 
which were not or there was personal doubt that they were indeed the same, were not used. 
It was also verified that the mutated or wild type form of the genes stated in the database 
matched those stated in the publications. All databases were last accessed in September 2016, 
to include as many up-to-date entries as possible.  
2.5.2 Selection of Mutations 
After being collected, the appropriate data from the databases were organised per cancer type 
(breast and lung) in two excel spreadsheets. Each spreadsheet listed all the genes for which 
information for at least one cell line of that type was found, either a mutation or a wild type 
entry. For the breast cancer cell lines that was a total of 3686 genes and for the lung cancer 
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cell lines 1150 genes. Out of the 8 breast cancer cell lines studied (LCC9, MCF7, MM361, 
BT474, MLET5, T47D, MM453 and ZR751), information was available for at least one gene for 6 
cell lines; BT474, MCF7, MM361, MM453, T47D and ZR751. Out of the 8 lung cancer cell lines 
studied (MOR, HCC95, Hop92, H226, H460, H292, A549 and H1650), information for at least 
one gene was available for 7 cell lines; A549, H226, H292, H460, H1650, HCC95 and Hop92. 
Genes for which there was conflicting publications for cell line mutational status, were only 
included if there were at least three reports that agreed and a minimum ratio of 3 to 1. 
Information for the gene status in a minimum of four cell lines, with at least one of the cell 
lines’ mutation status being different than the rest, was the minimum requirement for the 
statistical analysis performed. This criterion reduced the number of genes to 7 for the breast 
cancer cell lines and 8 for the lung cancer cell lines. All mutant forms of each gene were 
grouped together so as to maximise the number of genes, as not all mutations were 
characterised at that level or their effects defined. 
2.5.3 Statistical Analysis 
Analysis of this data was performed using R statistical software (Team, 2015). The effect of 
each gene (as per the selection process described) on the relationship between TDP2 levels or 
TOP2/TDP2 ratios was independently assessed by estimating parameters of a linear regression 
model, where etoposide IC50 (for breast cancer cell lines) or D37 (for lung cancer cell lines) 
concentrations and gene status of a cell line predict the TDP2 levels or TOP2/TDP2 ratios. The 
significance for each parameter was assessed using an F test from an analysis of variance 
(ANOVA) between models with and without terms of interest. 
The interaction between IC50/D37 values and gene status, i.e. giving a different slope to the 
mt and wt lines of best fit, was not considered, because it would be a substantially more 
complex model requiring more data to estimate parameters. Both the effect of IC50/D37 
values and gene status were considered on their own as predictors of TDP2 levels or 
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TOP2/TDP2 ratios or in conjunction with the other term (e.g. the effect of IC50 alone on TDP2 
levels, or the effect of IC50 on TDP2 levels once the effect of gene mutation status has been 
taken into account). This leads to two estimates and two p-values for each term as shown in 
Tables 6.2-6.5. These may be very different, because for example high IC50 values may have 
high TDP2 levels but actually result from a mutant form of the gene which has high IC50 value 
and high TDP2 levels. As is clear from this example it is important to know the effect of each 
variable on TDP2 levels or TOP2/TDP2 ratios independently which is why these values are 
reported in Tables 6.2-6.5. Additionally the effect of gene status on etoposide IC50 values can 
allow better interpretation so these values (again from an ANOVA) are reported in Table 6.1. 
2.6 Selection process and statistical analysis of drugs for which TDP2 could 
potentially be used as a biomarker of sensitivity 
2.6.1 Drug Selection 
The first step in selecting drugs that were good candidates to be studied for a possible 
correlation with TDP2 protein levels was to find a database with accurate, curated information 
about the most drugs and their pharmacological profiling across the largest number of cancer 
cell lines. This resulted in the selection of CancerDR, a database that has collected information 
from COSMIC and CCLE databases, curated that information, organised it and presented it in a 
user-friendly manner (Kumar et al., 2013).  
The first list made contained anti-cancer drugs, for which there was information on IC50 values 
for the breast and lung cancer cell lines that had been studied in Chapters 3 and 4 and had 
been characterised for TDP2 protein levels and TOP2/TDP2 protein ratios. For both breast and 
lung cancer cell lines separately, the initial list of drugs (113 for breast and 194 for lung) was 
reduced to drugs for which IC50 values were available for 5 or more cell lines and where there 
was some variation in IC50 values. This left 16 drugs for the breast cancer cell lines and 25 for 
the lung cancer cell lines.   
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2.6.2 Statistical Analysis 
Analysis of this data was performed using R statistical software (Team, 2015). For each drug 
independently a Pearson correlation coefficient was calculated for the correlation between the 
IC50 value for the drug of interest and either TDP2 levels, TOP2A/TDP2 ratio or TOP2B/TDP2 
ratio. The Pearson correlation coefficient measures the amount that two variables change in a 
similar manner (co-vary) relative to the variation of the two components. It varies between -1 
and 1 with large magnitude values (either positive or negative) showing strong positive and 
negative correlation for positive or negative correlation coefficients respectively.  The 
significance of the correlation was tested against a null hypothesis that the correlation 
coefficient was zero (no correlation) using a t-test with degrees of freedom equal to the 
number of cell lines minus 2. Correlation coefficients (r-values) and associated p-values are 
shown in Tables 7.1 and 7.2. 
2.7 Analysis of relationship of impact of a combination treatment of estradiol, 
PARP1 inhibitor and etoposide on TDP2 repair in breast cancer cell lines 
2.7.1 Alamar Blue Assay and Combination Treatment 
For these experiments, the protocol for Alamar Blue was used as described previously, with a 
few differences described below. On the first day, MCF7, LCC9 and MLET5 cells were seeded, 
using 10% charcoal-stripped foetal bovine serum in phenol-red-free DMEM with streptomycin, 
penicillin, L-glutamine and pyruvate to allow the cells to attach. The next day, the cells were 
treated with 500nM PARP1 inhibitor Ku58948 (AstraZeneca) or DMSO for 30 min, 100nM 
estradiol or EtOH for 3h and 15μM, 30μM, 45μM etoposide or DMSO for 3h, followed by two 
washes with PBS and the addition of the appropriate media for each cell line as described 
previously. The next day, the protocol for Alamar Blue proceeded as detailed in the ‘Alamar 
Blue Assay’ section.  
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2.7.2 Clonogenic Cell Survival Assay and Combination Treatment  
For these experiments, the protocol for clonogenic cell survival assay was used as described 
previously, with the only difference being the media and the treatment. On the first day, MCF7 
cells were seeded, using 1% charcoal-stripped foetal bovine serum in phenol-red-free DMEM 
with streptomycin, penicillin, L-glutamine and pyruvate to allow the cells to attach. The next 
day, media was changed to 0.1% DMEM as above, to begin cell cycle synchronisation. Five days 
later, the cells were treated with different combination treatments.  
For the first set of experiments, the treatment that was used was either only etoposide (0μM, 
15μM, 30μM, 45μM and 60μM) for 3h or 500nM PARP1 inhibitor for 30 min, 100nM estradiol 
for 3h and 0μM, 15μM, 30μM, 45μM and 60μM etoposide for 3h.  
For the second set of experiments, the treatment consisted of 500nM PARP1 inhibitor or 
DMSO for 30 min, 100nM estradiol or EtOH for 3h and 30μM, 45μM, 60μM etoposide or 
DMSO for 3h. 
For the cells treated with etoposide only the control was DMSO and EtOH, for cells treated 
with estradiol and etoposide the control was DMSO and estradiol, for cell treated with 
etoposide and PARP1 inhibitor the control was DMSO/EtOH and PARP1 inhibitor and finally for 
cells treated with etoposide, estradiol and PARP1 inhibitor, the control was DMSO, estradiol 
and PARP1 inhibitor. 
After the different treatments, the cells were washed twice with PBS and the appropriate 
media was added, as described under section ‘Cell Lines’. After 14 days, cells were fixed as 
described under section ‘Clonogenic Cell Survival Assay’. 
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2.8 Analysis of the impact of TOP2B-mediated DSBs during estradiol-induced 
transcription on cell viability and repair kinetics in TDP2-depleted breast 
cancer cell line MCF7 
2.8.1 Establishing a stable TDP2 knock-down in MCF7 cell lines 
The first step in creating a stable TDP2 knock-down in MCF7 breast cancer cell lines is to obtain 
the right plasmid vectors. In this instance the relevant plasmids were pSUPER empty vector for 
the control knock-down and pSUPER-TDP2 for the TDP2 knock-down. pcD2E was used as the 
selectable marker, as it will allow transfected MCF7 cells to grow in the presence of G418.  
In order to obtain enough quantities of the vectors, a competent Escherichia coli (E.coli) 
transformation protocol was used. The E.coli strain used was DH5α. Initially, E.coli cells were 
slowly thawed on ice. They were then separated equally (50μl per tube) in as many pre-
labelled eppendorf tubes as the number of different plasmid DNA that would be used. 1-5µl of 
each plasmid DNA was added in the appropriate eppendorf tube and it was mixed gently for a 
few seconds. That was followed by incubation on ice of 15 min. Then the cells were heat 
shocked for 45 sec in a water bath at 42oC and left on ice for 1 min afterwards. 500μl of LB was 
added and the tubes were transferred to a shaking incubator for 1h at 37oC. Finally, the cells 
were seeded on culture plates with ampicillin and were left to incubate at 37oC for 16h 
overnight.  
The following day, single colonies were picked and were incubated at 37oC shaking for 16h 
overnight in 100ml of LB containing ampicillin, as a starter culture for Midi preps. The next day, 
QIAGEN’s QIAfilter Midi kit was utilised for purifying the plasmid DNA for each vector. The 
provided protocol was followed.  
The next step was transfection of MCF7 cells with the appropriate vectors. On the first day, 3x 
105 MCF7 cells per well were seeded in a 6-well-plate and were incubated at 37oC overnight 
61 
 
until they had reached 50-80% confluency. The following day, 100μl of Opti-MEM media was 
added in a sterile tube for each well plate that would be transfected. The vector ratio that was 
used for this transfection was 2:1 for pcD2E, and pSUPER or pSUPPER-TDP2 respectively. It was 
established through optimisation that the best transfection conditions were 2.5μl of GeneJuice 
Transfection Reagent for every 0.5μg of plasmid DNA used. Therefore, 7.5μl GeneJuice 
Transfection Reagent was added drop-wise into each tube containing the Opti-MEM media. 
They were then mixed by vortexing and incubated at room temperature for 5 min. Following 
that, 0.5μg of pSUPER or pSUPER-TDP2 and 1μg of pcD2E plasmid DNA were added per tube 
and were mixed gently by pipetting. The mixture was then incubated for 20 min in room 
temperature. It was then distributed drop-wise over the entire surface of the well containing 
the MCF7 cells that were ready for transfection. The cells were placed in an incubator set at 
37oC for 24h. The next day, G418 was added to allow for the selection process to begin. After 
10 days, the cells were re-seeded in 10mm plates in order for them to grow in G418-selectable 
colonies. Once the size of the colonies was visible enough to be identified, several colonies 
were picked and re-seeded to a number large enough for a western blot. They were screened 
via western blot as described previously for TDP2 and the successful TDP2 knock-down MCF7 
cell line was identified, as well as a mock knock-down cell line.  
2.8.2 Characterisation of the TDP2 knock-down MCF7 cell line 
The first step in characterising the TDP2 knock-down MCF7 cell line was to explore its 
sensitivity to etoposide, compared to the mock knock-down and the wild type MCF7 cell lines. 
This was carried out by following the previously described protocol for clonogenic cell curvival 
assay. Three biological replicates were done. MCF7 cells were treated with increasing 
concentrations of etoposide (0μM, 15μM, 30μM, 45μM and 60μM) for 3h and then were left 
to grow for two weeks. On the 14th day, the colonies were fixed with 100% ethanol, washed 
with PBS and stained with 1% methylene blue in 70% ethanol. 
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An additional approach to clonogenic cell survival assays was investigating etoposide repair 
kinetics. In order to do so, a protocol for γH2AX immunolabelling was followed for both TDP2 
and mock knock-down MCF7 cell lines. 104 cells per well were seeded in normal media on a 4-
well plate each containing a single glass coverslip per well. One well per condition was used 
and the cells were left to attach overnight at 37oC. The next day, the cells were washed with 
PBS and 10% charcoal-stripped foetal bovine serum, phenol-red-free DMEM media was added. 
The cells were left to grow for 3 days. On the fourth day, the cells were treated with DMSO or 
20μM etoposide for 30 min. Then the cells were washed with PBS twice and fresh normal 
media was added. Cells were then collected after 0h, 3h or 6h after treatment and were fixed 
with 4% PFA for 5 min and then washed with PBS. That was followed by permeabilising the 
cells by treating them with 0.2% Triton in PBS for 2 min. The cells were then blocked with 5% 
BSA in PBS for 1h. Blocking was followed by the primary antibodies incubation. The antibodies 
used were mouse monoclonal anti-γH2AX (Millipore) and rabbit polyclonal anti-CENP-F (Sigma) 
(Table 2.4). They were diluted in 1% BSA in PBS at 1:1000 and 1:500 dilutions respectively. The 
incubation was at room temperature for 1h rocking. Following that, the cells were washed 
three times with PBS with 0.1% Tween and 0.02% SDS (which will be known as PBS-TS) for 5 
min each time. That was followed by the secondary antibodies incubation. The antibodies 
were goat anti-rabbit IgG Alexa Fluor 555 and goat anti-mouse IgG Alexa Fluor 488 (both 
Invitrogen) (Table 2.5). The antibodies were diluted in 1% BSA in PBS at 1:500 for both. The 
incubation was carried out at room temperature for 1h on rocker. The cells were then washed 
three times with PBS-TS, for 5 min each time. 1:10000 DAPI in PBS was then added for 2 min at 
room temperature protected from light, rocking and then the cells were washed twice in PBS 
and once in dH20, 5 min each time. Finally, the glass coverslips were mounted on a drop of 
Vectashield (Vector Labs) placed on slides and the edges were sealed with clear nail polish. 
Microscopy was then carried out with a Nikon E400 or a Zeiss Axioplan 2. Only cells negative 
for CENP-F were counted. 
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Table 2.4: Primary antibodies for immunofluorescence  
Primary Antibodies Type Organism Company 
anti-γH2AX  Monoclonal Mouse Millipore 
anti-CENP-F Polyclonal Rabbit Sigma 
 
Table 2.5: Secondary antibodies for immunofluorescence 
Secondary Antibodies Company 
Goat anti-rabbit IgG Alexa Fluor 555 Invitogen 
Goat anti-mouse IgG Alexa Fluor 488 Invitrogen 
 
To further characterise the TDP2 knock-down MCF7 cell line, Alamar Blue was also utilised. The 
protocol that was followed was the same one described previously. The TDP2 knock-down cell 
line was compared to the mock knock-down and the wild type MCF7 cell lines. Initially, high 
concentrations of etoposide were used in an acute manner, which were 0μM, 25μM, 50μM, 
100μM and 150μM. Then another set of experiments was carried out with lower etoposide 
concentrations (0μM, 5μM, 10μM, 20μM and 40μM). Finally, a set of experiments with 
continuous etoposide treatment was utilised and was done the same way as previously 
described. The concentrations were 0nM, 250nM, 500nM, 750nM and 1μM. 
2.8.3 Effects of etoposide on TDP2 knock-down MCF7 breast cancer cells after 
induction of transcription by estradiol treatment 
In order to explore the effects of treating TDP2 knock-down MCF7 breast cancer cells with 
etoposide once transcription has been induced by estradiol treatment, the first thing is to 
establish the best conditions for induction of transcription in MCF7 breast cancer cells. The 
conditions that were used were 100nM estradiol for 3h, 6h, 12h and 24h (24h EtOH was the 
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control). 5x 105 TDP2 knock-down, mock knock-down or wild type MCF7 cells were seeded on 
100mm plates in normal media and left to attach overnight. The next day, the media was 
changed to 1% charcoal-stripped foetal bovine serum in phenol-red-free DMEM and the cells 
were left to synchronise for 5 days. After synchronisation, the cells were treated with estradiol 
for the amount of time stated above. Once the treatment time was completed, cells were 
washed with PBS, were detached from the plate with Trypsin and frozen in LN2 until all the 
samples had been collected.  
The samples were then processed for RNA extraction. QIAGEN’s RNeasy Plus Mini Kit was used 
and the provided protocol was followed with the modifications below. For the Buffer RPE, 
300μl was added and the column was spun for 3 min, then 10μl of RQ1 DNAse and 10x Buffer 
(8μl RNAse free H20, 1μl RQ1 DNAse and 1μl 10x Buffer) was added and the samples were 
incubated at room temperature for 5 min. That was followed by the addition of 400μl Buffer 
RPE and a 3-min spin, and finally the addition of 300μl Buffer RPE and another 3-min spin. The 
protocol was then resumed with placing the RNeasy spin columns in new 2ml collection tubes. 
Once all the RNA samples were obtained, they were quantified by NanoDrop and its 
accompanying software. Two measurements were taken per sample and the average was 
calculated. High-capacity cDNA reverse transcription kit without RNAse inhibitor by Applied 
Biosystems was used to obtain cDNA from these samples, as described previously. SYBR Green 
qPCR was then utilised to assess induction of transcription. The genes that were used were 
TFF1 and GREB1, with TBP and Actin as controls. Primers can be seen in Table 2.6. 
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Table 2.6: SYBR Green qPCR primers 
TFF1 Forward Primer Sequence 
GAG-AAC-AAG-GTG-ATC-TGC-GC 
TFF1 Reverse Primer Sequence 
TGG-TAT-TAG-GAT-AGA-AGC-ACC 
GREB1 Forward Primer Sequence 
GTG-GTA-GCC-GAG-TGG-ACA-AT 
GREB1 Reverse Primer Sequence 
AAA-CCC-GTC-TGT-GGT-ACA-GC 
Actin Forward Primer Sequence 
GAA-GTG-TGA-CGT-GGA-CAT-CC 
Actin Reverse Primer Sequence 
CTC-GTC-ATA-CTC-CTG-CTT-GC 
TBP Forward Primer Sequence 
CAC-GAA-CCA-CGG-CAC-TGA-TT 
TBP Reverse Primer Sequence 
TTT-TCT-TGC-TGC-CAG-TCT-GGA-C 
 
For each sample, 12.5μl QIAGEN’s SYBR Green mix, 10.5μl ddH20, 1μl of primer mix (containing 
both forward and reverse primers for each gene, 10nM concentration) and 1μl cDNA (10ng/μl 
concentration) was added in a qPCR tube (Agilent Technologies). All samples were run in 
technical triplicates. The cycling parameters used were:  
 PCR initial heat activation – 95oC for 10 min  
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 3-Step cycling (x40):  
o Denaturation – 95oC for 15 sec 
o Annealing – 53oC for 15 sec 
o Extension – 60oC for 30 sec 
The qPCR machine that was used was an MX3005P Stratagen, with the accompanying MxPro 
QPCR Software. 
The next step was to visualise TOP2B-induced DSBs during induction of transcription by 
estradiol. The protocol for γH2AX immunolabelling was followed as described previously, for 
TDP2 and mock knock-down MCF7 cell lines, as well as wild type MCF7.  The differences were 
during the treatment. The cells were treated with estradiol for 2h, 6h, 24h and 48h. The 
control used was a 48h-treatment with EtOH. As with the γH2AX repair kinetics described 
above, γH2AX foci counts were conducted blind with either a Nikon E400 or a Zeiss Axioplan 2. 
Only cells negative for CENP-F were counted. 
In order to verify beyond any doubt that only G1 cells have been counted and not G2 or S-
phase, and any difference between γH2AX foci numbers is due to the lack of TDP2, EdU 
labelling was utilised. The treatment part of the experiment was performed as described in the 
previous paragraph. 15 min before the cells were to be collected, 10μM EdU was added so it 
could be incorporated in the cells that are synthesising DNA to distinguish S-phase cells. 
Following that the cells were fixed as previously described with PFA. Invitrogen’s Click-iT 
Imaging Kit was then used and the accompanying protocol was followed from step 3.6 to step 
4.1. After that, DAPI was used as previously described. The cells were visualised with either a 
Nikon E400 or a Zeiss Axioplan 2. In addition to the acute EdU labelling described, a continuous 
EdU labelling protocol was followed. The only difference between the acute and the 
continuous was that during the continuous, EdU was added at the same time as the estradiol 
instead of 15 min before the cells were due to be collected.  
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The next step was to explore any differences between the TDP2 and the mock knock-down 
MCF7 cell lines by clonogenic cell survival assays. The protocol that was followed was the same 
as described previously. The differences were that 2000 cells/plate were seeded in 10% 
charcoal-stripped foetal bovine serum in phenol-red-free DMEM. The treatments were the 
following for each condition: 
 100nM estradiol or ETOH for 3h, then 15μM, 30μM, 45μM and 60μM etoposide of 
DMSO for 3h together with the estradiol.  
 100nM estradiol or EtOH for control for 3h. 
Finally, one more experiment that utilised γH2AX foci was done. The protocol for visualising 
DSBs via γH2AX foci was followed, but the treatment was either estradiol, etoposide (50nM), 
or both for 24h only. The cells were collected and fixed with PFA, as previously described and 
the γH2AX foci protocol was followed. As before, the counts were conducted blind with either 
a Nikon E400 or a Zeiss Axioplan 2. Only cells negative for CENP-F were counted. 
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3. CHAPTER THREE - Characterisation of TDP2, TOP2A and TOP2B mRNA 
and protein levels in lung cancer cell lines 
3.1 Introduction 
Recently, data that have emerged suggest that expression levels of TDP2 vary greatly in 
different cancer cell lines, ranging from almost no expression to very high levels of expression 
(Li et al., 2011a). Since TDP2 repairs abortive TOP2-mediated DSBs, it is possible that levels of 
TDP2 correlate with cancer cell resistance to TOP2 poisons such as etoposide, which are widely 
used in cancer treatment. Published studies that have directly manipulated TDP2 protein levels 
are encouraging in this respect. For example, TDP2 depletion by RNAi in the lung cancer cell 
line A549 results in increased sensitivity to etoposide, an established and specific TOP2 poison, 
while the addition of recombinant human TDP2 increases resistance (Cortes Ledesma et al., 
2009). The same is true in chicken DT40 cells, in which deletion of TDP2 similarly results in an 
increased sensitivity to etoposide (Zeng et al., 2011). This suggests that cancers possessing 
high levels of TDP2 might be relatively resistant to TOP2 poisons, while cancers with low levels 
of TDP2 might be hypersensitive to such treatment. Consistent with this idea, increased levels 
of TDP2 have been observed in several non-small cell lung cancer cell lines and a possible 
oncogenic role of TDP2 in such cancers has been suggested (Li et al., 2011a). Non-small cell 
lung cancers represent 80-85% of all lung cancer cases and are thus of major clinical concern 
(Breathnach et al., 2001, Bareschino et al., 2011). In addition to variations in TDP2 expression 
across different tumour types, chemoresistance frequently occurs. One possible contributing 
factor to this is increased DNA repair, and TDP2 has been reported to contribute to such 
resistance (Li et al., 2011b). As a first step to establishing the utility of TDP2 as biomarker of 
sensitivity to topoisomerase 2-targeting agents in lung cancer, I examined whether differences 
exist in TDP2 mRNA and protein levels across a panel of lung cancer cell lines. 
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3.1.1 Aims of this chapter 
The aim of this chapter was to examine the possible utility of TDP2 as biomarker for 
therapeutic sensitivity to TOP2 poisons, by measuring its mRNA expression and protein levels 
in a panel of lung cancer cell lines. 
3.2 Results 
3.2.1 TDP2, TOP2A and TOP2B mRNA expression levels vary significantly in lung 
cancer cell lines. 
To measure TDP2 expression levels in a panel of lung cancer cell lines, I first measured TDP2 
mRNA using RT-qPCR. Eight lung cancer cell lines were employed, which were A549, H292, 
H1650, H460, H226, MOR, Hop92 and HCC95. All eight cell lines are non-small cell lung cancer 
cell lines, which is the most common type of lung cancer. These cell lines were chosen because 
they are all well characterised.  
Cell pellets were collected for each cell line and were immediately frozen in LN2, and stored at 
-20oC until use. RNA was extracted and RT-qPCR was performed in triplicate to obtain the 
average Ct values for each sample. Human RPLP0 (large ribosomal protein) was employed as a 
“housekeeping” control for the calculation of the relative expression of TDP2. The RPLP0 cDNA 
nucleotide sequence is consisted of highly conserved regions in the 5-prime end of its open 
reading frame (Liu et al., 2005, Lyng et al., 2008). The expression levels of RPLP0 remain the 
same across different tissue types, which will become more relevant in the next chapter, 
where breast cancer cell lines were used for a similar set of experiments (Liu et al., 2005, Lyng 
et al., 2008). In addition, when compared to the transcription levels of other common 
reference genes, RPLP0 was found to be more consistent and reliable (Schmid Lab; 
unpublished observations), which agrees with previous studies (Lyng et al., 2008). 
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TDP2 expression levels, relative to the RPLP0 control, are shown in Figure 3.1A, with a 
representative amplification profile for TDP2 and the control shown in Figure 3.1B. In the 
amplification curve, the highest level of expression is that for which the amplification 
fluorescence crosses the threshold value in the smallest number of cycles; in this case 27 
cycles. From Figure 3.1A it can be seen that Hop92 is the cell line with the highest TDP2 
expression level, whereas H292 and H226 are the cell lines with the lowest TDP2 expression 
levels.  The difference in expression levels between Hop92 and H292/H226 is 4.5-fold, and is 
statistically significant. Of those cell lines between these extremes, A549, H1650, and MOR 
have ~2-fold more TDP2 mRNA than H292 and H226.  
Similarly, the expression levels of TOP2A (Fig.3.2) and TOP2B (Fig.3.3) were also measured 
using RT-qPCR. As TDP2 is responsible for repairing abortive TOP2-induced DNA double-strand 
breaks, I believed it was important to determine the levels of both of these proteins, as it 
would be an essential part of the direction of the project in the future, especially when trying 
to find a possible correlation between sensitivity to a TOP2 poison and TDP2 levels (Chapter 7). 
Both Figures 3.2 and 3.3 clearly show a variation in TOP2A and TOP2B mRNA levels. Figure 
3.2A indicates that the cell lines with the lowest levels of TOP2A mRNA are H460 and Hop92, 
with A549, H1650, MOR and HCC95 exhibiting the highest expression levels. The difference 
between H460/Hop92 and A549/H1650/MOR/HCC95 is more than 2-fold in magnitude. Figure 
3.3A reveals that the highest level of TOP2B mRNA is present in H1650, with all of the other 
cell lines (A549, H292, H460, H226, MOR, Hop92 and HCC95) exhibiting 2-4-fold lower levels. 
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3.2.2 TDP2, TOP2A and TOP2B protein levels vary significantly in lung cancer cell 
lines. 
Because mRNA levels do not necessarily reflect the level of protein expression, I conducted 
western blotting to compare levels of TDP2, TOP2A and TOP2B protein.  
Whole cell extracts prepared from each of the eight cell lines were analyzed by western 
blotting using antibodies against TDP2, TOP2A, TOP2B, and Actin. Actin was used as a control, 
to normalise the TDP2, TOP2A and TOP2B signals for differences in sample loading. Three 
different cell extract protein concentrations were employed for each sample, enabling me to 
ensure that quantification of the western blot signal was linearly related to protein quantity 
and was thus accurate. The first protein concentration for each sample is denoted C1, the 
second is denoted C2 and was twice that of C1, and the third is denoted C3 and was four-fold 
that of C1.  Figure 3.4 reveals that MOR and HCC95 possess the highest levels of TDP2 protein, 
and H1650 the lowest levels, while the remaining cell lines (A549, H292, H460, H226 and 
Hop92) somewhere in between. The difference in TDP2 protein levels between H1650 (lowest 
expressor) and MOR/HCC95 (highest expressors) was 6-10-fold, depending on the amount of 
cell extract protein employed. Figure 3.4E and 3.4F reveal a linear relationship between TDP2 
band intensity and amount of cell extract protein loaded on the gels, with correlations (R2) 
close to 1 in all cases.  
Figure 3.5 indicates that the cell lines A549, H226, and MOR possess the highest levels of 
TOP2A, and that H1650 and Hop92 possess the lowest. The difference between highest and 
lowest TOP2A levels was 6-12-fold. Most of the R2 values (Fig.3.5E and 3.5F) were close to 1, 
with the exception of H226, suggesting that the relationship between band intensity and 
quantity of protein extract employed was close to linear. Similarly, H226 and MOR possessed 
the highest levels of TOP2B, with H1650, H460, Hop92 and HCC95 the lowest, with a variation 
of ~5-fold. Once again, R2 values were very close to 1 (Fig.3.6). 
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3.3 Discussion 
The RT-qPCR and western blot data in this chapter reveal there is a clear variation in mRNA 
and protein levels in TDP2, TOP2A and TOP2B. The results obtained by RT-qPCR and western 
blotting, however, were not the same. It is not unusual that protein levels do not reflect mRNA 
levels, since there are many mechanisms that act after translation that have an impact on 
protein production and stability (Vogel and Marcotte, 2012, Stark et al., 2006, Dickson et al., 
2007, Taquet et al., 2009). Nevertheless, both provide information in regard to how variant 
TDP2, TOP2A and TOP2B mRNA and protein levels are in different lung cancer cell lines.  
TDP2 has already been linked to cancer development and progression. In addition, it is 
believed to protect cancer cells from entering apoptosis, a hallmark of cancer (Gomez-
Herreros et al., 2013). A previous study, the only one that had investigated TDP2 protein levels 
in cancer cells before the start of this project, showed that in non-small cell lung cancer cell 
lines the levels of TDP2 varied, with H460, A459 and H226 demonstrating medium to high 
levels, and H292 and H1650 showing almost no TDP2 (Li et al., 2011a). Furthermore, in the 
same study, knocking down TDP2 in H460 lung cancer cells led to apoptosis (Li et al., 2011a). 
The TDP2 antibody that was used for this study is different to the one used in this project and 
side by side comparisons showed it was non-optimal, but it still showed that TDP2 protein 
levels vary in lung cancer cell lines, which is what the results of this chapter also reveal. 
For TDP2, MOR and HCC95 possess the highest levels of TDP2 protein, followed by A549, H292, 
H460, H226 and Hop92 with intermediate levels, and H1650 with the lowest levels. For TOP2A, 
A549, H226, and MOR possess the highest protein levels, followed by H292, H460 and HCC95 
with intermediate levels, and H1650 and Hop92 with the lowest. For TOP2B, H226 and MOR 
possess the highest protein levels, followed by A549 and H292 with intermediate levels and, 
H1650, H460, Hop92 and HCC95 with the lowest levels. It is clear that the levels of these three 
proteins do not directly correlate with each other. Just because a cell line has very high levels 
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of TDP2, doesn’t mean it will also have very high levels of TOP2A and TOP2B, although that 
doesn’t mean that it can’t, MOR being an example of that. But what is interesting to explore is 
what impact high levels of TDP2 might have in addition to low levels of TOP2A and TOP2B or 
the opposite, in how a cell line responds to treatment with a drug that targets TOP2. Would 
high levels of TOP2A and TOP2B and low levels of TDP2 translate to low resistance to a TOP2 
poison? Would TDP2 be overwhelmed with the high volume of TOP2-induced DSBs made 
abortive by the interference of the drug, leading the cell to enter apoptosis? And on the other 
hand, would high levels of TDP2 in combination with low levels of TOP2A and TOP2B result in 
high resistance to a TOP2 drug?  
The variation in protein among the three different concentrations of protein used in TDP2, 
TOP2A and TOP2B, can probably be attributed to the affinity of antibodies used. It is clear that 
the TDP2 antibody has high affinity, while TOP2A has affinity to a lesser extent. The TOP2B 
antibody is the least capable out of the three, but nevertheless still demonstrates a variation in 
protein levels within the lung cancer cell line panel. 
The results of this chapter mean that potentially TDP2 could be a biomarker of sensitivity to 
TOP2 targeting agents, at least in lung cancer cell lines. Cell lines with low levels of TDP2 and 
high levels of TOP2A and TOP2B, such as H226 and A549, would be the ideal target for 
treatment with a TOP2 poison. High levels of TOP2A and TOP2B could result in elevated TOP2-
mediated abortive DSBs within a cell, while the low levels of TDP2 would be unable to repair 
these breaks, resulting in hypersensitivity. On the other end of the spectrum, cell lines with 
high levels of TDP2 and low levels of TOP2A and TOP2B, such as HCC95 and Hop92, would be 
the least desirable candidates, as the situation would be reversed with an abundance of TDP2 
free to deal with fewer TOP2-mediated DSBs. Table 3.1 summarizes the protein levels for 
TDP2, TOP2A and TOP2B in the cell lines of the lung cancer panel.  
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Next, I repeated these experiments to explore the relative expression levels of TDP2, TOP2A 
and TOP2B in breast cancer cell lines. 
 
 
 
  
Table 3.1: Rank order of TDP2, TOP2A and TOP2B 
protein levels in lung cancer cell line panel. 8 
corresponds to the highest protein levels and 1 
corresponds to the lowest levels.  
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4. CHAPTER FOUR - Characterisation of TDP2, TOP2A and TOP2B mRNA 
and protein levels in breast cancer cell lines  
4.1 Introduction 
As demonstrated in the previous chapter, TDP2, TOP2A and TOP2B mRNA and protein levels 
vary in different lung cancer cell lines. The next step was to explore mRNA and protein levels in 
a panel of breast cancer cell lines, to further examine the possible utility of TDP2 as a 
biomarker of sensitivity to TOP2 poisons in this type of cancer, as discussed in the previous 
chapter. 
There is an emerging model which suggests that inducing transcription by simulating breast 
cancer cells with estrogen leads to the formation of DSBs. These DSBs are mediated by TOP2B, 
which is recruited with the estrogen receptor to regulatory sites on target genes for efficient 
activation of those genes (Haffner et al., 2011, Ju et al., 2006, Williamson and Lees-Miller, 
2011). Failure to repair those DSBs, due to a TOP2B-targeting drug for example, could lead to 
apoptosis. This could potentially be more effective in breast cancer cell lines with low levels of 
TDP2 and higher levels of TOP2B, as this would mean there would not be enough TDP2 to 
repair the TOP2B-induced DSBs, increasing the chance of success of such a treatment. 
Breast cancer is the most common cancer type in women worldwide (Siegel et al., 2015). 
Around 20-30% of breast cancer cases will become metastatic (O'Shaughnessy, 2005). In 
addition, about 6% of non pre-existing breast cancer cases begin as metastatic, also known as 
Stage 4 (Program, 2015). Etoposide is a commonly employed drug that is regaining popularity 
for patients that suffer from metastatic breast cancer and have received previous treatment 
(Yuan et al., 2015, Valabrega et al., 2015). Therefore, establishing a TDP2 profile for these 
patients could potentially predict the possibility of success of such a treatment, following the 
82 
 
hypothesis explained previously. A panel consisting of eight breast cancer cell lines was utilised 
for my thesis to further explore this potential.  
4.1.1 Aims of this chapter 
The aim of this chapter was to examine the possible utility of TDP2 as biomarker for 
therapeutic sensitivity to TOP2-poisons, by measuring its mRNA expression and protein levels 
in a panel of breast cancer cell lines. 
4.2 Results 
4.2.1 TDP2, TOP2A and TOP2B mRNA expression levels vary significantly in breast 
cancer cell lines.  
To demonstrate a potential variation in TDP2 expression levels in a panel of breast cancer cell 
lines, TDP2 mRNA levels were measured using RT-qPCR. Initially six breast cancer cell lines 
were used, which were MDA-MB-453 (MM453), MDA-MB-361 (MM361), T47D, MCF7, ZR-75-1 
(ZR751), BT-474 (BT474), LCC9 and MLET5. MM453 and MCF7 were added to this panel shortly 
after, to expand the types of breast cancer cell lines to include an ER negative cell line 
(MM453) and because MCF7 is the cell line from which LCC9 and MLET5 are derived from. 
MCF7 is ERα positive and grows in an estrogen-dependent manner, but both LCC9 and MLET5 
whilst ERα positive, grow in an estrogen-independent manner 
Cell pellets were collected, immediately frozen in LN2, and stored at -20
oC until use. RNA was 
extracted and RT-qPCR was performed in triplicate to obtain the average Ct values for each 
sample, as with the lung cancer cell lines. Human RPLP0 (large ribosomal protein) was 
employed as a “housekeeping” control for the calculation of the relative expression of TDP2. 
As mentioned in the previous chapter, the RPLP0 cDNA nucleotide sequence is consisted of 
highly conserved regions in the 5-prime end of its open reading frame and its expression levels 
remain the same across different tissue types (Lyng et al., 2008, Liu et al., 2005). 
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TDP2 expression levels, relative to the RPLP0 control, are shown in two groups in Figures 4.1A 
and B, with a representative amplification profile for TDP2 per group shown in Figures 4.1C 
and D. In the amplification curve, the highest level of expression is that for which the 
amplification fluorescence crosses the threshold value in the smallest number of cycles; in this 
case 27 cycles. In the first group of breast cancer cell lines examined, T47D exhibited the 
lowest TDP2 mRNA levels and LCC9 the highest, with a 7-fold difference between them. In the 
second set, comprised of just MM453 and MCF7, the latter exhibited the lowest level, at 2-fold 
lower than MM453. It is not possible to directly compare the two groups to each other and 
one can observe that the scales of the Fold Expression graphs in Figures 4.1A and B are very 
different. That can be attributed to several different factors. The two series of experiments 
were done at different times during this project and the cells for each group were grown in 
different labs. In addition, all subsequent methods used to acquire the RT-qPCR results were 
also done in different labs. The materials used were also different for each group, such as the 
master mix, the pipettes etc. Although there are differences in the scales, the error bars 
suggest that the results of the second group are consistent.  
As with the lung cancer cells, the expression levels of TOP2A and TOP2B were also measured 
using RT-qPCR. These results are shown in Figure 4.2 and Figure 4.3, respectively. These 
experiments revealed a 5-fold difference in TOP2A mRNA levels between the cell lines with the 
lowest levels (exhibited by MLET5, T47D and MM361), and the cell line with the highest TOP2A 
mRNA level (LCC9). In the second group, TOP2A mRNA levels in MCF7 and MM453 were not 
significantly different. Levels of TOP2B mRNA were generally similar in terms of variation 
across the cell lines to those observed for TOP2A (Fig.4.3). For example, similar to TOP2A 
mRNA levels, LCC9 possessed the highest level of TOP2B mRNA, with T47D and MLET5 
amongst the lowest and more than 10-fold lower than LCC9.  
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4.2.2 TDP2, TOP2A and TOP2B protein levels vary significantly in breast cancer cell 
lines. 
As before, TDP2, TOP2A and TOP2B, protein levels were also measured, because mRNA levels 
do not necessarily reflect the level of protein expression.  
The same panel of breast cancer cell lines as the one for RT-qPCRs was used, but the 
experiments were done with all the cell lines at the same time, unlike the RT-qPCRs. Whole cell 
extracts prepared from each of the eight cell lines were analyzed by western blotting using 
antibodies against TDP2, TOP2A, TOP2B, and Actin. Actin was used as a control, to normalise 
the TDP2, TOP2A and TOP2B signals for differences in sample loading. Three different cell 
extract protein concentrations were employed for each sample, enabling me to ensure that 
quantification of the western blot signal was linearly related to protein quantity and was thus 
accurate. The first protein concentration for each sample is denoted C1, the second is denoted 
C2 and was twice that of C1, and the third is denoted C3 and was four-fold that of C1. 
There was a good correlation between TDP2 band intensity and amount of extract protein 
included in the western blots in Figure 4.4 (Fig.4.4E). Whilst the relative level of TDP2 protein 
detected in the different cell lines differed slightly, depending on the amount of cell extract 
employed, ZR751 consistently exhibited the lowest levels of TDP2 protein. However, the 
difference between the lowest and highest expressing cell lines was no more than 2-3-fold, 
and thus much less than the difference observed with mRNA levels. Moreover, there was very 
little correlation between the level of TDP2 mRNA and the level of TDP2 protein, in this panel 
of cell lines. 
TOP2A immunoblots revealed that MLET5, ZR751 and BT474 possessed the highest levels of 
TOP2A protein (Fig.4.5). However, there was considerable inconsistency in the TOP2A blots, as 
indicated by the lack of similarity in relative expression levels across the cell lines at different 
protein extract concentrations. The results for TOP2B were more consistent, with LCC9 
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possessing highest TOP2B levels at all cell extract concentrations employed, and up to ~8-fold 
more than the lowest expressing cell lines, MM361 and MM453 (Fig.4.6).   
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4.3 Discussion 
The RT-qPCR and western blot data in this chapter demonstrate a difference in mRNA and 
protein levels in TDP2, TOP2A and TOP2B among the panel of breast cancer cell lines used. As 
with the lung cancer cell lines, the results measured with RT-qPCR and western blot, i.e. mRNA 
levels and protein levels are not the same, since mRNA levels do not correlate directly with 
protein levels of any gene. There is an abundance of post-transcriptional and post-translational 
mechanisms that have the ability to affect the amount of protein produced, as well as its half-
life (Vogel and Marcotte, 2012, Stark et al., 2006, Dickson et al., 2007, Taquet et al., 2009). But 
as with the lung cancer cell lines, the information is still valuable, although for future work, it 
was decided that the project would focus on the protein levels instead of the mRNA levels, as 
the proteins are the active cellular components that take part in enzymatic functions in the 
cell.  
As with the lung cancer cell lines, a variation in protein levels among the three different 
concentrations of protein used in TDP2, TOP2A and TOP2B can also be observed. As previously, 
the most probable explanation for this inconsistency can be attributed to the different potency 
of the antibodies used. Once again, one can observe that the TDP2 antibody has highest 
affinity in detecting the protein, as the relative protein levels remain consistent among the 
three different concentrations used. TOP2A antibody appears to be the most inconsistent, and 
more specifically for the second concentration, compared to the other two. Given the large 
error bars in the graphs of the first and third concentration for MLET5, this could also be 
attributed to an error during protein transfer or antibody incubation. The TOP2B antibody 
seems to have worked better than the TOP2A antibody, but nevertheless still demonstrates a 
variation in protein levels within the breast cancer cell line panel. Furthermore, even though 
measures were taken to maximize the accuracy of the samples loaded, there are instances 
where Actin levels show problematic loading. This could perhaps be attributed to the vastly 
different sizes of the cells among the cells lines. For example, MM361 cells are very small 
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compared to the majority of the other cell lines, which could explain why its Actin levels are 
usually significantly lower than the rest. Actin, being a major component of the cytoskeleton of 
a cell, could appear in fewer quantities in a smaller cell, leading to smaller and fainter Actin 
bands, even though the same number of cells was used in each loaded sample. These reasons 
demonstrate the importance of the use of three different concentrations, instead of just one, 
as this would allow for more accurate interpretation of the results obtained. 
Combining the results obtained from the lung cancer cell lines and the ones in this chapter 
(obtained from the breast cancer cell lines), re-enforces the idea that TDP2 has the potential of 
being used as a biomarker of sensitivity to TOP2 targeting agents. As explained in the previous 
chapter, cell lines with low levels of TDP2 and high levels of TOP2A and TOP2B would be the 
ideal target for treatment with a TOP2 poison and cell lines with high levels of TDP2 and low 
levels of TOP2A and TOP2B would be the least desirable candidates. High levels of TOP2A and 
TOP2B could mean more TOP2-mediated abortive DSBs within a cell and low levels of TDP2 
could mean that TDP2 could be overwhelmed by abortive DSBs, leading the cell to apoptosis.  
An abundance of TDP2 (high protein levels), on the other hand, would be able to resolve the 
fewer TOP2-mediated DSBs caused by low levels of TOP2A and TOP2B.  
Among the breast cancer cell line panel, there doesn’t appear to be many cell lines that can 
readily be described as ideal candidates for TOP2 poisons. One exception is ZR751, which is the 
cell line with the lowest levels of TDP2 and also one of the cell lines with the highest levels of 
TOP2A. On the other hand, other cell lines with high levels of TOP2A or TOP2B, such as MLET5, 
BT474 and LCC9, also demonstrate medium to high levels of TDP2. Finally, MM361 and 
MM453 could perhaps be considered as the baseline, as they demonstrated the lowest levels 
of TOP2B and their TDP2 levels are around medium. Table 4.1 summarizes the protein levels 
for TDP2, TOP2A and TOP2B in the cell lines of the breast cancer panel. With this in mind, I 
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proceeded to explore a possible correlation of TDP2 levels and sensitivity to the TOP2 poison 
etoposide, in both lung and breast cancer cells. 
 
 
 
  
Table 4.1: Rank order of TDP2, TOP2A and TOP2B protein 
levels in breast cancer cell line panel. 8 corresponds to the 
highest protein levels and 1 corresponds to the lowest 
levels.  
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5. CHAPTER FIVE - Relationship between TDP2 protein levels and 
sensitivity to TOP2 poison etoposide in lung and breast cancer cells  
5.1 Introduction 
Etoposide is a cytotoxic chemotherapy drug used to treat a variety of cancers. It is classified as 
a topoisomerase inhibitor (Hande, 1998). It is not uncommon for patients to develop 
resistance to etoposide and there is data that shows a link between that resistance and TDP2 
(Zeng et al., 2011, Lage et al., 2000). I hypothesized that high TDP2 protein levels would 
translate to high resistance to etoposide, since more TDP2 might allow the DNA double-strand 
breaks to be repaired. In the previous two chapters, it was established that TDP2 mRNA and 
protein levels differed among two panels of lung and breast cancer cell lines. This in turn raises 
the question of whether there is a correlation between TDP2 protein levels, and possibly TOP2 
levels, with resistance to the TOP2 poison etoposide.  
If such a correlation were to be established, then TDP2 could be used as a predictive biomarker 
to etoposide resistance. Drug resistance is a severe problem in cancer treatment and due to 
common resistance mechanisms, cancer cells can acquire resistance to multiple structurally 
and functionally unrelated drugs, with enhanced DNA repair being one of those mechanisms 
(Alpsoy et al., 2014). As etoposide is a widely used anti-cancer agent, it would be very useful to 
establish a possible biomarker that could predict how responsive a patient is going to be to this 
treatment and how likely they are to develop resistance to etoposide. 
5.1.1 Aims of this chapter 
The aim of this chapter is to investigate the possible existence of a link between TDP2 protein 
levels in lung and breast cancer cell line panels and cellular sensitivity/resistance to etoposide. 
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5.2 Results 
The effects of TDP2 expression levels on sensitivity to TOP2 poison etoposide were assessed 
using both cell viability assays and clonogenic cell survival assays.  
For the cell viability assays I employed Alamar Blue, which is a resazurin based assay. Resazurin 
is a weakly fluorescent blue dye that is converted to resorufin, a highly red fluorescent dye in 
the presence of metabolically active cells. Alamar Blue was preferred to MTT (Microculture 
Tetrazolium Assay) for these experiments, because of its ease of use and reduced toxicity to 
cells. This allowed for more flexibility in experimental design. Where possible, for adherent 
cells that can grow in colonies, I also employed clonogenic survival assays, which are less 
susceptible to the short term impact of cytotoxins on cell cycle arrest and growth rate.  
In Figure 5.1, the results of the Alamar Blue assays for the breast cancer cell line panel are 
depicted. The cells were seeded at plating concentrations established from Alamar Blue 
growth curves. Increasing concentrations of etoposide ranging from 0-30μM were employed 
and fluorescence measurements were taken at days 1,3,6,8 and 10 post-treatment. The mean 
fluorescence units from three experiments can be seen for each cell line. BT474, MM361 and 
MM453 were the most etoposide resistant, as suggested by the limited impact of increasing 
etoposide concentrations on their growth rate. This is evident from the plot in Figure 5.2A, in 
which cell doubling times (calculated from the slopes in Fig.5.1) were plotted against etoposide 
concentration. In Figure 5.2B, IC50 values have been calculated from the trendlines in Figure 
5.2A and are shown in a table in descending order. To summarise, in these experiments T47D, 
LCC9 and ZR751 appear to be the most sensitive cell lines and MM453, BT474 and MM361 are 
the most resistant.  
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To further establish the Alamar Blue results for the breast cancer cell line panel, an additional 
experiment was designed in order to explore the sensitivity of this assay. The protocol was 
similar to what was described above, with the only difference being that the cells were not 
treated acutely on the day before fluorescent measurements started being taken, but they 
were subjected to a continuous treatment of lower concentrations of etoposide. This was 
done in order to determine if Alamar Blue is sensitive enough to detect such small differences 
and to establish whether it would be more suitable as a treatment option for the breast cancer 
cell line panel. Only two cell lines were picked for this experiment, based on the western blot 
results for the breast cancer cell line panel in Chapter 4. LCC9 had one of the highest levels of 
TDP2 and ZR751 had one of the lowest levels of TDP2. These two extremes were picked to 
maximise the chance of detecting a difference. Figure 5.3 depicts these results. LCC9 appears 
to demonstrate very similar resistance to increasing concentrations of etoposide, compared to 
ZR751 (Fig.5.3A). This can be verified by looking at the dose-dependent inhibition of growth 
graph in Figure 5.3B. The slope values for both of these cell lines are very close, with LCC9 
demonstrating a slightly lower resistance to increasing etoposide concentrations, compared to 
ZR751. These results demonstrate that Alamar Blue is not sensitive enough to detect delicate 
differences that derive from continuous treatment with etoposide and therefore the acute 
treatment previously used, was determined as the most suitable.   
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Because the lung cancer cell lines grew efficiently in colonies as adherent cell lines, I was able 
to employ clonogenic cell survival assays to examine their sensitivity to etoposide. The 
experiments were carried out in two experimental sets, with A549 cell line included in both 
groups as an internal control for experimental consistency between the two sets. The first 
group consisted of A549, H1650, HCC95, Hop92 and MOR and the second group consisted of 
A549, H292, H226 and H460. The results of these experiments are shown in Figures 5.4A and 
5.5A, respectively. In both groups, A549 was the cell line displaying greatest resistance to 
etoposide. For the first group, HCC95 was the cell line displaying greatest sensitivity. For the 
second group, H460 was the cell line least resistant to etoposide. To compare the relative 
sensitivity of the cell lines, I calculated D37 values (Fig.5.4B and 5.5B). D37 values are defined 
as the concentration of drug at which cell survival is 37% of the initial cell population. The 
relative sensitivity of the lung cancer cell lines in order of increasing sensitivity for the first 
group was A549, MOR, Hop92, H1650 and HCC95. For the second group, the order was A549, 
H292, H226 and H460, from least to most sensitive to etoposide. 
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In order to demonstrate that Alamar Blue assay does not provide as clear results as clonogenic 
cell survival assay, similar experiments to Figure 5.1 were conducted for the three lung cancer 
cell lines MOR, HCC95 and H292 (Fig.5.6). This was done in order to further explain why it is 
more challenging to interpret results derived from it. These three cell lines were picked based 
on the preliminary western blot results for the lung cancer cell lines and they represent cell 
lines with low (H292) and high (HCC95 and MOR) levels of TDP2. The experiments were done 
in pairs, MOR with HCC95 and MOR with H292. The conditions were the same. This series of 
experiments also show different levels of etoposide resistance. For the first pair, MOR and 
HCC95, one can observe that they both have relatively high resistance to etoposide, but it is 
very difficult to establish which one is more sensitive (Fig.5.6A). For the second pair, MOR and 
H292, it can also be said that H292 shows high resistance to etoposide (Fig.5.6A). In Figure 
5.6B the dose-dependent inhibition of growth is shown, which allows the reader to derive 
more accurate conclusions. As the slope for HCC95 is of higher value than the one for MOR, it 
means that HCC95 is less sensitive to etoposide than MOR (Graph on the left). H292 also has a 
slope of higher value than MOR, making H292 less sensitive than MOR (Graph on the right), 
which was not expected. In conclusion, it is clear that Alamar Blue is a useful technique for cell 
lines that cannot grow in colonies, but it has proven limitations. 
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In order to be able to understand the results for etoposide sensitivity in lung and breast cancer 
cells, the protein levels of TDP2, TOP2A and TOP2B were plotted as ratios in Figure 5.7. Figures 
5.7A and B depict the TOP2A/TDP2 and TOP2B/TDP2 ratios for the lung cancer cell lines and 
Figure 5.7C and D depict the TOP2A/TDP2 and TOP2B/TDP2 ratios for the breast cancer cell 
lines. This allows the reader to visualise which cell lines have very high levels of TOP2A and 
TOP2B compared to TDP2, such as A549, H226, ZR751 and BT474, and which cell lines 
demonstrate the opposite, such as H460, HCC95, MM361 and MM453.  
In Figure 5.8, one can observe two scatter plots. Figure 5.8A depicts the D37 values for the 
lung cancer cell lines from Figure 5.4, plotted against the TDP2/Actin protein ratio from 
Chapter 3. Figure 5.8B depicts the IC50 for the breast cancer cell lines from Figure 5.2, plotted 
against the TDP2/Actin protein ratio from Chapter 4. It is quite clear from the spread of the 
data points for both lung and breast cancer cell lines, that there is no correlation between 
etoposide resistance and TDP2 protein levels. Figures 5.9 and 5.10 depict similar results to 
Figure 5.8 for the TOP2A/TDP2 and TOP2B/TDP2 protein ratios of Figure 5.7, in lung and breast 
cancer cell lines respectively. The same D37 and IC50 values were used as in Figure 5.8. From 
these scatter plots, no relationship is apparent. To verify that there is no correlation between 
any of the phenotypes and etoposide sensitivity, the Pearson correlation coefficient or r 
coefficient and the corresponding p-values were calculated. These results are shown in Table 
5.1. The p-values for all the r-values are less than 0.05 and are therefore not significant, which 
verified the conclusion from the scatter plots.  
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Figure 5.9: Scatter plot of TOP2A/TDP2 and TOP2B/TDP2 protein level ratios versus D37 values of lung cancer 
cell lines. Protein level ratios were obtained from Fig.5.7 and D37 values from Fig.5.4 and 5.5. Averaged values 
of concentration C1 were used. A) Scatter plot of TOP2A/TDP2 ratio for indicated lung cancer cell lines. B) 
Scatter plot of TOP2B/TDP2 ratio for indicated lung cancer cell lines.  
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Figure 5.10: Scatter plot of TOP2A/TDP2 and TOP2B/TDP2 protein level ratios versus IC50 values of breast 
cancer cell lines. Protein level ratios were obtained from Fig.5.7 and IC50 values from Fig.5.2. Averaged values 
of concentration C1 were used. A) Scatter plot of TOP2A/TDP2 ratio for indicated breast cancer cell lines. B) 
Scatter plot of TOP2B/TDP2 ratio for indicated breast cancer cell lines.  
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Phenotype r-value p -value 
Lung TDP2 0.33296 0.42030 
TOP2A/TDP2 0.58616 0.12675 
TOP2B/TDP2 0.14642 0.72936 
Breast TDP2 0.16212 0.70130 
TOP2A/TDP2 -0.21519 0.60881 
TOP2B/TDP2 -0.49259 0.21492 
 
5.3 Discussion 
A comparison of TDP2 protein levels and cell survival did not yield a positive correlation 
between TDP2 protein levels and sensitivity to etoposide, in neither breast nor lung cancer cell 
lines. It appears that protein levels do not necessarily translate to etoposide sensitivity or 
resistance. In addition, there seems to be no correlation between sensitivity to etoposide and 
TOP2A/TDP2 and TOP2B/TDP2 protein ratios either. For the lung cancer cell lines, MOR and 
HCC95 possess the highest levels of TDP2 protein, followed by A549, H292, H460, H226 and 
Hop92 with intermediate levels, and H1650 with the lowest levels (Chapter 3). On the other 
hand A549 was the cell line least sensitive to etoposide, followed by H292, MOR, Hop92, H226, 
H1650, H460 and HCC95, based on the D37 values in Figures 5.4B and 5.5B. This is not 
expected, as it was anticipated that cell lines with high levels of TDP2 would be resistant to 
etoposide and cell lines with low levels of TDP2 would be sensitive. For example, HCC95 
demonstrated very high levels of TDP2 but very low levels of etoposide resistance. This cannot 
be explained simply by just looking at the levels of TOP2A and TOP2B, since in Figure 5.7A the 
ratio of TOP2A/TDP2 and TOP2B/TDP2 is very low indicating that TOP2A and TOP2B levels are 
very low compared to TDP2. A549 demonstrated intermediate levels of TDP2 (Chapter 3) and, 
while having a high ratio of TOP2A/TDP2 and intermediate ratio of TOP2B/TDP2, it 
demonstrated the highest resistance to etoposide, when it was expected that it would be 
intermediate. To further observe the lack of correlation one can look at Figure 5.8A, in which a 
Table 5.1: Statistical analysis results of TDP2 protein levels, TOP2A/TDP2 protein ratios and TOP2B/TDP2 protein 
ratios and their correlation with sensitivity to etoposide in lung and breast cancer cell lines (D37 or IC50 values, 
respectively). 
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scatter plot depicts the D37 values of the lung cancer cell lines plotted against TDP2 protein 
levels normalised to Actin. It is very clear that the data points form a cloud, rather than falling 
on a best fit line. The same can be said for TOP2A/TDP2 and TOP2B/TDP2 protein level ratios.  
A similar picture is seen for the breast cancer cell lines, as comparing the Alamar Blue results 
with the protein levels for each cell line, does not demonstrate a correlation between the 
number of viable cells in culture after etoposide treatment and the TDP2 protein levels 
observed previously. Although Alamar Blue has been proven to be an assay with limitations, 
has exhibited lower sensitivity and its results are more difficult to interpret compared to 
clonogenic cell survival assay, it is still the only kind of assay that can be used for many of the 
breast cancer cell lines in the panel used. LCC9 and T47D demonstrated the highest levels of 
TDP2 protein, followed by MLET5, MM361, BT474, MM453 and MCF7 with intermediate 
levels, and ZR751 consistently had the lowest levels of TDP2 protein (Chapter 4). From the IC50 
values of Figure 5.2B, one can see that MM453 and BT474 are the most resistant to etoposide, 
followed by MM361, MLET5, MCF7, ZR751, LCC9 and T47D. Taking LCC9 as an example, it is 
not difficult to show the lack of correlation between TDP2 protein levels and sensitivity to 
etoposide. It is one of the cell lines with the highest levels of TDP2, but demonstrated one of 
the lowest levels of resistance to etoposide. In addition, its TOP2A/TDP2 ratio is very low, 
although its TOP2B/TDP2 ratio is relatively high (Fig.5.8B). Another example is T47D, another 
cell line with very high levels of TDP2 and yet it’s the one with the highest sensitivity to 
etoposide, while having very low ratios of TOP2A/TDP2 and TOP2B/TDP2. Similar to the lung 
cancer cell lines, this lack of correlation is also easier to visualise in Figure 5.5B, which depicts a 
scatter plot of the IC50 values of the breast cancer cell lines plotted against TDP2 protein levels 
normalised to Actin. It is very clear again that the data points form a cloud, rather than falling 
on a best fit line. Similarly, no correlation can be observed in the scatter plots for TOP2A/TDP2 
and TOP2B/TDP2 protein ratios. 
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I was able to obtain etoposide IC50 values for some of the cell lines I utilised in my 
experiments from a drug database, CancerDR (for selection and details, please refer to Chapter 
2.5.1) and used them as a means of explaining my results. I calculated the r-values and their 
corresponding p-values, using my experimentally defined TDP2/Actin, TOP2A/TDP2 and 
TOP2B/TDP2 protein ratios, the results of which can be found in Table 5.2. Agreeing with my 
results, these p-values are not significant.  
 
  Phenotype r-value p -value 
Lung TDP2 0.42630 0.47414 
TOP2A/TDP2 0.87138 0.05429 
TOP2B/TDP2 0.52240 0.36649 
Breast TDP2 -0.09065 0.88473 
TOP2A/TDP2 0.70098 0.18723 
TOP2B/TDP2 -0.30377 0.61926 
 
All the data that has shown impact on etoposide sensitivity while manipulating TDP2 levels, 
either by overexpressing it or by inhibiting it, have used a closed system where the parameters 
were less variable. My system is more complicated with multiple parameters. Looking at 
intrinsic values of TDP2 on its own or as a protein ratio with other relevant proteins is more 
challenging, since there are a lot of factors that could be contributing to how the cell responds 
to etoposide, or to how TDP2 responds to the formed DSB.  
A recent study similar to mine investigated whether TDP1 or TOP1 levels alone could be a 
predictive biomarker of sensitivity to irinotecan, a TOP1 poison, in colorectal cancer 
(Meisenberg et al., 2015). Their conclusion was similar to my results, that there was no 
correlation between intrinsic TDP1 or TOP1 levels and irinotecan, a system very similar to the 
TDP2-TOP2-etoposide system I was investigating.  
Table 5.2: Statistical analysis results of TDP2 protein levels, TOP2A/TDP2 protein ratios and TOP2B/TDP2 protein 
ratios and their correlation with sensitivity to etoposide (IC50 values), obtained from CancerDR in lung and 
breast cancer cell lines. 
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Very recently, data has emerged that TDP2 is a novel substrate of extracellular signal-regulated 
kinase 3, an atypical mitogen-activated protein kinase (ERK3) (Bian et al., 2016). ERK3 was 
shown to phosphorylate TDP2 and promote its phosphodiesterase activity, and as a result up-
regulating TDP2-mediated DNA damage response, which leads to the desensitizing of lung 
cancer cell lines H460 and A549 to TOP2 inhibitor-induced growth inhibition (Bian et al., 2016). 
Interestingly, the same paper showed that lung cancer cell lines displayed highly differential 
response to etoposide; H157 lung cell line showed high basal levels of γ-H2AX that were not 
changed after etoposide treatment with concentrations up to 20 µM, H1395 cells 
demonstrated undetectable γ-H2AX levels post etoposide treatment even when TDP2 was 
knocked down. Finally, H1437 etoposide treatment did increase γ-H2AX levels but knockdown 
of TDP2 did not show an obvious effect (Bian et al., 2016).  
A very recent paper suggests that Mre11, which initiates DSBR by HR via a complex with Rad50 
and NBs1, and TDP2 operate in separate pathways for the repair of etoposide-induced breaks 
(Hoa et al., 2016). Moreover, in the same paper it was shown that the heterozygous mutant 
MRE11+/-, but not the heterozygous TDP2+/- cells, were more sensitive to etoposide than wt 
cells, which could imply that even small presence of TDP2 is enough to respond to etoposide-
induced abortive DSBs. This observation could explain why the intrinsic variability of TDP2 
protein levels in the cell lines I studied is too subtle to have a significant impact on etoposide 
resistance. Interestingly, in the same paper it was also demonstrated that TDP2-/- cells showed 
no significant genome instability unlike MRE11-/H129N/TDP2-/- cells, suggesting a functional 
redundancy between the nuclease activity of Mre11 and TDP2 in terms of genome stability, 
which could be interpreted as another reason why no correlation was observed in my 
experiments 
Nevertheless, the lack of correlation could be attributed to the levels of activity of TDP2 or 
perhaps even mutations that render it inactive. There is a wealth of information available for 
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characterised mutations in cancer cell lines. It would be very interesting and a great first step 
in determining if a gene mutation, other than TDP2, is responsible for the lack of correlation I 
observed between resistance to etoposide and TDP2 protein levels or TOP2A/TDP2 and 
TOP2B/TDP2 protein ratios. Such a study is conducted in the next chapter. 
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6. CHAPTER SIX – Mutational profiles of breast and lung cancer cell lines 
as a predictor of relationship between TDP2 and resistance to etoposide 
6.1 Introduction 
In the previous chapter, I investigated the possibility of a correlation between sensitivity to the 
TOP2 poison etoposide and TDP2 protein levels, TOP2A/TDP2 protein ratios or TOP2B/TDP2 
protein ratios in a panel of lung and breast cancer cell lines. Unfortunately, I was not able to 
detect a simple linear correlation, where TDP2 levels or the previously mentioned ratios can 
accurately predict how sensitive a cell line would be to treatment with etoposide. Given that 
previous studies of etoposide sensitivity and TDP2 levels were manipulations within the same 
cell line (Cortes Ledesma et al., 2009, Gómez-Herreros et al., 2014, Zeng et al., 2011), one 
hypothesis for the lack of correlation is that some of the cell lines may have mutations that 
affect the relationship between TDP2 levels and etoposide sensitivity. 
There is a wealth of information available online via several different kinds of database, but it 
is not easy even for trained researchers to access this information without experience. But 
through reviewing the literature and consulting people familiar with the field, I selected a 
number of sources that provided information on mutations found in the cancer cell lines I used 
(Futreal et al., 2004, Pavlopoulou et al., 2015, Abaan et al., 2013, Yang et al., 2015b). These 
were Cancer Cell Line Encyclopedia v2.17 (CCLE), IARC TP53 Database R18, Cell Lines Project 
v78 and COSMIC Database v78 (Barretina et al., 2012, Bouaoun et al., 2016, Forbes et al., 
2015).  
The Cancer Cell Line Encyclopedia (CCLE) is a collaborative project between the Broad Institute 
in Cambridge and the Novartis Institutes for Biomedical Research and its Genomics Institute, 
the Novartis Research Foundation. It is an ongoing project and currently has information on 
gene expression, chromosomal copy number and massively parallel sequencing data available 
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for about 1000 cell lines. CCLE also has pharmacological profiles available for 24 cancer drugs 
across 479 of the total cell lines, a collection that allows identification of genetic, lineage and 
gene-expression-based predictors of drug sensitivity (Barretina et al., 2012). 
The IARC TP53 Database consists of TP53 mutation data from published literature since 1989. 
The database includes information on TP53 somatic mutations in sporadic cancers, TP53 
germline mutations in familial cancers, common TP53 polymorphisms identified in human 
populations, functional and structural properties of p53 mutant proteins, mouse-models with 
engineered TP53, experimentally-induced mutations and the most relevant to this chapter, 
TP53 gene status in human cell-lines (Bouaoun et al., 2016). 
The Cell Lines Project (CLP) of the COSMIC database exclusively displays the results of genomic 
analysis across a large set of common cancer cell lines used in research. At the moment the 
number of cell lines is 1015 but it is expected to grow to include about 500 additional cell lines. 
This project is maintained in a parallel but separate system along the COSMIC database (Forbes 
et al., 2015).  
The Catalogue of Somatic Mutations in Cancer (COSMIC) is the largest and most 
comprehensive resource for researching the impact of somatic mutations in human cancer. 
High-impact genes are selected from the Cancer Gene Census, which lists hundreds of genes 
with substantial published evidence in oncology; this is a very high-confidence list based on 
good-quality publications. All publications mentioning mutations for these genes in human 
cancer are collected and exhaustively curated before the information is released into a new 
version of COSMIC (Forbes et al., 2015).  
The information available in all these databases is expert-curated. For the COSMIC Database, 
the primary source is papers in scientific journals, therefore I was able to personally verify that 
the samples listed were of the same type as the cell lines I had previously used, as multiple 
instances of the same sample name exist as separate entries, indicating that it was not clear 
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for the curator whether these samples were the same. In addition, I also looked to verify that 
the mutated or wild type form of the genes stated in the database matched those stated in the 
publications. All databases were last accessed in September 2016, to include as many up-to-
date entries as possible.   
After mining the results, I organised them per cancer type (breast and lung) in two excel 
spreadsheets. Each spreadsheet listed all the genes for which I was able to find information for 
at least one cell line of that type, either a mutation or a wild type entry. For the breast cancer 
cell lines that was a total of 3686 genes and for the lung cancer cell lines 1150 genes. Out of 
the 8 breast cancer cell lines I studied (LCC9, MCF7, MM361, BT474, MLET5, T47D, MM453 and 
ZR751), I was able to find information for at least one gene for 6 cell lines: BT474, MCF7, 
MM361, MM453, T47D and ZR751. Out of the 8 lung cancer cell lines I studied (MOR, HCC95, 
Hop92, H226, H460, H292, A549 and H1650), I was able to find information for at least one 
gene for 7 cell lines: A549, H226, H292, H460, H1650, HCC95 and Hop92.  
In order to be able to do statistical analyses for these genes, I could only use genes for which I 
had information about its status from at least four cell lines, but one of those cell lines had to 
have a different status for that gene, meaning genes with at least one of both the mutated and 
wild type form. This criterion reduced the number of genes to 7 for the breast cancer cell lines 
and 8 for the lung cancer cell lines. I used these genes for statistical modelling, in order to 
determine the existence of an effect of these gene mutations on the relationship between 
TDP2 protein levels, TOP2A/TDP2 protein ratios or TOP2B/TDP2 protein ratios and sensitivity 
to etoposide, and if one exists, how severe it is. For a detailed description of the data analysis, 
please refer to Chapter 2.5. Focusing my analysis at the level of genes allowed me to identify 
similarities between my cell lines rather than limiting myself by specific mutations which may 
not be known and whose specific effect is not understood. 
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6.1.1 Aims of this chapter 
This chapter aims to identify genes that may affect the correlation between previously 
experimentally defined etoposide IC50 or D37 concentrations and TDP2 protein levels, 
TOP2A/TDP2 protein ratios and TOP2B/TDP2 protein ratios in a panel of lung and breast 
cancer cell lines, thus obscuring the correlation between the two when gene status isn't taken 
into account. 
6.2 Results 
Before exploring the possibility of an effect of TDP2 protein levels, TOP2A/TDP2 and 
TOP2B/TDP2 protein ratios, the possible direct effect of these gene mutations on average 
etoposide sensitivity (in the form of the etoposide IC50 for breast cell lines and D37 values for 
lung cell lines values shown in Chapter 5) in mutated cell lines versus wild type was 
determined first. These results are depicted in Figures 6.1 and 6.2 for breast and lung cancer 
cell lines respectively.  The colour scheme is the same for both Figures. In red are shown the 
cell lines that carry a mutation for that gene and in blue are the wild type cell lines. The 
horizontal lines correspond to the average etoposide sensitivity for each group; the greater the 
distance between these two cell lines, the greater the possible effect of the mutation on 
etoposide sensitivity.  
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Figure 6.1: A) Graph depicting all breast cancer cell lines with available information for mutation status for gene 
CDH1, in red the cell lines that carry a mutation for CDH1 and in blue the cell lines that are wild type for this 
gene. On the y axis are shown the IC50 values for etoposide derived from experimental data discussed in 
Chapter 5. The red and blue lines represent the mean of the IC50 values of each cell line group and the colours 
correspond to the mutation status. B) Similar to A but for gene CDKN2A. C) Similar to A but for gene CREBBP. D) 
Similar to A but for gene EGFR. E) Similar to A but for gene PIK3CA. F) Similar to A but for gene PTEN. G) Similar 
to A but for gene TP53. 
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Figure 6.2: A) Graph depicting all lung cancer cell lines with available information for mutation status for gene 
EGFR, in red the cell lines that carry a mutation for EGFR and in blue the cell lines that are wild type for this 
gene. On the y axis are shown the D37 values for etoposide derived from experimental data discussed in 
Chapter 5. The red and blue lines represent the mean of the D37 values of each group and the colours 
correspond to the mutation status. B) Similar to A but for gene KRAS. C) Similar to A but for gene MAX. D) 
Similar to A but for gene PIK3CA. E) Similar to A but for gene PTEN. F) Similar to A but for gene SMARCA4. G) 
Similar to A but for gene STK11. H) Similar to A but for gene TP53. 
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It is immediately noticeable that not all genes appear in both Figures 6.1 and 6.2, but EGFR, 
PIK3CA, PTEN and TP53 are shown in both Figures. This simply means that there was 
information available for the mutation status of these genes for most of the cell lines that I 
utilised in my experiments, regardless of the tissue of origin. This results from the sheer 
volume of publications and studies involving these genes and the study of their mutations and 
their effects on cancer biology. 
Table 6.1 shows statistical analysis of the plots for the breast and lung cancer cell lines. The 
first column for each cell line lists the relevant genes that were derived from the rigorous 
screening method described previously. The second column depicts the p-values that show the 
significance of the difference between etoposide IC50 or D37 concentrations of cell lines that 
carry a mutation for one of the listed genes compared to the wild type cell lines for the same 
gene. None of those differences are significant for the breast cancer cell lines, as all the p-
values are greater than 0.05. For the lung cancer cell lines though, there is one gene, MAX, for 
which the difference is significant, meaning that this mutation has an effect on etoposide 
sensitivity independently of TDP2 protein levels or TOP2/TDP2 protein ratios.  
The third column shows the estimate of the effect of each mutation on sensitivity to 
etoposide. If the value is positive, the mutation causes a higher IC50 or D37 value, meaning 
that it increases resistance to etoposide. In contrast, if the value is negative, then the mutation 
has the opposite effect, i.e. it causes the cell line to be more sensitive to etoposide. The 
absolute value depicts the numerical difference between the IC50 or D37 concentrations for 
the mutated cell lines versus the wild type ones (for that gene), essentially demonstrating how 
big the effect is. For the breast cancer cell lines, the genes that appear to have the biggest 
impact judging by the estimates are CDH1 and CREBBP, with EGFR having the smallest impact. 
All genes apart from CDKN2A appear to have a positive effect on etoposide resistance, 
meaning that they render the affected cell lines more resistant to etoposide. That is interesting 
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due to the nature of genes and the cell activities they are associated with. As mentioned 
though, the observed differences are not significant. For the lung cancer cell lines, the 
estimate of the mutation effect of the MAX gene is a positive value, thus it is likely that it 
decreases sensitivity to etoposide in the cell lines that it is found mutated, by increasing the 
etoposide D37 value by 14.5μM. 
Table 6.1: Significance of the differences in the means of etoposide IC50 and D37 
concentrations between mutated and wild type forms of genes for breast and lung cancer 
cell lines, respectively. 
Breast Cancer Cell Lines Lung Cancer Cell Lines 
Gene 
p-value 
of mean 
IC50 
Estimate size of 
mutation effect on 
etoposide IC50 (μM) Gene 
p-value 
of mean 
D37 
Estimate size of 
mutation effect on 
etoposide D37 (μM) 
CDH1 0.12981 24.68760 EGFR 0.55818 -4.04000 
CDKN2A 0.65560 -6.62175 KRAS 0.40100 5.41833 
CREBBP 0.19688 22.12750 MAX 0.00253 14.51667 
EGFR 0.92805 2.23833 PIK3CA 0.44510 -5.18000 
PIK3CA 0.44228 14.03520 PTEN 0.57994 -4.53250 
PTEN 0.65380 6.65775 SMARCA4 0.25621 7.30000 
TP53 0.37629 11.10150 STK11 0.50526 5.95000 
   
TP53 0.46534 -4.69167 
The next step was looking into the relationship between the mutations, sensitivity to 
etoposide and protein levels of TDP2 or TOP2/TDP2 and TOP2B/TDP2 protein ratios. All 
protein levels and ratios for the breast and lung cancer cell lines were obtained from the 
experimental results described in Chapters 3 and 4. Figure 6.3 depicts the results of this 
analysis for the breast cancer cell lines and Figure 6.4 for the lung. The black lines represent 
the best fit lines for TDP2 protein levels or TOP2A/TDP2 or TOP2B/TDP2 protein ratios against 
etoposide IC50 values, when only the cell lines for which mutation data was available for the 
gene of interest are taken into consideration, but not accounting for mutation status of that 
gene. The red lines represent the best fit line of just the cell lines that have been found to be 
mutated for that gene and the blue lines show the non-mutated cell lines for that same gene. 
The red and blue lines are always parallel for each gene, due to the limitation imposed by the 
statistical analysis that requires more data points to add a slope variation.  
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Figure 6.3: Graphs depicting best fit lines of (from left to right) the relationship between TDP2 protein levels 
and corresponding etoposide IC50 concentrations (μM), TOP2A/TDP2 protein ratios and corresponding 
etoposide IC50 concentrations (μM), and TOP2B/TDP2 protein ratios and corresponding etoposide IC50 
concentrations (μM) in breast cancer cell lines for different genes. The black best fit lines are derived when all 
the cell lines are considered as one group independent of gene mutation status for each phenotype. The blue 
and the red lines are derived when the gene mutation status is taken into account, with blue being the wild 
type cell lines and red the mutated cell lines for that particular gene and phenotype. The genes are: A) CDH1, B) 
CDKN2A, C) CREBBP, D) EGFR, E) PIK3CA, F) PTEN and G) TP53. 
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What is important to notice is how far the red and blue lines are from each other and from the 
black line, as this indicates a greater effect of the mutation on etoposide sensitivity when 
taking into account TDP2 levels or ratios. Differences between the best fit lines of the mutants 
and the wild type cell lines can be observed in all genes. For example, in breast cancer cell 
lines, for most genes apart from CDKN2A, mutation appears to have had an effect on the 
Figure 6.4: Graphs depicting best fit lines from left to right, of the relationship between TDP2 protein levels and 
corresponding etoposide IC50 concentrations (μM), TOP2A/TDP2 protein ratios and corresponding etoposide 
IC50 concentrations (μM), and TOP2B/TDP2 protein ratios and corresponding etoposide IC50 concentrations 
(μM) in lung cancer cell lines for different genes. The black best fit lines are derived when all the cell lines are 
considered as one group independent of gene mutation status for each phenotype. The blue and the red fit 
lines are derived when the gene mutation status is taken into account, with blue being the wild type cell lines 
and red the mutated cell lines for that particular gene and phenotype. The genes are: A) EGFR, B) KRAS, C) 
MAX, D) PIK3CA, E) PTEN, F) SMARCA4, G) STK11 and H) TP53. 
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relationship between TDP2 protein levels and etoposide sensitivity, but not in the same way. 
For CDH1, CREBBP and PTEN, the red line is lower than the blue line, which means that overall, 
the mutated cell lines will be more resistant to etoposide treatment compared to the wild type 
cell lines for those genes. On the other hand, the opposite is true for the genes EGFR, PIK3CA 
and TP53, for which the red line is higher than the blue line, indicating mutation reduces 
etoposide resistance. For TOP2A/TDP2 and TOPB/TDP2 protein ratios, the least severe genes 
seem to be CDH1 and CREBBP, and with PIK3CA and TP53 showing the greatest differences for 
both ratios.  In lung cancer cell lines, the striking graphs of gene MAX clearly show that the 
mutation of this gene has had an impact on etoposide sensitivity, rather than on the 
relationship between TDP2 levels or TOP2/TDP2 ratios and etoposide D37 values. For the rest 
of the lung cell lines, there seems to be a variable appearance of the best fit lines. EGFR and 
PTEN mutations appear to have the greatest impact on the relationship between TDP2 levels 
and D37 concentrations. Another interesting of piece information that we can get from these 
graphs is the best fit line slope, which implies either a negative or a positive correlation.  
The data in Figures 6.3 and 6.4 are easier to interpret with the help of Tables 6.2, 6.3, 6.4 and 
6.5, in which the statistical analyses of the graphs are shown. Tables 6.2 and 6.3 refer to the 
breast cancer cell lines and tables 6.4 and 6.5 to the lung cancer cell lines. The overall question 
that the analysis is attempting to answer is whether the observed differences are significant or 
not, how significant and what these differences mean. The first columns of all these Tables 
depict the genes of interest, with the second ones explaining the phenotype that is explored 
(TDP2 protein levels, TOP2A/TDP2 protein ratios or TOP2B/TDP2 protein ratios) for each gene. 
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Table 6.2: Statistical analysis results for the curated gene mutations in breast cancer cell 
lines – Part 1 
Gene Phenotype 
p-value of 
single best fit 
line slope 
Estimate of 
slope of single 
best fit line 
p-values when 
only mutation 
effect is 
considered 
Estimate 
effect of mt 
only for 
phenotype  
CDH1 TDP2  0.36590 0.00193 0.98322 -0.00171 
CDKN2A TDP2 0.36590 0.00193 0.84588 0.01244 
PIK3CA TDP2 0.36590 0.00193 0.17424 0.09711 
PTEN TDP2 0.36590 0.00193 0.29912 -0.06176 
CREBBP TDP2 0.28808 0.00287 0.97947 0.00249 
TP53 TDP2 0.24754 0.00375 0.01561 0.12007 
EGFR TDP2 0.83665 0.00061 0.18768 0.09483 
            
CDH1 TOP2A/TDP2 0.54642 -0.86151 0.79764 -13.39996 
CDKN2A TOP2A/TDP2 0.54642 -0.86151 0.48881 -27.76849 
PIK3CA TOP2A/TDP2 0.54642 -0.86151 0.00006 -98.07523 
PTEN TOP2A/TDP2 0.54642 -0.86151 0.13875 52.92204 
CREBBP TOP2A/TDP2 0.37084 -1.57277 0.74832 -19.34841 
TP53 TOP2A/TDP2 0.61764 -1.15003 0.24937 -51.78307 
EGFR TOP2A/TDP2 0.33926 0.22156 0.42945 -5.95159 
            
CDH1 TOP2B/TDP2 0.40775 -0.15019 0.60672 -3.44545 
CDKN2A TOP2B/TDP2 0.40775 -0.15019 0.54659 -3.16780 
PIK3CA TOP2B/TDP2 0.40775 -0.15019 0.00209 -12.34286 
PTEN TOP2B/TDP2 0.40775 -0.15019 0.25979 5.56088 
CREBBP TOP2B/TDP2 0.27042 -0.24469 0.59103 -4.17701 
TP53 TOP2B/TDP2 0.58078 -0.15981 0.16205 -7.50754 
EGFR TOP2B/TDP2 0.55542 -0.04741 0.30317 -2.31174 
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Table 6.3: Statistical analysis results for the curated gene mutations in breast cancer cell 
lines – Part 2 
Gene Phenotype 
p-value of 
mt & wt 
best fit 
lines slope 
Estimate of 
slope of mt 
& wt best fit 
lines 
p-value of mt 
& wt 
intercepts 
Estimate of 
difference 
between mt & 
wt intecepts 
CDH1 TDP2  0.24754 0.00375 0.38881 -0.09420 
CDKN2A TDP2 0.39732 0.00215 0.69547 0.02670 
PIK3CA TDP2 0.63822 0.00103 0.32690 0.08266 
PTEN TDP2 0.19926 0.00259 0.17516 -0.07900 
CREBBP TDP2 0.19037 0.00539 0.31800 -0.11674 
TP53 TDP2 0.46008 0.00122 0.06671 0.10657 
EGFR TDP2 0.88456 0.00040 0.39504 0.09394 
            
CDH1 TOP2A/TDP2 0.61764 -1.15003 0.85286 14.99160 
CDKN2A TOP2A/TDP2 0.46349 -1.15397 0.43070 -35.40981 
PIK3CA TOP2A/TDP2 0.15958 0.24994 0.00023 -101.58324 
PTEN TOP2A/TDP2 0.22474 -1.37713 0.09351 62.09060 
CREBBP TOP2A/TDP2 0.46256 -2.20893 0.74308 29.52977 
TP53 TOP2A/TDP2 0.96819 0.10791 0.41424 -52.98104 
EGFR TOP2A/TDP2 0.34496 0.23655 0.38168 -6.48107 
            
CDH1 TOP2B/TDP2 0.58078 -0.15981 0.96041 0.49978 
CDKN2A TOP2B/TDP2 0.35478 -0.18655 0.42989 -4.40312 
PIK3CA TOP2B/TDP2 0.78558 -0.01789 0.01118 -12.09181 
PTEN TOP2B/TDP2 0.21147 -0.20786 0.15849 6.94475 
CREBBP TOP2B/TDP2 0.43196 -0.29563 0.83024 2.36463 
TP53 TOP2B/TDP2 0.93401 0.02505 0.31102 -7.78563 
EGFR TOP2B/TDP2 0.62820 -0.04228 0.46571 -2.21709 
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Table 6.4: Statistical analysis results for the curated gene mutations in lung cancer cell 
lines – Part 1 
Gene Phenotype 
p-value of 
single best 
fit line 
slope 
Estimate of 
slope of 
single best 
fit line 
p-values when 
only  mutation 
effect is 
considered 
Estimate 
effect of mt 
only for 
phenotype 
EGFR TDP2 0.20798 0.01554 0.00819 -0.31857 
PIK3CA TDP2 0.20798 0.01554 0.91320 0.01995 
TP53 TDP2 0.23647 0.01707 0.30214 -0.16595 
PTEN TDP2 0.24889 0.01631 0.02557 -0.31891 
SMARCA4 TDP2 0.36179 0.01301 0.60560 -0.09042 
KRAS TDP2 0.28404 0.01562 0.38555 0.14487 
MAX TDP2 0.44462 0.01373 0.38719 0.22047 
STK11 TDP2 0.36553 0.01628 0.35120 0.20026 
            
EGFR TOP2A/TDP2 0.20174 5.75785 0.50541 -43.30980 
PIK3CA TOP2A/TDP2 0.20174 5.75785 0.53068 -40.91746 
TP53 TOP2A/TDP2 0.00942 7.37883 0.34314 -45.19626 
PTEN TOP2A/TDP2 0.26653 5.36715 0.41385 -56.09904 
SMARCA4 TOP2A/TDP2 0.18567 5.97560 0.80925 14.85592 
KRAS TOP2A/TDP2 0.25353 5.93554 0.73921 21.41217 
MAX TOP2A/TDP2 0.00763 6.81010 0.00165 99.70762 
STK11 TOP2A/TDP2 0.33718 5.54654 0.97979 2.03344 
            
EGFR TOP2B/TDP2 0.98853 0.00547 0.52470 -3.12402 
PIK3CA TOP2B/TDP2 0.98853 0.00547 0.41182 -3.95507 
TP53 TOP2B/TDP2 0.91069 0.04955 0.65988 -2.06402 
PTEN TOP2B/TDP2 0.99613 -0.00218 0.55704 -3.43446 
SMARCA4 TOP2B/TDP2 0.99741 -0.00072 0.68558 -1.02972 
KRAS TOP2B/TDP2 0.82748 -0.04875 0.27185 -2.42550 
MAX TOP2B/TDP2 0.21650 0.04846 0.25930 0.66675 
STK11 TOP2B/TDP2 0.87888 -0.04305 0.39524 -2.58515 
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Table 6.5: Statistical analysis results for the curated gene mutations in lung cancer cell lines 
– Part 2 
Gene Phenotype 
p-value of mt & 
wt best fit lines 
slope 
Estimate of 
slope of mt & 
wt best fit 
lines 
p-value of 
mt & wt 
intercepts 
Estimate of 
difference 
between mt 
& wt 
intercepts 
EGFR TDP2 0.04794 0.00910 0.00483 -0.28180 
PIK3CA TDP2 0.20920 0.01901 0.50934 0.11844 
TP53 TDP2 0.45960 0.01283 0.56017 -0.10576 
PTEN TDP2 0.10423 0.00942 0.02501 -0.27623 
SMARCA4 TDP2 0.01834 0.02959 0.02291 -0.30642 
KRAS TDP2 0.53083 0.01208 0.69844 0.07939 
MAX TDP2 0.06111 -0.27372 0.05806 4.19393 
STK11 TDP2 0.68559 0.01065 0.66772 0.13688 
            
EGFR TOP2A/TDP2 0.32488 5.25292 0.73492 -22.08801 
PIK3CA TOP2A/TDP2 0.33555 5.37455 0.84753 -13.07730 
TP53 TOP2A/TDP2 0.04190 6.85577 0.49307 -13.03127 
PTEN TOP2A/TDP2 0.44729 4.47282 0.63324 -35.82596 
SMARCA4 TOP2A/TDP2 0.20914 8.54731 0.47385 -47.53945 
KRAS TOP2A/TDP2 0.37844 6.56555 0.84675 -14.16219 
MAX TOP2A/TDP2 0.35717 -4.70270 0.15957 167.97520 
STK11 TOP2A/TDP2 0.45880 7.23343 0.68642 -41.00545 
            
EGFR TOP2B/TDP2 0.86969 -0.07266 0.57249 -3.41756 
PIK3CA TOP2B/TDP2 0.76643 -0.13023 0.44857 -4.62967 
TP53 TOP2B/TDP2 0.94562 -0.04102 0.73295 -2.25646 
PTEN TOP2B/TDP2 0.86067 -0.09913 0.62137 -3.88378 
SMARCA4 TOP2B/TDP2 0.79451 0.09086 0.68083 -1.69303 
KRAS TOP2B/TDP2 0.76045 0.07794 0.36737 -2.84780 
MAX TOP2B/TDP2 0.22908 0.54748 0.24863 -7.28090 
STK11 TOP2B/TDP2 0.83433 0.08381 0.56480 -3.08383 
 
The third column of Tables 6.2 and 6.4 represents the significance of the slope of the best fit 
line when both mutant and wild type cell lines are considered together for each gene, which in 
the graphs of Figures 6.3 and 6.4 are drawn in black. The p-value is the probability of the null 
hypothesis that the slope is 0, therefore lower p-values mean better support for a non zero 
slope. Significant p-value means that there is a significant relationship between each 
phenotype and resistance to etoposide regardless of mutation status for each gene. If these 
values are greater than 0.05, then there is no significant relationship between each phenotype 
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and etoposide resistance when both wt and mt forms of the gene are considered together. 
Most of the slopes are not significant, which is precisely what I saw in Chapter 5, when I was 
investigating a possible correlation between TDP2 protein levels and TOP2/TDP2 ratios, before 
investigating the possible role of mutations. In the lung cancer cell lines, though, for the 
TOP2A/TDP2 ratio, there are two genes that give a significant p-value and these are TP53 and 
MAX. That could just mean though, that for the cell lines for which I had data for these two 
mutations, there is the possibility of a relationship between that protein ratio and D37 
concentrations. Which is why in the discussion, a more rounded picture for every gene will be 
presented. The next column of the same tables shows the estimate of the slopes of the best fit 
line for both mt and wt cell lines for each gene and phenotype. A positive estimate means 
there is a positive slope and negative means a negative slope, while a large absolute value 
means a steeper slope.  
The next column in Tables 6.2 and 6.4 shows the p-values of the difference between TDP2 
levels or TOP2/TDP2 ratios when they are considered on their own, independently of 
etoposide sensitivity, but when the mutation status of the genes is taken into account. These 
p-values represent the probability of the null hypothesis that the difference is 0. If a value is 
lower than 0.05, then the difference is considered significant. For most of the genes, there is 
no significant difference, which means that the mutations do not have an effect on the levels 
of TDP2 or the TOP2/TDP2 ratios. For the breast cancer cell lines there is one exception to this, 
gene PIK3CA, which appears to have a significant effect on both the TOP2A/TDP2 and the 
TOP2B/TDP2 protein ratio. For the lung cancer cell lines, gene mutations EGFR and PTEN have 
a significant effect on TDP2 protein levels. MAX has a significant effect on TOP2/TDP2 ratio, 
although that is probably the effect the mutation has on etoposide sensitivity rather than on 
the protein ratio. The adjacent column of Tables 6.2 and 6.4 lists the estimate of effect of the 
gene mutations on TDP2 levels and TOP2/TDP2 ratios independent of etoposide sensitivity. If 
that value is negative, the mutation’s effect is a decrease of TDP2 protein or of the protein 
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ratio TOP2/TDP2 and if positive then the effect is the opposite. The absolute value depicts the 
magnitude of the effect. As one can observe, there is variety of how each mutation has 
affected each phenotype, with the biggest effect being the one on the TOP2A/TDP2 protein 
ratio for both types of cancer cell lines, where there is a significant large effect of PIK3CA in the 
breast cancer cell lines and MAX in lung. While EGFR and TP53 had a significant p-value for 
TDP2 levels, the estimate effect is small. The smallest changes are seen in TDP2 levels, so 
perhaps the larger levels of change for the ratio phenotypes could be due to TOP2-mutation 
interactions.  
Moving on to Tables 6.3 and 6.5, the third column lists the p-values of the slope for the two 
best fit lines (red and blue in the graphs of Figures 6.3 and 6.4) that result when the mutation 
status for each gene is taken into consideration and the cell lines are considered separately. If 
these values are significant (less than 0.05), then there is a significant relationship between 
etoposide resistance and TDP2 levels or TOP2/TDP2 ratios when the mutation for each gene is 
taken into account, while the opposite is true when the p-values are not significant. There are 
no significant values in this list for the breast cancer cell lines, but it is interesting to observe 
how these p-values compare to the p-values when the mutation status of the gene is not 
considered. A lower p-value for the mt and wt best fit line slopes compared to the non-
discriminatory best fit line slopes suggests that the separate best fit lines fit the data better, 
meaning that taking into account the mutation of the genes results in a stronger relationship 
between etoposide sensitivity and TDP2 levels or TOP2/TDP2 ratios. If the opposite is true, 
then taking into account the mutation status doesn’t increase the relationship. There appears 
to be a variation, with several gene mutations seemingly fitting better to the separate best fit 
lines, for example CDH1, PTEN and CREBBP for TDP2 protein levels. This doesn’t necessarily 
carry onto both TOP2A/TDP2 and TOP2B/TDP2 ratios, where for the same genes, only PTEN 
showed an improved relationship for TOP2A/TDP2 ratio with etoposide sensitivity when the 
mutation is taken into account. For the lung cancer cell lines, there is a significant p-value for 
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the EGFR and SMARCA4 mutations for TDP2 levels and TP53 for the TOP2A/TDP2 ratio. Similar 
to the breast cancer cell lines, there is a variation in how well the data all together fit a single 
best fit versus two best fit lines, which separate the mt and wt cell lines for each gene. The 
estimate of the slope of mt and wt best fit lines shows the magnitude and direction of the 
relationship between TDP2 and etoposide sensitivity when considering mt cell lines separate 
from wt cell lines. As one can observe, none of the mutations have a big effect from the 
absolute values, but they vary in whether they are positive or negative.  
The next column of Tables 6.3 and 6.5 shows the significance of mutation status on the gene 
when considered in conjunction with etoposide resistance (as an effect on TDP2 levels or 
TOP2/TDP2 ratios). While the previous p-values measure the probability of the null hypothesis 
that the slope is 0 when taking into account the mutation status of each gene, the p-values of 
this column show how significant the difference is in TDP2 levels or TOP2/TDP2 ratios for 
points with the same etoposide sensitivity but different forms of the gene. This is measured by 
identifying if the intercept between the best fit lines for mutant and wt is different. In other 
words, how likely is it for a cell line with a mutation for a gene of interest to have a different 
response to etoposide, compared to another cell line that doesn’t carry that mutation but has 
the same TDP2 levels or TOP2/TDP2 ratios as the mutated cell line? If this p-value is significant, 
then the answer to the above question is that it’s likely, while if the p-value is not significant, 
then the answer is unlikely. While for most of the genes in breast cancer cell lines, this p-value 
is not significant, there is one gene that demonstrated significant p-values for both 
TOP2A/TDP2 and TOP2B/TDP2 ratios and that is PIK3CA, although it doesn’t show this for 
TDP2 protein levels. This is interesting, because the same gene for the same phenotypes 
demonstrated a significant p-value for when only the phenotypes and not sensitivity to 
etoposide where considered, along with the mutation status of the genes. It is likely that the 
significant p-value seen for the intercepts is due to the difference in TOP2/TDP2 ratios 
between mutated and wild type cell lines, rather than the response to etoposide. For TP53, the 
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p-value is the lowest non-significant value for TDP2 protein levels. In the lung cancer cell lines, 
there are more genes that have a significant p-value, but that is limited to TDP2 protein levels 
only. These genes are EGFR, PTEN and SMARCA4. The final column of Table 6.3 and 6.5 lists the 
estimate of difference between the intercepts of the mt and the wt cell lines for each gene. If 
this value is positive, the mutation is likely to decrease resistance to etoposide for the same 
levels of TDP2 or TOP2/TDP2 ratios and if negative it is likely to have the opposite effect and 
increase resistance to etoposide. There is a variation of the effect of each mutation to the 
three studied phenotypes. For most of the cell lines the absolute value is far greater for 
TOP2A/TDP2 ratio compared to the other phenotypes, with PIK3CA demonstrating the highest 
change compared to all the other mutations in breast cancer cell lines and MAX in lung cancer 
cell lines.  
6.3 Discussion 
Given the complexity of the statistical model used and due to the large amount of data that 
needed to be organised and analysed, a summary of all the available information for each gene 
is essential in order to reach a conclusion of the nature of the effect a mutation can have in 
TDP2 protein levels, TOP2/TDP2 protein ratios and sensitivity to etoposide, when these effects 
are considered together or separate. Although the method used to analyse this data is 
complex, it is to my knowledge the simplest possible way of investigating the relationship 
between the 3 variables (Etoposide sensitivity, mutation status and TDP2 levels or ratios). 
CDH1 is a gene that plays a role in cell proliferation by targeting multiple cell-cycle regulators 
for ubiquitin-dependent degradation (Eguren et al., 2014). This is a high-penetrance breast 
cancer gene and its mutation has been reported to be associated with hereditary breast cancer 
(Shiovitz and Korde, 2015). It has also been reported that cells lacking CDH1 expression display 
various defects, including impaired DNA repair (de Boer et al., 2016). TOP2A has been 
identified as a CDH1 target, with TOP2A levels showing an increase in CDH1 depleted cells, and 
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lack of CDH1 has been shown to result in dramatic sensitivity to etoposide (Eguren et al., 
2014). My results have shown that the CDH1 mutation affects etoposide resistance in breast 
cancer cell lines by increasing the IC50 concentration of mutated cells by 24 μM, rendering 
them more resistant. That result, however, is not significant and therefore cannot be taken as 
a disagreement to what other people have seen. When considering the mutated cell lines 
separately from the wt ones in regard to a possible relationship between TDP2 levels and 
etoposide sensitivity, there was an increase in how well the data fit the best fit lines, but the p-
values for the slopes showed than none of them were significant. The same can be said for the 
intercepts of the mt and wt best fit lines. There was also no significant effect of the mutation 
on TDP2 levels on their own. For TOP2/TDP2 levels, none of the results are significant too, but 
there is a difference in the slope p-values of the single best fit line versus the separate best fit 
lines, where the data appear to fit better to the single best fit line, as the p-value for that is 
lower. Due to only having data for 6 breast cancer cell lines for this gene and the fact that all 
the statistical analysis points towards non-significant mutation effect, I cannot draw the 
conclusion that CDH1 mutation has an effect on etoposide sensitivity alone or in relation to 
TDP2 protein levels and TOP2/TDP2 ratios, or the phenotypes on their own.  
The next gene is CDKN2A, which is a gene known to cause cancer susceptibility, with increased 
breast cancer risk described in families with CDKN2A mutations (Maxwell et al., 2015). It is 
estimated to be one of the most commonly mutated genes in cancer (for example, pancreatic 
and melanoma) and its proteins act as tumour suppressors, by preventing premature 
transition from G1 to S phase (Zhen et al., 2015). My results for the breast cancer cell lines, 
much like CDH1, did not produce significant p-values. CDKN2A mutation does not affect 
etoposide sensitivity, TDP2 levels or TOP2/TDP2 ratios. The slope p-values for a single best fit 
line were lower than the slope for the two best fit lines for TDP2, but the opposite for both 
TOP2/TDP2 ratios. The difference between the intercepts for the mutated cell lines and the wt 
ones also didn’t have a significant p-value. Therefore, I cannot conclude that a CDKN2A 
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mutation could have an effect on etoposide sensitivity alone or in relation to TDP2 protein 
levels and TOP2/TDP2 ratios, or the phenotypes studied on their own. 
CREBBP is a gene involved in the transcriptional co-activation of different transcription factors, 
and chromosomal translocations involving CREBBP have been associated with acute myeloid 
leukemia, especially after adjuvant chemotherapy for breast cancer (Gupta et al., 2014). The 
analysis results for this gene were not significant and were very similar to the CDKN2A results. 
CREBBP mutation does not have an effect on etoposide IC50 concentration, TDP2 levels or 
TOP2/TDP2 ratios. The slope p-values for the single best fit line were lower than the slope of 
the two best fit lines for TDP2, but the opposite was true for both TOP2/TDP2 ratios. The 
difference between the intercepts for the mt cell lines and the wt ones also didn’t produce a 
significant p-value. Therefore, I conclude that CREBBP is unlikely to have an effect on 
etoposide sensitivity alone or in relation to TDP2 protein levels and TOP2/TDP2 ratios, or the 
phenotypes studied on their own. 
EGFR (epidermal growth factor receptor) is a well studied gene in relation to both breast and 
lung cancer. It is overexpressed in a subset of HER2-positive breast cancers, and co-expression 
of HER2 and EGFR has been associated with poor clinical outcome (Lee et al., 2015b). 
Inhibition of EGFR activation has been shown to limit proliferation in breast cancer cells 
(Sathya et al., 2014). Patients with NSCL cancer tumours have common and uncommon 
mutations at the EGFR gene (Yang et al., 2015a). Inhibition of EGFR has been shown to 
downregulate TOP2 expression (Qi et al., 2013). EGFR mutation did not have a significant 
effect in breast cancer cells. It didn’t have a significant impact on etoposide sensitivity, TDP2 
levels or TOP2/TDP2 ratios. The slope p-values when the mutation was taken into 
consideration and when it wasn’t, were very similar. A much higher number of data points 
seems to be necessary in order to study this mutation’s effect on the phenotypes and 
relationships I was investigating. On the other hand, even though most p-values are also not 
140 
 
significant in the lung cancer cell lines, the p-value for the effect of EGFR mutation on TDP2 
protein levels independent of etoposide sensitivity, is significant and combined with the 
estimate of the effect, it appears that the mutation decreased the TDP2 level. This is likely the 
explanation for why there is also a significant difference between the intercepts of the best fit 
lines when the mt and wt cell lines are considered separately, which shows that the data fits 
the separate best fit lines better, as well as the slope p-value of these best fit lines. This is a 
very interesting result, that could be studied further in a laboratory setting, where additional 
lung cancer cell lines for which information about EGFR mutation status is available, can be 
pre-selected for measuring TDP2 protein levels, rather than using cell lines with an unavailable 
EGFR profile.  
PIK3CA is another gene that has been shown to be involved in cancer. PIK3CA mutations are 
the most common in breast cancer, having been reported in over one third of cases. They are 
very prominent in HER2-positive breast tumours (as high as 23%), which is associated with 
poor prognosis (Majewski et al., 2015). They frequently co-exist with other common cancer 
related mutations, such as EGFR and KRAS - two genes that are relevant to this chapter, in 
NSCLC and they are related to poor prognosis for that type of cancer (Wang et al., 2014). 
PIK3CA mutations have also been found to be negatively associated with TOP2A gene 
amplifications, where 28% of the wt breast tumours studied had an amplified TOP2A gene, 
compared to 14% of mt breast tumours (Fountzilas et al., 2012). In the breast cancer cells, the 
PIK3CA mutation did not have a significant effect on etoposide sensitivity or TDP2 protein 
levels, but it did have a significant effect on TOP2A/TDP2 and TOP2B/TDP2 ratios. The effect 
estimate is negative for both ratios, thus a negative correlation, meaning the mutation 
decreases the ratio. This could be interpreted as the PIK3CA mutation having a possible 
negative effect on TOP2 protein levels, which agrees with the group that saw a similar effect 
on TOP2A expression levels (Fountzilas et al., 2012). The results for the lung cancer cell lines 
are not as interesting, as none of the observed differences are significant. The mutation has no 
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effect on etoposide sensitivity, TDP2 levels or TOP2/TDP2 ratios on their own, or etoposide 
sensitivity in relation to all the studied phenotypes.  
PTEN is a commonly known tumour suppressor that is frequently mutated in a large number of 
cancers, including breast and NSCL cancers (Kechagioglou et al., 2014, Pérez-Ramírez et al., 
2015). In breast cancer cell lines, none of the calculated p-values were of significance, but for 
all phenotypes studied, the slope p-value of the best fit lines arising when the mt cell lines are 
considered separately from the wt cell lines, is smaller than when all cell lines are grouped 
together. For the lung cancer cell lines, the PTEN mutation has a significant effect on TDP2 
protein levels, but not the other phenotypes or on etoposide sensitivity. From the value of the 
effect estimate, one can see that the mutation reduces the levels of TDP2, as this value is 
negative. When looking at the relationships between the phenotypes and etoposide 
sensitivity, the difference seen between the intercepts of the best fit lines that arise from 
separating the cell lines into two groups is only significant for the TDP2 phenotype, which can 
be attributed to the effect the mutation has on TDP2 protein levels.  
Even a quick search for TP53 and cancer will give thousands of results. There are dedicated 
databases that collect information on mutations solely of this gene. TP53 mutations in breast 
cancer have been associated with poor prognosis, but they have different clinical relevance in 
different breast cancer subtypes (Silwal-Pandit et al., 2014). TP53 mutations are also very 
common in NSCLC, but their role as a prognostic marker is not clear due to the large variation 
(Govindan and Weber, 2014). TDP2 has been found to be a transcriptional target of mt p53 
and a mt p53 knock-down reduced both the mRNA and protein levels of TDP2 (Do et al., 2012). 
In the same publication it was also shown that suppressing of TDP2 sensitizes cells that express 
mt p53 to etoposide, and that mt p53 and TDP2 are frequently overexpressed in lung cancer 
(Do et al., 2012). In the breast cancer cell lines, I indeed observed a significant effect of TP53 
mutation on TDP2 protein levels, with a positive estimate effect, which means that the 
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mutation increased TDP2 levels. I didn’t find a similar effect in the lung cancer cells, which 
could be attributed to lack of enough data points. On the other hand there was a significant 
slope for both the single and double best fit lines.  
KRAS is a gene that is normally involved in normal tissue signalling, but its mutation predicts an 
increased risk of several cancers, including NSCLC and triple negative breast cancer, especially 
for women (McVeigh et al., 2015). KRAS mutant lung cancers comprises of 25-30% of lung 
adenocarcinomas (subtype of NSCLC) without an effective treatment available (Mortazavi et 
al., 2015). However any differences observed in the lung cancer cell lines, were unfortunately 
non-significant.  
MAX encodes a protein that interacts with the Myc protein, an oncoprotein implicated in cell 
proliferation, differentiation and apoptosis (Cascón and Robledo, 2012). Mutations of MAX 
have been associated with hereditary pheochromocytoma, which is a rare neural crest cell 
tumour that localises mainly within the adrenal medulla and rarely metastasizes (Cascón and 
Robledo, 2012). This gene was found to have a significant effect on both etoposide sensitivity 
(the highest observed in lung cancer) and TOP2A/TDP2 protein ratio in lung cancer cell lines. 
With all statistical analysis, there is always a chance that a significant result is a false positive 
and it’s likely that this is true for this gene, as it has been shown to be involved in a rare form 
of cancer and not in breast or lung cancer. The gene did not, however, demonstrate a 
significant effect when these two factors were considered together, likely because there is 
very little variation in either the mt or wt group for etoposide IC50 values.  
SMARCA4, also known as BRG1, has been proposed as a possible tumour suppressor, as it has 
been found to induce cell growth arrest after ectopic expression in tumour cells lacking 
SMARCA4, as well as its possible interaction with tumour suppressor proteins, such as BRCA2 
(Medina et al., 2008). In lung cancer cell lines for TDP2 protein levels, the mt cell lines and the 
wt cell lines, when considered separately, fit their respective best fit lines significantly better 
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that when considered separately, with the slope being of significance too. These results 
suggest that this gene may be of interest when studying the effect of TDP2 levels. 
STK11, also known as LKB1, is somatically inactivated through point mutations and large 
deletions in lung cancers, which are very common in non-small cell lung cancer, especially 
adenocarcinomas and colorectal cancer (Rodriguez-Nieto and Sanchez-Cespedes, 2009, 
Launonen, 2005). Unfortunately, the statistical analysis for this gene in lung cancer cell lines 
has shown that any differences are not significant. 
In summary, this chapter has revealed some very interesting results in its attempt to explain 
why no correlation was found between sensitivity to etoposide and TDP2 protein levels or 
TOP2/TDP2 ratios. After a rigorous process of elimination of available data from different 
database sources and statistical modelling, mutations in certain genes were shown to have 
played a possible role. EGFR mutation in lung cancer cell lines shows a significant positive 
correlation with TDP2 protein levels, and could possibly affect the relationship between TDP2 
protein levels and sensitivity to etoposide, although that could be through its effect on TDP2. 
PIK3CA mutation in breast cancer cell lines had a significant negative effect on TOP2A/TDP2 
and TOP2B/TDP2 ratios, but not on TDP2 protein levels. This is in agreement with a group that 
has shown that the PIK3CA mutation decreased TOP2 expression levels (Fountzilas et al., 
2012). PTEN mutation in lung cancer cell lines had a significant negative effect on TDP2 protein 
levels and it was also shown to have a possibly significant effect on the relationship between 
TDP2 protein levels and sensitivity to etoposide, although similar to EGFR that could be due to 
its effect on TDP2 levels. TP53 mutation in breast cancer cell lines shows a significant positive 
correlation with TDP2 protein levels. SMARCA4 mutation in lung cancer cell lines appears to 
have a significant effect on the relationship between TDP2 protein levels and etoposide 
sensitivity, when the mutation is taken into account. 
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In conclusion, I identified three mutations (EGFR, PTEN and TP53) that could possibly have an 
effect on TDP2 protein levels, something that would be interesting to explore further, 
especially how this effect arose. Mutant TP53 has already been shown to target TDP2 
transcription and mt p53 knock-down was shown to reduce both the mRNA and protein levels 
of TDP2, which agrees with the positive correlation I discovered (Do et al., 2012). I also 
identified a mutation (PIK3CA) that appears to negatively affect TOP2 protein levels, which also 
agrees with published work (Fountzilas et al., 2012). Finally, I identified a mutation (SMARCA4) 
that has a significant effect on the relationship between TDP2 protein levels and etoposide 
sensitivity. These 5 mutations could all be contributing to the lack of correlation I observed in 
Chapter 5, between etoposide sensitivity and either TDP2 protein levels or TOP2/TDP2 protein 
ratios. 
All this data serves to show how certain biological relationships that might appear in a 
hypothesis as straightforward, simple and logical, are actually very difficult to verify in a 
laboratory setting. It is not surprising that many research groups have moved on to exploring 
TDP2 inhibitors, rather than looking at intrinsic levels of TDP2. As I have shown here the 
naturally occurring variation in two types of cancer cell lines, is not enough to significantly 
affect etoposide sensitivity.  
This chapter has also made a contribution in the mutation profiles of several breast and lung 
cancer cell lines that are available for use in the Caldecott lab and as an extension, the whole 
Genome Damage and Stability Centre, as well as other collaborators. This extensive list of 
thousands of mutations is available in Appendices 6 and 7. This chapter demonstrated the 
importance of being aware of the mutation profiles of the cell lines that a researcher is 
considering using for an experiment, as certain cell lines are not used as extensively in 
scientific experiments and therefore a lot less information is available to help with data 
interpretation. Having this information available for the cell lines used can serve to explain 
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certain unexpected results. In some cases potentially interesting mutations may have been 
missed simply because information was unavailable for enough cell lines. 
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7. CHAPTER SEVEN – Potential use of TDP2 as a biomarker of sensitivity 
to a panel of ant-cancer drugs 
7.1 Introduction 
As it has been discussed in previous chapters, TDP2 is an important factor in TOP2-mediated 
DSBs that has received little attention in terms of its possible relationship with non-TOP2 
related drugs. There are a number of anti-cancer drugs or compounds currently in clinical 
trials, and so it stands to reason that some of them may have unknown interactions with TDP2 
or a possible correlation with TDP2 protein levels. I have access to TDP2 protein levels in 8 lung 
cancer cell lines and 8 breast cancer cell lines from my experimental results from Chapters 3 
and 4, and there are several databases dedicated to anti-cancer drugs. Therefore I decided to 
mine data and take a first step towards identifying other relevant compounds for which TDP2 
might be a biomarker for sensitivity or clinical outcome based on the phenotype profiles I have 
experimental data for. Using statistical tests, I was able to organise and analyse the data 
collected, combined with my own data to make a shorter list that could be tested 
experimentally in the future. 
The first step was to collect the appropriate data. The database with information about the 
most drugs and their pharmacological profiling across the largest number of cancer cell lines 
was CancerDR (Kumar et al., 2013). CancerDR is a database that has collected information for 
148 anti-cancer drugs and their profile in 952 cancer cell lines from the COSMIC and CCLE 
databases and has organised it in an accessible manner. Out of these drugs, 36 are FDA 
approved drugs, 48 are or have been in clinical trials and 64 are experimental drugs. Figure 7.1 
summarises the curation methods applied to the data collected from COSMIC and CCLE 
databases. 
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CancerDR is composed of a curated version of the release 2 of ‘Genomics of drug sensitivity in 
cancer’ (a COSMIC project), where 138 anti-cancer drugs targeting a wide range of therapeutic 
targets were screened in 714 cancer cell lines, and a study by CCLE, where 24 drugs were 
screened in 503 cancer cell lines (Barretina et al., 2012, Garnett et al., 2012). Further 
information about the anti-cancer drugs is mined from PubChem (Bolton et al., 2008). I also 
utilised PubChem as an information source to acquire information about the relevant anti-
cancer drugs I studied in this chapter. In addition I used DrugBank, a large bioinformatics and 
cheminformatics resource that combines chemical, pharmacological and pharmaceutical drug 
data with sequence, structure, and pathway information for the drug target (Wishart et al., 
2006). To access further information about certain drugs’ clinical trial status, I also referred to 
ClinicalTrials.gov, a clinical trial database maintained by the U.S. National Library of Medicine 
Figure 7.1: Schematic representation of the curation procedure followed by CancerDR (Kumar et al., 2013). 
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at the National Institutes of Health that currently lists 230,427 studies with locations in 194 
countries (Zarin et al., 2016). 
7.1.1 Aims of this chapter 
This chapter aims to use existing information on drug sensitivities to assess whether TDP2 
protein levels could be used as a biomarker for sensitivity to drugs other than etoposide. 
7.2 Results 
The first step of selection was to search for anti-cancer drugs in CancerDR, for which there was 
information on IC50 values for the breast and lung cancer cell lines I had studied in the 
previous chapters and had characterised for TDP2 protein levels and TOP2/TDP2 protein 
ratios. As with the mutations in the previous chapter, I was not able to find this information for 
each drug in every cell line I had utilised. In order to obtain meaningful statistical results, I 
required drugs for which I had information for a minimum of 5 cancer cell lines for each type, 
with at least one variation in IC50 values. The statistical analysis method is described in detail 
in Chapter 2.6. This limitation reduced the analysed drugs to 113 for the breast cancer cells 
and 194 for the lung cancer cells.  
For these two sets of drugs the Pearson correlation coefficient or r coefficient and the 
corresponding p-values were calculated for the three phenotypes. r coefficients show how 
good the correlation is between drug resistance and the studied phenotypes. Negative values 
mean that there is a negative correlation (when one value increases, the other decreases) and 
positive values mean that there is a positive correlation (when one value increases, the other 
increases too in a similar manner). The values can only be between -1 and 1, with the extreme 
values showing a perfect correlation. The question it is trying to answer is, do TDP2 protein 
level values (or the other two phenotype values) and drug IC50 concentrations co-vary, i.e. 
change in a co-dependent manner, when compared with the variance in TDP2 levels and drug 
resistance for the available cell lines? The drugs that produced at least one significant p-value 
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for any of the three phenotypes were shortlisted. These results are shown in Tables 7.1 and 7.2 
for breast and lung cell lines respectively. The complete data for all drugs 113 for the breast 
cancer cells and all 194 for the lung cancer cells can be found in Appendices 8 and 9, 
respectively. 
Table 7.1: Statistical analysis results of TDP2 protein levels, TOP2A/TDP2 protein ratio 
and TOP2B/TDP2 protein ratio and their correlation with sensitivity (IC50 values) to 
each curated anti-cancer drug in breast cancer cell lines.   
Drug 
Original 
source 
 
TOP2A/ 
TDP2  
r-value 
TOP2B/ 
TDP2  
r-value 
TDP2  
p-value 
TOP2A/ 
TDP2 
p-value 
TDP2B/ 
TDP2 
p-value 
TDP2  
r-value 
ABT888 COSMIC -0.508 0.934 0.513 0.382 0.020 0.376 
AEW541 CCLE 0.967 -0.571 -0.749 0.007 0.314 0.145 
AKT inhibitor 
VIII COSMIC -0.859 0.434 0.896 0.062 0.466 0.039 
AP24534 COSMIC 0.972 -0.059 -0.782 0.006 0.925 0.118 
Axitinib COSMIC -0.113 0.984 0.062 0.856 0.002 0.921 
AZD6482 COSMIC -0.826 0.020 0.911 0.085 0.975 0.032 
BIBW2992 COSMIC -0.931 0.277 0.616 0.022 0.652 0.269 
FTI277 COSMIC -0.724 0.125 0.924 0.166 0.841 0.025 
Nilotinib COSMIC -0.343 0.947 0.432 0.572 0.015 0.468 
NU7441 COSMIC -0.240 0.895 -0.014 0.697 0.040 0.982 
Nutlin3 CCLE 0.643 -0.995 -0.922 0.242 0.000 0.026 
PD0332991 COSMIC 0.050 0.901 -0.193 0.936 0.037 0.755 
TKI258 CCLE 0.862 -0.932 -0.959 0.060 0.021 0.010 
Vorinostat COSMIC -0.751 0.146 0.972 0.143 0.815 0.006 
VX702 COSMIC -0.601 0.892 0.467 0.283 0.042 0.428 
ZM447439 COSMIC -0.165 0.968 0.041 0.791 0.007 0.948 
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Table 7.2: Statistical analysis results of TDP2 protein levels, TOP2A/TDP2 protein ratio and 
TOP2B/TDP2 protein ratio and their correlation with sensitivity (IC50 values) to each curated 
anti- cancer drug in lung cancer cell lines.   
Drug 
Original 
source 
  TOP2A/ 
TDP2  
r-value 
TOP2B/ 
TDP2  
r-value 
TDP2   
p-value 
TOP2A/ 
TDP2  
p-value 
TDP2B/ 
TDP2  
p-value 
TDP2  
r-value 
AG014699 COSMIC -0.860 -0.324 -0.390 0.028 0.531 0.445 
AKT inhibitor 
VIII COSMIC 0.251 0.972 0.213 0.684 0.005 0.731 
AS601245 COSMIC 0.358 0.607 0.949 0.554 0.277 0.014 
Bicalutamide COSMIC 0.960 0.539 0.469 0.010 0.349 0.426 
Bleomycin COSMIC 0.351 0.953 0.186 0.563 0.012 0.765 
BMS708163 COSMIC -0.852 -0.486 -0.497 0.031 0.329 0.316 
BMS754807 COSMIC -0.639 -0.239 -0.917 0.245 0.699 0.028 
BX795 COSMIC -0.920 -0.220 -0.272 0.009 0.675 0.602 
Camptothecin COSMIC -0.919 -0.313 -0.403 0.010 0.546 0.428 
CEP701 COSMIC -0.931 -0.298 -0.327 0.007 0.567 0.527 
CHIR99021 COSMIC 0.440 0.922 0.111 0.458 0.026 0.859 
CI1040 COSMIC -0.939 -0.371 -0.411 0.005 0.469 0.419 
DMOG COSMIC 0.361 0.906 0.172 0.551 0.034 0.782 
FTI277 COSMIC 0.293 0.975 0.561 0.632 0.005 0.326 
Nilotinib COSMIC 0.310 0.054 -0.836 0.550 0.919 0.038 
Obatoclax 
Mesylate COSMIC -0.983 -0.329 -0.418 0.003 0.589 0.484 
PF562271 COSMIC -0.064 0.918 0.183 0.918 0.028 0.768 
QS11 COSMIC -0.938 -0.288 -0.442 0.018 0.639 0.456 
RDEA119 COSMIC -0.924 -0.247 -0.292 0.008 0.637 0.575 
SL01011 COSMIC 0.302 0.943 -0.049 0.561 0.005 0.927 
Thapsigargin COSMIC -0.994 -0.356 -0.367 0.001 0.556 0.543 
Tipifarnib COSMIC 0.170 0.964 0.205 0.785 0.008 0.741 
TW37 COSMIC -0.873 -0.102 -0.171 0.023 0.848 0.746 
Vinblastine COSMIC -0.889 -0.514 -0.562 0.018 0.297 0.246 
AZD6482 COSMIC -0.862 -0.203 -0.487 0.027 0.700 0.327 
 
There is a large variety in the results of both r-values and p-values. When an r-value is close to 
either -1 or 1, it is highly likely that its p-value will be significant. p-values can also depend on 
other factors, such as the number of data points. For the breast cancer cell lines, the drugs that 
showed a significant (p-value < 0.05) correlation between how resistant the different cell lines 
were based on their TDP2 protein levels, were AEW541 (positive), AP24534 (positive) and 
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BIBW2992 (negative). Based on the breast cell lines’ TOP2A/TDP2 protein ratios, the drugs that 
showed significant results were ABT888 (positive), Axitinib (positive), Nilotinib (positive), 
NU7441 (positive), Nutlin3 (negative), PD0332991 (positive), TKI258 (negative), VX702 
(positive) and ZM447439 (positive). For the TOP2B/TDP2 protein ratios for the same type of 
cell lines, significant correlation results were found for AKT inhibitor VIII (positive), AZD6482 
(positive), FTI277 (positive), Nutlin3 (negative), TKI258 (negative) and Vorinostat (positive).  
For the lung cancer cell lines, the drugs that showed a significant correlation (p-value < 0.05) 
between how resistant the different cell lines were based on their TDP2 protein levels, were 
AG014699 (negative), Bicalutamide (positive), BMS708163 (negative), BX795 (negative), 
Camptothecin (negative), CEP701 (negative), CI1040 (negative), Obatoclax Mesylate (negative), 
QS11 (negative), RDEA119 (negative), Thapsigargin (negative), TW37 (negative), Vinblastine 
(negative) and AZD6482 (negative). The drugs that showed significant results for the 
TOP2A/TDP2 ratio phenotype were AKT inhibitor VIII (positive), Bleomycin (positive), 
CHIR99021 (positive), DMOG (positive), FTI277 (positive), PF562271 (positive), SL01011 
(positive) and Tipifarnib (positive). The significant results for TOP2B/TDP2 ratios were 
AS601245 (positive), BMS754807 (negative) and Nilotinib (negative). 
Figures 7.2 and 7.3 depict the scatter plots for the drugs listed in Tables 7.1 and 7.2 for breast 
and lung cancer cell lines respectively. The x axis shows the IC50 concentrations for each drug 
and the y axis each of the studied phenotypes (TDP2 levels and TOP2/TDP2 ratios). Next to 
each drug name, the original source of the information is also stated (COSMIC or CCLE). These 
scatter plots can be used to better visualise the results in Tables 7.1 and 7.2, which will be 
analysed in the next few paragraphs.  
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Figure 7.2: Breast cancer cell lines: Scatter plots for curated anti-cancer drugs depicting IC50 concentrations for 
each drug obtained from CancerDR database, plotted against the three experimentally studied phenotypes, 
TDP2 protein levels, TOP2A/TDP2 protein ratios and TOP2B/TDP2 protein ratios. Each set of plots also shows 
the original source of the database data. A) Drug: ABT888, Source: COSMIC. B) Drug: AEW541, Source: CCLE. C) 
Drug: AKT Inhibitor VIII, Source: COSMIC. D) Drug: AP24534, Source: COSMIC. E) Drug: Axitinib, Source: 
COSMIC. F) Drug: AZD6482, Source: COSMIC. G) Drug: BIBW2992, Source: COSMIC. H) Drug: FTI277, Source: 
COSMIC. I) Drug: Nilotinib, Source: COSMIC. J) Drug: NU7441, Source: COSMIC. K) Drug: Nutlin3, Source: CCLE. 
L) Drug: PD0332991, Source: COSMIC. M) Drug: TKI258, Source: CCLE. N) Drug: Vorinostat, Source: COSMIC. O) 
Drug: VX702, Source: COSMIC. P) Drug: ZM44739, Source: COSMIC. 
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The drug targets, alternative names, their targets and their present use can be found in Table 
7.3. 
Figure 7.3: Lung cancer cell lines: Scatter plots for curated anti-cancer drugs depicting IC50 concentrations for 
each drug obtained from CancerDR database, plotted against the three experimentally studied phenotypes, 
TDP2 protein levels, TOP2A/TDP2 protein ratios and TOP2B/TDP2 protein ratios. Each set of plots also shows 
the original source of the database data. A) Drug: AG014699, Source: COSMIC. B) Drug: AKT Inhibitor VIII, 
Source: COSMIC. C) Drug: AS601245, Source: COSMIC. D) Drug: Bicalutamide, Source: COSMIC. E) Drug: 
Belomycin, Source: COSMIC. F) Drug: BMS708163, Source: COSMIC. G) Drug: BMS754807, Source: COSMIC. H) 
Drug: BX795, Source: COSMIC. I) Drug: Camptothecin, Source: COSMIC. J) Drug: CEP701, Source: COSMIC. K) 
Drug: CHIR99021, Source: COSMIC. L) Drug: CI1040, Source: COSMIC. M) Drug: DMOG, Source: COSMIC. N) 
Drug: FTI277, Source: COSMIC. O) Drug: Nilotinib, Source: COSMIC. P) Drug: Obatoclax Mesylate, Source: 
COSMIC. Q) Drug: PF562271, Source: COSMIC. R) Drug: QS11, Source: COSMIC. S) Drug: RDEA119, Source: 
COSMIC. T) Drug: SL01011, Source: COSMIC. U) Drug: Thapsigargin, Source: COSMIC. V) Drug: Tipifarnib, Source: 
COSMIC. W) Drug: TW37, Source: COSMIC. X) Drug: Vinblastine, Source: COSMIC. Y) Drug: AZD6482, Source: 
COSMIC. 
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Table 7.3: A list of all the curated drugs discussed in this chapter with their alternative 
names, targets and present use. 
Drug 
Also known 
as Target Use References  
ABT888 Veliparib PARP1/2 
Phase 1/2/3 
clinical trials for 
cancer therapy 
(Donawho et al., 
2007) 
AEW541   IGF-IR 
Commercially 
available for 
laboratory use 
as inhibitor 
(García-Echeverría 
et al., 2004) 
AG014699 Rucaparib PARP 
Phase 1/2/3 
clinical trials for 
cancer therapy 
(White et al., 
2000) 
AKT inhibitor 
VIII   Akt1/2 
Commercially 
available for 
laboratory use 
as inhibitor 
(Lindsley et al., 
2005) 
AP24534 Ponatinib BCR-ABL wt/mt Cancer therapy 
(O'Hare et al., 
2009) 
AS601245   JNK 
Commercially 
available for 
laboratory use 
as inhibitor 
(Carboni et al., 
2004) 
Axitinib   
VEGFR 1/2/3,  
PDGFRβ, c-Kit Cancer therapy (Rugo et al., 2005) 
AZD6482   PI3Kβ 
Has been in 
clinical trials for 
its antiplatelet 
effect 
(Nylander et al., 
2012) 
BIBW2992 Afatinib EGFR, HER2/4 Cancer therapy (Reid et al., 2007) 
Bicalutamide ICI 176,334 Androgen receptor Cancer therapy (Furr et al., 1987) 
Bleomycin   DNA Cancer therapy (Umezawa, 1965) 
BMS708163   γ-Secretase 
Has been in 
clinical trials for 
Alzheimer's 
(Gillman et al., 
2010) 
BMS754807   IGF-IR 
Has been in 
clinical trials for 
cancer 
(Wittman et al., 
2009) 
BX795   TBK1, IKKε, PDK1 
Commercially 
available for 
laboratory use 
as inhibitor (Clark et al., 2009) 
Camptothecin 
Topotecan, 
Irinotecan TOP1 
Derivatives used 
in cancer 
therapy (Wall et al., 1966) 
CEP701 KT-5555 
FLT3, JAK2, 
TrkA/B/C 
Has been in 
clinical trials for 
cancer 
(Miknyoczki et al., 
1999) 
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CHIR99021   GSK-3 
Commercially 
available for 
laboratory use 
as inhibitor (Tighe et al., 2007) 
CI1040 PD184352 MAPK 
Commercially 
available for 
laboratory use 
as inhibitor 
(Sebolt-Leopold et 
al., 1999) 
DMOG   
Prolyl 4-
hydroxylase 
Commercially 
available for 
laboratory use 
as inhibitor 
(Asikainen et al., 
2005) 
FTI277   Farnesyltranserase 
Commercially 
available for 
laboratory use 
as inhibitor 
(Lerner et al., 
1995) 
Nilotinib   AMN107 
BCR-ABL, c-kit, 
PDGF Cancer therapy 
(Weisberg et al., 
2005) 
NU7441   DNA-PK 
Commercially 
available for 
laboratory use 
as inhibitor (Leahy et al., 2004) 
Nutlin3   
MDM2-p53 
interaction 
Commercially 
available for 
laboratory use 
as inhibitor 
(Vassilev et al., 
2004) 
Obatoclax 
Mesylate   Bcl-2 
Has been in 
clinical trials for 
cancer 
(Nguyen et al., 
2007) 
PD0332991 Palbociclib CDK4/6 Cancer therapy (Fry et al., 2004) 
PF562271   FAK 
Commercially 
available for 
laboratory use 
as inhibitor 
(Roberts et al., 
2008) 
QS11   
ARFGAP1, Wntβ-
catenin pathway 
Commercially 
available for 
laboratory use 
as inhibitor 
(Zhang et al., 
2007) 
RDEA119 
Refametinib, 
Bay 86-9766 MEK1/2 
Commercially 
available for 
laboratory use 
as inhibitor 
(Iverson et al., 
2009) 
SL01011   RSK 
Commercially 
available for 
laboratory use 
as inhibitor (Smith et al., 2005) 
Thapsigargin   SERCA 
Commercially 
available for 
laboratory use 
as inhibitor (Hakii et al., 1986) 
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Tipifarnib   Farnesyltransferase 
Phase 1/2/3 
clinical trials for 
cancer therapy (End et al., 2001) 
TKI258 
CHIR-258, 
Dovitinib Multiple kinases 
Phase 1/2/3 
clinical trials for 
cancer therapy 
(Trudel et al., 
2005) 
TW37   Bcl-2 
Commercially 
available for 
laboratory use 
as inhibitor 
(Zeitlin et al., 
2006) 
Vinblastine   Tubulin Cancer therapy 
(Jordan and 
Wilson, 2004) 
Vorinostat   Histone kinases Cancer therapy 
(Marks and 
Breslow, 2007) 
VX702   p38 MAPKs 
Has been in 
clinical trials for 
rheumatoid 
arthritis 
(Kuliopulos et al., 
2004) 
ZM447439   Aurora B 
Commercially 
available for 
laboratory use 
as inhibitor 
(Ditchfield et al., 
2003) 
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7.3 Discussion 
The drugs that I will be focusing on in the discussion are drugs currently in use for cancer 
therapy, or are presently in clinical trials for their potential use in cancer therapy. A summary 
of these drugs and the correlation (positive or negative) of TDP2 protein levels, TOP2A/TDP2 
protein ratios and TOP2B/TDP2 protein ratios of the breast and lung cancer cell lines used in 
this chapter, with their resistance to these drugs (database data of IC50 values) can be seen in 
the following Table (Table 7.4). 
Table 7.4: Relevant drugs and the correlation of different phenotypes of breast and lung 
cancer cell lines used in this chapter, with resistance to these drugs (database data). 
  Breast cancer cell lines Lung cancer cell lines 
Phenotype Positive 
correlation 
Negative 
correlation 
Positive 
correlation 
Negative 
correlation 
TDP2 protein 
levels 
AP24534 BIBW2992 Bicalutamide AG014699 
      Camptothecin 
      Vinblastine 
TOP2A/TDP2 
protein 
ratios 
ABT888 TKI258 Bleomycin   
Axitinib   Tipifarnib   
Nilotinib       
PD0332991       
TOP2B/TDP2 
protein 
ratios Vorinostat TKI258   Nilotinib 
 
Anti-cancer drugs generally liaise with the cell cycle stages and fall under multiple categories, 
some of which are relevant to DNA damage and repair. Given how precious research funding 
is, a hypothesis is worth exploring when it is based on sound reasoning. My analysis looked at a 
large number of drugs with a variety of targets and thus some of the results, even though their 
IC50 values’ correlation was statistically significant with the phenotypes studied, could be false 
positives. That means that the phenotypes might not actually be affecting the IC50 
concentrations of these drugs found in the available cell lines.  Drugs that fall under this 
category are AP24534, that targets Bcr-Abl, a tyrosine kinase; BIBW2992, whose targets EGFR 
and HER2 are also tyrosine kinases; Axitinib, whose targets VEGFR 1/2/3,  PDGFRβ and c-Kit are 
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receptor protein kinases; PD0332991, that targets CDK4/6, both cyclin-dependent kinases; 
Vorinostat, whose targets are histone kinases; and finally Tipifarnib, that targets 
farnesyltransferase, an enzyme protein that modifies Ras proteins, which play a role in cellular 
signal transduction.  
TKI258 produced two significant correlations, unlike other drugs whose target does not seem 
relevant to TDP2, which is why I do not include it in that group. TKI258, which targets receptor 
tyrosine kinases that participate directly or indirectly in tumour growth, survival, angiogenesis, 
and vascular development, is currently in clinical trials for different types of cancer, including 
breast and NSCLC (Lee et al., 2015a). In the breast cancer cell lines, I found a negative 
correlation between resistance to TKI258 and both TOP2A/TDP2 and TOP2B/TDP2 protein 
ratios. It is interesting, because TKI258 has been shown to also target TOP2A by stabilizing the 
enzyme-cleavage complex and inducing DSBs (Hasinoff et al., 2012). This makes the correlation 
I saw very interesting and worth of further exploration in vivo. 
The only drug that both types of cell lines have in common is Nilotinib. Nilotinib is used as 
treatment for chronic myeloid leukaemia and has been designed to increase its affinity and 
specificity for the oncogenic tyrosine kinase Bcr-Abl (Ostendorf et al., 2014). Tyrosine kinases 
are responsible for the activation of many proteins by signal transduction cascades. Patients 
with chronic myeloid leukaemia have shown resistance to TOP2 inhibitors due to low TOP2 
expression (Valkov and Sullivan, 1997, Silber et al., 1989). I was not able to find further data 
about whether this meant TOP2A or TOP2B. Even though Nilotinib has been identified as 
having significant results for both types of cell lines, it is not used for treatment of breast or 
lung cancers. I believe that it would be interesting to further explore TDP2, TOP2A and TOP2B 
protein levels and Nilotinib resistance, as for the lung cancer cell lines I found that high 
TOP2B/TDP2 ratios mean lower resistance to Nilotinib. It is likely that TDP2 does not play a 
role, as a significant correlation was not found. 
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Vinblastine is a mitotic inhibitor that targets tubulins, which polymerise into microtubules, a 
major component of the cytoskeleton of eukaryotic cells. It has been shown that Vinblastine 
along with etoposide induced the formation of apoptotic TOP1 cleavage complexes (Sordet et 
al., 2006). TDP2 has been shown to promote the repair of TOP1-mediated DNA damage in 
TDP1 knock-out cells (Zeng et al., 2012). But I propose that the negative correlation between 
resistance to Viblastine and TDP2 protein levels that I found in the panel of lung cancer cell 
lines, can be explained by the increased proliferation in NSCLC observed when TDP2 is 
overexpressed (Li et al., 2011a). As high levels of TDP2 mean that there is increased 
proliferation, that also means that there is increased mitosis too, which is the target of 
Vinblastine.  Therefore, its target binding-target tubulin is available in larger numbers, making 
the drug more effective. This is a very interesting and unexpected correlation, which merits 
further investigation. 
ABT888 and AG014688 are both drugs that target PARP1 and are currently in multiple clinical 
trials at different stages, varying from stage 1 to stage 3 and for different types of cancer. The 
importance of PARP1 has been discussed in the introduction of this thesis extensively, as well 
as the upsurge of interest in PARP inhibitors. AG014688 was the first PARP inhibitor to enter 
clinical trials (Plummer et al., 2008). It is the phosphate salt of AG14447 and has improved 
aqueous solubility, but this name might be of use if one is interested further in this inhibitor’s 
background (Thomas et al., 2007). In lung cancer cell lines, I found a negative correlation 
between AG014688 resistance and TDP2 protein levels, which means that when TDP2 levels 
decrease there is higher resistance to AG014688. In breast cancer cells, I saw that when 
TOP2A/TDP2 protein ratios increase, then the resistance to ABT888 increases, which could be 
attributed to high TOP2A levels or low TDP2 levels. It would be very interesting to further 
investigate this result in a larger panel of cell lines. It has been shown that TOP2B associates 
with Ku70 and PARP1 during DSBR in primary neurons after peroxide mediated damage; DSBs 
in neurons follow two repair pathways, a Ku70 dependent and a PARP1 dependent (Mandraju 
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et al., 2011). Activation of gene transcription has been shown to involve TOP2B-mediated DSBs 
and following that PARP1 enzymatic activity (Ju et al., 2006, Ju and Rosenfeld, 2006). In 
addition, another group has shown that inhibition of PARP1 with the NU1025 inhibitor 
sensitized HeLa cells to the TOP2 inhibitor C-1305 (Sabisz et al., 2010). There is evidence that 
alludes to an interesting relationship between PARP1 and TOP2, and since TOP2 is so closely 
related to TDP2, I believe there is a possibility for TDP2 or its ratio to TOP2 to be a candidate 
for sensitivity to PARP1 inhibitors.  
Bleomycin was first characterised as an antibiotic, but due to its cytotoxic effects it is used as 
an anti-cancer drug. It works by binding to the DNA and introducing DSBs and SSBs, and their 
ratio in addition to absolute values, can determine which pathway will be followed for cell 
death: apoptosis, mitotic cell death, or pseudoapoptosis (Tounekti et al., 2001). It has also 
been shown that Bleomycin resistance is characterised by reduced DNA damage, shown via 
COMET and γH2AX assays in resistant cell lines (Wang et al., 2013). My results showed that 
TOP2A/TDP2 protein ratios had a positive correlation with Bleomycin resistance and given the 
role of both of these proteins in DSBR, Bleomycin could be a candidate for further exploring 
how its effect on cancer cells can be affected by TDP2 and TOP2.  
Camptothecin is a TOP1 inhibitor; TDP2-depleted cells have shown lack of hypersensitivity to 
it, compared to etoposide (Zeng et al., 2011). Further studies that look into intrinsic levels of 
TDP2 have not been published and as TDP2 has been shown to step in when TDP1 is absent 
and promote the repair of TOP1-mediated DNA damage in its place, it is not unlikely that the 
protein levels of TDP2 might have an effect on how a cancer cell will respond to treatment 
with camptothecin (Zeng et al., 2012). Therefore, it might be interesting to further expand on 
my results showing that high TDP2 protein levels had a negative impact on camptothecin 
resistance.  
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Bicalutamide, a non-steroidal anti-androgen, is a selective antagonist of the androgen 
receptor, preventing androgens from binding on and activating the androgen receptor; it is 
used primarily for the treatment of prostate cancer, as androgen receptor signalling is 
essential to the growth and survival of prostate cancer (Singh et al., 2000). It has been shown 
that androgen-deprived prostate cancer cells display transient TOP2B-dependent DSBs when 
exposed to androgen; the same group also showed that exposing androgen-deprived prostate 
cancer cells to Bicalutamide lead to increased DSB γH2AX foci formation (Coulter et al., 2015). 
In this chapter, I showed that there is a positive correlation between resistance to 
Bicalutamide and TDP2 protein levels. Given the involvement of TDP2 in resolving TOP2-
mediated DSBs, I believe that it merits further exploration in vivo. 
To conclude, I propose that TDP2 could be investigated as a possible biomarker of sensitivity 
for other anti-cancer drugs in a similar manner to my investigation of etoposide, as preliminary 
data show significant correlations of sensitivity and protein levels. Such research projects 
though entail a relatively high risk, as they are not mechanistic and therefore additional 
preliminary checks should be carried out. I would propose inclining towards investing in cell 
lines that are relevant to the types of cancer that these drugs are used for. But even before 
proceeding to obtain such cell lines for experimental data, they should be scrutinised for 
whether extensive information is available for their profile; for example, are IC50 values for 
these drugs available and do they vary? Have other researchers used those cell lines for similar 
models? And are their mutation profiles rich with information? These are important questions 
that need to be answered to ensure that risk in minimised.  
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8. CHAPTER EIGHT - Impact of the co-operative effects of etoposide, 
estradiol and PARP1 inhibitor on the survival of breast cancer cell lines  
8.1 Introduction 
In Chapter 5, a comparison of TDP2 protein levels and cell survival failed to show a correlation 
between TDP2 protein levels and sensitivity to etoposide, in neither breast nor lung cancer cell 
lines. In this chapter, I examined the co-operative effects of etoposide, estradiol and PARP1 
inhibitor on the survival of breast cancer cell lines.   
Estradiol, as mentioned in the introduction, is one of the most common estrogen hormones 
and is sometimes used as part of hormone cancer therapy in both women and men, especially 
breast cancer (Ingle, 2002). In addition, it has been implicated in higher breast and ovarian 
cancer risk in women that have been prescribed estradiol for menopause (Beral, 2003, Beral et 
al., 2007). My interest in estradiol reflects the ability of this hormone to induce TOP2-
dependent transcription programmes, which in turn are predicted to generate TOP2-
dependent DSBs. This may render breast cancer cells more sensitive to loss or inhibition of 
TDP2, either as a synthetic lethal effect or in conjunction with etoposide treatment. It has been 
previously shown that for successful signal-dependent activation of transcription by the 
estrogen receptor (ER), TOP2B needs to be recruited with the ER to regulatory sites on target 
genes in order for it to generate transient TOP2B-mediated DSBs (Haffner et al., 2011). 
Furthermore, there is evidence that shows PARP1 recruitment with TOP2B after treatment 
with estradiol (Ju et al., 2006). Inhibition of PARP1 decreased ERα binding to estrogen 
response element (short DNA sequence within ERα promoter) and prevented ERα-dependent 
gene transcription (Zhang et al., 2013). 
PARP1 is a protein that is crucial for the repair of SSBs. If such breaks persist unrepaired until 
the DNA is replicated, then DSBs can form (Rouleau et al., 2010). Drugs that work as PARP1 
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inhibitors can induce the formation of such DSBs by interfering with the repair of SSBs. In 
addition, it has been shown that tumours experiencing acute or chronic hypoxia (such as solid 
or fast growing tumours) are sensitive to PARP1 inhibitors (Chan et al., 2010). Furthermore, 
there is data which suggests that certain types of breast cancer might be sensitive to PARP1 
inhibitors (Weil and Chen, 2011). Whilst the generation of SSBs is part of TOP1’s activity, the 
two subunits of TOP2 introduce DNA breaks in an independent but coordinated process and 
therefore can be trapped as a SSB if the activity of TOP2 on both strands is not coordinated, 
which normally would be a target for PARP1 (Zechiedrich et al., 1989, Nitiss, 2009b). Whether 
SSBs or DSBs will result from etoposide treatment has been shown to depend on the molar 
ratio between etoposide and TOP2 (Bromberg et al., 2003). PARP1 has also been shown to 
promote repair by HR by suppressing components of NHEJ, the pathway that TDP2-resolved 
cleavage complexes of TOP2 follow for their repair (Saberi et al., 2007, Gomez-Herreros et al., 
2013). PARP1 is also required for replication fork slowing on damaged DNA (Sugimura et al., 
2008). Combining both a PARP1 inhibitor and etoposide could result in an overwhelmed DNA 
repair system, with accumulating damage leading to apoptosis. 
PARP1 inhibitors are very popular at the moment in clinical studies and a quick search in 
clinicaltrials.gov, the U.S. National Institutes of Health depository for past and current clinical 
trials in 194 countries, will return over 200 results of studies in different phases, for different 
types of cancer and different PARP1 drugs (either alone or in combination with other drugs). In 
December 2014, the FDA and the EMA approved Olaparib, a PARP1 inhibitor as monotherapy 
for the treatment of recurrent ovarian cancer in women with a BRCA1 or BRCA2 mutation 
(Frampton, 2015). Not only that, but there is currently a trial (NCT01642251) that is testing a 
combination of the PARP1 inhibitor veliparib, cisplatin and etoposide for extensive stage small-
cell lung cancer, metastatic large cell neuroendocrine NSCLC and small-cell carcinoma of 
unknown primary or extrapulmonary origin. This trial is at Phase II and due to conclude in 
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January 2018, demonstrating that combination therapy targeting both PARP1 and TOP2 
simultaneously shows promise (Hosoya and Miyagawa, 2014). 
Combining a PARP1 inhibitor with estradiol and etoposide is hypothesised to have a big impact 
on the cancer cells’ ability to repair the estradiol-induced abortive DSBs. The cancer cells 
would have to repair TOP2-mediated DSBs caused by induction of transcription with estradiol, 
and DSBs created by unrepaired SSBs due to the PARP1 inhibitor or SSBs that formed from 
uncoordinated function of TOP2. All of this DNA damage will have been rendered abortive with 
the addition of etoposide at a frequency that TDP2 cannot cope with, thus inducing apoptosis 
and killing the cells. 
As the precise impact of hormone treatment on TOP2-dependent transcription and DSB 
induction in breast cancer is not clear, I adopted the approach of selecting breast cancer cell 
lines representative of several clinically relevant scenarios. For example, MCF7 is one of the 
most commonly used breast cancer cell lines in experiments and appears in many published 
papers (Comsa et al., 2015). It is also ERα positive and grows in an estrogen-dependent 
manner. That means that types of cancer with the MCF7 profile usually respond well to 
inhibitors of ERα activity or drugs that block estrogen synthesis. MLET5 is an MCF7 derivative, 
which grows in an estrogen-independent manner despite being ERα positive. It was 
established by over-expressing ERα in MCF7 cells using adenovirus gene transduction, which 
resulted in ligand-independent expression of pS2 and PR (estrogen-regulated genes) and the 
cell line to be able to grow in an estrogen-independent manner (Tolhurst et al., 2011). 
Similarly, LCC9 is an MCF7 derivative that grows in an estrogen-independent manner, but it 
was acquired in a different way. Brunner et al. had previously established an MCF7 derivative, 
LCC1, which is able to grow in vivo and in vitro independent of estrogen, but still remains 
sensitive to antiestrogens by cultural selection for resistance (Brunner et al., 1993a). The same 
group was also able to grow an MCF7/LCC1 derivative, LCC2, which in addition to estrogen 
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independent growth, is also resistant to 4OH-TAM, again via cultural selection for resistance, 
but was not cross-resistant to the steroidal anti-estrogens ICI 182,780 and ICI 164,384 
(Brunner et al., 1993b). ICI 182,780 and ICI 164,384 are C7-acyl-substituted analogues of 
estradiol and have a higher affinity for ER than TAM (Wakeling et al., 1991, Thompson et al., 
1989). Therefore, a few years later, Brunner et al published a paper in which they reveal 
another MCF7/LCC1 derivative, LCC9, which was selected against ICI 182,780, but through that 
it also acquired cross-resistance for TAM (Brünner et al., 1997).  
8.1.1 Aims of this chapter 
The aim of this chapter is to investigate the effects of a combination treatment of PARP1 
inhibitor, estradiol and etoposide on cell viability and survival in a selection of breast cancer 
cell lines relevant to the clinical situation (MCF7, MLET5 and LCC9). It is hypothesised that 
initial treatment with PARP1 inhibitor will induce DSBs due to the unrepaired SSBs caused by 
the inability of the inhibited PARP1 to repair them. The addition of estradiol will induce 
transcription and thus TOP2B-mediated DSBs. Those DSBs will be rendered abortive with the 
addition of etoposide, which will target TOP2 and interfere with the re-ligation of the DNA. 
Finally, TDP2 will not be able to cope with all these breaks, the cells’ DNA damage response 
system will be overwhelmed and the cells will enter apoptosis. Etoposide, olaparib and 
estradiol are already used in cancer therapy. Therefore, it is a very attractive idea that if the 
results of this chapter are positive, it could be converted into a proposal for a wider preclinical 
trial. 
8.2 Results 
The effect of the combination treatment of PARP1 inhibitor, estradiol and etoposide was 
assessed using cell viability (Alamar Blue) and clonogenic cell survival assays.  The results for 
the Alamar Blue assays for MCF7 are depicted in Figure 8.1. Comparing the different 
treatments in Figures 8.1B-D, it is clear than none of the combinations increased the sensitivity 
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of MCF7 cells above that observed with etoposide alone (Fig.8.1A). Similar results were 
observed for MLET5 (Fig.8.2) and LCC9 (Fig.8.3). 
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As previously discussed, Alamar Blue has significant disadvantages when compared to 
clonogenic cell survival. Although Alamar Blue was the only option for MLET5 and LCC9 cells, 
which cannot grow colonies from single cells as they require close contact with each other to 
multiply, I was able to repeat these experiments for MCF7 using clonogenic cell survival assays. 
Figure 8.4A shows the impact of etoposide alone or in combination with PARP1 inhibitor and 
estradiol. As one can observe, the combination did not further sensitise MCF7 cells to 
etoposide. Even though there appears to be no difference between cell survival for cells 
treated with etoposide only and the combination treatment of etoposide/estradiol/PARP1 
inhibitor, in order to verify this observation I undertook an additional experiment to compare 
etoposide only to treatment with etoposide and estradiol or PARP1 inhibitor or both.  Figure 
8.4B depicts these results. It is clear that there is no difference between these two treatments 
in regard to cell survival. Figure 8.4C depicts the cloning efficiency of the cell lines in etoposide 
vehicle DMSO alone (set at 100%) compared to DMSO plus either PARP1 inhibitor and/or 
estradiol, and indicates that PARP1 and estradiol had only a small but significant (Fig.8.4D) 
impact on survival of MCF7 cells separately or together. 
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8.3 Discussion 
This chapter examined whether triggering TOP2-dependent transcription by estradiol 
treatment resulted in cell sensitivity in the presence of PARP1 inhibitor (either by inhibition of 
SSBR and/or replication fork maintenance (Sugimura et al., 2008)) and/or etoposide (to 
convert TOP2 cleavage complexes into DSBs). However, I failed to detect such an effect. 
There have been other studies in the past, in which treatment of etoposide and a PARP1 
inhibitor only showed weak or no combination effect. One study used Olaparib, a PARP 
inhibitor currently used in cancer therapy, and etoposide, but the results were disappointing in 
terms of a synergistic effect, where an insignificant difference was found between single 
treatment and combined treatment (Murai et al., 2014). An older study showed that PARP 
inhibitor NU1025 did not increase DSBs or cytotoxic effect caused by etoposide alone and in 
addition, PARP was not activated after treatment with etoposide, even after the 
concentrations caused significant levels of apoptosis (Bowman et al., 2001). Finally, a different 
study had shown that the PARP inhibitor, 3-Aminobenzamide, when combined with etoposide 
had no significant effect in the human lymphoma cell line HT58 (Sebestyén et al., 1997). 
In 2010, a group investigated the effects of estradiol on the cytotoxicity of etoposide in A549 
lung cancer cells and did not see an increase in etoposide cytotoxicity, even though estradiol 
treatment showed a tendency towards increased proliferation rates (Sebestyén et al., 1997). 
This observation agrees with the lack of a synergistic effect in my results. 
In Chapter 5, I showed that there isn’t a direct correlation between sensitivity to etoposide and 
either TDP2 protein levels, TOP2A/TDP2 protein ratios, or TOP2B/TDP2 protein ratios. One 
possible explanation for the failure to detect an effect is that there is still enough intrinsic 
TDP2 in the cancer cells to cope with the induced abortive DSBs.  
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Another reason why the combination treatment was unsuccessful in increasing etoposide 
sensitivity in the breast cancer cell lines used, could be that the level of induction of 
transcription due to the estradiol treatment was not significant enough to result in many 
TOP2B-mediated DSBs that then could be rendered abortive via etoposide treatment.  
Therefore, to test these ideas, I manipulated TDP2 protein levels in cancer cells and also 
measured the impact of hormone treatment on the expression of TOP2-dependent genes.  
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9. CHAPTER NINE – Impact of TDP2 depletion on TOP2B DSB repair in 
MCF7 breast cancer cells during estrogen-dependent transcription.  
9.1 Introduction 
Previous chapters explored the possibility that intrinsic levels of TDP2 might correlate with 
sensitivity of cancer cells to etoposide, however I did not find evidence for this. I also examined 
the possibility of combining etoposide treatment with PARP1 inhibition, testing the idea that 
the elevated DSBs arising in breast cancer cells due to the estrogen-induced transcription may 
render them hypersensitive to PARP1 inhibition. This is because the PARP1 protein is 
implicated in proper protection of replication forks that encounter DSBs by HR (Sugimura et 
al., 2008). However, my studies were unable to provide evidence to support this hypothesis. 
In this chapter, I adopted a different approach. I directly manipulated TDP2 levels in cancer 
cells, with the view that if loss of TDP2 sensitises to etoposide-induced DSBs, or to those 
caused simply by inducing an estrogen-driven transcription program, then this would provide 
proof in principle for the development and utility of small molecule inhibitors of TDP2. There 
are already promising in vitro and in vivo results in that field (Raoof et al., 2013, Kankanala et 
al., 2016, Marchand et al., 2016, Kont et al., 2016, Kossmann et al., 2016, Hornyak et al., 2016). 
The cell line that was chosen for this series of experiments was the breast cancer cell line 
MCF7. 
9.1.1 Aims of this chapter 
The aim of this chapter was to demonstrate that introducing TOP2B-mediated DSBs via 
estradiol-induced transcription and rendering them abortive by etoposide treatment would 
have a larger effect on cell viability and repair kinetics in TDP2-depleted MCF7 cells than in 
mock-depleted MCF7 cells.  
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9.2 Results 
I first attempted to establish a TDP2 knock-down in MCF7 breast cancer cells. This was possible 
with the help of two vectors: pSUPER-TDP2 in order to knock-down TDP2 or empty pSUPER for 
the mock knock-down and pcD2E as the selectable marker for G418 (Brummelkamp et al., 
2002). This approach was successful, as indicated by the western blot in Figure 9.1A. The next 
step was to examine differences in cell viability after etoposide treatment in the wild type, 
mock-depleted, and TDP2-depleted MCF7 cell lines, using Alamar Blue assays. As indicated in 
Figures 9.1B-D, there was no significant difference between the mock-depleted and TDP2-
depleted MCF7 cell lines for the lowest and highest concentrations of etoposide, but a small 
yet significant difference was observed at 500nM and 750nM of etoposide (Appendix 1). Next, 
I examined the TDP2-depleted MCF7 cell line by clonogenic cell survival assay. As expected, 
TDP2 depletion significantly decreased cellular resistance to etoposide, compared to both the 
mock-depleted and wild type MCF7 cells (Fig.9.1E, Appendix 2). 
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Next, I examined the impact of TDP2 depletion on DSB repair rates, as measured by 
immunostaining for γH2AX. Figure 9.2A revealed that there is a significant increase in foci per 
cell in TDP2-depleted cells, at six hours after irradiation. This suggests that there is a delayed 
response in DSB repair in the TDP2-depleted cells. Representative images of the γH2AX foci in 
mock-depleted and TDP2-depleted cells are presented in Figure 9.2B. 
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Next, I established the conditions for estradiol induced transcription in the mock-depleted and 
TDP2-depleted MCF7 cells using two known TOP2-dependent genes, TFF1 and GREB1 and two 
control genes, Actin and TBP. TFF1 (Trefoil factor 1) is a protein expressed in breast cancer 
cells, among others and it contains an estrogen-inducible sequence, so that its expression can 
be regulated by estrogen (Pelden et al., 2013). GREB1 (Growth regulation by estrogen in breast 
cancer 1) is an early response gene in the estrogen receptor-regulated pathway and is 
expressed in hormone-responsive breast cancers (Ghosh et al., 2000). Actin is a commonly 
used housekeeping gene that has been proven to be reliable for use in breast cancer cell lines 
(Liu et al., 2015, Morse et al., 2005). In addition, TBP (TATA-binding protein) has also been 
determined as a suitable housekeeping gene for RT-qPCR in breast cancer cell lines (Lyng et al., 
2008). From preliminary experiments (data not shown) it was determined that the best 
concentration for maximum induction of the TOP2-dependent genes was 100nM of estradiol 
over a period of 24h. From the graphs in Figure 9.3, it was evident that TFF1 and GREB1 were 
induced in a time dependent manner by exposure to 100nM estradiol in both mock-depleted 
and TDP2-depleted MCF7 cells. TDP2 depletion had no impact on the transcript levels, because 
any difference in the graphs was not statistically significant (Paired t-test p-values>0.05 for all 
samples).  
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Once the induction of transcription was evaluated, I proceeded to examine the formation of 
DSBs as measured above. Figure 9.4A, reveals that in the TDP2-depleted cells the number of 
foci per cell was significantly higher than the mock-depleted and wild type cell lines after 
estradiol treatment. Representative images are presented in Figure 9.5.  Because TOP2 activity 
and DSBs are higher in S-phase, I wanted to confirm that the differences detected here 
between mock-depleted and wild type versus TDP2-depleted cells reflected transcription-
induced DSBs, rather than differences in cell cycle progression. This was unlikely since I 
counted only cells that lacked CENP-F staining, and which were thus most likely in G1. 
However, to confirm this I measured EdU incorporation. I conducted  two different 
experiments; one in which EdU was present for a short time before cell fixation and one in 
which it was present the entire time of the treatment with estradiol. The results are presented 
in Figures 9.4B and C respectively, and reveal that there was no difference in the number or 
fraction of S-phase cells in mock-depleted and TDP2-depleted MCF7 cells.  
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Next, I explored the possible synergistic impact of combining estradiol treatment with 
etoposide. These experiments revealed that the survival of TDP2-depleted cells is significantly 
lower that of the mock-depleted cells, but this is not further enhanced by additional treatment 
with estradiol (Fig.9.6). Estradiol treatment alone did not affect cell survival.  
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As a final experiment of my project, I utilised the TDP2-depleted MCF7 cell line to explore DSB 
formation in the form of γH2AX foci after a combined treatment of estradiol and etoposide. As 
previously shown, treating these cell lines with estradiol caused a significant increase in γH2AX 
foci per cell in the TDP2-depleted cells (Fig.9.4A). This can also be seen in Figure 9.7. When 
both cell lines were treated with a high dose of etoposide only, they both responded with a 
high number of γH2AX foci per cell. Interestingly, when both cell lines were treated with a 
combination of estradiol and etoposide, the number of foci per cell increased significantly in 
the TDP2-depleted cells, but not in the mock-depleted cells. 
 
  
198 
 
9.3 Discussion 
This chapter of my project attempted to determine whether TDP2 can be exploited 
therapeutically in cancer treatment, in the context of hormone driven cancers such as breast 
cancer.  The hypothesis was that inducing TOP2-dependent transcription programmes with 
estradiol in breast cancer cells lacking TDP2 might cause sufficient TOP2B-induced DSBs, 
before or after etoposide treatment, to overwhelm cells with DSBs. 
To answer this question, the first step was to directly manipulate TDP2 protein levels by 
knocking down TDP2 in a cell line that is both relevant and accessible. For those reasons, MCF7 
was chosen. After successfully knocking down TDP2, the TDP2-depleted cell line was 
characterised. It is more sensitive to etoposide treatment compared to both wild type and 
mock-depleted cells (established by clonogenic cell survival assays) and it demonstrated 
delayed repair kinetics. Cell viability was also lower, though these results were not as clear as 
the clonogenic cell survival assay results. The differences observed via clonogenic cell survival 
assay results are statistically significant, while the differences observed in the Alamar Blue 
result are not consistently statistically significant. Unlike in previous Alamar Blue experiments 
where small variations in TDP2 levels among different lung and breast cancer cell lines proved 
difficult to be recognised, depletion of TDP2 was enough to be detected by Alamar Blue assay 
after continuous treatment with increasing concentrations of etoposide. Furthermore, the 
small observed difference was significant for the concentrations of 500nM and 750nM of 
etoposide (Appendix 1).  Additional Alamar Blue experiments demonstrated that very high 
concentrations of etoposide do not have a distinguishable effect on all three MCF7 cell lines 
(Appendices 3 & 4).  
The observations that showed increased etoposide sensitivity in cell lacking TDP2 are in 
agreement with multiple publications that have shown similar results in different cell lines. For 
example, it has been shown that depletion of TDP2 in A549 and MEF cells, resulted in 
199 
 
increased sensitivity to etoposide treatment (Gomez-Herreros et al., 2013). The same has been 
shown for DT40 cells, where they exhibited higher sensitivity to etoposide after TDP2 
depletion (Zeng et al., 2011). 
Transcription can be induced by estradiol treatment, peaking at 24h of treatment in wild type 
MCF7 cells (Appendix 5), mock-depleted MCF7 cells and TDP2-depleted MCF7 cells. Similar 
results were found when treatment with DHT (Dihydrotestosterone – an androgen hormone) 
induced transcription of AR (androgen receptor) responsive genes, but not control genes in 
both wt and TDP2-depleted LNCaP prostate cancer cells (Gómez-Herreros et al., 2014). Even 
though the differences I observed were not significant, there was a trend that showed lower 
induction levels in TDP2-depleted MCF7 cells compared to mock-depleted cells. This was seen 
at significant levels by (Gómez-Herreros et al., 2014), agreeing with their suggestion that TDP2 
is required for induction of AR (and in my system perhaps ER too, although it will require 
targeted experiments) responsive genes, even at endogenous levels of TOP2-induced DSBs. 
This is a very important observation as TOP2B has already been shown to be essential in 
transcription regulation by introducing transient, site-specific DSBs, which probably occur 
frequently enough to cause an important demand of TDP2 (Ju et al., 2006, Pommier et al., 
2016). 
Estradiol alone also seems to cause increased number of DSBs in TDP2-depleted cells 
compared to wild type and mock-depleted cells, shown as γH2AX foci per cell. This supports 
the hypothesis that inducing TOP2B-dependent transcription programmes with estradiol 
generates TOP2B-dependent DSBs, visualised as γH2AX foci. This has been seen before by 
other groups (Williamson and Lees-Miller, 2011). At the same time, the impact of TDP2 
depletion on the repair of TOP2B-mediated DSBs is evident by the near 2-fold increase of the 
number of DSBs after 24h of estradiol treatment.  
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Combining the two treatments (estradiol and etoposide) has a significant effect in cell survival 
in the TDP2-depleted cells, compared to the mock-depleted cells. When I tried to determine 
whether this was due to the induction of transcription and what that means for a cell, the 
results were not as expected. There seemed to be no significant difference in the percentage 
of survival between TDP2-depleted cells treated with etoposide only, compared with estradiol 
and etoposide treatment. The same lack of significant difference was observed in the mock-
depleted cells. In the previous chapter, I showed that there was no significant difference 
between these treatments in wild type MCF7 cells.  
A reason for this is that the induction of transcription and the subsequent DSBs are possibly 
not enough to have a significant impact on cell survival, although my results are in accordance 
with what other people have seen (Williamson and Lees-Miller, 2011). Another study has also 
reported lack of an increased effect on etoposide sensitivity after treatment with estradiol, 
even though that group also saw induction of transcription (Sebestyén et al., 1997). At the 
point of choosing a cell line, I could not have foreseen that the level of transcriptional 
induction might have been an issue. In hindsight I would have chosen a cell line with higher 
transcriptional induction. In addition, perhaps even the fractional levels of TDP2 remaining in 
the TDP2-depleted cells might have been enough to compensate for all the abortive DSBs. 
Nevertheless, I was able to demonstrate by observation of γH2AX foci that treatment with 
estradiol alone caused a significantly higher number of DSBs in TDP2 depleted cells than in 
mock-depleted cells. In addition I showed that a combined treatment of etoposide and 
estradiol caused a significantly higher number of DSBs (depicted as γH2AX foci per cell) in the 
TDP2-depleted cells than the mock-depleted cells. Furthermore, I have shown that lack of 
TDP2 causes delayed DSB repair kinetics. Delayed repaired kinetics after etoposide treatment 
have also been shown in TDP2Δ1-3 mice primary cortical astrocytes compared to TDP2+/+,  in 
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TDP2+/Δ1-3 mice cerebellar granule neurons compared to TDP2Δ1-3 and in human 
lymphoblastoid cells with mutated TDP2 compared to normal (Gómez-Herreros et al., 2014).  
Based on these two observations, the following hypothesis can be generated. Firstly, inhibiting 
TDP2, while inducing transcription with estradiol, will increase TOP2B-mediated DSBs 
(compared to estradiol-treated uninhibited cells). By treating these cells with etoposide, the 
DSBs will be made abortive. The lack of functional TDP2 will lead to delayed repair kinetics, 
meaning that abortive DSBs will persist long enough to cause cells to enter apoptosis and die. 
Therefore, I believe that under the right conditions, TDP2 can be therapeutically exploited. Any 
future studies would greatly benefit from a cell line with higher transcription induction levels 
and the development of a TDP2-targeting agent, in the same manner that one exists for TOP2. 
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10. CHAPTER TEN – Discussion 
10.1 Overview 
TDP2 has been identified as the enzyme that efficiently restores 5’-phosphate termini at DNA 
double-strand breaks in preparation for DNA ligation in human cells (Cortes Ledesma et al., 
2009). It has been previously shown that cellular depletion of TDP2 leads to increased 
sensitivity to the commonly used TOP2-targeting agent etoposide (Zeng et al., 2011). In a 
recent small scale study that includes some lung and breast cancer cell lines, it was shown that 
TDP2 levels vary among the different cell lines, ranging from very high to very low (Li et al., 
2011a).  
Induction of transcriptional programs, for example by stimulating breast or prostate cancer 
cells with estrogens or androgens respectively, can involve the formation of TOP2B-mediated 
DSBs and the recruitment of DSB repair proteins, such as PARP1 (Ju et al., 2006). TOP2B is 
believed to be recruited with the estrogen receptor to regulatory sites on target genes for 
efficient activation of those genes (Haffner et al., 2011, Ju et al., 2006, Williamson and Lees-
Miller, 2011). TDP2 has been shown to protect such genes from these naturally occurring DSBs, 
as cells with depleted TDP2 have demonstrated reduced induction of transcription, suggesting 
how important the resolution of those TOP2B cleavage complexes is (Gómez-Herreros et al., 
2014). 
Bringing all this information together, the aim of this thesis was to characterise the mRNA and 
protein levels of TDP2, TOP2A and TOP2B in a panel of non-small cell lung cancer cell lines and 
a panel of breast cancer cell lines, to explore whether these levels exhibit a large variation, as 
previously reported. The next step was to investigate the correlation between intrinsic TDP2, 
TOP2A and TOP2B protein levels and resistance to the TOP2-targeting agent etoposide, based 
on the hypothesis that cell lines with low levels of TDP2 and high levels of TOP2A and TOP2B 
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will be more sensitive to etoposide, compared to cell lines with high levels of TDP2 and low 
levels of TOP2A and TOP2B. The target of the first part of my project was to establish TDP2 as a 
biomarker for sensitivity to etoposide and a clinical predictor of treatment outcome.  
The second part of my project was based on the model of TOP2B-mediated DSBs during 
estradiol-induced transcription. This aimed to explore the possibility of TDP2 as a novel 
therapeutic target for inhibition. The hypothesis was that inducing transcription in selected 
breast cancer cell lines with estradiol would lead to TOP2B-mediated DSBs and treating them 
with etoposide, thus making DSBs abortive, would overwhelm TDP2 and render it unable to 
cope with the high number of abortive DSBs, leading to apoptosis. It was also important to 
explore this model in a breast cancer cell line that lacked TDP2, which, if the results were 
promising, would steer future projects towards a compound that is able to inhibit TDP2 
directly without the need of a knock-out.  
10.2 TDP2, TOP2A and TOP2B mRNA and protein levels vary among a panel of 
lung and breast cancer cell lines. 
I first investigated the mRNA and protein levels of TDP2, TOP2A and TOP2B in a panel of lung 
and a panel of breast cancer cell lines. The RT-qPCR and western blot data that emerged 
revealed a clear variation in mRNA and protein levels in TDP2, TOP2A and TOP2B among both 
cancer cell line panels. However, these results were not the same. It is very common for 
protein levels to not reflect mRNA levels, due to the abundance of mechanisms that act post-
translation, which have an impact on protein production and stability (Vogel and Marcotte, 
2012, Stark et al., 2006, Dickson et al., 2007, Taquet et al., 2009). Nonetheless, they both 
provide information in regard to how variant TDP2, TOP2A and TOP2B mRNA and protein 
levels are in different lung and breast cancer cell lines. These observations agree with a 
previous study that showed that in non-small cell lung cancer cell lines the levels of TDP2 
varied, with H460, A459 and H226 demonstrating medium to high levels, and H292 and H1650 
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showing almost no TDP2 (Li et al., 2011a). I was also able to demonstrate that there was no 
correlation between the protein levels of TDP2, TOP2A and TOP2B. Just because a cell line has 
very high levels of TDP2, doesn’t mean it will also have very high levels of TOP2A and TOP2B, 
although that doesn’t mean that it can’t, as shown by MOR and LCC9 which have high TDP2 
and TOP2 levels. From these results, certain cell lines emerged as the ideal candidates to 
potentially be utilised to explore whether TDP2 could be a biomarker for sensitivity to the 
TOP2-targeting agent etoposide and therefore exploited therapeutically. The ideal candidate 
to further this idea would be a cell line with low levels of TDP2 and high levels of TOP2A and 
TOP2B. On the other hand, a cell line with high levels of TDP2 and low levels of TOP2A and 
TOP2B would be the least desirable candidate, which could serve as the baseline. High levels of 
TOP2A and TOP2B could mean more TOP2-mediated abortive DSBs within a cell and low levels 
of TDP2 could mean that TDP2 could be overwhelmed by these abortive DSBs, leading the cell 
to apoptosis.  An abundance of TDP2 (high protein levels), on the other hand, would be able to 
resolve the fewer TOP2-mediated DSBs caused by low levels of TOP2A and TOP2B. Among the 
lung cancer cell lines, H226 and A549 emerged as good candidates and among the breast 
cancer cell lines ZR751 fulfilled the criteria. 
In an attempt to minimise problems with the detection of the protein levels, three different 
concentrations of whole cell extract were used, that were determined by accurate cell 
counting and a strict sample preparation protocol. There had been attempts to utilise Bradford 
protein assay to measure protein concentrations experimentally, but significant protein 
degradation was observed and therefore this technique was abandoned. The repetition of the 
experiments a minimum of three times and the use of three volume based concentrations was 
implemented to maximise accuracy. Available equipment that could accommodate the 
number and volumes of the samples was used, but I believe that larger gels that could hold 
more samples at the same time might have improved the consistency of the results through 
the different concentrations. Perhaps a lower transfer voltage and longer transfer times could 
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have also helped with reducing discrepancies further, but the current protocol was assessed to 
be acceptable given the time available.  
10.3 No direct correlation was detected between TDP2, TOP2A and TOP2B 
protein levels and sensitivity to etoposide in a panel of lung and breast cancer 
cell lines. 
Once levels of TDP2, TOP2A and TOP2B were measured, the project progressed to explore the 
effects of etoposide on cell viability and survival of increasing treatment with etoposide. All the 
cell lines were treated with etoposide only. A549 was the lung cancer cell line least sensitive to 
etoposide and HCC95 the most sensitive. MM453 and BT474 were the breast cancer cell lines 
with highest resistance to etoposide and LCC9 and T47D the least resistant. A comparison of 
TDP2 protein levels and cell viability or survival failed to correlate TDP2 protein levels and 
sensitivity to etoposide in either breast or lung cancer cell lines. It appears that the protein 
levels do not necessarily translate to etoposide sensitivity or resistance. Cell viability and cell 
survival did not necessarily agree either, but it is important to remember that they offer 
different kinds of information. Alamar Blue is an assay that essentially demonstrates how 
many cells are still metabolically active after a certain treatment. This possesses limitations 
and makes this assay less sensitive at detecting small differences. It cannot differentiate 
between cells that have entered the path to apoptosis and healthy cells and this is a restriction 
not found in the clonogenic cell survival assay. The latter is able to show how many cells 
survived the treatment and were able to proliferate and produce colonies. Unfortunately, not 
all cells I utilised are able to grow in colonies and therefore are not suitable for that type of 
assay.  In addition, there seemed to be no correlation between sensitivity to etoposide and 
TOP2A/TDP2 and TOP2B/TDP2 protein ratios either. All these results were verified with the 
calculation of correlation coefficients and their corresponding p-values. 
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I corroborated my results by using etoposide IC50 values from an appropriate database 
(CancerDr), for all of the tested cell lines that had this information available. I calculated the 
correlation coefficients and corresponding p-values against the TDP2 and TOP2 protein level 
results that I had obtained experimentally. None of these results were significant either. 
The lack of correlation could be attributed to the levels of activity of TDP2 or perhaps even 
mutations that render it inactive. To explore this mechanistically, I would have utilised an 
activity assay to establish TDP2 catalytic activity for 5'-phosphotyrosyl linkage at the 5' ends of 
a 32P-radiolabeled 20-bp oligonucleotide substrate analyzed by denaturing 
PAGE/phosphorimaging as described by Cortes Ledesma and co-workers; or I could have used 
a more recently developed assay that uses p-nitrophenyl-thymidine-5′-phosphate (T5PNP), a 
well-established substrate for snake venom phosphodiesterase, as a substrate for TDP2 
(Cortes Ledesma et al., 2009, Adhikari et al., 2011). The biggest advantage of a T5PNP assay 
compared to the gel-based assay is that it can be used as continuous colorimetric assays in a 
96-well format (Adhikari et al., 2011). In previous publications results obtained from both 
assays were comparable, but they also showed that TDP2 works more efficiently on the 
traditional 5′-phosphotyrosyl substrate than on T5PNP, while T5PNP is not a non-specific 
general phosphodiesterase substrate (Adhikari et al., 2011). Although this could have 
potentially explained the lack of direct correlation between TDP2 protein levels and resistance 
to etoposide, it would not have been particularly useful in a clinical setting. If the project ever 
moved outside of a molecular lab and into a diagnostics lab, running an activity assay would be 
very expensive and time consuming, and therefore unlikely to be used. Nevertheless, TDP2 
mutations have been identified in individuals with intellectual disability, seizures and ataxia, 
where mutant TDP2 mRNA was found to be truncated and subject to nonsense-mediated 
decay (Gómez-Herreros et al., 2014). 
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A recently published study with a similar structure to mine investigated whether TDP1 or TOP1 
levels alone could be a predictive biomarker of sensitivity to the TOP1 poison irinotecan, in 
colorectal cancer cell lines (Meisenberg et al., 2015). Their conclusion was that there was no 
correlation between intrinsic TDP1 or TOP1 levels and irinotecan, a system very similar to the 
TDP2-TOP2-etoposide system I was investigating. They only used 6 cell lines to study their 
colorectal cancer model, while I used two types of models (breast and lung cancer) with 8 cell 
lines each. Perhaps neither of those numbers is large enough to observe such correlation, or 
the opposite is true, as handling a large number of cell lines at the same time only serves to 
complicate the experimental study process rather than contributing to the observations made. 
In addition, the same group has shown in a previous study that TDP1 levels alone had failed to 
show a correlation to Topotecan (another water soluble analog of camptothecin) (Meisenberg 
et al., 2014). Instead they observed a correlation of Topotecan resistance with TDP1/TOP1 
ratios only when certain data points were excluded, without a clear and logical reason other 
than being outliers. Furthermore, they used cell viability assays and not cell survival assays, the 
differences of which I have discussed earlier. Even though their aim was similar to mine, the 
differences in approach mean that it’s not surprising that their results do not agree with the 
results detailed here. 
There is always the question of whether immortalised cell lines accurately represent what is 
occurring in vivo – a more complex and variable model. They usually differ but there are 
methodologies that can be followed to bring those two models closer (Pan et al., 2009).  
Another variable that makes the system I use more complicated than the studies that just 
looked into effects of cells lacking TDP2, is the use of multiple cell lines. Even though every 
precaution was taken to maintain the cell lines at optimum conditions, by checking for 
mycoplasma and not over-culturing the cells, one fact still remains; some of the cell lines were 
obtained directly from a cell line repository and some were obtained from resources available 
within the University. Although the hypothesis that I was working under did not consider the 
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background of each cell line as much, and was based on experimental observations, this is a 
situation that should be considered carefully when using immortalised cell lines for research 
(Hughes et al., 2007). 
Moving forward from cell line limitations in laboratory research, my results were not the only 
ones unable to show a correlation between TDP2 levels and response to etoposide. Although 
at a much smaller scale, earlier this year a group showed such lack of correlation in a much 
smaller number of lung cancer cell lines, in which even knocking down TDP2 didn’t increase 
the number of DSBs after etoposide treatment, compared to wt (Bian et al., 2016). 
There is also data that suggests a functional redundancy between the nuclease activity of 
Mre11 and TDP2 in terms of genome stability, which could be interpreted as another reason 
why no correlation was observed in my experiments (Hoa et al., 2016). The same paper 
demonstrated that heterozygous TDP2+/- cells were not more sensitive to etoposide than wt 
cells, which could imply that even a small presence of TDP2 is enough to respond to etoposide-
induced abortive DSBs. This could explain why the intrinsic variability of TDP2 protein levels in 
the cell lines I studied is too subtle to have a significant impact on etoposide resistance 
10.4 Database-derived mutational profiles of cancer cell lines are a primary 
useful tool in experimental result interpretation 
In my attempt to investigate further why a correlation between TDP2 protein levels, 
TOP2A/TDP2 protein ratios or TOP2B/TDP2 protein ratios and etoposide sensitivity does not 
exist, I decided to collate mutational profiles of the cell lines I utilised with curated databases. 
This process differs from all the previous experimental methods that I used, as it relies on 
information provided by other people. Therefore, very strict guidelines needed to be followed. 
Chapter 6 has revealed some very interesting results and has demonstrated how useful such 
collections of information can be. This work also highlights the synergy in combining 
experimental work with database and literature mining. 
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The first interesting mutation is EGFR. In lung cancer cell lines it was shown to have a 
significant positive correlation with TDP2 protein levels, and could possibly affect the 
relationship between TDP2 protein levels and sensitivity to etoposide, although that could be 
through its effect on TDP2. PIK3CA mutation in breast cancer cell lines had a significant 
negative effect on TOP2A/TDP2 and TOP2B/TDP2 ratios, but not on TDP2 protein levels. This is 
in agreement with a group that has shown that the PIK3CA mutation decreased TOP2 
expression levels (Fountzilas et al., 2012). Another interesting gene was PTEN, whose mutation 
in lung cancer cell lines had a significant negative effect on TDP2 protein levels and it was also 
shown to have a possibly significant effect on the relationship between TDP2 protein levels 
and sensitivity to etoposide, although similar to EGFR that could be due to its effect on TDP2 
levels. A very frequent mutation in cancer, TP53 in breast cancer cell lines showed a significant 
positive correlation with TDP2 protein levels. SMARCA4 mutation in lung cancer cell lines 
appeared to have a significant effect on the relationship between TDP2 protein levels and 
etoposide sensitivity, when the mutation is taken into account. 
To summarise, I propose that three mutations (EGFR, PTEN and TP53) could possibly have an 
effect on TDP2 protein levels, something that would be interesting to explore further, 
especially how this effect arises at a molecular level. Mutant TP53 has already been shown to 
target TDP2 transcription and mtp53 knock-down was shown to reduce both the mRNA and 
protein levels of TDP2, which agrees with the positive correlation I discovered (Do et al., 2012). 
I also identified a mutation (PIK3CA) that appears to negatively affect TOP2 protein levels, 
which also agrees with published work (Fountzilas et al., 2012). Finally, I identified a mutation 
(SMARCA4) that has a significant effect on the relationship between TDP2 protein levels and 
etoposide sensitivity. These 5 mutations could all be contributing to the lack of correlation 
between etoposide sensitivity and either TDP2 protein levels or TOP2/TDP2 protein ratios 
observed in Chapter 5. As certain cell lines are not used as extensively in scientific 
experiments, in some cases potentially interesting mutations may have been missed simply 
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because information was unavailable for the minimum required number of cell lines for 
statistical analysis. 
Chapter 6 has resulted in a collection of mutation profiles of several breast and lung cancer cell 
lines that are available for use in the Caldecott lab and as an extension, the whole Genome 
Damage and Stability Centre, as well as other collaborators. This extensive list of thousands of 
mutations is available in Appendices 6 and 7. This chapter demonstrated the usefulness of 
mutation profiles in research, information that is consistently used in cancer pathology and the 
focus of many studies (McConechy et al., 2012, Chang et al., 2014, Bolli et al., 2014, Pereira et 
al., 2016). 
10.5 Exploring the possibility of the use of TDP2 as a potential biomarker of 
sensitivity to other anti-cancer drugs 
As evidence is pointing toward TDP2 not being a predictive biomarker of sensitivity to the 
TOP2 poison etoposide, I decided to further utilise my results from Chapters 3 and 4 and 
search for another anti-cancer drug for which TDP2 could potentially be a predictive 
biomarker. My decision was also based on the comparison of the statistical analysis of my 
results for etoposide IC50 and D37 values and the same analysis of IC50 values mined from 
appropriate databases, which were in agreement. Since there is a wealth of curated 
information on anti-cancer drug IC50 values in a broad range of cancer cell lines, I searched 
and found as many anti-cancer drugs as possible for which there was enough information to be 
able to use statistical methods for analysis.  
Given how precious research funding is, a hypothesis is worth exploring when it is based on 
sound reasoning. My analysis looked at a large number of drugs with a variety of targets and 
thus, even though their IC50 values’ correlation was statistically significant with the 
phenotypes studied, some of the results could be false positives. That means that the 
phenotypes might not actually correlate with the IC50 concentrations of these drugs if a 
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broader set of cell lines was examined. Taking this into consideration I supplemented 
correlation tests with further literature searches so as to focus only on drugs currently in use 
for cancer therapy, or presently in clinical trials for their potential use in cancer therapy, rather 
than commercially available inhibitors for laboratory use. I propose that the following anti-
cancer drug results are significant enough to warrant further investigation. Vinblastine, 
ABT888, AG014688, Bleomycin, Camptothecin and Bicalutamide. Bicalutamide, AG014699, 
Camptothecin and Vinblastine all showed a direct correlation with TDP2 protein levels. 
Bicalutamide showed a positive correlation and the rest a negative. ABT888 and Bleomycin 
demonstrated a positive correlation with TDP2 via its TOP2A/TDP2 protein ratio. The 
background of these drugs offers a logical explanation as to why it is reasonable that TDP2 
should be explored as a biomarker of sensitivity for these drugs.  
The negative correlation between resistance to Vinblastine and TDP2 protein levels could be 
due to increased proliferation in NSCLC observed when TDP2 is overexpressed (Li et al., 
2011a). With high levels of TDP2 there is increased proliferation, and thus more tubulin 
(Vinblastine's target). Additionally, Vinblastine along with etoposide induces the formation of 
apoptotic TOP1 cleavage complexes (Sordet et al., 2006), which TDP2 has been shown to 
promote the repair of in TDP1 knock-out cells (Zeng et al., 2012). 
ABT888 and AG014688 are PARP1 inhibitors in which resistance was negatively correlated with 
TDP2 protein levels in lung cancer cell lines (AG014688) and positively correlated with 
TOP2A/TDP2 protein ratios in breast lines (ABT888). If the positive correlation between 
TOP2A/TDP2 protein ratios is due to lower levels of TDP2 rather than high TOP2A levels, then 
these results agree; even if the opposite is true, they are not mutually exclusive.  Multiple lines 
of  evidence allude to an interesting relationship between PARP1 and TOP2 (Sabisz et al., 2010, 
Ju et al., 2006, Mandraju et al., 2011), and since TOP2 is so closely related to TDP2, I believe 
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there is possibility for TDP2 or its ratio to TOP2 to be a candidate for sensitivity to PARP1 
inhibitors. 
Bleomycin works by introducing DSBs and SSBs, whose ratio and absolute values can 
determine which pathway will be followed for cell death: apoptosis, mitotic cell death, or 
pseudoapoptosis (Tounekti et al., 2001). Given that Bleomycin resistance is characterised by 
reduced DNA damage and the role of TOP2A and TDP2 in DSBR, this correlation is worth 
exploring further (Wang et al., 2013). 
TDP2-depleted cells have shown lack of hypersensitivity to Camptothecin (compared to 
etoposide). However TDP2 has been shown to step in when TDP1 is absent and promote the 
repair of TOP1-mediated DNA damage in its place (Zeng et al., 2011, Zeng et al., 2012). Thus, it 
might be interesting to further expand on my results showing that high TDP2 protein levels 
had a negative impact on Camptothecin resistance. 
Bicalutamide is a selective antagonist of the androgen receptor, used primarily for the 
treatment of prostate cancer (Singh et al., 2000). Androgen-deprived prostate cancer cells 
display transient TOP2B-dependent DSBs, when exposed to androgen; the same group also 
showed that exposing androgen-deprived prostate cancer cells to Bicalutamide lead to 
increased DSBs via γH2AX foci formation (Coulter et al., 2015). In Chapter 7, I showed that 
there is a positive correlation between resistance to Bicalutamide and TDP2 protein levels. 
Given the involvement of TDP2 in resolving TOP2-mediated DSBs, I believe that it merits 
further exploration in vivo. 
It is important to note that similar to my project, such research projects entail a relatively high 
risk, as they are not mechanistic and therefore additional preliminary checks should be carried 
out. I would propose an investment in cell lines that are relevant to the types of cancer that 
these drugs are used for. But even before proceeding to obtain such cell lines for experimental 
data, they should be scrutinised for how extensive the available information on their profile is, 
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for example are IC50 values for these drugs available and do they vary, something that could 
be influenced by how frequently these cell lines are used in similar models. These are 
important questions that need to be answered to ensure that risk in minimised.  
It is not easy to identify biomarkers. Cancer therapy is becoming more targeted, but the 
progress of developing tools to determine which patients will benefit from such therapies is 
slower. A biomarker should be highly sensitive, specific, and reliable with high prognostic 
value, organ specificity and it should correlate with tumour stages, according to (Daniel and 
Lalitha, 2016). That is of course not always the case. There are several research groups or even 
centres dedicated to the sole purpose of identifying and characterising new cancer biomarkers 
(e.g. the Biomarkers and Systems Medicine (BSM) group at the University of Glasgow, the 
Centre for Cancer Biomarkers (CCBIO) at the University of Bergen), suggesting how challenging 
and complicated this type of research can be. New proteomic and genomic technologies are 
utilised, but advance bioinformatics tools are equally indispensible as they allow the 
simultaneous analysis of thousands of biological molecules (Mäbert et al., 2014). 
10.6 PARP1 inhibition and estradiol treatment failed to further sensitise LCC9, 
MLET5 and MCF7 breast cancer cells to etoposide treatment 
Chapter 8 examined whether triggering TOP2-dependent transcription by estradiol treatment 
would result in cell sensitivity to PARP1 inhibitor (to inhibit SSBR and/or replication fork 
maintenance), either in the presence or absence of etoposide (to convert TOP2 cleavage 
complexes into abortive DSBs). However, a difference between etoposide treatment and the 
combination treatment was not observed. 
There have been other studies in the past, in which treatment of etoposide and a PARP1 
inhibitor only showed weak or no combination effect. One study used Olaparib, a PARP 
inhibitor currently used in cancer therapy, and etoposide, but the results were disappointing in 
terms of a synergistic effect, where an insignificant difference was found between single 
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treatment and combined treatment (Murai et al., 2014). An older study showed that PARP 
inhibitor NU1025 did not increase DSBs or cytotoxic effect caused by etoposide alone and, in 
addition, PARP was not activated after treatment with etoposide, even after the 
concentrations caused significant levels of apoptosis (Bowman et al., 2001). Finally, a different 
study had shown that the PARP inhibitor 3-Aminobenzamide, when combined with etoposide 
had no significant effect in the human lymphoma cell line HT58 (Sebestyén et al., 1997). 
In 2010, a group investigated the effects of estradiol on the cytotoxicity of etoposide in A549 
lung cancer cells and did not see an increase in etoposide cytotoxicity, even though estradiol 
treatment showed a tendency towards increased proliferation rates (Sebestyén et al., 1997). 
These observations agree with the lack of a synergistic effect in my results. 
10.7 TDP2-depletion in MCF7 breast cancer cells increases sensitivity to 
etoposide and formation of TOP2B-mediated DSBs due to estradiol treatment. 
I attempted to determine whether TDP2 can be exploited therapeutically in cancer treatment, 
in the context of slow proliferating hormone-dependent cancers such as breast tumours, 
where resistance has developed or other types of treatment have failed.  The hypothesis was 
that inducing TOP2-dependent transcription programmes with estradiol in breast cancer cells 
lacking TDP2 might cause sufficient TOP2B-induced DSBs, before or after etoposide treatment, 
to overwhelm cells with DSBs. I successfully knocked down TDP2 in MCF7 breast cancer cell 
and I characterised the TDP2-depleted cell line.  
The first important result was that TDP2 knock-down cells demonstrated increased sensitivity 
to etoposide treatment in clonogenic cell survival assays, compared to wild type and mock-
depleted cells. This observation is in agreement with multiple publications that have shown 
similar results in different cell lines. It has been shown that depletion of TDP2 in A549 and MEF 
cells, resulted in increased sensitivity to etoposide treatment (Gomez-Herreros et al., 2013). 
The same has been shown for DT40 cells, which exhibited higher sensitivity to etoposide after 
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TDP2 depletion (Zeng et al., 2011). The increased sensitivity was also observed with cell 
viability assays. More specifically, unlike in previous cell viability experiments in this thesis 
where small variations in TDP2 levels among different lung and breast cancer cell lines proved 
difficult to be recognised, depletion of TDP2 was enough to be detected after continuous 
treatment with increasing concentrations of etoposide.  
The second important result was that the TDP2 knock-down demonstrated delayed repair 
kinetics following etoposide treatment. Delayed repaired kinetics after etoposide treatment 
have been shown in TDP2Δ1-3 mice primary cortical astrocytes compared to TDP2+/+, in 
TDP2+/Δ1-3 mice cerebellar granule neurons compared to TDP2Δ1-3 and in human 
lymphoblastoid cells with mutated TDP2 compared to normal (Gómez-Herreros et al., 2014). 
The third important result was that transcription can be induced by estradiol treatment, 
peaking at 24h of treatment in wild type MCF7 cells, mock-depleted MCF7 cells and TDP2-
depleted cells. Similar results were observed when treatment with DHT induced transcription 
of AR (androgen receptor) responsive genes, but not control genes, in both wt and TDP2-
depleted LNCaP prostate cancer cells (Gómez-Herreros et al., 2014). Even though the 
differences I observed were not significant, there was a trend that showed lower induction 
levels in TDP2-depleted MCF7 cells compared to mock-depleted cells. This was seen at 
significant levels by (Gómez-Herreros et al., 2014), agreeing with their suggestion that TDP2 is 
required for induction of AR responsive genes (and in my system perhaps ER too, although it 
will require targeted experiments), even at endogenous levels of TOP2-induced DSBs. This is a 
very important observation as TOP2B has already been show to be essential in transcription 
regulation by introducing transient, site-specific DSBs, which probably occur frequently enough 
to cause an important demand of TDP2 (Ju et al., 2006, Pommier et al., 2016). 
Furthermore, estradiol alone also seems to cause a significantly increased number of DSBs in 
TDP2-depleted cells compared to mock-depleted cells, shown as γH2AX foci per cell. This 
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supports the hypothesis that inducing TOP2-dependent transcription programmes with 
estradiol generates TOP2-dependent DSBs. This agrees with a previously published study 
(Williamson and Lees-Miller, 2011). At the same time, the impact of TDP2 depletion on the 
repair of TOP2B-mediated DSBs is evident by the near 2-fold increase of the number of DSBs 
after 24h of estradiol treatment.  
Additionally, I was able to demonstrate that combining the two treatments (estradiol and 
etoposide) has a significant effect on cell survival in the TDP2-depleted cells, compared to the 
mock-depleted cells. I was not able to demonstrate though, that induction of transcription was 
the reason behind this difference. There was no observed significant difference in the 
percentage of survival between TDP2-depleted cells treated with etoposide only, compared 
with estradiol and etoposide treatment. The same lack of significant difference was observed 
in the mock-depleted cells. This agrees with my results in Chapter 8, where I observed no 
significant difference between these treatments in wild type MCF7 cells. A reason for this 
could be that the level of induction of transcription in MCF7 cells and the subsequent DSBs are 
possibly not enough to have a significant impact on cell survival even in the absence of TDP2, 
although my results are in accordance with what other people have seen (Williamson and 
Lees-Miller, 2011). Another study has also reported lack of an increased effect on etoposide 
sensitivity after treatment with estradiol, even though that group also saw induction of 
transcription (Sebestyén et al., 1997). In hindsight, perhaps there would have been a benefit if 
I had chosen a cell line with higher levels of induction of transcription. Or perhaps the 
explanation lies with the fractional levels of TDP2 remaining in the TDP2-depleted cells, 
meaning that they might have been enough to compensate for all the abortive DSBs. 
To summarise, I demonstrated that treatment with estradiol induces a significantly higher 
number of DSBs (depicted as γH2AX foci per cell) in the TDP2-depleted cells compared with the 
mock-depleted cells; a combined treatment of etoposide and estradiol causes a significantly 
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higher number of DSBs (depicted as γH2AX foci per cell) in the TDP2-depleted than the mock-
depleted cells; and lack of TDP2 causes delayed DSB repair kinetics. Based on these 
observations the following hypothesis can be generated. Firstly, inhibiting TDP2, while 
inducing transcription with estradiol, will increase TOP2B-mediated DSBs (compared to 
estradiol-treated uninhibited cells). By treating these cells with etoposide, the DSBs will be 
made abortive. The lack of functional TDP2 will lead to delayed repair kinetics, meaning that 
abortive DSBs will persist long enough to overwhelm the cell and result in permanent cell cycle 
arrest and cell death. Therefore, I believe that under the right conditions, TDP2 can be 
therapeutically exploited.  
10.8 Overview and further work 
In my thesis I showed that inherent TDP2 protein levels or inherent TOP2A/TDP2 and 
TOP2B/TDP2 protein level ratios do not have the potential for use as predictive biomarkers of 
etoposide resistance in lung and breast cancer cells. I investigated whether this could be due 
to the mutational profile of the cell lines I used and I proposed that EGFR, PIK3CA, PTEN, TP53 
and SMARCA4 mutations could have contributed to the lack of correlation that I observed. I 
also investigated the potential of using TDP2 as a biomarker of sensitivity for other anti-cancer 
drugs. I proposed that a correlation between TDP2 and drug resistance should be explored 
experimentally for Vinblastine, ABT888, AG014688, Bleomycin, Camptothecin and 
Bicalutamide. I was not able to show a synergistic effect of treatment with estradiol, PARP1 
inhibitor and etoposide when comparing clonogenicity after the combination treatment and 
treatment with etoposide. Finally, I showed that treatment with estradiol induces a 
significantly higher number of DSBs (depicted as γH2AX foci per cell) in TDP2-depleted cells; a 
combined treatment of etoposide and estradiol causes a significantly higher number of DSBs 
(depicted as γH2AX foci per cell) in the TDP2-depleted cells; and lack of TDP2 causes delayed 
DSB repair kinetics. Based on these observations I proposed a hypothesis. Treating breast 
cancer cells lacking TDP2 with estradiol will induce a higher number of transcription-related, 
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TOP2B-mediated DSBs compared to cells with TDP2. At that stage, treating these cells with 
etoposide will render this large number of breaks abortive. Finally the lack of functional TDP2 
will lead to delayed repair kinetics, meaning that abortive DSBs will persist long enough to 
overwhelm the cell and result in permanent cell cycle arrest and cell death. Therefore, I 
believe that under the right conditions, TDP2 can be therapeutically exploited and targeted for 
inhibition, especially in slow proliferating hormone-dependent cancers such as breast tumours, 
where resistance has developed or other types of treatment have failed. 
I believe the future of therapeutic exploitation of TDP2 lies with the development of a TDP2 
targeting agent, in the same manner that one exists for TOP2. Such work would allow 
successful inhibition of TDP2 in different types of cell lines, which will have an effect on 
resistance to etoposide; something that I believe has been proven conclusively. The acquisition 
of such a useful tool could open up the possibility of targeting TDP2 for pharmacological 
inhibition to potentially increase tumour sensitivity to TOP2 poisons, particularly those that 
develop resistance during the course of treatment. This of course is the opinion of several 
research groups too, as there are many encouraging published papers about the future of a 
successful TDP2 inhibitor.  
Toxoflavin derivatives and deazaflavins were identified as sub-micromolar and selective 
inhibitors of TDP2 via a high-throughput screening; however, even though they both 
demonstrated a structure-activity relationship, both posed challenges (Raoof et al., 2013). 
Isoquinoline-1,3-dione compounds were also reported as selective TDP2 inhibitors (Kankanala 
et al., 2016). Deazaflavin was identified by another study as a good candidate (Marchand et al., 
2016). Another paper identified a selective inhibitor via a high-throughput screening and 
subsequent validation studies, NSC111041 (Kont et al., 2016). A different group reported 
another collective of TDP2 inhibitors that emerged from experimentally verifying the selective 
inhibitory activity of relevant molecules from the NCI diversity small molecule database 
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(Kossmann et al., 2016). Finally, another group confirmed that deazaflavin inhibits TDP2 using 
a fluorescence-based assay suitable for high-throughput screening, but they went one step 
further and determined the crystal structures of these compounds bound to a ‘humanized’ 
form of murine TDP2. Interestingly, these structures demonstrated that the compounds act as 
competitive ligands for the binding site of an incoming DNA substrate, something that could 
potentially point the way towards generating new and effective TDP2 inhibitors (Hornyak et 
al., 2016). 
Administering such an inhibitor to patients might have an effect on cell viability on its own, 
although additional experiments would need to be designed to specifically explore this. Even 
though the MCF7 TDP2 knock-down I used was not utilised for comparison of physiological 
differences compared to the MCF7 mock knock-down in the absence of any treatment, I 
observed a difference during cell culture of those two cell lines. TDP2-depleted cells’ growth 
rate was slower than the mock-depleted, which could imply that near-absence of TDP2 had an 
effect on proliferation rates. Furthermore, it is interesting that treatment with estradiol 
induced a higher number of DSBs (visualised as γH2AX foci) in the TDP2-depleted cells, while 
induction of transcription of ER responsive genes was not significantly different for the TDP2-
depleted and mock-depleted cells, although there is evidence that suggest that it is lower for 
AR-responsive genes in TDP2-depleted cells (Gómez-Herreros et al., 2014). Even though 
treatment with estradiol alone did not yield different cell survival results between these two 
cell lines, it is still possible that the introduction of a significantly higher number of DSBs could 
potentially have therapeutic applications. As previously discussed, perhaps a different TDP2-
inhibited cell line in which induction of transcription could be achieved at higher levels could 
be a good candidate, so that treatment with estradiol would introduce a high enough number 
of TOP2B-mediated DSBs, which in turn would lead to significantly different results in cell 
survival. 
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High-throughput RNA interference (RNAi) screens could be used to identify synthetic lethal 
interactions with TDP2. The approach that my project had, required considerable 
infrastructure and a substantial investment for each cell line that I screened. Screens that are 
designed to be specific to the context of the inactivated contender, in this case TDP2, and 
specific to treatments previously characterised have been shown to be successful in generating 
interpretable data and exposing genotype-specific sensitivities (Silva et al., 2008, Ngo et al., 
2006, Schlabach et al., 2008).  
My project was solely focused on lung and breast cancer cells, as initially the objective was to 
compare levels of TDP2 in various cancer cells and if these levels were variable enough, to 
investigate a correlation between TDP2 levels and sensitivity to etoposide, as a clinical 
predictor for treatment outcome. Using cells derived from normal tissue was not considered as 
it would not have an impact on the outcome and the conclusions of the findings. One of the 
hallmarks of cancer is increased proliferation and it was hypothesised that cancer cells would 
rely heavily on TDP2 for repairing TOP2-mediated DSBs, unlike normal tissue.  
As with any kind of cancer treatment though, etoposide causes side effects due to the inability 
of the treatment to distinguish between healthy cells and cancer cells when targeting TOP2. 
Targeted therapies though, still strike cancer cells more effectively as the small molecule 
compounds usually used, target specific proteins that play a key role in cancer cell growth and 
survival. Inhibiting TDP2 with a drug would potentially have similar side effects, as it would 
probably target all cells indiscriminately. On the other hand, there is a way of administering 
such treatments in a more specific manner, by using monoclonal antibodies. Monoclonal 
antibodies can recognise specific areas unique to cancer cells, bind to them and deliver the 
small molecule compound directly to the cancer cell without harming the healthy cells of the 
patient (Scott et al., 2012). Therefore even once an effective TDP2 inhibitor is developed, the 
compound may need to be optimised with targeted delivery to ensure minimal side effects on 
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healthy tissue. On the other hand strong synergy with other drugs that are specific to cancer 
cells may reduce the detrimental effect on healthy tissue. 
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Appendix 6: A collection of gene mutation status in a panel of breast cancer cell lines. No indicates wild type gene 
status and Yes indicates mutant gene status. 
Gene Name BT474 MCF7 MM361 MM453 T47D ZR751 
A2ML1     Yes       
AAK1 Yes Yes   Yes     
AARS Yes Yes         
AARS2       Yes     
AASS Yes           
ABCA1 Yes   Yes       
ABCA10         Yes   
ABCA12 Yes   Yes       
ABCA13     Yes Yes     
ABCA2 Yes     Yes     
ABCA3     Yes       
ABCA4     Yes       
ABCA6       Yes     
ABCA7       Yes     
ABCA8   Yes     Yes   
ABCA9         Yes   
ABCB1     Yes       
ABCB11     Yes       
ABCB4   Yes         
ABCB6   Yes         
ABCC1     Yes       
ABCC12     Yes Yes     
ABCC3 Yes           
ABCC5 Yes     Yes Yes   
ABCC8 Yes           
ABCE1       Yes     
ABHD1     Yes       
ABHD16A Yes           
ABHD2 Yes   Yes       
ABHD3     Yes       
ABI3BP   Yes         
ABL2     Yes       
ABLIM1     Yes       
ABLIM3 Yes           
AC007731_16 Yes           
AC010872_2   Yes         
AC092031.1         Yes   
AC112491_4     Yes       
AC142381_2     Yes       
ACACA         Yes   
ACACB     Yes Yes     
ACAD10       Yes     
ACAN       Yes     
ACAT1       Yes     
ACAT2       Yes     
ACCN1     Yes Yes     
ACCN3   Yes         
ACE   Yes         
ACO1     Yes       
ACOT12   Yes         
ACPP       Yes     
ACSM3         Yes   
ACSM4     Yes       
ACSM5     Yes       
ACTB Yes           
ACTG2   Yes         
ACTL7A       Yes     
ACTL7B         Yes   
ACTN2         Yes   
ACTR8       Yes     
ACVR1   Yes     Yes   
ACVR1C     Yes       
ACVR2A Yes           
ACVR2B Yes           
ADAM17 Yes   Yes   Yes Yes 
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ADAM18       Yes     
ADAM20 Yes           
ADAM22       Yes     
ADAM28 Yes   Yes Yes Yes Yes 
ADAM29       Yes     
ADAMTS1       Yes     
ADAMTS12         Yes   
ADAMTS15 Yes           
ADAMTS16   Yes         
ADAMTS18   Yes         
ADAMTS19     Yes       
ADAMTS3   Yes         
ADAMTS6     Yes       
ADAMTSL2       Yes     
ADAMTSL3 Yes   Yes       
ADAP1 Yes           
ADARB2     Yes       
ADCK1         Yes   
ADCK3       Yes     
ADCY2     Yes Yes     
ADCY4   Yes   Yes     
ADCY6 Yes     Yes     
ADCYAP1R1 Yes           
ADD1 Yes Yes         
ADD2     Yes       
ADD3     Yes       
ADGB   Yes   Yes     
ADK       Yes     
ADORA3 Yes           
ADPRHL1 Yes           
ADRA1D Yes           
ADRM1   Yes         
AES Yes           
AFF3 Yes     Yes     
AGAP1       Yes     
AGAP2     Yes       
AGBL1 Yes Yes         
AGBL4         Yes   
AGC1       Yes     
AGER Yes           
AGFG1   Yes         
AGPAT6     Yes       
AGPS       Yes     
AHCTF1         Yes   
AHI1     Yes       
AHNAK Yes Yes         
AHNAK2 Yes   Yes Yes     
AHSA2 Yes           
AIRE     Yes       
AK5       Yes     
AK7     Yes       
AKAP10     Yes       
AKAP12 Yes   Yes Yes Yes   
AKAP2 Yes           
AKAP3 Yes     Yes     
AKAP6     Yes       
AKAP8L       Yes     
AKAP9 Yes     Yes     
AKR1B1       Yes     
AKR1C4       Yes     
AKT1 No No   No No No 
AL589988.1 Yes           
ALB     Yes       
ALCAM Yes           
ALDH16A1     Yes       
ALDH1L1         Yes   
ALDH8A1   Yes         
ALDOB       Yes     
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ALG10B       Yes     
ALG11       Yes     
ALG3     Yes       
ALKBH1       Yes     
ALKBH3     Yes       
ALOXE3       Yes     
ALPK1 Yes Yes         
ALPK2 Yes Yes   Yes Yes Yes 
ALPK3     Yes Yes     
ALS2CL   Yes         
ALS2CR11       Yes     
ALS2CR8     Yes       
AMACR       Yes     
AMIGO2     Yes       
AMOTL1     Yes       
ANAPC1 Yes           
ANAPC4     Yes       
ANAPC5     Yes Yes     
ANGPT1 Yes           
ANGPTL1       Yes     
ANGPTL3     Yes       
ANK2 Yes     Yes     
ANK3 Yes Yes         
ANKFN1   Yes         
ANKHD1         Yes   
ANKLE2     Yes       
ANKRD1 Yes           
ANKRD12     Yes       
ANKRD18A     Yes       
ANKRD26 Yes     Yes     
ANKRD27     Yes       
ANKRD30A         Yes   
ANKRD30B       Yes     
ANKRD30BL     Yes       
ANKRD34A Yes           
ANKRD36     Yes       
ANKRD36C     Yes Yes     
ANKRD56 Yes           
ANKRD6       Yes     
ANO1   Yes Yes       
ANO2     Yes       
ANO3 Yes   Yes       
ANO4       Yes     
ANO9     Yes       
ANTXR1     Yes       
ANXA1 Yes           
ANXA4 Yes           
AOX1 Yes           
AP1G2 Yes     Yes     
AP1M1 Yes           
AP2A1       Yes     
AP2A2       Yes     
AP2M1     Yes       
AP3B1       Yes     
APBA2         Yes   
APBB2         Yes   
APC No No No No No No 
APC2         Yes   
APEX2 Yes           
APOA5 Yes           
APOLD1     Yes       
APP     Yes       
APPL1       Yes     
AQP8 Yes           
AR       Yes     
ARAP1       Yes     
ARFGEF1     Yes       
ARFGEF2 Yes           
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ARFIP1       Yes     
ARG1     Yes       
ARG2 Yes           
ARHGAP11A         Yes   
ARHGAP17     Yes       
ARHGAP19 Yes           
ARHGAP21 Yes           
ARHGAP22     Yes       
ARHGAP25   Yes         
ARHGAP29 Yes           
ARHGAP31     Yes       
ARHGAP32     Yes       
ARHGAP39     Yes       
ARHGAP4       Yes     
ARHGEF1 Yes           
ARHGEF12 Yes           
ARHGEF15 Yes           
ARHGEF18   Yes Yes       
ARHGEF26 Yes           
ARHGEF38       Yes     
ARHGEF40 Yes           
ARID1A   Yes Yes   Yes   
ARID4B     Yes       
ARL13B   Yes         
ARL4C       Yes     
ARL6     Yes       
ARL6IP4 Yes           
ARMC3 Yes           
ARMC7     Yes       
ARMC9       Yes     
ARNT     Yes       
ARNTL2     Yes       
ARRDC4   Yes         
ARSB         Yes   
ARSD       Yes     
ASAP1       Yes     
ASB10     Yes       
ASB11       Yes     
ASB12       Yes     
ASB9     Yes       
ASCC1   Yes         
ASGR1   Yes         
ASH1L   Yes         
ASH2L     Yes       
ASPH       Yes   Yes 
ASPM   Yes Yes Yes     
ASPSCR1     Yes       
ASTE1 Yes   Yes       
ASTN1       Yes     
ASTN2     Yes       
ASXL2       Yes     
ATAD2B Yes   Yes       
ATAD5 Yes           
ATF1     Yes       
ATF7IP         Yes   
ATG13   Yes         
ATG2A   Yes         
ATG2B     Yes       
ATG4C Yes           
ATM Yes           
ATN1     Yes       
ATP10A         Yes   
ATP10B     Yes       
ATP10D Yes Yes         
ATP11B       Yes     
ATP11C       Yes     
ATP13A4     Yes       
ATP13A5     Yes       
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ATP2A2 Yes           
ATP2B1 Yes           
ATP2B3   Yes         
ATP2B4   Yes         
ATP2C1       Yes     
ATP2C2     Yes       
ATP5A1       Yes     
ATP5C1 Yes           
ATP6V0A1 Yes           
ATP6V0A4       Yes     
ATP6V1A       Yes     
ATP6V1B1       Yes     
ATP8B1       Yes     
ATP8B2 Yes           
ATP8B3     Yes Yes     
ATP9A   Yes         
ATR No No   Yes     
ATRIP     Yes       
ATRNL1       Yes     
ATRX     Yes       
ATXN7       Yes     
AUTS2     Yes       
AXIN1   No   No No No 
B3GNT4       Yes     
B3GNT5     Yes       
BAALC     Yes       
BAAT   Yes         
BACH1 Yes           
BAG6     Yes       
BAI1       Yes     
BAI2     Yes       
BAI3   Yes         
BANK1     Yes   Yes   
BAP1     Yes       
BASP1       Yes     
BAT2D1 Yes Yes Yes       
BAZ2B   Yes   Yes     
BBS10   Yes         
BBS4   Yes         
BCAP31     Yes       
BCAS1     Yes   Yes   
BCKDK     Yes       
BCL11B       Yes     
BCL2L13   Yes         
BCL2L15 Yes           
BCMO1     Yes       
BCOR Yes           
BCORL1       Yes     
BCR Yes Yes Yes   Yes Yes 
BDKRB1 Yes           
BDP1         Yes   
BEND3       Yes     
BET1L       Yes     
BFAR Yes           
BICD1 Yes   Yes       
BIN1         Yes   
BIN3     Yes       
BIRC6     Yes Yes     
BLK Yes           
BMP10       Yes     
BMP2 Yes     Yes     
BMP6 Yes           
BMPR2     Yes       
BNC1   Yes         
BOC       Yes     
BOD1L       Yes     
BOK Yes           
BPIL3       Yes     
253 
 
BPTF     Yes       
BRAF No No No No No No 
BRAP       Yes     
BRCA1 No No No No No No 
BRCA2 Yes   Yes       
BRD2     Yes       
BRD4       Yes     
BRD7 Yes           
BRDT Yes           
BRIP1 Yes           
BRMS1       Yes     
BRPF1   Yes         
BRWD1   Yes Yes       
BSPH1         Yes   
BTBD11         Yes   
BTBD2     Yes       
BTBD6   Yes         
BTBD8     Yes       
BTG1     Yes       
BTG3 Yes           
BTN1A1 Yes           
BTN2A1         Yes   
BTN3A3 Yes           
BTNL8 Yes           
BUB1B Yes           
BUB3     Yes       
BVES   Yes         
C10orf11     Yes       
C10orf112 Yes   Yes       
C10orf129       Yes     
C10orf137     Yes       
C10orf18       Yes     
C10orf31     Yes       
C10orf35       Yes     
C10orf46     Yes       
C10orf55       Yes     
C10orf6     Yes       
C10orf71       Yes     
C10orf85     Yes       
C10orf92       Yes     
C10orf96     Yes       
C11orf63 Yes           
C11orf80       Yes     
C12orf4   Yes         
C12orf51     Yes       
C12orf73       Yes     
C12orf77   Yes         
C14orf102   Yes         
C14orf118     Yes       
C14orf39     Yes       
C14orf43       Yes     
C15orf27 Yes           
C15orf43     Yes       
C15orf55   Yes Yes   Yes   
C15orf59         Yes   
C16orf13     Yes       
C16orf46     Yes       
C16orf71     Yes       
C16orf85 Yes           
C16orf88 Yes           
C16orf93 Yes           
C17ORF37       Yes     
C17orf39 Yes           
C17orf46 Yes           
C17orf57       Yes     
C17orf63 Yes           
C17orf70   Yes         
C18orf34     Yes       
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C18orf54       Yes     
C19orf28     Yes       
C19orf29     Yes       
C19orf40 Yes           
C19orf44 Yes           
C19orf55       Yes     
C19orf69     Yes       
C1orf106     Yes       
C1orf112     Yes       
C1orf127 Yes           
C1orf129       Yes     
C1orf159       Yes     
C1orf164 Yes           
C1orf173     Yes       
C1orf186       Yes     
C1orf187   Yes         
C1orf54     Yes       
C1orf86       Yes     
C1QTNF7   Yes         
C1QTNF9B       Yes     
C1R       Yes     
C20orf132     Yes       
C20orf152 Yes           
C20orf173 Yes           
C20orf195 Yes           
C20orf78 Yes           
C21orf33       Yes     
C22orf29         Yes   
C22orf42     Yes       
C22orf43 Yes           
C2CD2     Yes       
C2orf67   Yes     Yes   
C2orf71     Yes   Yes   
C2orf77     Yes       
C3AR1       Yes     
C3orf15     Yes Yes     
C3orf21 Yes           
C3orf65         Yes   
C3orf67     Yes       
C3orf77       Yes     
C4BPA Yes     Yes     
C4orf21 Yes     Yes     
C4orf29         Yes   
C4orf41       Yes     
C5orf28       Yes     
C5orf38     Yes       
C5orf44         Yes   
C5orf5     Yes       
C6orf103   Yes   Yes     
C6orf146 Yes           
C6orf163 Yes           
C6orf165 Yes           
C6orf168       Yes     
C6orf174       Yes     
C6orf70   Yes         
C6orf89     Yes       
C7orf31       Yes     
C7orf44       Yes     
C8A     Yes       
C8G   Yes         
C8orf48       Yes     
C8orf76 Yes           
C9orf102     Yes       
C9orf117 Yes           
C9orf125     Yes       
C9orf128     Yes       
C9orf131     Yes       
C9orf156   Yes         
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C9orf174 Yes           
C9orf24 Yes           
C9orf48 Yes           
C9orf5     Yes       
C9orf78 Yes           
C9orf80   Yes         
C9orf84       Yes     
C9orf93       Yes     
CA2       Yes     
CAB39       Yes     
CABC1 Yes   Yes Yes     
CACNA1A Yes   Yes       
CACNA1B     Yes       
CACNA1C       Yes     
CACNA1E   Yes Yes       
CACNA1I     Yes       
CACNA1S       Yes     
CACNA2D2         Yes   
CACNA2D3 Yes           
CACNA2D4 Yes     Yes     
CACNB2 Yes Yes Yes Yes Yes Yes 
CACNG7       Yes     
CAD       Yes     
CADPS2 Yes   Yes       
CAGE1         Yes   
CALM3       Yes     
CALN1 Yes           
CAMK1G     Yes       
CAMTA2     Yes Yes     
CANX       Yes     
CAPN11   Yes         
CAPN12     Yes       
CAPN13       Yes     
CAPN14     Yes Yes     
CAPN3 Yes           
CAPN5       Yes     
CAPRIN2       Yes     
CARD11 Yes           
CARKD     Yes       
CASC3 Yes           
CASKIN1 Yes           
CASKIN2 Yes           
CASP12   Yes         
CASP14 Yes           
CASP2 Yes           
CASP3   Yes         
CASP7     Yes       
CASP8AP2     Yes Yes     
CAT     Yes       
CATSPER1     Yes Yes     
CATSPER3       Yes     
CATSPERG Yes           
CBL Yes           
CBR3     Yes       
CBX2     Yes       
CBX5 Yes           
CBX8 Yes           
CCAR1     Yes       
CCDC116       Yes     
CCDC132       Yes     
CCDC136   Yes         
CCDC140     Yes       
CCDC163P     Yes       
CCDC165       Yes     
CCDC33 Yes           
CCDC34         Yes   
CCDC38     Yes Yes     
CCDC39     Yes       
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CCDC48     Yes       
CCDC60 Yes           
CCDC64B   Yes         
CCDC66   Yes         
CCDC67       Yes     
CCDC74A       Yes     
CCDC77     Yes Yes     
CCDC83         Yes   
CCDC87 Yes           
CCDC88C Yes           
CCDC89     Yes       
CCDC97     Yes       
CCK Yes           
CCKAR   Yes         
CCNA1       Yes     
CCNB1IP1     Yes       
CCNB3     Yes       
CCND1 Yes           
CCNE2 Yes           
CCNF     Yes       
CCNL1   Yes         
CCNT1     Yes       
CCNY Yes           
CCR8         Yes   
CCT4 Yes           
CCT8       Yes     
CD163       Yes     
CD177   Yes Yes       
CD19     Yes       
CD1A         Yes   
CD1C     Yes       
CD1E         Yes   
CD200   Yes         
CD302   Yes         
CD3E   Yes         
CD68   Yes         
CD69     Yes       
CD80 Yes           
CD97 Yes           
CDAN1       Yes     
CDC14A Yes           
CDC25B Yes           
CDC40       Yes     
CDC42 No No         
CDC42BPA   Yes         
CDC42BPB   Yes   Yes     
CDC42BPG       Yes     
CDCP1   Yes         
CDCP2     Yes       
CDH1 No No No Yes No No 
CDH10         Yes   
CDH18     Yes       
CDH2 Yes     Yes     
CDH20     Yes       
CDH22       Yes     
CDH24   Yes     Yes   
CDH3 Yes           
CDH6 Yes     Yes     
CDH7 Yes           
CDHR5     Yes       
CDK11A Yes           
CDK11B Yes Yes Yes Yes Yes   
CDK13           Yes 
CDK18         Yes   
CDK2 No No         
CDK4 No No         
CDK5RAP2 Yes Yes         
CDK6 No No         
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CDK8 Yes           
CDKL4     Yes       
CDKN1B     Yes       
CDKN2A No Yes Yes No No No 
CDKN2C No No No No No No 
CDRT15       Yes     
CDS2         Yes   
CDT1       Yes     
CEACAM8       Yes     
CELF5     Yes       
CELSR1 Yes           
CELSR2 Yes           
CENPB Yes           
CENPE Yes   Yes       
CENPF Yes   Yes       
CENPH       Yes     
CENPJ     Yes       
CENPT Yes     Yes     
CEP110     Yes       
CEP112 Yes           
CEP135     Yes       
CEP170       Yes     
CEP192 Yes           
CEP290     Yes       
CEP350     Yes       
CEP68 Yes       Yes   
CEP70   Yes         
CEP78     Yes       
CEP85       Yes     
CEP95 Yes           
CERK   Yes         
CES2       Yes     
CFH     Yes       
CFI     Yes       
CGI-77 Yes           
CGN     Yes       
CHAF1B     Yes       
CHAT       Yes     
CHCHD3     Yes       
CHD1     Yes Yes   Yes 
CHD2     Yes       
CHD5 Yes           
CHD7       Yes     
CHD8     Yes Yes     
CHD9           Yes 
CHEK2 No No         
CHKA       Yes     
CHL1 Yes     Yes     
CHMP2A         Yes   
CHN2 Yes           
CHST1       Yes     
CHST2         Yes   
CHST9   Yes         
CHSY1   Yes         
CHTF18       Yes     
CHTOP       Yes     
CIB3   Yes         
CIC Yes           
CIITA       Yes     
CINP       Yes     
CIR1 Yes           
CIRH1A     Yes       
CIT         Yes   
CKAP2L   Yes         
CLCN2     Yes       
CLCN3   Yes   Yes     
CLDN1   Yes         
CLDN16         Yes   
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CLEC4D       Yes     
CLEC4F     Yes       
CLEC4G Yes           
CLEC7A       Yes     
CLINT1     Yes       
CLIP1   Yes Yes       
CLIP3     Yes       
CLK1   Yes         
CLK3           Yes 
CLN8 Yes           
CLPB   Yes         
CLSPN     Yes       
CLSTN3     Yes       
CLTA Yes           
CLTCL1 Yes Yes Yes   Yes Yes 
CLU Yes           
CLUL1 Yes           
CLVS1     Yes       
CMAHP Yes           
CMKLR1     Yes       
CMTM1     Yes       
CNDP1   Yes     Yes   
CNGA1 Yes           
CNIH     Yes       
CNKSR1   Yes         
CNKSR3 Yes           
CNNM2       Yes     
CNNM4 Yes           
CNOT1 Yes           
CNTLN Yes           
CNTN2     Yes       
CNTN3   Yes         
CNTN4   Yes   Yes     
CNTN5     Yes       
CNTN6 Yes     Yes Yes   
CNTNAP2 Yes   Yes       
CNTNAP3 Yes           
CNTNAP4   Yes         
CNTNAP5     Yes       
CNTRL     Yes Yes     
COG4 Yes   Yes       
COG8 Yes           
COL11A1     Yes       
COL12A1     Yes       
COL14A1       Yes     
COL17A1 Yes           
COL18A1         Yes   
COL19A1     Yes       
COL1A1     Yes       
COL1A2   Yes     Yes   
COL22A1     Yes       
COL24A1     Yes       
COL2A1 Yes           
COL3A1     Yes       
COL5A1     Yes       
COL6A2     Yes       
COL6A6 Yes   Yes       
COL7A1 Yes           
COL8A1 Yes   Yes       
COL9A1   Yes         
COL9A3 Yes           
COMP Yes           
COPB1 Yes           
COPS4         Yes   
COPS5     Yes Yes     
CORO1A Yes           
CORO2B Yes           
CORO6 Yes           
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CORO7     Yes Yes     
COX10 Yes           
COX7C     Yes       
CP     Yes Yes     
CPAMD8   Yes         
CPB2       Yes     
CPD Yes           
CPE       Yes     
CPLX2       Yes     
CPLX4   Yes         
CPNE1     Yes Yes     
CPNE9         Yes   
CPO       Yes     
CPS1 Yes           
CPXM2         Yes   
CR1     Yes       
CR1L       Yes     
CRB2       Yes     
CREB1 Yes     Yes     
CREB3L2 Yes   Yes       
CREBBP No No No Yes   No 
CREBZF       Yes     
CREG2 Yes           
CRIP1     Yes Yes     
CROT     Yes       
CRSP3         Yes   
CRTAC1         Yes   
CRYBG3     Yes       
CRYGN Yes           
CSDC2   Yes         
CSE1L Yes           
CSF1R     Yes   Yes   
CSGALNACT2     Yes       
CSMD1 Yes   Yes       
CSMD2       Yes     
CSMD3 Yes   Yes       
CSNK1G3 Yes           
CSPG4   Yes     Yes   
CSRP1     Yes       
CSTF1   Yes         
CSTF2T   Yes   Yes     
CTBP2   Yes   Yes Yes   
CTC1 Yes           
CTCFL     Yes       
CTDSP2 Yes           
CTNNA1 No No No No No No 
CTNNA2 Yes           
CTNNB1 No No No No No No 
CTPS Yes           
CTPS1 Yes           
CTR9 Yes           
CTTNBP2     Yes       
CTU1       Yes     
CTU2 Yes       Yes   
CUBN     Yes Yes     
CUL7   No         
CUL9 Yes Yes   Yes     
CUX1 Yes           
CUX2 Yes           
CWC22     Yes       
CWF19L1 Yes           
CXCL12         Yes   
CXCR1       Yes     
CXorf57     Yes       
CXorf58       Yes     
CXorf67 Yes           
CXXC4     Yes       
CYB5R4     Yes       
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CYC1 Yes           
CYFIP2   Yes         
CYP11B1     Yes       
CYP11B2 Yes Yes         
CYP17A1     Yes       
CYP27B1       Yes     
CYP2A6       Yes     
CYP2A7   Yes   Yes     
CYP3A43     Yes       
CYP3A5 Yes           
CYP3A7 Yes           
CYP7A1 Yes           
CYTH1   Yes         
DAAM1     Yes       
DAB1     Yes       
DACH1 Yes   Yes       
DAG1 Yes           
DAGLA   Yes         
DAGLB     Yes       
DAPK1 Yes Yes         
DARS2 Yes           
DAXX     Yes       
DBF4B         Yes   
DBN1 Yes           
DBT     Yes       
DCAF12     Yes       
DCAF17 Yes           
DCAF4     Yes       
DCAKD       Yes     
DCDC1     Yes       
DCDC5       Yes Yes   
DCHS2 Yes Yes   Yes     
DCLK2     Yes Yes   Yes 
DCLRE1A     Yes       
DCTN2     Yes       
DCTN4 Yes           
DCXR     Yes   Yes   
DDHD1   Yes         
DDR2         Yes   
DDRGK1 Yes           
DDX1 Yes       Yes   
DDX12     Yes       
DDX27 Yes           
DDX39B   Yes         
DDX4 Yes           
DDX50       Yes     
DDX51 Yes           
DDX55     Yes       
DDX60     Yes       
DDX60L Yes Yes         
DEDD2         Yes   
DEFB118         Yes   
DEFB133         Yes   
DENND1C   Yes         
DENND2A     Yes       
DENND4A     Yes       
DENND4C Yes     Yes     
DEPDC1       Yes     
DFFA       Yes     
DFNB31 Yes   Yes       
DGKA     Yes       
DGKB       Yes     
DGKI   Yes Yes       
DHCR24     Yes       
DHFRL1       Yes Yes   
DHX16   Yes         
DHX34       Yes     
DHX38     Yes       
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DIAPH2 Yes   Yes       
DIDO1   Yes Yes Yes     
DIP2C     Yes       
DIS3L       Yes     
DISC1 Yes     Yes     
DISP2     Yes       
DKFZP434P1750     Yes       
DKK1 Yes           
DLAT     Yes       
DLEU7       Yes     
DLG2     Yes       
DLGAP1     Yes       
DLL3       Yes     
DLX3         Yes   
DMBT1     Yes Yes Yes   
DMD Yes   Yes       
DMPK Yes         Yes 
DNAAF1     Yes       
DNAH1     Yes       
DNAH10 Yes   Yes       
DNAH11 Yes   Yes   Yes   
DNAH12 Yes           
DNAH14 Yes           
DNAH17 Yes   Yes Yes     
DNAH2   Yes Yes       
DNAH5 Yes Yes         
DNAH7 Yes   Yes Yes Yes   
DNAH8 Yes Yes Yes   Yes   
DNAJB7     Yes       
DNAJC10     Yes       
DNAJC11       Yes     
DNAJC16 Yes           
DNAJC22     Yes       
DNAJC7         Yes   
DNASE1L1   Yes         
DNASE1L2     Yes       
DNHD1   Yes         
DNM2   Yes         
DNM3         Yes   
DNPEP       Yes     
DOC2A   Yes         
DOCK6 Yes           
DOCK8   Yes         
DOCK9     Yes       
DOK4     Yes       
DOT1L     Yes       
DPAGT1   Yes         
DPCR1     Yes Yes     
DPH1     Yes       
DPP10 Yes           
DPP4     Yes       
DPP6 Yes     Yes     
DPP7     Yes       
DPT     Yes       
DPYD       Yes     
DRD2 Yes   Yes       
DRD3       Yes     
DSCAML1   Yes     Yes   
DSCC1   Yes         
DSEL Yes   Yes Yes     
DSG1         Yes   
DSG3 Yes           
DSG4 Yes   Yes       
DST   Yes Yes   Yes   
DSTYK Yes     Yes     
DTHD1   Yes         
DUOX2     Yes       
DUPD1 Yes           
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DUSP4   Yes     Yes   
DVL1       Yes     
DYDC1       Yes     
DYNC1H1 Yes           
DYNC1I2       Yes     
DYSF   Yes Yes       
DZIP1L     Yes Yes     
DZIP3     Yes       
E2F7     Yes       
EBF3       Yes     
EBI3       Yes     
EBNA1BP2 Yes           
ECI1     Yes       
ECM2     Yes       
ECT2L   Yes         
EDAR     Yes       
EDC4     Yes       
EDN1     Yes       
EDNRA     Yes       
EEA1   Yes         
EEF1D Yes           
EEPD1       Yes     
EFCAB3   Yes         
EFCAB4A       Yes     
EFCAB5     Yes       
EFR3B Yes           
EFTUD2     Yes       
EGFR   No Yes No No   
EHD1     Yes       
EHMT1         Yes   
EID1 Yes           
EIF2AK4   Yes Yes   Yes   
EIF3D     Yes       
EIF3G     Yes       
EIF4A1   Yes         
EIF4B Yes           
EIF4E Yes         Yes 
EIF4G1   Yes Yes       
ELAC2     Yes       
ELFN2         Yes   
ELOVL1       Yes     
ELOVL4     Yes       
ELP2 Yes           
ELP4       Yes     
ELTD1   Yes         
EMB         Yes   
EME2     Yes       
EMP3     Yes       
EMR2   Yes         
EMR4     Yes       
ENDOU   Yes         
ENGASE Yes           
ENO1 Yes           
ENOX1 Yes           
ENPEP       Yes     
ENPP3 Yes           
ENSG00000103472       Yes     
ENSG00000121031     Yes Yes     
ENSG00000132356     Yes       
ENSG00000156509       Yes     
ENSG00000172261     Yes       
ENSG00000174450 Yes           
ENSG00000174501     Yes Yes     
ENSG00000182053     Yes       
ENSG00000183059     Yes       
ENSG00000187686 Yes           
ENSG00000196960 Yes           
ENSG00000204815   Yes         
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ENSG00000206044     Yes       
ENSG00000213993     Yes       
ENSG00000214581     Yes       
ENSG00000215019     Yes       
ENSG00000226232   Yes         
ENTHD1 Yes Yes         
ENTPD7       Yes     
ENTPD8     Yes       
EP300     Yes   No No 
EP400 Yes Yes         
EPB41L1   Yes   Yes     
EPB41L4A   Yes         
EPC1       Yes     
EPG5     Yes       
EPHA2 Yes           
EPHA5   Yes Yes Yes     
EPHA6 Yes   Yes   Yes Yes 
EPHA8 Yes           
EPHB1       Yes     
EPHB3       Yes     
EPHB6           Yes 
EPS15 Yes Yes     Yes   
ERAP2       Yes     
ERBB2 No No   Yes     
ERBB3 No No         
ERBB4 No Yes         
ERCC5     Yes       
ERCC6 Yes Yes         
ERCC8   Yes         
ERF Yes           
ERI2     Yes       
ESPL1   Yes Yes       
ESR1 No No   No No No 
ESR2 Yes     Yes     
ESRP2       Yes     
ESRRB     Yes       
ESRRG Yes           
ESYT1       Yes     
ESYT3     Yes       
ETAA1   Yes         
ETHE1 Yes   Yes       
ETV1 Yes     Yes   Yes 
ETV4     Yes       
ETV5     Yes       
ETV6     Yes       
ETV7 Yes           
EVC   Yes         
EVC2     Yes       
EVPL   Yes Yes       
EXD3 Yes           
EXOC1 Yes   Yes       
EXOC2       Yes     
EXOC3     Yes       
EXOC3L1       Yes     
EXOC6B   Yes         
EXOSC10 Yes           
EYS   Yes Yes       
F12     Yes       
F13A1     Yes       
F2       Yes     
FABP6     Yes       
FADS1 Yes           
FAM100A     Yes       
FAM105A     Yes       
FAM116A Yes           
FAM117B Yes           
FAM123A       Yes     
FAM125B     Yes       
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FAM126A Yes           
FAM131A   Yes         
FAM134A     Yes       
FAM135A       Yes     
FAM135B       Yes     
FAM13A   Yes         
FAM13B     Yes       
FAM151A   Yes         
FAM160A1     Yes       
FAM166B       Yes     
FAM175B     Yes       
FAM178A     Yes       
FAM184A     Yes       
FAM184B     Yes       
FAM186B   Yes         
FAM188A       Yes     
FAM190A       Yes     
FAM193A       Yes     
FAM204A     Yes       
FAM20A   Yes         
FAM221B     Yes       
FAM46A     Yes       
FAM47A   Yes         
FAM48A         Yes   
FAM5B       Yes     
FAM65B   Yes     Yes   
FAM71A Yes           
FAM71F1     Yes       
FAM81A       Yes     
FAM81B     Yes       
FAM82B Yes           
FAM83D     Yes       
FAM83H Yes           
FAM86C1       Yes     
FAM90A1     Yes       
FAM98A     Yes       
FANCA Yes           
FANCB       Yes     
FANCE       Yes     
FANCM     Yes       
FAP     Yes       
FASN       Yes     
FAT2       Yes     
FAT4     Yes Yes     
FBF1     Yes       
FBLN2 Yes           
FBLN7     Yes       
FBN2   Yes Yes Yes Yes   
FBN3   No Yes Yes     
FBXL14     Yes       
FBXL16   Yes         
FBXL19     Yes       
FBXL5 Yes           
FBXL6 Yes           
FBXL8 Yes           
FBXO27 Yes           
FBXO3     Yes       
FBXO4     Yes       
FBXO42       Yes     
FBXO43       Yes     
FBXO47 Yes           
FBXW10       Yes     
FBXW12       Yes     
FBXW7 No No     No No 
FCF1       Yes     
FCGR2B Yes     Yes     
FCHO1     Yes       
FCHO2 Yes           
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FCRL4     Yes Yes     
FCRL5 Yes       Yes   
FDXR       Yes     
FES     Yes       
FETUB     Yes   Yes   
FGD4       Yes     
FGF10     Yes       
FGF19     Yes       
FGFR1OP     Yes   Yes   
FGFR3 No No   No No No 
FGFR4       Yes     
FHOD3     Yes       
FIG4 Yes           
FIGNL1   Yes         
FILIP1         Yes   
FIZ1   Yes Yes       
FKBP15     Yes       
FKBP6       Yes     
FKBP8       Yes     
FKRP       Yes     
FLG       Yes Yes   
FLG2     Yes       
FLI1 Yes   Yes Yes Yes   
FLII       Yes     
FLJ13236     Yes       
FLJ14075 Yes           
FLJ16369         Yes   
FLJ45224     Yes       
FLNA         Yes   
FLNC Yes Yes Yes       
FLT1 No No   Yes     
FLT3   Yes         
FLT4 Yes No         
FMNL2     Yes       
FMO3 Yes           
FMO5   Yes         
FMR1     Yes       
FMR1NB Yes           
FN1 Yes   Yes   Yes Yes 
FN3KRP   Yes         
FNBP1     Yes       
FNDC1     Yes       
FOLH1B Yes           
FOPNL         Yes   
FOS     Yes       
FOSL1   Yes         
FOXD4   Yes         
FOXL2   No     No   
FPGS Yes           
FRAS1     Yes Yes     
FREM1   Yes         
FREM3   Yes Yes       
FRMD3 Yes           
FRMD8     Yes       
FRMPD2   Yes   Yes     
FRMPD3   Yes         
FRS3   Yes         
FRY       Yes Yes   
FRYL     Yes Yes     
FSCB Yes           
FSIP2       Yes     
FTSJ3       Yes     
FTSJD2       Yes     
FUK       Yes     
FUS   Yes         
FUSIP1 Yes           
FUT10       Yes     
FUT9 Yes           
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FXR1 Yes           
FYB     Yes       
FYN   Yes         
FZD1     Yes       
FZD10     Yes       
FZD6     Yes       
FZD7     Yes       
G2E3 Yes           
G6PC2   Yes         
GAA       Yes     
GAB3     Yes       
GAB4         Yes   
GABBR1 Yes     Yes     
GABRA6 Yes   Yes       
GABRB1       Yes Yes   
GABRB2       Yes     
GABRG1     Yes       
GABRP Yes           
GABRR3 Yes           
GADL1       Yes     
GAL3ST4 Yes           
GALNT16 Yes           
GALNT6   Yes         
GALNTL1 Yes           
GAPDH     Yes       
GAPDHS Yes           
GAPVD1         Yes   
GARNL3 Yes           
GATA2     Yes       
GATA3   Yes     No No 
GBA2       Yes     
GBF1     Yes       
GCLC     Yes       
GCLM     Yes       
GCNT7     Yes       
GDAP1L1 Yes           
GDF3     Yes       
GDPD3     Yes   Yes   
GDPD5 Yes           
GEM Yes           
GEN1 Yes           
GFPT2     Yes       
GGA2         Yes   
GGCX     Yes       
GGT5   Yes         
GHR Yes   Yes       
GHRHR Yes           
GHSR       Yes     
GIGYF1   Yes         
GIMAP4 Yes           
GIN1 Yes           
GIT1     Yes       
GJA10 Yes           
GJC2       Yes     
GJC3     Yes       
GJD2 Yes           
GKAP1         Yes   
GLB1L3     Yes Yes     
GLI1   Yes     Yes   
GLIPR1L1     Yes       
GLOD5     Yes Yes     
GLS2 Yes           
GLTPD1     Yes       
GMEB1     Yes       
GMFB       Yes     
GNA11 Yes           
GNAI3 Yes           
GNAO1     Yes       
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GNG8 Yes           
GNL1     Yes       
GNS     Yes       
GOLGA4       Yes     
GOLGA8H       Yes     
GOLGA8J         Yes   
GOLGB1 Yes   Yes       
GOLPH3L   Yes         
GP2       Yes     
GP5     Yes   Yes   
GPAA1 Yes           
GPAM       Yes     
GPATCH2L     Yes       
GPATCH3     Yes       
GPC6   Yes Yes       
GPHN     Yes   Yes   
GPNMB     Yes       
GPR111         Yes   
GPR112   Yes Yes Yes Yes   
GPR113 Yes           
GPR12 Yes           
GPR125   Yes         
GPR128       Yes     
GPR132     Yes       
GPR133 Yes Yes         
GPR144   Yes         
GPR172A   Yes         
GPR20       Yes     
GPR26     Yes       
GPR3     Yes       
GPR56   Yes Yes       
GPR64     Yes       
GPR68   Yes         
GPR77     Yes       
GPR85 Yes Yes         
GPR89A     Yes       
GPR98   Yes Yes Yes     
GPRASP1       Yes     
GPRC5B   Yes         
GPRIN2     Yes       
GPRIN3     Yes       
GPT   Yes         
GPX5     Yes       
GRAMD2         Yes   
GRAMD4     Yes       
GRIA1 Yes           
GRIA3 Yes Yes Yes Yes Yes Yes 
GRID1         Yes   
GRID2     Yes       
GRIK1   Yes     Yes   
GRIK2     Yes       
GRIK4       Yes     
GRIN2A     Yes       
GRIN3A     Yes       
GRM1     Yes       
GRM4     Yes       
GRM7     Yes       
GRM8   Yes   Yes     
GSDMB         Yes   
GSG1 Yes           
GSK3A Yes           
GSTA4     Yes       
GSTO1         Yes   
GSTO2       Yes     
GTF2H3 Yes           
GTF2IRD1     Yes       
GTF3C1       Yes     
GTPBP3     Yes       
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GTSE1     Yes       
GUCY1B3     Yes       
GUCY2C   Yes Yes Yes Yes Yes 
GUF1     Yes       
GULP1 Yes           
GYPB       Yes     
HABP4 Yes           
HACE1 Yes           
HAPLN1       Yes     
HAPLN3         Yes   
HAUS4 Yes Yes         
HAVCR1         Yes   
HCN2     Yes       
HCRTR2       Yes     
HDAC6       Yes     
HDAC7 Yes   Yes       
HDAC9   Yes         
HEATR1       Yes     
HEATR5B     Yes       
HEATR7B2 Yes   Yes       
HECTD3 Yes           
HEG1   Yes         
HELLS       Yes     
HELQ Yes           
HEPH           Yes 
HERC1     Yes       
HERC2 Yes Yes Yes   Yes   
HERC4 Yes Yes         
HERC5     Yes       
HERC6     Yes Yes     
HES1 Yes           
HES5   Yes         
HEXDC     Yes       
HFM1     Yes       
HHLA1   Yes         
HIF1A Yes   Yes Yes Yes Yes 
HIP1R         Yes   
HIST1H1C   Yes         
HIST1H2AM   Yes         
HIST1H2BB Yes           
HIST1H2BC         Yes   
HIST1H2BH   Yes Yes       
HIST1H2BL   Yes         
HIST1H2BO     Yes       
HIST1H3B Yes           
HIST1H4D       Yes     
HIVEP1     Yes       
HK1 Yes           
HK2         Yes   
HKR1     Yes       
HLA-A     Yes       
HLA-DPA1     Yes       
HLA-G     Yes       
HLTF   Yes         
HM13     Yes       
HMCN1   Yes   Yes     
HMGCR     Yes       
HMGXB3         Yes   
HNF1A Yes   Yes Yes   Yes 
HNF1B     Yes       
HNRNPR     Yes       
HNRPR     Yes       
HOXA13 Yes           
HOXB1   Yes   Yes     
HP   Yes         
HPCAL1 Yes           
HPX Yes           
HRAS No No No No No No 
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HRASLS     Yes       
HRCT1     Yes       
HRH3       Yes     
HS2ST1     Yes       
HS3ST3B1   Yes         
HSD17B2     Yes       
HSD3B7       Yes     
HSP90B1 Yes       Yes Yes 
HSPA12A Yes           
HSPA4L Yes           
HSPD1 Yes           
HSPG2 Yes Yes   Yes     
HTT Yes           
HVCN1   Yes         
HYAL1       Yes     
HYDIN       Yes Yes   
HYOU1 Yes           
IBTK     Yes       
ICAM1 Yes           
ICAM2         Yes   
ICAM5     Yes       
IDE Yes           
IDH1   No       No 
IDH3G       Yes     
IDI2       Yes     
IDO2 Yes           
IER5     Yes       
IFI16     Yes Yes     
IFI44     Yes       
IFNK   Yes         
IFT122       Yes     
IFT140     Yes Yes     
IFT88     Yes       
IGF1R No No         
IGF2BP2       Yes     
IGF2R       Yes     
IGFALS     Yes       
IGFBP6 Yes           
IGFN1     Yes       
IGSF10     Yes       
IGSF6     Yes       
IKZF4 Yes           
IKZF5     Yes       
IL16     Yes       
IL17RA       Yes     
IL17RC Yes           
IL17RE     Yes       
IL17REL     Yes       
IL5RA         Yes   
IL6R   Yes         
ILDR2     Yes       
ILK Yes Yes Yes Yes Yes Yes 
ILVBL   Yes Yes       
IMMT     Yes       
IMPG1 Yes           
INCENP     Yes       
INHBA     Yes       
INO80D     Yes       
INPP4B         Yes   
INPP5B   Yes         
INPP5E     Yes       
INPP5J       Yes     
INPPL1     Yes       
INTS1 Yes           
INTS2 Yes           
INTS3 Yes           
INTS5     Yes       
IPO13 Yes           
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IPPK       Yes     
IQCC         Yes   
IQCH       Yes     
IQCK         Yes   
IQGAP2   Yes         
IQSEC3     Yes       
IQUB     Yes       
IREB2     Yes       
IRF1   Yes         
IRG1 Yes           
IRS1 Yes Yes Yes   Yes   
IRX1     Yes       
IRX2 Yes           
IRX6 Yes           
ISL1   Yes         
ISM1   Yes         
ISYNA1 Yes           
ITFG3     Yes       
ITGA10 Yes           
ITGA11 Yes           
ITGA2     Yes   Yes   
ITGA4       Yes     
ITGA6     Yes       
ITGAD Yes           
ITGAM   Yes         
ITGAV Yes     Yes     
ITGAX   Yes     Yes   
ITGB1BP3   Yes         
ITGB4       Yes     
ITIH1 Yes           
ITIH5       Yes     
ITIH5L     Yes       
ITPR1 Yes           
ITPR2 Yes Yes Yes Yes Yes Yes 
ITPR3 Yes     Yes Yes   
IVNS1ABP         Yes   
IZUMO3 Yes           
JAKMIP2 Yes Yes Yes       
JKAMP Yes           
JMJD6     Yes       
JMJD7-PLA2G4B Yes           
JMJD8 Yes           
JPH1     Yes       
KALRN Yes           
KANK2     Yes       
KANK4     Yes       
KARS     Yes       
KAT2A Yes           
KAT6B       Yes     
KATNB1       Yes     
KBTBD2     Yes       
KBTBD5     Yes   Yes   
KCNA6       Yes     
KCNA7       Yes     
KCNG1 Yes           
KCNH5       Yes     
KCNJ14   Yes         
KCNJ8     Yes       
KCNK13   Yes   Yes     
KCNK6     Yes       
KCNK9         Yes   
KCNMA1 Yes       Yes   
KCNMB3       Yes     
KCNN2   Yes         
KCNN3     Yes       
KCNQ3     Yes       
KCNQ5 Yes           
KCNS2     Yes       
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KCNT1     Yes       
KCNU1     Yes       
KCNV1       Yes     
KCTD1       Yes     
KDELR2 Yes           
KDM2A Yes           
KDM2B     Yes       
KDM3A   Yes         
KDM3B     Yes Yes     
KDM4E       Yes     
KDM5A     Yes       
KDM5C     Yes   Yes   
KDM6A No No No   No   
KDR No No Yes       
KHDRBS2     Yes       
KHSRP   Yes         
KIAA0100 Yes           
KIAA0182     Yes       
KIAA0195 Yes     Yes     
KIAA0247       Yes     
KIAA0319         Yes   
KIAA0408       Yes     
KIAA0586   Yes     Yes   
KIAA0649   Yes         
KIAA0701 Yes   Yes Yes     
KIAA0746 Yes Yes         
KIAA0802       Yes     
KIAA0913 Yes           
KIAA0922     Yes       
KIAA0947 Yes           
KIAA0953 Yes           
KIAA1009     Yes Yes     
KIAA1109     Yes Yes     
KIAA1161 Yes           
KIAA1199   Yes         
KIAA1211         Yes   
KIAA1217       Yes     
KIAA1239     Yes       
KIAA1244 Yes     Yes     
KIAA1377   Yes         
KIAA1404       Yes     
KIAA1429 Yes           
KIAA1462   Yes         
KIAA1467     Yes       
KIAA1468 Yes           
KIAA1529 Yes           
KIAA1530 Yes           
KIAA1671   Yes         
KIAA1731       Yes     
KIAA1755     Yes       
KIAA1804 No No         
KIAA1841     Yes       
KIAA1967   Yes Yes   Yes   
KIAA2022       Yes     
KIF13A Yes           
KIF19       Yes     
KIF1C     Yes       
KIF20B     Yes Yes     
KIF21B Yes           
KIF22     Yes       
KIF24 Yes           
KIF26A Yes           
KIF26B Yes           
KIF27 Yes           
KIF2B   Yes         
KIF3B     Yes Yes     
KIF5B Yes           
KIF5C Yes           
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KIF6   Yes Yes       
KIFC1     Yes       
KIR2DL4 Yes   Yes       
KIR3DL1 Yes           
KIRREL         Yes   
KLHDC2       Yes     
KLHDC7A       Yes     
KLHL1 Yes     Yes     
KLHL10         Yes   
KLHL18       Yes     
KLHL24 Yes           
KLHL25     Yes       
KLHL26 Yes           
KLHL29 Yes           
KLK6 Yes   Yes       
KLK7     Yes   Yes Yes 
KMO       Yes     
KMT2C   Yes     Yes   
KMT2D Yes           
KNG1 Yes           
KNTC1     Yes       
KPNA2     Yes       
KPNB1         Yes   
KPRP Yes           
KRAS No No No No No No 
KRT19     Yes       
KRT2   Yes Yes       
KRT28 Yes           
KRT40 Yes           
KRT5     Yes       
KRT6B     Yes       
KRT6C       Yes     
KRT7     Yes       
KRT74 Yes           
KRT80         Yes   
KRTAP10-3 Yes           
KRTAP10-8 Yes           
KRTAP1-5         Yes   
KRTAP26-1       Yes     
KRTAP5-1       Yes     
KRTAP5-6 Yes           
KSR1     Yes       
KTN1     Yes       
KY Yes           
L1CAM Yes   Yes       
L3MBTL1     Yes       
L3MBTL2       Yes     
LAD1     Yes       
LAIR1   Yes         
LAMA1 Yes   Yes Yes     
LAMA2     Yes       
LAMA3   Yes Yes       
LAMA5     Yes       
LAMB1 Yes           
LAMB3     Yes       
LAMB4       Yes     
LAMC2       Yes     
LAMC3   Yes         
LANCL1     Yes       
LAPTM4B Yes           
LARP1B       Yes     
LARP4B         Yes   
LARP6       Yes     
LASS2 Yes           
LASS5     Yes       
LATS1 Yes Yes         
LBR       Yes     
LCE1B       Yes     
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LCE2A       Yes     
LCE2B         Yes   
LCE2C Yes           
LCE5A         Yes   
LCK       Yes     
LCMT1     Yes Yes     
LCP2     Yes       
LCT Yes   Yes       
LCTL         Yes   
LDHA Yes           
LDHAL6A Yes           
LDHAL6B       Yes     
LDHD     Yes       
LDLR Yes           
LELP1       Yes     
LETM2     Yes       
LGALS3BP   Yes         
LGALS8     Yes       
LGR4       Yes     
LIAS   Yes         
LIG1 Yes   Yes       
LILRA2     Yes       
LILRA5     Yes       
LILRB2 Yes   Yes       
LILRB5     Yes       
LIMA1       Yes     
LIMK2   Yes Yes       
LIPC     Yes       
LIPF   Yes         
LIX1         Yes   
LMBR1L     Yes       
LMLN Yes Yes         
LMOD3 Yes           
LMX1A Yes           
LNPEP Yes     Yes     
LNX2     Yes       
LOC283849       Yes     
LOC440345       Yes     
LOC51059       Yes     
LOC541473       Yes     
LOC652153       Yes Yes   
LOC652737         Yes   
LOC728194 Yes           
LOC731173     Yes       
LOC91807     Yes       
LONP1       Yes     
LONRF2 Yes           
LOXHD1       Yes     
LOXL4   Yes         
LPA Yes   Yes   Yes   
LPCAT1         Yes   
LPCAT4       Yes     
LPGAT1       Yes     
LPHN1 Yes           
LPHN3       Yes     
LRBA       Yes     
LRCH3       Yes     
LRFN2       Yes     
LRGUK     Yes       
LRIG2 Yes           
LRIG3     Yes       
LRP1   Yes         
LRP11     Yes       
LRP12     Yes       
LRP1B       Yes   Yes 
LRP2 Yes     Yes     
LRP5 Yes           
LRR1 Yes           
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LRRC14   Yes         
LRRC16A Yes       Yes   
LRRC16B Yes   Yes       
LRRC2     Yes       
LRRC33   Yes         
LRRC36       Yes     
LRRC37A3   Yes   Yes     
LRRC37B       Yes     
LRRC4 Yes           
LRRC41 Yes           
LRRC43     Yes       
LRRC48 Yes           
LRRC4C     Yes       
LRRC8A   Yes Yes       
LRRIQ1       Yes Yes   
LRRK2   Yes Yes Yes     
LRRTM1     Yes       
LRRTM3       Yes     
LRRTM4   Yes         
LSP1 Yes           
LTA     Yes       
LTB4R2     Yes       
LTBP2     Yes       
LTBP4 Yes           
LTN1       Yes     
LUZP1     Yes       
LY6G6D     Yes       
LY6G6E Yes           
LY75 Yes           
LYN   Yes         
LYPD2     Yes       
LYRM2 Yes           
LYST Yes Yes   Yes     
LZTR1     Yes       
LZTS2 Yes           
MAATS1     Yes       
MACF1     Yes Yes     
MAD1L1       Yes     
MAD2L1 Yes           
MAD2L2       Yes     
MADD       Yes     
MAEL         Yes   
MAF Yes   Yes Yes     
MAGEB3     Yes       
MAGEC1         No   
MAGED2 Yes           
MAML2   Yes Yes       
MAML3 Yes Yes Yes   Yes   
MAMSTR     Yes       
MAN1A1       Yes     
MAN2A2 Yes           
MAN2B2     Yes       
MAP1B     Yes Yes     
MAP1S         Yes   
MAP2   Yes         
MAP2K1 No No         
MAP2K2 No No         
MAP2K3     Yes       
MAP2K4 No No No No No No 
MAP2K5     Yes       
MAP2K6 Yes   Yes       
MAP3K1 Yes Yes Yes Yes Yes Yes 
MAP3K10       Yes     
MAP3K11 Yes           
MAP3K13   Yes Yes       
MAP3K14 Yes Yes Yes Yes Yes Yes 
MAP3K15     Yes       
MAP3K3     Yes       
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MAP3K5   Yes         
MAP3K6         Yes   
MAP3K7       Yes     
MAP3K8 Yes           
MAP4K3 Yes Yes Yes       
MAP4K4 No No         
MAP6       Yes     
MAP7     Yes       
MAPK1 Yes           
MAPK10 Yes           
MAPK12 Yes           
MAPK13 Yes           
MAPK4       Yes     
MAPK8IP1       Yes     
MAPK8IP3       Yes     
MAPKAPK3           Yes 
MAPKAPK5     Yes       
MARCH2     Yes       
MARCKS Yes           
MARK4   Yes         
MAST1     Yes       
MAST2       Yes     
MAST4     Yes       
MAT1A       Yes     
MATN2   Yes         
MATN4     Yes       
MATR3     Yes       
MAZ Yes           
MB21D2 Yes           
MBD1     Yes       
MBTPS1 Yes           
MCF2   Yes         
MCF2L     Yes       
MCM3AP     Yes       
MCM3APAS         Yes   
MCM5     Yes       
MDH1B Yes           
MDN1   Yes Yes Yes     
MECOM   Yes         
MED13L     Yes       
MED16 Yes           
MED21       Yes     
MED23         Yes   
MEFV     Yes       
MEGF10     Yes Yes     
MEGF6 Yes           
MEGF8 Yes           
MEI1       Yes     
MEIG1 Yes           
MEIR5     Yes       
MERTK Yes   Yes       
MET No No     No No 
METTL13 Yes     Yes     
METTL16 Yes           
METTL20 Yes           
METTL22       Yes     
METTL2A Yes           
METTL3 Yes           
MFGE8         Yes   
MFI2   Yes   Yes     
MFN1     Yes   Yes   
MFSD1       Yes     
MFSD6 Yes           
MGA Yes     Yes     
MGAM Yes   Yes       
MGRN1       Yes     
MGST3       Yes     
MICAL1     Yes       
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MICALL2 Yes       Yes   
MID1       Yes     
MIIP Yes           
MINK1 Yes           
MINPP1     Yes       
MIOS Yes           
MIPEP   Yes         
MIS18BP1       Yes     
MKI67     Yes       
MKI67IP   Yes         
MKKS       Yes     
MKL1     Yes       
MKLN1 Yes     Yes     
MKNK1       Yes     
MKX Yes           
MLH1 Yes           
MLKL       Yes     
MLL Yes           
MLL2 Yes           
MLL3   Yes   Yes Yes   
MLL4 Yes           
MLLT10     Yes       
MLLT4   Yes     Yes   
MLLT6 Yes     Yes     
MLXIP       Yes     
MMP1   Yes         
MMP20       Yes     
MMS19     Yes       
MMS22L Yes     Yes     
MNDA       Yes     
MON1B       Yes     
MON2     Yes       
MORN1 Yes     Yes     
MPEG1 Yes           
MPND Yes           
MPP2     Yes       
MPP4     Yes       
MPRIP Yes     Yes     
MR1 Yes           
MRAP       Yes     
MRC2     Yes       
MRGPRX2     Yes       
MRPL4     Yes       
MRPS16   Yes   Yes     
MRPS34     Yes       
MRVI1     Yes       
MS4A1   Yes         
MS4A4E       Yes     
MSH3         Yes   
MSH6   No No No No No 
MSL2       Yes     
MSMB       Yes     
MSRA     Yes       
MST1     Yes       
MST1R No No         
MT1E     Yes       
MTA1 Yes           
MTA3         Yes   
MTCP1         Yes   
MTCP1NB   Yes     Yes   
MTERFD2       Yes     
MTF1     Yes       
MTHFD2L   Yes     Yes   
MTIF2     Yes       
MTMR3       Yes     
MTMR8       Yes     
MTOR No No Yes       
MTX1       Yes     
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MUC12 Yes           
MUC16 Yes   Yes Yes     
MUC17       Yes Yes   
MUC20 Yes           
MUC4     Yes Yes     
MUC5AC         Yes   
MUC5B         Yes   
MUC6       Yes Yes   
MUT   Yes Yes   Yes   
MYBBP1A   Yes         
MYBL2 Yes           
MYBPC1   Yes         
MYBPC2 Yes           
MYCBP       Yes     
MYCBPAP     Yes       
MYH1     Yes       
MYH11       Yes     
MYH13 Yes   Yes       
MYH14       Yes     
MYH15 Yes           
MYH2   Yes Yes Yes     
MYH3   Yes         
MYH4 Yes Yes         
MYH6     Yes       
MYH8 Yes           
MYH9   Yes Yes       
MYLK   Yes Yes     Yes 
MYLK3     Yes       
MYLK4       Yes     
MYLPF Yes           
MYO10         Yes   
MYO15A Yes           
MYO18A Yes           
MYO18B Yes   Yes       
MYO1A       Yes     
MYO1C         Yes   
MYO1D Yes           
MYO1G     Yes       
MYO3B   Yes         
MYO5A       Yes     
MYO5C       Yes     
MYO7B     Yes       
MYO9A     Yes       
MYOC         Yes   
MYOCD       Yes     
MYOF     Yes   Yes   
MYOM1 Yes           
MYPN       Yes     
MYST3     Yes       
MYST4       Yes     
MYT1L       Yes     
MZF1         No   
N4BP2 Yes   Yes       
N6AMT1       Yes     
NAALADL2       Yes     
NAG6   Yes         
NALCN Yes           
NAP1L4       Yes     
NAPA       Yes     
NAT10       Yes     
NAV3 Yes     Yes     
NBAS Yes           
NBEA   Yes         
NBEAL1 Yes           
NBEAL2       Yes     
NBN   Yes         
NCAM1 Yes Yes Yes Yes Yes Yes 
NCAM2       Yes     
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NCAPD2 Yes   Yes       
NCAPD3 Yes   Yes       
NCAPG       Yes     
NCBP1   Yes         
NCBP2L   Yes         
NCEH1   Yes         
NCKAP1L     Yes       
NCKAP5     Yes       
NCL   Yes         
NCOA3         Yes   
NCOA5       Yes     
NCOR1 Yes           
NCR1     Yes       
NCR2   Yes         
NDST2   Yes         
NDUFV1     Yes       
NEB Yes     Yes     
NEDD1 Yes           
NEDD4   Yes Yes       
NEIL3     Yes       
NEK11     Yes       
NEK3     Yes       
NEK6 No No         
NEK8     Yes       
NELF     Yes       
NELL1   Yes         
NELL2     Yes       
NES   Yes Yes       
NEU2 Yes           
NFASC       Yes     
NFATC2       Yes     
NFATC4       Yes     
NFE2         Yes   
NFE2L2   No         
NFIA Yes   Yes     Yes 
NFIX Yes   Yes       
NFKB1 Yes           
NFKB2 Yes           
NFS1         Yes   
NFX1     Yes Yes     
NGEF       Yes     
NHS         Yes   
NIPAL2     Yes       
NIPBL Yes Yes         
NIPSNAP3B   Yes         
NIT2 Yes           
NKD2 Yes           
NLGN4X     Yes       
NLRC3 Yes     Yes     
NLRC5     Yes       
NLRP1   Yes         
NLRP12 Yes           
NLRP13       Yes     
NLRP7     Yes Yes     
NLRP8 Yes           
NLRP9     Yes   Yes   
NLRX1 Yes   Yes       
NMNAT2       Yes     
NOL10 Yes           
NOL11       Yes     
NOL6 Yes   Yes       
NOL8         Yes   
NOM1 Yes           
NOMO1 Yes           
NOP14         Yes   
NOP16     Yes Yes     
NOP58     Yes       
NOS1       Yes     
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NOS2       Yes     
NOTCH1     Yes       
NOTCH4 Yes           
NOX3         Yes   
NPAS4     Yes       
NPAT   Yes         
NPEPPS   Yes     Yes   
NPHP4 Yes           
NPL Yes           
NPM1 Yes     Yes Yes   
NPR1 Yes       Yes   
NPSR1 Yes           
NPVF         Yes   
NR0B1     Yes       
NR1H2 Yes   Yes Yes Yes Yes 
NR3C1       Yes Yes   
NR5A1   Yes         
NRAS No No No No No No 
NRCAM   Yes         
NRD1 Yes           
NRP2     Yes       
NRXN2 Yes Yes         
NSD1 Yes           
NSMAF     Yes       
NSMCE4A       Yes     
NT5C1A Yes Yes         
NTSR1     Yes       
NUAK1     Yes       
NUCKS1 Yes           
NUDT3   Yes         
NUMA1 Yes           
NUMB Yes           
NUP133     Yes       
NUP155 Yes           
NUP188 Yes   Yes       
NUP210     Yes       
NUP214         Yes   
NUP54 Yes Yes         
NUP98       Yes     
NUPR1       Yes     
NXF1       Yes     
NXF3       Yes     
NYNRIN       Yes     
OAS3     Yes       
OBFC2B       Yes     
OBSCN Yes   Yes Yes     
OBSL1 Yes           
ODF2L     Yes       
ODZ1   Yes         
ODZ2 Yes           
ODZ4       Yes     
OFCC1 Yes           
OIP5   Yes         
OLR1       Yes     
ONECUT1   Yes         
OPCML Yes     Yes     
OPHN1       Yes     
OPTN Yes           
OR10AD1     Yes       
OR10G2 Yes           
OR10G6 Yes       Yes   
OR10G9         Yes   
OR10H5     Yes Yes     
OR10S1       Yes     
OR10X1 Yes           
OR13A1 Yes           
OR13C5         Yes   
OR13C8     Yes       
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OR14J1       Yes     
OR1E1 Yes           
OR1F1       Yes     
OR2B2     Yes       
OR2B3   Yes         
OR2B6       Yes     
OR2D3 Yes Yes         
OR2G2         Yes   
OR2G6 Yes           
OR2L2 Yes           
OR2S2     Yes       
OR2T11 Yes           
OR2T12     Yes       
OR2T33     Yes       
OR2W3         Yes   
OR2Z1   Yes         
OR4A16     Yes       
OR4C15 Yes           
OR4C5_HUMAN   Yes         
OR4F6 Yes           
OR4K14     Yes       
OR4N4     Yes       
OR51L1       Yes     
OR51M1       Yes     
OR51Q1   Yes Yes       
OR52I1       Yes     
OR52I2       Yes     
OR52N1         Yes   
OR5AK2     Yes       
OR5AN1     Yes       
OR5H14     Yes       
OR5I1     Yes       
OR5K2       Yes     
OR5M9     Yes       
OR7A2P Yes Yes         
OR7C2 Yes           
OR8D2         Yes   
OR8J1       Yes     
OR9G1     Yes       
ORC1       Yes     
ORC3     Yes       
OS9   Yes         
OSBPL11       Yes     
OSBPL1A Yes   Yes Yes     
OSBPL3       Yes     
OSBPL6       Yes     
OSCP1     Yes       
OSGEPL1   Yes         
OSR2       Yes     
OSTbeta     Yes       
OSTM1 Yes           
OTC Yes           
OTOF     Yes       
OTOGL       Yes     
OTUD6B Yes           
OTX2 Yes   Yes       
OXR1 Yes           
P2RX5     Yes       
P2RY13       Yes     
PAAF1     Yes       
PABPC1 Yes           
PABPC3 Yes           
PACS2 Yes           
PACSIN3         Yes   
PADI2       Yes     
PADI3 Yes           
PAGE3     Yes       
PAIP1       Yes     
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PAK1       Yes     
PAK4   No         
PAK6   Yes         
PALB2   Yes         
PALM2-AKAP2 Yes           
PAN2     Yes       
PAPLN Yes       Yes   
PARD3       Yes     
PARD3B   Yes         
PARN Yes           
PARP1 Yes           
PARP12     Yes       
PARP15     Yes       
PARP9     Yes       
PARVB Yes           
PASD1       Yes     
PASK   Yes         
PAX1     Yes       
PAX3 Yes   Yes Yes Yes Yes 
PAX4     Yes       
PAX5   Yes   Yes     
PAX6       Yes     
PAX9     Yes       
PBX2 Yes   Yes       
PBX3     Yes       
PBXIP1   Yes         
PCBD1     Yes       
PCBP2 Yes           
PCBP4   Yes         
PCDH1     Yes       
PCDH15 Yes   Yes       
PCDH17       Yes     
PCDH19     Yes       
PCDH9       Yes     
PCDHA1       Yes     
PCDHA12 Yes   Yes       
PCDHA13 Yes           
PCDHA8 Yes           
PCDHA9 Yes           
PCDHB13 Yes           
PCDHB16 Yes           
PCDHB3       Yes     
PCDHB5 Yes           
PCDHB6       Yes     
PCDHB7     Yes       
PCDHGA10         Yes   
PCDHGA12   Yes         
PCDHGA5         Yes   
PCDHGA7 Yes           
PCDHGA9   Yes         
PCDHGB1 Yes           
PCDHGC5     Yes       
PCLO     Yes       
PCNT       Yes Yes   
PCNX   Yes Yes Yes     
PCYOX1     Yes       
PDCD6 Yes           
PDE10A     Yes       
PDE1C       Yes     
PDE4DIP Yes   Yes Yes Yes   
PDE8A     Yes       
PDE8B   Yes         
PDGFA     Yes       
PDGFRA Yes       Yes   
PDGFRL Yes           
PDIA3       Yes     
PDK1 No No         
PDLIM5       Yes     
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PDP2     Yes       
PDZD2     Yes       
PDZD4     Yes       
PDZD7 Yes   Yes       
PDZD8     Yes       
PDZRN4     Yes       
PEG3 Yes Yes Yes       
PELI3 Yes           
PER1 Yes           
PEX14   Yes         
PEX5L Yes   Yes       
PFAS     Yes       
PFKP     Yes       
PGAP3 Yes           
PGBD4       Yes     
PGBD5   Yes         
PGC     Yes       
PGGT1B     Yes       
PGLS Yes           
PGLYRP2 Yes           
PGM2L1     Yes       
PHACTR1         Yes   
PHF1 Yes           
PHF11 Yes           
PHF16 Yes           
PHF19         Yes   
PHF20       Yes     
PHF20L1 Yes           
PHF3       Yes     
PHKB       Yes     
PHKG1     Yes       
PHLDA3       Yes     
PHLDB1     Yes       
PHLPP Yes           
PHLPP1 Yes           
PHOX2A     Yes       
PI16         Yes   
PIEZO1     Yes       
PIEZO2   Yes         
PIF1 Yes     Yes     
PIGF   Yes         
PIGG   Yes         
PIGR   Yes         
PIGZ       Yes     
PIK3AP1   Yes         
PIK3C2A No No     Yes   
PIK3C2G     Yes Yes Yes Yes 
PIK3CA Yes Yes Yes Yes Yes No 
PIK3CD       Yes     
PIK3CG     Yes Yes     
PIK3R1           Yes 
PILRB     Yes       
PION     Yes       
PITPNM1 Yes           
PITRM1     Yes       
PIWIL4   Yes         
PJA2       Yes     
PKD1 Yes       Yes   
PKD1L1         Yes   
PKD1L2     Yes       
PKDCC       Yes     
PKHD1     Yes Yes     
PKIA     Yes       
PKMYT1 Yes         Yes 
PKN1 Yes Yes         
PLA2G3         Yes   
PLAG1 Yes           
PLAU       Yes     
283 
 
PLB1 Yes           
PLCB1 Yes           
PLCB2     Yes       
PLCE1     Yes       
PLCG2         Yes   
PLCL1 Yes           
PLCZ1 Yes           
PLD1 Yes           
PLD2   Yes         
PLEC   Yes     Yes   
PLEKHA5 Yes           
PLEKHA6 Yes           
PLEKHG1     Yes       
PLIN4 Yes           
PLIN5       Yes     
PLK1     Yes       
PLK3 Yes           
PLUNC Yes           
PLXDC2     Yes       
PLXNA2     Yes       
PLXNB2   Yes Yes       
PLXND1   Yes         
PMFBP1 Yes           
PML Yes     Yes     
PMS1 Yes         Yes 
PNPLA6   Yes         
PNPLA7     Yes       
PNPT1       Yes     
PNRC1 Yes           
POC1A       Yes     
POC1B     Yes       
PODN     Yes       
POLA1     Yes       
POLB     Yes       
POLD2     Yes       
POLG       Yes     
POLK Yes           
POLM Yes           
POLQ Yes     Yes     
POLR1B       Yes     
POLR2B       Yes     
POLR2D     Yes       
POLR2E       Yes     
POLR2G   Yes         
POLR3E     Yes       
POLR3K     Yes       
POM121     Yes       
POM121C       Yes     
POP1 Yes           
POSTN         Yes   
POU5F1       Yes     
PPAPDC1A   Yes         
PPAPDC3     Yes       
PPARA Yes           
PPARG     Yes       
PPEF2     Yes       
PPFIA2     Yes       
PPFIA3     Yes       
PPFIA4     Yes       
PPFIBP1 Yes   Yes       
PPIA Yes           
PPL   Yes Yes       
PPM1E Yes           
PPM1G     Yes       
PPM1H     Yes       
PPP1R12B Yes Yes         
PPP1R14D   Yes         
PPP1R16B         Yes   
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PPP1R2 Yes           
PPP1R3A     Yes Yes     
PPP1R3D       Yes     
PPP1R7       Yes     
PPP2CB Yes           
PPP2R1A   No No No No   
PPP2R2B       Yes     
PPP2R3A Yes           
PPP3CA       Yes     
PPP4R4   Yes   Yes     
PPP6R1     Yes Yes     
PRAMEF10       Yes     
PRB3     Yes       
PRCC       Yes     
PRDM15 Yes Yes Yes       
PRDM5 Yes           
PRDX2         Yes   
PREX2     Yes       
PRG4 Yes No         
PRICKLE2 Yes           
PRKAA1     Yes       
PRKAG2     Yes       
PRKCA         Yes   
PRKCH           Yes 
PRKCSH     Yes       
PRKD3         Yes   
PRKDC Yes Yes Yes   Yes   
PRKG1       Yes     
PRLHR     Yes       
PRMT10 Yes Yes   Yes     
PROKR2 Yes           
PROM2     Yes Yes     
PROS1   Yes         
PROX1   Yes         
PRPF3     Yes       
PRPF39       Yes     
PRPF40A     Yes       
PRPF40B Yes   Yes       
PRPF4B     Yes       
PRR14L     Yes       
PRR22       Yes     
PRR3   Yes         
PRR5L Yes           
PRRC2B Yes Yes         
PRSS21     Yes       
PRSS23   Yes         
PRSS3 Yes           
PRSS58   Yes         
PRUNE2 Yes           
PRX Yes           
PSD         Yes   
PSD3       Yes     
PSG6       Yes     
PSG9 Yes           
PSKH1 Yes           
PSKH2 Yes   Yes       
PSMA8 Yes           
PSMB11         Yes   
PSMC4     Yes       
PSMC5   Yes         
PSMD1 Yes           
PSMD11     Yes       
PSMD14     Yes       
PSME4       Yes     
PTCH1     Yes       
PTCHD3       Yes     
PTDSS1     Yes       
PTDSS2 Yes     Yes     
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PTEN No No No Yes No Yes 
PTGS1     Yes       
PTH2R Yes           
PTK2     Yes       
PTK2B Yes           
PTK6     Yes       
PTPN21 Yes           
PTPN22     Yes       
PTPN23   Yes         
PTPN3   Yes         
PTPN4     Yes       
PTPRA     Yes Yes     
PTPRB     Yes       
PTPRD   Yes         
PTPRE     Yes       
PTPRG       Yes     
PTPRK Yes   Yes       
PTPRM   Yes         
PTPRN2     Yes       
PTPRO       Yes     
PTPRR     Yes       
PTPRS     Yes Yes     
PUS10   Yes         
PUS3       Yes     
PVRIG Yes           
PVRL1   Yes         
PWP1     Yes       
PXDNL     Yes Yes     
PXN Yes           
PYCR1 Yes           
PYGL       Yes     
PZP   Yes         
Q5I0X0_HUMAN     Yes       
Q5JXA8_HUMAN       Yes     
Q5VZ43_HUMAN     Yes       
Q6YL47_HUMAN       Yes     
Q6ZQU9_HUMAN       Yes     
Q6ZUG5_HUMAN Yes           
Q86U89_HUMAN Yes           
Q8IVF9_HUMAN       Yes     
Q8N1G8_HUMAN   Yes         
Q8NGM0_HUMAN     Yes       
Q8NH46_HUMAN Yes           
Q96NP5_HUMAN   Yes         
Q9HAD2_HUMAN Yes           
Q9NSQ0_HUMAN Yes           
Q9NT31_HUMAN     Yes       
Q9NW32_HUMAN         Yes   
Q9Y6V0-3     Yes       
QDPR   Yes         
QPCT     Yes       
QRICH2   Yes         
QSER1     Yes       
RAB11FIP1 Yes           
RAB11FIP4     Yes       
RAB13 Yes           
RAB22A Yes           
RAB3B Yes           
RAD21 Yes   Yes       
RAD50       Yes     
RAD51B     Yes       
RAD51L1     Yes       
RAD54B Yes           
RADIL     Yes       
RAG2     Yes       
RALGAPA2 Yes           
RALGPS1 Yes           
RALY         Yes   
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RAP1GDS1 Yes           
RAPGEF2     Yes       
RAPGEF4 Yes Yes Yes       
RAPGEF5 Yes     Yes     
RAPGEF6 Yes     Yes     
RARB           Yes 
RARRES3 Yes           
RASA2     Yes   Yes   
RASAL3       Yes     
RASEF Yes           
RASGRF1     Yes       
RASGRP2   Yes   Yes     
RASIP1     Yes       
RASSF3 Yes           
RASSF6         Yes   
RAVER2   Yes         
RB1 No No No No No No 
RB1CC1       Yes     
RBBP8 Yes           
RBCK1     Yes       
RBFOX2     Yes       
RBL2 Yes           
RBM14   Yes         
RBM15       Yes     
RBM23 Yes   Yes       
RBM26 Yes           
RBM43     Yes       
RBMS2     Yes       
RC3H1     Yes       
RC3H2 Yes           
RCCD1 Yes           
RDH10 Yes           
RDH12       Yes     
RECQL4 Yes     Yes Yes   
REG4     Yes       
RELB       Yes     
RELL2         Yes   
RELN     Yes       
REPIN1   Yes         
RFPL2     Yes       
RFT1   Yes         
RFWD3         Yes   
RFX6 Yes   Yes       
RGL2 Yes           
RGL3 Yes   Yes       
RGMB   Yes         
RGS20 Yes           
RGS22 Yes     Yes     
RGS3     Yes       
RGS7BP Yes           
RHBDF2     Yes       
RHOA Yes           
RHOT2     Yes       
RHPN2       Yes     
RIC8A         Yes   
RIMBP2       Yes     
RIMKLB   Yes         
RIMS2     Yes       
RIN1 Yes           
RIOK1     Yes       
RIOK2 Yes           
RIT1 Yes           
RLTPR Yes           
RMI1   Yes     Yes   
RMND5A Yes           
RNASEH1       Yes     
RNASEL       Yes     
RNF10 Yes           
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RNF111 Yes           
RNF123       Yes     
RNF13 Yes           
RNF148   Yes         
RNF150         Yes   
RNF151 Yes           
RNF165       Yes     
RNF166     Yes       
RNF168     Yes       
RNF186     Yes       
RNF19A   Yes         
RNF20 Yes           
RNF213 Yes     Yes     
RNF216 Yes           
RNF220 Yes           
RNF31     Yes       
RNF39   Yes         
RNF40     Yes       
ROBO2 Yes           
ROCK1     Yes       
ROPN1 Yes           
RORB     Yes       
ROS1 Yes   Yes Yes     
RP1     Yes       
RP11-1220K2.2     Yes   Yes   
RP11-366L20.2       Yes     
RP11-551L14.1       Yes     
RP11-694I15.6     Yes       
RPF2       Yes     
RPGR   Yes         
RPL10L   Yes         
RPL3L       Yes     
RPL4     Yes Yes     
RPS11     Yes       
RPS19     Yes       
RPS6KA1       Yes     
RPS6KA2     Yes       
RPS6KA3 Yes           
RPS6KA5 Yes         Yes 
RPS6KB1     Yes       
RPS6KL1           Yes 
RRAD         Yes   
RRN3     Yes       
RRP7A Yes           
RSBN1L         Yes   
RSF1 Yes     Yes     
RSPH1       Yes     
RSPH10B2 Yes           
RSPH4A     Yes       
RSPO3     Yes       
RSPRY1     Yes       
RTCA         Yes   
RTCD1         Yes   
RTDR1     Yes Yes     
RTEL1 Yes   Yes       
RTL1       Yes Yes   
RTN4IP1     Yes Yes     
RTTN Yes     Yes     
RUFY2     Yes   Yes   
RUNX1 No No         
RUNX1T1 Yes           
RUSC2 Yes           
RWDD1     Yes       
RXFP1 Yes           
RYR1 Yes           
RYR2 Yes   Yes Yes     
RYR3 Yes   Yes       
S100A10   Yes         
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S100A16     Yes       
S1PR2 Yes           
SAAL1 Yes   Yes       
SACM1L Yes           
SACS     Yes       
SAE1 Yes           
SALL1       Yes     
SALL3   Yes Yes       
SAMD13     Yes       
SAMD14       Yes     
SAMD15       Yes     
SAMD9     Yes       
SAP30 Yes           
SARDH     Yes   Yes   
SART3       Yes     
SASH1 Yes           
SAT1 Yes           
SBF2       Yes     
SBNO1     Yes       
SCAF1     Yes       
SCAI     Yes       
SCAPER     Yes       
SCD         Yes   
SCGB1A1     Yes       
SCIN   Yes Yes       
SCML2         Yes   
SCN10A     Yes       
SCN2A     Yes       
SCN3B Yes           
SCN5A       Yes     
SCN7A     Yes       
SCN8A   Yes   Yes     
SCNN1B     Yes       
SCO2     Yes       
SCRIB Yes   Yes       
SCRN3         Yes   
SCTR     Yes       
SCYL3     Yes   Yes   
SDC4     Yes       
SDCBP     Yes       
SDCCAG3     Yes       
SDCCAG8       Yes     
SDF4 Yes           
SDHA     Yes       
SDK1     Yes       
SDK2         Yes   
SDR42E1     Yes       
SEC23A         Yes   
SEC24B     Yes Yes     
SEC24C       Yes     
SEC31B     Yes   Yes   
SEC61A2       Yes     
SEC62     Yes       
SECISBP2L     Yes       
SECTM1 Yes           
SEL1L     Yes       
SEL1L2   Yes         
SEL1L3 Yes Yes Yes       
SELE Yes           
SELENBP1 Yes   Yes       
SELP     Yes       
SEMA3E Yes           
SEMA3G       Yes     
SEMA4B     Yes       
SEMA4C       Yes     
SEMA4G       Yes     
SEMA5A   Yes Yes       
SEMA5B Yes           
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SEMG2     Yes       
SENP1         Yes   
SENP2 Yes           
SENP7     Yes       
SEPT6       Yes     
SERP1     Yes       
SERPINA2 Yes           
SERPINA6     Yes       
SERPINB2   Yes         
SERPINB3     Yes       
SERPINB4       Yes     
SERPINB7     Yes       
SERPIND1 Yes           
SERPINI2       Yes     
SERTAD1     Yes       
SETBP1   No     No   
SETDB1     Yes       
SETX     Yes       
SEZ6L   Yes         
SF1   Yes         
SF3A1     Yes       
SF3A2     Yes       
SF3A3 Yes           
SF3B1 No     No     
SF3B2 Yes   Yes       
SFR1     Yes       
SFRP2 Yes           
SG269_HUMAN     Yes       
SGCG       Yes     
SgK085       Yes     
SGK1     Yes       
SgK269     Yes       
SGK3 Yes           
SGOL2     Yes       
SGSM2         Yes   
SH2B1 Yes           
SH2B3     Yes       
SH3BGR   Yes         
SH3BP5L       Yes     
SH3D21 Yes           
SH3GL3       Yes     
SH3KBP1     Yes       
SHC3   Yes         
SHE       Yes     
SHKBP1         Yes   
SHOX2 Yes           
SHPRH       Yes     
SI     Yes       
SIDT1 Yes           
SIGLEC10 Yes       Yes   
SIGLEC12 Yes     Yes Yes   
SIGLEC14 Yes           
SIK3     Yes Yes     
SIL1     Yes       
SIM1     Yes       
SIPA1L1   Yes Yes       
SIPA1L2 Yes       Yes   
SIPA1L3   Yes         
SIRPB2       Yes     
SIRT2       Yes     
SIRT3 Yes           
SIT1 Yes           
SKAP2     Yes       
SKOR1       Yes     
SLC10A3 Yes           
SLC12A2   Yes         
SLC12A6     Yes       
SLC13A4     Yes       
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SLC15A2     Yes       
SLC16A12     Yes       
SLC17A4 Yes           
SLC17A5       Yes     
SLC17A7 Yes           
SLC1A3 Yes           
SLC1A6     Yes       
SLC22A11       Yes     
SLC22A13     Yes       
SLC22A17         Yes   
SLC22A25         Yes   
SLC22A3     Yes       
SLC22A4     Yes       
SLC22A8 Yes           
SLC22A9 Yes           
SLC23A3 Yes           
SLC24A5       Yes     
SLC25A2         Yes   
SLC25A20   Yes         
SLC25A23         Yes   
SLC25A25 Yes           
SLC25A27   Yes         
SLC25A29   Yes         
SLC25A38 Yes       Yes   
SLC25A40       Yes     
SLC25A44 Yes           
SLC25A46     Yes       
SLC26A1       Yes     
SLC26A10 Yes           
SLC26A4       Yes     
SLC26A7   Yes         
SLC26A8 Yes Yes   Yes     
SLC26A9       Yes     
SLC28A1       Yes     
SLC28A2       Yes     
SLC28A3     Yes       
SLC2A1 Yes           
SLC2A3     Yes       
SLC30A3       Yes     
SLC30A9 Yes           
SLC35B1       Yes     
SLC35B4   Yes         
SLC35F1 Yes   Yes       
SLC36A3 Yes           
SLC37A4 Yes           
SLC38A4       Yes     
SLC38A6       Yes     
SLC39A12   Yes         
SLC39A6       Yes     
SLC44A2 Yes           
SLC44A4 Yes     Yes     
SLC45A4 Yes   Yes       
SLC4A11     Yes   Yes   
SLC4A3     Yes       
SLC4A4 Yes           
SLC4A5 Yes           
SLC5A1   Yes         
SLC5A11       Yes     
SLC5A3       Yes     
SLC5A7   Yes         
SLC5A8     Yes       
SLC5A9 Yes     Yes     
SLC6A15     Yes       
SLC6A18     Yes       
SLC6A20         Yes   
SLC6A8     Yes       
SLC6A9 Yes   Yes       
SLC7A11     Yes       
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SLC7A7 Yes   Yes       
SLC7A8     Yes       
SLC9A11   Yes         
SLC9A5   Yes         
SLCO1B3 Yes           
SLCO5A1     Yes       
SLFN11 Yes           
SLFN5 Yes           
SLITRK2     Yes       
SLITRK5       Yes     
SLX4 Yes           
SMAD2     Yes       
SMAD4 No No No No No No 
SMARCAD1 Yes   Yes       
SMARCAL1     Yes       
SMARCB1 Yes           
SMARCC1 Yes           
SMC2   Yes         
SMC2L1   Yes         
SMCP   Yes         
SMCR7       Yes     
SMCR7L     Yes       
SMG1     Yes       
SMG5 Yes           
SMO     Yes       
SMTN       Yes     
SMURF2     Yes       
SMYD1         Yes   
SNAI2     Yes       
SNAP25         Yes   
SNAPC1     Yes       
SNAPC4       Yes     
SNCG     Yes       
SND1     Yes       
SNIP1   Yes         
SNTG1     Yes       
SNX13   Yes         
SNX17     Yes       
SNX2       Yes     
SNX21   Yes         
SNX25     Yes       
SNX32     Yes Yes     
SNX9     Yes       
SOCS1   No   No No No 
SOCS2         Yes   
SON         Yes   
SORBS2     Yes       
SORL1 Yes           
SORT1         Yes   
SOX21     Yes       
SOX4 Yes           
SOX6     Yes       
SP100     Yes       
SP140 Yes           
SPACA1       Yes     
SPACA3       Yes     
SPACA7     Yes       
SPAG16     Yes       
SPAM1     Yes       
SPATA18       Yes     
SPATA2       Yes     
SPATA9       Yes     
SPATS1     Yes       
SPEF1 Yes           
SPEG Yes           
SPEM1   Yes         
SPEN     Yes   Yes   
SPG11 Yes     Yes     
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SPG21     Yes Yes     
SPINK5     Yes       
SPOCD1     Yes       
SPOCK2       Yes     
SPOCK3     Yes       
SPON2 Yes           
SPP1     Yes       
SPRED2 Yes   Yes       
SPRYD3 Yes           
SPTAN1 Yes           
SPTBN1     Yes       
SPTBN2       Yes Yes   
SPTBN4 Yes           
SPTLC3   Yes         
SQLE     Yes       
SQSTM1   Yes         
SRA1   Yes         
SRC No No Yes       
SRCAP       Yes     
SRCRB4D   Yes         
SREBF2     Yes       
SRF     Yes       
SRGAP1     Yes       
SRGN     Yes       
SRRM1   Yes         
SRRM2 Yes Yes Yes       
SRSF5         Yes   
SRSF6     Yes       
SS18 Yes           
SSRP1       Yes     
SSX1 Yes           
SSX3 Yes           
ST3GAL4 Yes Yes         
ST6GAL1       Yes     
ST6GAL2     Yes       
ST8SIA5 Yes           
STAB1       Yes     
STAB2   Yes   Yes     
STAG1 Yes   Yes       
STAG2       Yes     
STAM2       Yes     
STAT3 Yes       Yes   
STAT4     Yes       
STAU2       Yes     
STK11   No No No No No 
STK24     Yes       
STK25     Yes       
STK31 Yes   Yes Yes Yes Yes 
STK36       Yes     
STK4       Yes     
STOX1     Yes       
STRADA     Yes       
STRBP Yes           
STRC         Yes   
STT3A Yes           
STUB1       Yes     
STX17         Yes   
SUFU     Yes       
SUGT1   Yes         
SULT1C3       Yes     
SUN2     Yes       
SUN3 Yes           
SUPT16H Yes           
SUPT6H     Yes       
SUPT7L     Yes       
SURF6   Yes         
SUSD2   Yes         
SUSD5       Yes     
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SUZ12       Yes     
SV2A       Yes     
SVEP1   Yes Yes       
SVOPL Yes           
SWAP70         Yes   
SWT1     Yes       
SYBU       Yes     
SYCE1     Yes Yes     
SYCE1L     Yes       
SYCP2   Yes         
SYDE2       Yes     
SYMPK Yes     Yes     
SYN3 Yes           
SYNE1 Yes           
SYNGAP1 Yes     Yes     
SYNGR4       Yes     
SYNJ1       Yes     
SYNJ2     Yes       
SYNM     Yes       
SYNPO2L         Yes   
SYT10     Yes       
SYT12 Yes           
SYT4     Yes       
SYTL2     Yes       
SYTL3 Yes           
SYTL4   Yes         
TAB2     Yes       
TAF5L     Yes       
TAF7     Yes       
TANC1 Yes           
TAOK3     Yes       
TAP1 Yes           
TARBP1 Yes     Yes     
TARS     Yes       
TARSL2   Yes Yes       
TAS1R2 Yes     Yes     
TAS2R19     Yes       
TAS2R43 Yes           
TAS2R46 Yes           
TAS2R5 Yes           
TAT   Yes         
TATDN3 Yes     Yes     
TBC1D1 Yes           
TBC1D10B     Yes       
TBC1D15   Yes         
TBC1D19   Yes         
TBC1D4     Yes   Yes   
TBC1D7 Yes   Yes       
TBC1D8B       Yes     
TBCCD1 Yes   Yes       
TBCK Yes           
TBK1     Yes       
TBL3     Yes Yes     
TBP       Yes     
TBX10       Yes     
TBX19     Yes       
TBX2       Yes     
TBXAS1         Yes   
TCEA1   Yes         
TCEA3     Yes       
TCEB1       Yes     
TCERG1L   Yes   Yes     
TCF12 Yes   Yes       
TCF20 Yes   Yes       
TCF25 Yes Yes         
TCF3     Yes       
TCF7L2     Yes       
TCFL5       Yes     
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TCHH Yes           
TCP1     Yes       
TCP11 Yes           
TCTEX1D1     Yes       
TDGF1       Yes     
TDRD1     Yes       
TDRD5 Yes           
TDRD6   Yes   Yes     
TEAD3       Yes     
TEC Yes           
TELO2     Yes       
TENC1       Yes     
TENM1   Yes         
TENM2 Yes           
TET1       Yes     
TET2       Yes     
TET3 Yes           
TEX10 Yes           
TEX13B       Yes     
TEX14 Yes   Yes       
TEX15 Yes           
TFCP2L1     Yes       
TFDP3       Yes     
TFIP11 Yes Yes         
TFRC Yes           
TG   Yes         
TGFBR2 Yes           
TGFBRAP1 Yes   Yes       
TGS1 Yes           
THADA       Yes     
THAP2         Yes   
THAP4 Yes           
THAP9       Yes     
THBS2     Yes       
THBS3       Yes     
THOC3   Yes         
THOC6 Yes           
THRAP3       Yes     
TIAM2       Yes     
TIE1 Yes           
TIGD4     Yes       
TIMELESS     Yes       
TIRAP         Yes   
TJP1         Yes   
TLE1 Yes           
TLE4   Yes         
TLK2     Yes       
TLL2 Yes           
TLN1       Yes     
TLN2       Yes     
TLR2       Yes     
TLR3       Yes     
TLR6 Yes           
TLX1     Yes       
TM6SF1 Yes           
TM7SF4     Yes       
TM9SF1 Yes           
TM9SF2     Yes       
TM9SF3   Yes         
TMC1 Yes           
TMCC2       Yes     
TMCO3       Yes     
TMED5       Yes     
TMED8       Yes     
TMEFF2 Yes           
TMEM106A Yes           
TMEM110     Yes       
TMEM123 Yes   Yes   Yes   
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TMEM132A Yes   Yes       
TMEM132B     Yes       
TMEM132E   Yes Yes       
TMEM146     Yes       
TMEM14A     Yes       
TMEM151A Yes           
TMEM164   Yes         
TMEM174     Yes       
TMEM175   Yes         
TMEM178       Yes     
TMEM187       Yes     
TMEM19     Yes       
TMEM199       Yes     
TMEM201         Yes   
TMEM209 Yes           
TMEM39A Yes           
TMEM55B       Yes     
TMEM57       Yes     
TMEM62 Yes           
TMEM75 Yes           
TMEM87A         Yes   
TMEM87B   Yes         
TMEM89     Yes       
TMEM8B       Yes     
TMEM91     Yes       
TMOD2       Yes     
TMPO Yes   Yes       
TMPPE Yes           
TMPRSS11B   Yes Yes       
TMPRSS13         Yes   
TMTC1     Yes Yes     
TMUB1 Yes           
TMX1       Yes     
TNC     Yes       
TNFRSF13B Yes           
TNFRSF8 Yes           
TNFSF11     Yes       
TNIK   Yes Yes       
TNK2 Yes     Yes     
TNKS     Yes       
TNKS2 Yes           
TNMD       Yes     
TNN     Yes       
TNNI1         Yes   
TNNI3K Yes           
TNNT1 Yes   Yes       
TNR       Yes     
TNRC6A         Yes   
TNS1 Yes           
TNS4 Yes           
TOM1     Yes       
TOMM20L     Yes       
TOMM22     Yes       
TOP2A Yes           
TOP3B       Yes     
TOR1AIP2 Yes           
TP53 Yes No Yes   Yes No 
TP53BP1     Yes Yes     
TP53TG5       Yes     
TP63       Yes Yes   
TP73     Yes       
TPH2     Yes       
TPK1     Yes       
TPM3 Yes           
TPP1   Yes         
TPR       Yes     
TPSAB1     Yes       
TPST1 Yes           
296 
 
TPX2     Yes       
TRAD Yes           
TRAF3IP2 Yes           
TRAF4 Yes           
TRAF5     Yes       
TRAK2       Yes     
TRAPPC13         Yes   
TRAPPC8 Yes     Yes     
TRDN   Yes         
TRIM10 Yes   Yes       
TRIM13   Yes         
TRIM29       Yes     
TRIM3       Yes     
TRIM32     Yes       
TRIM33   Yes     Yes   
TRIM36       Yes     
TRIM41 Yes   Yes       
TRIM46       Yes     
TRIM60 Yes           
TRIM64B     Yes       
TRIM64C     Yes Yes     
TRIM66     Yes       
TRIML2 Yes           
TRIOBP         Yes   
TRIP11     Yes       
TRIQK     Yes       
TRMT1L     Yes       
TROAP       Yes     
TRPA1   Yes         
TRPC1 Yes           
TRPC4     Yes Yes     
TRPC5 Yes Yes         
TRPM1       Yes     
TRPM2   Yes         
TRPM3     Yes       
TRPS1 Yes Yes Yes   Yes Yes 
TRPV4       Yes     
TRPV6 Yes           
TRRAP     Yes       
TSGA13     Yes       
TSHR     Yes       
TSLP   Yes         
TSNARE1 Yes     Yes     
TSNAXIP1 Yes           
TSPAN2     Yes       
TSPEAR       Yes     
TSPYL2   Yes   Yes     
TSR1 Yes           
TSSK2       Yes     
TTBK1       Yes     
TTC13       Yes Yes   
TTC16   Yes         
TTC18 Yes           
TTC21B     Yes       
TTC22       Yes     
TTC25         Yes   
TTC28         Yes   
TTC30B Yes   Yes       
TTC31     Yes       
TTC33       Yes     
TTC39B   Yes         
TTC39C       Yes     
TTC40       Yes     
TTC5       Yes     
TTC7B       Yes     
TTL       Yes     
TTLL5       Yes     
TTN Yes Yes Yes Yes     
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TTYH3 Yes           
TUBA3E Yes           
TUBB     Yes       
TUBB8       Yes     
TUBD1       Yes     
TUBG2     Yes       
TUBGCP6       Yes     
TULP3 Yes           
TULP4     Yes       
TWF1       Yes     
TXLNG Yes           
TYK2   Yes         
U2AF1L4       Yes     
U2AF2 Yes           
U2SURP Yes           
UBA1     Yes       
UBA3   Yes         
UBA5       Yes     
UBASH3B Yes           
UBE2D3   Yes         
UBE2NL       Yes     
UBE2O     Yes       
UBE3A       Yes     
UBE3B       Yes     
UBFD1     Yes       
UBN2 Yes           
UBQLN3       Yes     
UBR3       Yes     
UBTD2 Yes           
UBXN2B       Yes     
UCK1   Yes         
UFSP2       Yes     
UGP2     Yes       
UGT1A4 Yes           
UGT1A7   Yes         
UGT2A1       Yes     
UGT2B11     Yes Yes     
UGT2B28 Yes           
UGT2B7     Yes       
UGT3A1       Yes     
UHMK1       Yes     
UHRF1BP1 Yes           
UHRF1BP1L Yes     Yes     
ULK1       Yes     
UNC13B     Yes       
UNC13C     Yes Yes Yes   
UNC45A     Yes       
UNC5B Yes           
UNK   Yes   Yes     
URB1 Yes           
URB2 Yes           
USH2A     Yes       
USHBP1     Yes       
USP10     Yes       
USP11 Yes           
USP14 Yes           
USP15         Yes   
USP19       Yes     
USP20     Yes       
USP28         Yes   
USP31 Yes           
USP33     Yes Yes     
USP34 Yes   Yes       
USP37   Yes   Yes     
USP38 Yes   Yes Yes     
USP4     Yes Yes     
USP5     Yes       
USP6 Yes           
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VAC14 Yes           
VAMP2     Yes       
VARS     Yes       
VARS2       Yes     
VASN     Yes       
VAV2     Yes       
VCAN Yes           
VCPIP1   Yes Yes       
VCX2     Yes       
VEGFC Yes Yes Yes Yes Yes Yes 
VEPH1   Yes         
VEZF1     Yes       
VHL No No No No No No 
VHLL     Yes       
VIT       Yes     
VN1R2       Yes     
VN2R1P     Yes       
VNN2     Yes       
VPS13B Yes   Yes Yes   Yes 
VPS13C       Yes     
VPS13D Yes           
VPS25   Yes         
VPS26B     Yes       
VPS35 Yes           
VPS41         Yes   
VPS53     Yes       
VPS8 Yes   Yes       
VSIG2     Yes       
VWA2     Yes       
VWA3A     Yes       
VWA3B Yes   Yes       
VWA5A         Yes   
VWDE   Yes         
WASF3   Yes         
WASL Yes           
WDFY3 Yes           
WDFY4   Yes Yes       
WDR17 Yes           
WDR19 Yes       Yes   
WDR27     Yes       
WDR3     Yes       
WDR37         Yes   
WDR44 Yes           
WDR52 Yes     Yes     
WDR64   Yes         
WDR67     Yes       
WDR87 Yes           
WDSUB1     Yes       
WFDC5       Yes     
WFIKKN2     Yes       
WHSC1L1 Yes     Yes     
WNK1 Yes           
WNK2 Yes Yes         
WNK4 Yes           
WNT10B     Yes       
WNT2       Yes     
WNT7A     Yes       
WRN Yes           
WSCD1 Yes           
WT1 Yes No     No   
WWC1     Yes Yes     
WWOX Yes           
XAB2     Yes       
XAGE5       Yes     
XIRP1 Yes           
XIRP2   Yes Yes Yes     
XKR3     Yes       
XPNPEP1       Yes     
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XPNPEP3     Yes       
XPO6 Yes           
XPOT       Yes     
XPR1       Yes     
XRCC4   Yes         
XRN1       Yes     
XRRA1         Yes   
YARS2     Yes       
YLPM1 Yes     Yes     
YWHAB       Yes     
YY1AP1     Yes Yes     
ZBBX     Yes       
ZBTB10 Yes           
ZBTB2     Yes       
ZBTB26       Yes     
ZBTB3     Yes       
ZBTB44     Yes       
ZBTB5 Yes           
ZBTB6     Yes       
ZBTB8B Yes           
ZC3H11A       Yes     
ZC3H13 Yes Yes         
ZC3H15 Yes     Yes     
ZC3H3 Yes           
ZC3HAV1       Yes     
ZCCHC11         Yes   
ZCCHC14     Yes       
ZCCHC2     Yes       
ZCRB1   Yes         
ZDHHC11 Yes           
ZDHHC16     Yes       
ZDHHC5       Yes     
ZEB1     Yes       
ZEB2       Yes     
ZER1     Yes       
ZFAT   Yes Yes Yes     
ZFC3H1   Yes Yes       
ZFHX4 Yes     Yes Yes   
ZFP1     Yes       
ZFP14 Yes           
ZFP36L1       Yes     
ZFP41     Yes       
ZFP42   Yes         
ZFP62     Yes       
ZFPM2   Yes Yes       
ZFR     Yes       
ZFX       Yes     
ZFYVE1   Yes         
ZFYVE16     Yes   Yes   
ZFYVE26       Yes     
ZFYVE9 Yes           
ZHX1 Yes           
ZHX2       Yes Yes   
ZIC1 Yes           
ZIK1   Yes     Yes   
ZIM2 Yes Yes Yes       
ZMAT1 Yes           
ZMPSTE24 Yes           
ZMYM6 Yes   Yes       
ZMYND11 Yes           
ZNF10       Yes     
ZNF121       Yes     
ZNF135 Yes           
ZNF146         Yes   
ZNF148     Yes       
ZNF157   Yes         
ZNF160       Yes     
ZNF167 Yes       Yes   
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ZNF182   Yes         
ZNF184   Yes         
ZNF189     Yes       
ZNF192 Yes           
ZNF197   Yes     Yes   
ZNF20     Yes       
ZNF215     Yes       
ZNF22   Yes   Yes     
ZNF222     Yes       
ZNF229   Yes         
ZNF233 Yes           
ZNF234 Yes           
ZNF236     Yes Yes     
ZNF250 Yes   Yes       
ZNF254   Yes         
ZNF257       Yes     
ZNF264     Yes       
ZNF274       Yes     
ZNF292   Yes Yes       
ZNF3   Yes     Yes   
ZNF30       Yes     
ZNF300     Yes       
ZNF318       Yes     
ZNF319   Yes         
ZNF324B       Yes     
ZNF330       Yes     
ZNF345     Yes       
ZNF346       Yes     
ZNF347   Yes         
ZNF350     Yes       
ZNF354A Yes   Yes       
ZNF382         Yes   
ZNF385 Yes           
ZNF385A Yes           
ZNF385D       Yes     
ZNF398 Yes           
ZNF407       Yes     
ZNF415   Yes         
ZNF423 Yes           
ZNF425   Yes         
ZNF43     Yes       
ZNF430     Yes       
ZNF432   Yes     Yes   
ZNF433       Yes     
ZNF436   Yes         
ZNF440 Yes           
ZNF441   Yes     Yes   
ZNF443   Yes   Yes     
ZNF445 Yes           
ZNF45     Yes       
ZNF451 Yes           
ZNF462 Yes           
ZNF467   Yes         
ZNF473     Yes       
ZNF480         Yes   
ZNF483     Yes       
ZNF491 Yes       Yes   
ZNF506     Yes       
ZNF511     Yes       
ZNF518B Yes Yes         
ZNF519     Yes       
ZNF521           Yes 
ZNF527         Yes   
ZNF528     Yes       
ZNF532 Yes           
ZNF536 Yes           
ZNF540     Yes       
ZNF554 Yes           
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ZNF556   Yes         
ZNF564         Yes   
ZNF571 Yes           
ZNF572   Yes         
ZNF577   Yes     Yes   
ZNF582       Yes     
ZNF594 Yes           
ZNF598       Yes     
ZNF610   Yes     Yes   
ZNF611       Yes     
ZNF615   Yes     Yes   
ZNF619   Yes Yes       
ZNF621   Yes         
ZNF630     Yes   Yes   
ZNF654 Yes           
ZNF660         Yes   
ZNF662       Yes     
ZNF664   Yes         
ZNF667 Yes           
ZNF668   No         
ZNF673 Yes           
ZNF677   Yes         
ZNF678   No     Yes   
ZNF688   Yes         
ZNF69     Yes       
ZNF699         Yes   
ZNF700       Yes     
ZNF705G     Yes Yes     
ZNF708 Yes Yes         
ZNF713     Yes       
ZNF716     Yes       
ZNF720     Yes       
ZNF729     Yes       
ZNF736 Yes           
ZNF738 Yes           
ZNF74       Yes     
ZNF746 Yes           
ZNF747 Yes           
ZNF76     Yes       
ZNF775     Yes       
ZNF781 Yes       Yes   
ZNF799     Yes       
ZNF8 Yes       Yes   
ZNF80   Yes     Yes   
ZNF81 Yes           
ZNF814     Yes       
ZNF821     Yes       
ZNF829 Yes           
ZNF839     Yes       
ZNF845 Yes           
ZNF846       Yes     
ZNF852         Yes   
ZNF860     Yes       
ZNF862   Yes         
ZNF92         Yes   
ZNF99   Yes     Yes   
ZNFX1       Yes     
ZNRF4       Yes     
ZPBP     Yes       
ZRANB3       Yes     
ZSCAN1 Yes           
ZSCAN23 Yes           
ZSCAN29   Yes         
ZSWIM5 Yes   Yes       
ZSWIM6 Yes           
ZWINT     Yes       
ZYX       Yes     
302 
 
 
Appendix 7: A collection of gene mutation status in a panel of lung cancer cell lines. No indicates wild type gene status and Yes 
indicates mutant gene status. 
Gene Name A549 H226 H292 H460 H1650 HCC95 Hop92 
AARS   Yes           
AATK Yes             
ABCA3         Yes     
ABCA9 Yes             
ABCB1 Yes             
ABCC11   Yes           
ABCD2 Yes             
ABHD3             Yes 
ACACA   Yes     Yes     
ACAT2       Yes       
ACER1             Yes 
ACOXL Yes             
ACTN1 Yes             
ACTRT1             Yes 
ACVR2A             Yes 
ADAM17 Yes Yes     Yes     
ADAM28 Yes Yes   Yes Yes Yes   
ADAM29       Yes Yes     
ADAMTS19 Yes             
ADAMTS2         Yes Yes   
ADAMTS7 Yes             
ADCK5           Yes   
ADCYAP1R1             Yes 
ADH1A Yes             
ADM2 Yes             
AGPAT9     Yes         
AGTR1 Yes             
AHNAK       Yes       
AIM1 Yes             
AKAP12 Yes Yes   Yes Yes Yes   
AKAP9 Yes Yes   Yes   Yes   
AKT1 No No No No No No   
ALPK1   Yes     Yes     
ALPK2   Yes   Yes Yes     
ALS2           Yes   
ALS2CL Yes             
AMT Yes             
ANGEL1       Yes       
ANKFY1   Yes           
ANKHD1             Yes 
ANKHD1-EIF4EBP3             Yes 
ANKIB1 Yes             
ANKMY2       Yes       
ANKZF1 Yes             
ANXA2     Yes         
AP5B1   Yes           
APC   Yes           
APLF   Yes           
APOB Yes             
APPL2       Yes       
AQP2             Yes 
ARFGEF2       No       
ARHGAP25 Yes             
ARHGEF18 Yes             
ARID1A       Yes       
ARID2         No     
ARID3A Yes             
ARIH1       Yes       
ARMC1 Yes             
ARMC4       Yes       
ARPC1B Yes             
ARSD   Yes           
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ARSH Yes             
ARSI Yes             
ARVCF             Yes 
ASB4       Yes       
ASB5 Yes             
ASTN2   Yes           
ATAD3B       Yes       
ATAD5       Yes       
ATG13 Yes             
ATG4B   No           
ATN1     Yes         
ATP1A3 Yes             
ATP6V0D1             Yes 
ATR       No       
ATRNL1             Yes 
AURKC         Yes     
AXL   No       Yes   
BAHD1             Yes 
BARD1 Yes             
BBOX1             Yes 
BBS2 Yes             
BBS7       Yes       
BCAR3   Yes           
BCAT1 Yes             
BCAT2   Yes           
BCCIP Yes             
BCL3 Yes             
BCORL1             Yes 
BCR Yes       Yes     
BCS1L       Yes       
BIN1     Yes         
BIRC6           Yes   
BMP4   Yes           
BMS1 Yes             
BNC2             Yes 
BRAF No No No No No   No 
BRD3 Yes     Yes       
BRPF1       Yes       
BTBD11 Yes             
BTG1 Yes Yes           
BTNL9       Yes       
BUD13       Yes       
BZRAP1       Yes       
C10orf112 Yes             
C10orf68 Yes     Yes     Yes 
C11orf40       Yes       
C11orf83 Yes             
C12orf35             Yes 
C12orf65     Yes         
C14orf126     Yes         
C14orf23 Yes             
C15orf2       Yes       
C15orf42 Yes             
C15orf55       Yes       
C16orf88   No           
C20orf107             Yes 
C2orf15 Yes             
C2orf55 Yes             
C2orf62       Yes       
C2orf67 Yes             
C3orf70 Yes             
C4BPB       Yes       
C7orf31 Yes             
C7orf34             Yes 
C7orf63       Yes       
C9orf174 Yes             
C9orf96             Yes 
CABC1         Yes     
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CACNA1B Yes             
CACNB2   Yes     Yes Yes   
CADM3 Yes             
CADPS       Yes       
CAGE1 Yes             
CALD1       Yes       
CaMK1b             Yes 
CANX Yes             
CAPN7 Yes             
CARD10   Yes   Yes Yes     
CARD11 Yes           Yes 
CASC1   Yes           
CASC5     Yes     Yes   
CASP10   Yes           
CASP4       Yes       
CASQ2       Yes       
CBL Yes             
CBLB             Yes 
CC2D2A Yes             
CCBL1 Yes             
CCDC129 Yes             
CCDC132 Yes             
CCDC80 Yes             
CCKBR             Yes 
CCNB1 Yes             
CCNT1 Yes             
CCNYL1     Yes         
CCR5         Yes     
CCR7       Yes       
CD164       Yes       
CD2AP Yes             
CD300C Yes             
CD83       Yes       
CDC42 No     No       
CDCP2 Yes           Yes 
CDH1     Yes         
CDH2       Yes       
CDK11B       Yes Yes Yes   
CDK2 No     No       
CDK4 No     No       
CDK5RAP3   Yes Yes         
CDK6 No     No       
CDKN2A Yes Yes Yes Yes Yes     
CDKN2AIPNL   Yes           
CDKN2C No             
CEBPE Yes             
CEBPZ   Yes   Yes       
CEP110       Yes       
CEP250     Yes         
CHCHD2     Yes         
CHD1   Yes           
CHD7 Yes             
CHEK2 No     No       
CHRDL2 Yes             
CHRNB4 Yes             
CHST8 Yes             
CHTF18     Yes         
CIAO1 Yes             
CIITA         Yes     
CKAP5 Yes             
CKMT2   Yes           
CLCN7 Yes             
CLDN16   Yes           
CLMP             Yes 
CLTC     Yes         
CLTCL1 Yes Yes   Yes Yes Yes   
CNDP1       Yes     Yes 
CNPPD1 Yes             
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CNTLN Yes             
CNTN6         Yes     
CNTNAP2             Yes 
COL14A1       Yes       
COL18A1   Yes           
COL21A1 Yes             
COL4A1             Yes 
COL4A6 Yes             
COL6A3   Yes           
COQ2     Yes         
CPO             Yes 
CPPED1 Yes             
CRB1             Yes 
CREB3L2 Yes     Yes Yes Yes   
CREB3L4     Yes         
CRISP2             Yes 
CRP         Yes     
CSF1R Yes       Yes     
CSMD2   Yes           
CSNK2A1       Yes       
CTNNA1 Yes             
CTNNB1 No No No No No No No 
CTNND2 Yes             
CTSA       Yes       
CUL2 Yes             
CUL9       Yes       
CXCL12           Yes   
CXorf22 Yes             
CYB5R4       Yes       
CYP27B1 Yes             
CYP39A1 Yes             
CYP7A1 Yes             
CYTH4       Yes       
DAB1             Yes 
DACH1 Yes         Yes   
DACT1 Yes             
DAXX           Yes   
DBC1       Yes       
DCAF4L2       Yes       
DCAF5 Yes             
DCAF6 Yes             
DCHS2   Yes           
DCLK3 Yes             
DDX60L Yes             
DFNA5   Yes     Yes     
DGKB       Yes   Yes   
DGKE Yes             
DHCR7       Yes       
DHDH       Yes       
DHX33     Yes         
DHX58 Yes             
DIP2C       Yes       
DLG2 Yes             
DMGDH Yes             
DMXL2   Yes           
DNAH8 Yes Yes   Yes       
DNAH9       Yes       
DNAJB12       Yes       
DNAJC5B             Yes 
DOCK7   Yes           
DOK2   Yes           
DPP10   Yes   Yes       
DPP8 Yes             
DSP     Yes         
DST     Yes         
DTNB Yes             
DYNC1I1 Yes             
DYRK1A   Yes           
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EDNRA         Yes     
EGF         Yes     
EGFR No No No No Yes   No 
EGLN1 Yes             
EIF2AK1           Yes   
EIF2AK3           Yes   
EIF2AK4   Yes           
EIF2C2 Yes             
EIF3A       Yes       
EIF4A2           Yes   
EIF4B       Yes       
EIF4E Yes       Yes     
EIF4G3   Yes           
ELL2 Yes             
ENPEP             Yes 
ENSG00000176515 Yes             
ENSG00000214944   Yes           
ENSG00000216560 Yes             
EP300   Yes   Yes       
EPB41L3 Yes             
EPHA1 Yes             
EPHA5   Yes         Yes 
EPHA6 Yes         Yes   
EPHA7       Yes     Yes 
EPHB6 Yes             
ERAP2       Yes       
ERBB2 No No No No No No   
ERBB2IP     Yes         
ERBB3 No     No       
ERBB4 No     No       
ERC1 Yes             
ERCC3   Yes           
ERCC5     Yes         
ERG         Yes     
ERV3-1     Yes         
ETV1         Yes     
EXOC3     Yes Yes       
EXT1         Yes Yes   
F12 Yes             
FAM160B2 Yes             
FAM171A2 Yes             
FAM174A Yes             
FAM175B Yes             
FAM184A       Yes       
FAM40B     Yes         
FAM47B             Yes 
FAM47C Yes             
FAM54B Yes             
FAM55B Yes             
FAM59A             Yes 
FAM5B       Yes       
FAM5C             Yes 
FAM63A Yes             
FAM63B Yes             
FAM71B             Yes 
FAM71C       Yes       
FAM75D1 Yes             
FAM75D4 Yes             
FAM82B Yes             
FANCA           Yes   
FANCB             Yes 
FANCD2         Yes     
FASTKD3   Yes           
FAT No Yes Yes         
FAT1 No Yes Yes         
FAT2             Yes 
FAT4             Yes 
FBN2 Yes             
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FBXL2 Yes             
FBXL5   Yes           
FBXO32             Yes 
FBXO48 Yes             
FBXW7             No 
FCGR3A Yes             
FCHSD2 Yes             
FCRL2 Yes             
FGD1 Yes             
FGF5             Yes 
FGFBP2 No             
FGFR1OP Yes Yes   Yes Yes Yes   
FGFR3 Yes       Yes     
FGL1 Yes             
FH Yes             
FLI1 Yes Yes   Yes   Yes   
FLJ16360 Yes             
FLNC Yes             
FLT1 No     No       
FLT3 Yes             
FLT4       No Yes     
FLVCR1 Yes             
FLYWCH1       Yes       
FMN1 Yes             
FMN2 Yes     Yes Yes Yes   
FMO5             Yes 
FN1       Yes Yes Yes   
FNDC3A   Yes           
FOXL2 No No   No     No 
FOXQ1             Yes 
FRA10AC1   Yes           
FRAS1 Yes             
FRMD6 Yes             
FRY             Yes 
FSTL5 Yes             
FUBP3     Yes         
FUCA2 Yes             
FUS Yes             
FZD10             Yes 
GABRB1       Yes       
GABRP             Yes 
GABRR1             Yes 
GAD2 Yes             
GALNT12       Yes       
GALNT13       Yes     Yes 
GAS2L3 Yes     Yes       
GAS7       Yes       
GCDH   Yes           
GDF15 Yes             
GDPD3       Yes       
GEMIN4     Yes         
GHSR       Yes       
GIMAP1 Yes             
GIMAP2   Yes           
GJB4       Yes       
GLB1     Yes         
GLB1L3 Yes             
GLE1 Yes             
GLE1L Yes             
GNAL       Yes       
GNAQ         No     
GNAS           Yes Yes 
GNL2     Yes         
GNPTAB       Yes       
GOLGA4 Yes     Yes       
GOLGA5       Yes       
GOLGB1   Yes   Yes       
GPR112       Yes   Yes   
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GPR137C Yes             
GPR85 Yes             
GRHL1 Yes             
GRIA2 Yes             
GRIA3 Yes     Yes Yes Yes   
GRIA4 Yes             
GRIN2A       Yes       
GRK7             Yes 
GRM2             Yes 
GRM7 Yes             
GTSE1 Yes             
GUCY1A2             Yes 
GUCY2C Yes     Yes Yes     
HBXIP       Yes       
HCLS1 Yes             
HECW1       Yes       
HEG1     Yes         
HERC1 Yes             
HFM1 Yes             
HIF1A Yes       Yes     
HIP1 Yes             
HIP1R Yes             
HIST1H1C             Yes 
HIST1H2AJ Yes             
HIST1H3A       No       
HIST1H3C             Yes 
HIST1H3J             Yes 
HLA-DOB Yes             
HLF             Yes 
HMCN1 Yes             
HMGN5 Yes             
HNF1A Yes     Yes Yes Yes   
HOOK1 Yes             
HOXA2             Yes 
HOXB7             Yes 
HOXD9             Yes 
HRAS No     No No   No 
HS6ST2 Yes             
HS6ST3 Yes             
HSP90B1       Yes       
HSPBP1 Yes             
HSPD1   Yes           
HSPG2   Yes           
HYDIN Yes             
ID1         Yes     
IDH1   No         No 
IFIH1 Yes             
IFRD2       Yes       
IGF1R No     No       
IKZF3 Yes             
IL1RL1       Yes       
IL22             Yes 
ILK Yes     Yes Yes Yes   
INPP5D Yes             
IPO7       Yes       
IQGAP3   Yes           
ITGA11 Yes             
ITGA4             Yes 
ITGB4           Yes   
ITGB5     Yes         
ITGB6       Yes       
ITIH5       Yes       
ITPKB       Yes       
ITPKC Yes     Yes       
ITPR1 Yes             
ITPR2 Yes       Yes Yes   
JAG1       Yes       
JAG2         Yes     
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JAK1           Yes   
JAKMIP2 Yes             
JHDM1D       Yes       
KAT6B No             
KCND2 Yes             
KCNH2             No 
KCNH5             Yes 
KCTD19             Yes 
KDELC2     Yes         
KDM5A           Yes Yes 
KDM6A No No No No No   No 
KDR No             
KEAP1 Yes     Yes       
KIAA0020     Yes         
KIAA0100 Yes             
KIAA0226L Yes             
KIAA0802           Yes   
KIAA0825       Yes       
KIAA1107     Yes         
KIAA1109             Yes 
KIAA1467 Yes             
KIAA1549 Yes             
KIAA1731     Yes         
KIAA1804 No     No       
KIAA1919 No             
KIF13A Yes             
KIF14       Yes       
KIF3B   Yes           
KIF3C       Yes       
KIRREL3 Yes             
KLHL20 Yes             
KLHL34             Yes 
KLHL36       Yes       
KLK13 Yes             
KLK7 Yes     Yes Yes Yes   
KLK9 Yes             
KMT2A     Yes         
KNTC1 Yes             
KRAS Yes No   Yes No   No 
KRT19   Yes           
KRT26       Yes       
KRTAP12-3       Yes       
LAMA1       Yes       
LAMA3 Yes     Yes       
LAMB3 Yes             
LAMB4             Yes 
LAMC2   Yes           
LANCL1 Yes             
LAT2       Yes       
LDHA       Yes       
LEPRE1   No           
LHCGR Yes             
LIFR       Yes       
LIM2             No 
LIMK2   Yes           
LMBRD2 Yes             
LMNB1           Yes   
LMNB2     Yes         
LNPEP       Yes       
LOC223075 Yes             
LOC442444 Yes             
LOC652153 Yes             
LRBA       Yes     Yes 
LRIG1       Yes       
LRIT2       Yes       
LRP1 Yes             
LRP2 Yes     Yes       
LRP5L   Yes           
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LRRC16A Yes             
LRRC32       Yes     Yes 
LRRFIP2     Yes         
LRRIQ1 Yes             
LTK           Yes   
LTN1     Yes         
LYST       Yes       
MAF Yes       Yes Yes   
MAG Yes             
MAGEA11 Yes             
MAGEB10 Yes             
MAGEB16 Yes             
MAML2 Yes     Yes       
MAML3 Yes     Yes Yes Yes   
MAN2A1   Yes           
MAP2K1 No     Yes No     
MAP2K2 No     No No     
MAP2K5           Yes   
MAP3K1       Yes Yes Yes   
MAP3K14 Yes     Yes Yes Yes   
MAP3K4       Yes       
MAP3K7         Yes     
MAP4K1           Yes   
MAP4K4 No     No       
MAPK11           Yes   
MAPKAPK3         Yes Yes   
MAPKBP1 Yes       Yes Yes   
MARK3             Yes 
MAST4     Yes   Yes     
MATN2 Yes             
MAX Yes     No No No   
MBLAC1 Yes             
MC2R Yes             
MC3R             Yes 
MCM3AP   Yes           
MCM3APAS Yes     Yes Yes     
MCPH1   Yes           
MECOM         Yes     
MECP2 Yes             
MED28   No           
MEF2A       Yes       
MEGF10 Yes             
MET No     No       
METTL19   No           
METTL23     Yes Yes       
METTL5       Yes       
METTL8 Yes             
MFN2 Yes             
MFSD10     Yes         
MGAM Yes             
MIB1 Yes             
MKI67 Yes             
MKI67IP Yes             
MKRN3           Yes   
MKS1     Yes         
MLL     Yes     Yes   
MLLT3 Yes             
MMP15     Yes         
MMP2       Yes       
MMP25             Yes 
MOGAT3 Yes             
MON1A Yes             
MPP2 Yes             
MRE11A     Yes         
MRGPRX2 Yes             
MRPL3       Yes       
MSH2 Yes             
MSH3 Yes             
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MST1R No     No       
MTM1   Yes           
MTMR10       No       
MTO1     Yes         
MTOR No     No       
MTUS1     Yes         
MTUS2 Yes         Yes Yes 
MUC17             Yes 
MUC4     Yes         
MUC5AC Yes             
MUC5B Yes             
MVP     Yes         
MXRA5 Yes             
MYCBPAP Yes             
MYH1         Yes     
MYH11       Yes       
MYH2 Yes             
MYH3 Yes           Yes 
MYH8       Yes       
MYO18A Yes             
MYO18B Yes             
MYO3A           Yes   
MYOM2       Yes       
MYST4         Yes     
N4BP3 Yes             
NAA10       Yes       
NAB1 Yes             
NADK   Yes           
NAMPT Yes             
NAT6       No       
NBEAL1 No             
NBN       Yes       
NCAM1 Yes     Yes Yes Yes   
NCOA3       Yes Yes     
NCOA6       Yes       
NDC80 Yes             
NDE1 Yes             
NDUFB4       No       
NEB Yes             
NEBL Yes             
NEK3 Yes     Yes   Yes   
NEK6 No     No       
NES Yes             
NEUROD6       Yes       
NF2   No   No       
NFAT5   Yes           
NFATC1 Yes             
NFE2L2 No       No     
NFIA         Yes Yes   
NIF3L1       Yes       
NIN Yes     Yes       
NIPBL Yes             
NKAP   Yes           
NLRP7             Yes 
NMNAT1 Yes             
NOL11       Yes       
NOL4             Yes 
NOTCH1 No         No   
NOTCH2 No Yes       No   
NOTCH3       Yes       
NOTCH4         Yes     
NP_001073948_1   Yes           
NPAT     Yes         
NPM1       Yes Yes Yes   
NPR1 Yes     Yes       
NR1H2 Yes     Yes Yes Yes   
NR2F1       Yes       
NR4A2             Yes 
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NRAS No No   No No   No 
NRSN2 Yes             
NRXN3       Yes       
NTF3             Yes 
NUDT6 Yes             
NUP210 Yes     Yes     Yes 
NUP98         Yes     
ODZ1 Yes             
OGFRL1       Yes       
OMG         Yes     
OR10G9       Yes       
OR1B1       Yes       
OR2A5             Yes 
OR2L2       Yes       
OR2T11             Yes 
OR2V2   Yes           
OR2W3 Yes     Yes       
OR4A15             Yes 
OR4M2 Yes             
OR4N2 Yes             
OR51A7             Yes 
OR52D1 Yes             
OR52H1 Yes             
OR56A3 Yes             
OR5B17 Yes             
OR5D13   Yes           
OR5M3 Yes             
OR8U1 No             
ORMDL2             Yes 
OSBP Yes             
OSBPL5   Yes           
OSTN       Yes       
OTOA       Yes       
OTOP1 Yes             
OTUD7B       Yes     Yes 
P2RX7         Yes     
PACSIN2   Yes           
PADI1 Yes             
PAF1 Yes             
PAK4 No     No       
PAK7 Yes             
PAPSS1   Yes           
PARP1       Yes       
PAX3 Yes       Yes     
PAX5 Yes             
PBRM1   Yes           
PCBP3 Yes             
PCDH15         Yes     
PCDHA4       No       
PCDHA7             Yes 
PCF11   No           
PCK1 Yes             
PCSK5 Yes             
PCSK7 Yes             
PDCD11     Yes         
PDE11A Yes Yes   Yes     Yes 
PDE4D Yes             
PDE4DIP       Yes Yes     
PDGFRL Yes             
PDK1 No     No     Yes 
PDP1     Yes         
PEAR1       Yes       
PEPD     Yes         
PGBD5 Yes             
PGK2       Yes       
PGR Yes       Yes Yes   
PHACTR3 Yes             
PHF20L1   Yes           
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PHKA1 Yes             
PHKA2 Yes             
PHLDB2             Yes 
PHRF1 Yes             
PIAS2 Yes             
PICALM           Yes   
PIGS   Yes           
PIK3C2A No     No Yes     
PIK3C2G Yes       Yes     
PIK3CA No No No Yes No   No 
PIP4K2A Yes             
PKD1L2 Yes           Yes 
PKHD1L1 Yes             
PLBD1 Yes             
PLCH1 Yes             
PLEC       Yes     Yes 
PLEK2 Yes     Yes       
PLEKHA4 Yes             
PLEKHG6   Yes           
PLEKHH3 Yes             
PLK1 Yes             
PLOD3             Yes 
PLUNC Yes             
PMPCB Yes             
PNCK             Yes 
PNPLA5 Yes             
POFUT1       Yes       
POLE Yes             
POLM     Yes         
POLN   Yes           
POLR1A   Yes           
POLR3B Yes             
POM121L12             Yes 
POMZP3 Yes             
POP1 Yes             
POU5F1B Yes             
PPA1   Yes           
PPARA           Yes   
PPFIBP2 Yes             
PPP1R3A   Yes         Yes 
PPP1R9A Yes             
PPP2R1A No             
PPP4R1             Yes 
PPP5C Yes             
PRAME             Yes 
PRG2       No       
PRIM2 Yes             
PRKAA1           Yes   
PRKCG       Yes       
PRKCH Yes             
PRKD3       Yes       
PRKDC Yes     Yes Yes Yes   
PRKG2           Yes   
PRKRA     Yes         
PRLR       Yes       
PRMT2     Yes         
PRPF39     No         
PRR11             Yes 
PRTG     Yes         
PRUNE2 Yes             
PSKH2       Yes       
PTCH1   No           
PTEN No No No No Yes     
PTGFRN   Yes           
PTK2       Yes       
PTK6           Yes   
PTPN13       No       
PTPN14 Yes             
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PTPN21 Yes             
PTRF       Yes       
PTX4       Yes       
PVRL3 Yes             
PWP2   Yes           
PYCRL Yes             
Q6ZSY1_HUMAN Yes             
Q86U89_HUMAN   Yes           
Q8N1G8_HUMAN Yes             
Q96RI3_HUMAN Yes             
QRFPR Yes             
QRICH2 Yes             
R3HDML       Yes       
RAB10             Yes 
RAB3GAP1 Yes             
RABGAP1   Yes           
RAD21       Yes       
RADIL             Yes 
RAI16 Yes             
RALGAPA1 Yes             
RALY No             
RALYL Yes             
RANBP2             Yes 
RAPGEF4 Yes             
RARG           Yes   
RASA1             Yes 
RASGRF1 Yes       Yes     
RASSF3 Yes             
RAVER1 Yes             
RB1 No             
RBFOX1 Yes             
RBM12B Yes             
RBM24 Yes             
RBM6   Yes           
RBPJ         Yes     
RECQL4 Yes       Yes Yes   
REM1           Yes   
REN       Yes       
REV3L       Yes       
RGPD3 Yes             
RHAG             Yes 
RHOA           Yes   
RIMBP2             Yes 
RNF111       Yes       
RNF133 Yes             
RNF181       Yes       
RNF213   Yes           
RNF214       Yes       
RNF41   Yes           
RNGTT Yes             
ROBO1   Yes   Yes       
ROBO2       Yes Yes     
ROCK2       Yes       
ROR1 Yes             
RP1L1 Yes             
RPGRIP1L             Yes 
RPL3 Yes             
RPL7L1       Yes       
RPS6KA5           Yes   
RPS6KB1 Yes             
RPS6KB2   No           
RPTOR       Yes       
RTEL1             Yes 
RTF1             Yes 
RTTN Yes             
SALL3       Yes       
SAMD9L Yes             
SBDS         Yes     
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SBF2 Yes             
SCAF4       Yes       
SCN4A Yes             
SCN9A Yes             
SDAD1 Yes             
SDK1 Yes             
SEMA3C       Yes       
SEPT9 Yes             
SEPX1     Yes         
SERPINB10       Yes       
SERPINI2 Yes             
SETBP1 No No No No No   No 
SF3B1     No   No   Yes 
SF3B3 Yes             
SG269_HUMAN Yes             
SgK269 Yes             
SGMS2       Yes       
SH3GL2 Yes             
SH3PXD2B       Yes       
SH3RF2 Yes             
SIGLEC14             Yes 
SIPA1 Yes             
SIPA1L2 Yes             
SIPA1L3       Yes       
SLC17A4       Yes       
SLC22A1             Yes 
SLC2A13 Yes             
SLC30A10 Yes             
SLC30A8 Yes             
SLC35B2       Yes       
SLC35F3             Yes 
SLC35F5             Yes 
SLC45A2       Yes       
SLC5A8   Yes           
SLC6A8 Yes       Yes     
SLC7A6 Yes   Yes         
SLC7A8 Yes             
SLCO1B1             Yes 
SLIT2 Yes             
SLITRK3             Yes 
SLITRK4 Yes             
SLX4 Yes             
SMAD4         No     
SMAP1 No             
SMARCA4 Yes No   No Yes No   
SMARCB1 No             
SMC6   Yes           
SMO   No           
SMOC1   Yes           
SMPDL3A   Yes           
SMURF2       Yes       
SMYD2 Yes             
SNAPC2   Yes           
SNX11     Yes         
SNX19           Yes   
SORCS1             Yes 
SORL1             Yes 
SOS1             Yes 
SOX6   Yes           
SPACA1   Yes           
SPAG9 Yes             
SPATA13 Yes             
SPATA5 Yes             
SPEG       Yes       
SPRY2         Yes     
SPRY4       Yes       
SPTBN2 Yes             
SRC No     No       
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SRPK2             Yes 
SRRM2       Yes       
ST6GAL2       Yes       
STAT1         Yes     
STAT2       Yes       
STAT5B Yes             
STK11 Yes No   Yes No     
STK25           Yes   
STK31 Yes     Yes Yes     
STK32A Yes         Yes   
STOX1     Yes         
STXBP5 Yes             
STXBP5L Yes             
SUFU Yes No           
SUGP2       Yes       
SULF1         Yes     
SUPT4H1 Yes             
SUPT6H   Yes           
SUZ12             Yes 
SYDE2       Yes       
SYK           Yes   
SYNE1 Yes           Yes 
SYT15     No         
TAAR1       Yes       
TAAR5 Yes             
TADA2A             Yes 
TAF13 Yes             
TAOK2     Yes         
TAOK3             Yes 
TAS2R1 Yes             
TAS2R3             Yes 
TBC1D23 Yes             
TBL1XR1 Yes             
TCEA2 Yes             
TCEB3B Yes             
TCF21         Yes     
TCHP Yes             
TCTE1 Yes             
TDRD12 Yes             
TEC Yes     Yes Yes     
TECTA             Yes 
TENM1 Yes             
TERT No             
TFRC           Yes   
TGFB2 Yes             
TGOLN2     Yes         
TH1L       Yes       
THAP2 Yes             
THNSL2 Yes             
THOP1 Yes             
THRA       Yes       
TIAM1       Yes     Yes 
TIAM2 Yes             
TINAGL1     Yes         
TJP1 Yes             
TLL1             Yes 
TLL2       Yes       
TLR3           Yes   
TM2D1     Yes         
TMC2 Yes             
TMC7 Yes             
TMEFF2             Yes 
TMEM123 Yes     Yes Yes Yes   
TMEM181   Yes           
TMEM218     Yes         
TMEM33       Yes       
TMEM41A     Yes         
TMEM57       Yes       
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TMEM63A Yes             
TMEM99     Yes         
TNC Yes             
TNFAIP2       Yes       
TNFAIP3       Yes       
TNK2           Yes   
TNN Yes             
TNNI3K           Yes   
TNR Yes             
TNRC6B Yes       Yes     
TNS3 Yes             
TOP1MT     Yes         
TP53 No   No No Yes   Yes 
TP63 Yes             
TPI1       Yes       
TPP1       Yes       
TPX2             Yes 
TRAK1   Yes           
TRAPPC8     Yes         
TRHDE       Yes       
TRIM13       Yes       
TRIM22       Yes       
TRIM33 Yes     Yes       
TRIM60             Yes 
TRIM65 Yes             
TRPM1 Yes             
TRPM2 Yes             
TRPM4     Yes         
TRPM7       Yes       
TRPS1       Yes Yes     
TRPV5 Yes             
TRPV6             Yes 
TRUB1 Yes             
TSC2           Yes   
TSEN34     Yes         
TSHZ3 Yes           Yes 
TSSK2       Yes       
TTBK1 Yes         Yes   
TTC26       Yes       
TTC28 Yes             
TTN Yes     Yes Yes Yes   
TYR       Yes       
UBQLNL             Yes 
UCMA   Yes           
UGP2   Yes           
UNC5D Yes             
URB1       Yes       
USH1C Yes             
USH2A             Yes 
USP10 Yes             
USP30       Yes       
USP34 Yes             
USP6 Yes             
UTP6     Yes         
VARS2 Yes             
VCL Yes             
VEGFC Yes     Yes Yes Yes   
VHL   No   No       
VPS41   Yes           
WAPAL Yes             
WDR72       Yes       
WDR73     Yes         
WEE2       Yes   Yes   
WISP2       Yes       
WNK1           Yes   
WNT5B       Yes       
XIRP2 No             
XPO1   Yes           
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XYLT2   No           
YES1           Yes   
YSK4 Yes             
YTHDF2   Yes           
ZAP70 Yes             
ZBBX       Yes       
ZBED5 Yes             
ZBTB25             Yes 
ZBTB43             Yes 
ZC3H11A   Yes           
ZC3H14             Yes 
ZCCHC4       No       
ZCWPW2 Yes             
ZDHHC20     Yes         
ZFHX3 Yes     Yes       
ZFP62     Yes         
ZFP64       Yes       
ZFPM2 Yes             
ZFY   Yes           
ZFYVE27 Yes             
ZMIZ1             Yes 
ZNF135 Yes             
ZNF14 Yes             
ZNF215 Yes             
ZNF217       Yes       
ZNF22 Yes             
ZNF251   No           
ZNF354B             Yes 
ZNF419       Yes       
ZNF425 Yes             
ZNF480   Yes           
ZNF498       Yes       
ZNF507   Yes           
ZNF516 No             
ZNF559   Yes           
ZNF560       Yes       
ZNF587     Yes         
ZNF589   Yes           
ZNF638       Yes       
ZNF652       Yes       
ZNF654 Yes             
ZNF655       Yes       
ZNF729 Yes             
ZNF737 Yes             
ZNF749 Yes             
ZNF766 Yes             
ZNF774       Yes       
ZNF845     Yes         
ZPLD1       Yes       
ZSCAN22     Yes         
ZSCAN29 Yes             
ZW10   Yes           
ZZEF1             Yes 
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Appendix 8: Estimates and statistical significance of correlations between drug sensitivities and TDP2 protein levels, 
TOP2A/TDP2 protein ratios or TOP2B/TDP2 protein ratios in a panel of breast cancer cell lines  
Drug 
Original 
source 
TDP2  
ρ-value 
TOP2A/ 
TDP2  
ρ-value 
TOP2B/ 
TDP2  
ρ-value 
TDP2  
p-value 
TOP2A/ 
TDP2  
p-value 
TDP2B/ 
TDP2  
p-value 
681640 COSMIC 0.385 -0.290 -0.688 0.522 0.636 0.199 
17AAG COSMIC -0.036 -0.416 -0.228 0.954 0.486 0.712 
17AAG CCLE 0.246 -0.162 -0.231 0.690 0.795 0.709 
ABT263 COSMIC 0.207 0.657 -0.447 0.738 0.229 0.450 
ABT888 COSMIC -0.508 0.934 0.513 0.382 0.020 0.376 
AEW541 CCLE 0.967 -0.571 -0.749 0.007 0.314 0.145 
AG014699 COSMIC 0.633 -0.378 -0.694 0.252 0.530 0.193 
AICAR COSMIC 0.345 0.600 0.111 0.570 0.284 0.859 
AKT inhibitor VIII COSMIC -0.859 0.434 0.896 0.062 0.466 0.039 
AMG706 COSMIC 0.324 0.814 -0.217 0.595 0.094 0.726 
AP24534 COSMIC 0.972 -0.059 -0.782 0.006 0.925 0.118 
AS601245 COSMIC -0.004 -0.027 -0.418 0.994 0.966 0.483 
ATRA COSMIC 0.069 0.843 -0.271 0.913 0.073 0.660 
AUY922 COSMIC -0.092 0.364 -0.434 0.883 0.547 0.466 
Axitinib COSMIC -0.113 0.984 0.062 0.856 0.002 0.921 
AZD0530 CCLE -0.659 0.205 0.225 0.227 0.741 0.716 
AZD2281 COSMIC 0.508 0.526 -0.689 0.382 0.362 0.198 
AZD6244 COSMIC -0.489 0.793 0.131 0.403 0.110 0.834 
AZD6482 COSMIC -0.826 0.020 0.911 0.085 0.975 0.032 
AZD7762 COSMIC 0.003 0.461 0.494 0.996 0.435 0.397 
AZD8055 COSMIC 0.283 0.837 -0.032 0.645 0.077 0.959 
BAY613606 COSMIC -0.156 0.580 -0.322 0.803 0.305 0.597 
Bexarotene COSMIC 0.172 0.391 0.333 0.782 0.515 0.583 
BIBW2992 COSMIC -0.930 0.277 0.616 0.022 0.652 0.269 
Bicalutamide COSMIC 0.692 -0.061 -0.178 0.196 0.922 0.774 
BID1870 COSMIC -0.283 0.463 -0.163 0.645 0.432 0.794 
BIRB0796 COSMIC -0.065 0.541 0.568 0.917 0.346 0.318 
Bleomycin COSMIC 0.344 0.491 0.139 0.571 0.401 0.824 
BMS708163 COSMIC -0.781 -0.233 0.843 0.119 0.706 0.073 
BMS754807 COSMIC 0.392 0.685 -0.033 0.514 0.202 0.958 
Bosutinib COSMIC -0.830 0.628 0.705 0.082 0.257 0.184 
Bryostatin1 COSMIC 0.397 0.733 -0.094 0.509 0.159 0.881 
BX795 COSMIC 0.411 0.763 -0.213 0.491 0.134 0.731 
Camptothecin COSMIC 0.344 0.516 0.147 0.570 0.374 0.813 
CCT007093 COSMIC 0.595 0.384 -0.743 0.290 0.524 0.150 
CCT018159 COSMIC -0.347 -0.480 0.417 0.567 0.413 0.485 
CEP701 COSMIC -0.067 -0.419 -0.006 0.915 0.483 0.993 
CHIR99021 COSMIC 0.603 0.284 -0.383 0.282 0.643 0.524 
CI1040 COSMIC 0.398 0.581 0.056 0.507 0.305 0.928 
Cisplatin COSMIC 0.348 0.480 0.132 0.566 0.413 0.832 
Cytarabine COSMIC 0.370 0.152 0.010 0.539 0.807 0.987 
DMOG COSMIC -0.253 0.636 -0.210 0.682 0.248 0.735 
Docetaxel COSMIC 0.337 0.520 0.152 0.579 0.369 0.807 
Doxorubicin COSMIC -0.079 0.653 -0.345 0.900 0.232 0.570 
EHT1864 COSMIC 0.731 -0.520 -0.449 0.160 0.369 0.448 
Elesclomol COSMIC -0.279 0.332 -0.143 0.649 0.585 0.819 
Embelin COSMIC -0.149 0.413 -0.382 0.811 0.490 0.526 
EpothiloneB COSMIC 0.032 -0.407 -0.321 0.959 0.497 0.599 
Etoposide COSMIC -0.091 0.701 -0.304 0.885 0.187 0.619 
FH535 COSMIC 0.016 -0.334 -0.314 0.980 0.583 0.607 
FTI277 COSMIC -0.724 0.125 0.924 0.166 0.841 0.025 
GDC0449 COSMIC -0.662 0.807 0.543 0.224 0.098 0.345 
GDC0941 COSMIC -0.106 0.773 -0.243 0.865 0.125 0.694 
Gefitinib COSMIC -0.192 -0.005 -0.414 0.757 0.993 0.488 
Gemcitabine COSMIC 0.294 0.743 0.002 0.631 0.150 0.998 
GSK650394 COSMIC 0.360 0.373 0.090 0.551 0.536 0.885 
GW441756 COSMIC 0.076 0.772 -0.052 0.903 0.126 0.934 
IPA3 COSMIC 0.160 0.200 -0.679 0.797 0.747 0.208 
JNJ26854165 COSMIC -0.204 0.769 0.236 0.742 0.128 0.702 
JNK9L COSMIC 0.003 -0.343 -0.315 0.996 0.572 0.606 
JNK Inhibitor VIII COSMIC 0.738 0.180 -0.439 0.155 0.771 0.459 
KU55933 COSMIC 0.662 0.517 -0.345 0.224 0.372 0.569 
L685458 CCLE -0.659 0.205 0.225 0.227 0.741 0.716 
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Lapatinib CCLE -0.431 0.516 0.484 0.468 0.374 0.408 
Lenalidomide COSMIC -0.667 0.642 0.356 0.219 0.242 0.557 
LFMA13 COSMIC -0.197 0.744 -0.046 0.751 0.149 0.941 
Metformin COSMIC -0.707 -0.074 0.874 0.182 0.906 0.053 
Methotrexate COSMIC -0.120 -0.680 0.201 0.848 0.206 0.746 
Midostaurin COSMIC 0.553 0.603 -0.188 0.333 0.282 0.761 
MitomycinC COSMIC 0.238 -0.323 -0.269 0.700 0.596 0.662 
MK2206 COSMIC -0.177 0.854 -0.112 0.776 0.065 0.858 
Nilotinib COSMIC -0.343 0.947 0.432 0.572 0.015 0.468 
NSC87877 COSMIC -0.325 0.022 0.025 0.594 0.972 0.968 
NU7441 COSMIC -0.240 0.895 -0.014 0.697 0.040 0.982 
Nutlin3 CCLE 0.643 -0.995 -0.922 0.242 0.000 0.026 
Nutlin3 COSMIC 0.445 0.760 -0.389 0.453 0.136 0.517 
NVPBEZ235 COSMIC -0.145 0.647 -0.293 0.815 0.238 0.632 
Obatoclax 
Mesylate COSMIC 0.178 0.111 -0.708 0.775 0.859 0.181 
OSI906 COSMIC 0.410 0.607 -0.021 0.492 0.278 0.973 
PAC1 COSMIC -0.212 0.391 -0.340 0.732 0.516 0.575 
Paclitaxel CCLE -0.139 -0.487 -0.214 0.824 0.405 0.729 
Pazopanib COSMIC 0.410 0.276 -0.269 0.493 0.654 0.662 
PD0325901 CCLE -0.155 0.194 0.435 0.803 0.754 0.464 
PD0325901 COSMIC -0.146 0.279 -0.311 0.815 0.649 0.610 
PD0332991 COSMIC 0.050 0.901 -0.193 0.936 0.037 0.755 
PD173074 COSMIC 0.307 -0.283 -0.212 0.615 0.645 0.732 
PF02341066 CCLE 0.512 0.269 -0.119 0.378 0.662 0.849 
PF4708671 COSMIC 0.056 -0.568 0.101 0.928 0.317 0.871 
PF562271 COSMIC 0.207 0.463 0.329 0.739 0.432 0.589 
PHA665752 CCLE -0.659 0.205 0.225 0.227 0.741 0.716 
PLX4720 COSMIC 0.730 0.396 -0.400 0.161 0.510 0.504 
QS11 COSMIC 0.601 -0.791 -0.619 0.284 0.111 0.265 
RAF265 CCLE 0.835 -0.384 -0.456 0.079 0.523 0.440 
RDEA119 COSMIC -0.514 0.563 0.012 0.375 0.323 0.984 
RO3306 COSMIC 0.385 -0.123 -0.341 0.522 0.843 0.575 
SB216763 COSMIC 0.010 0.873 -0.208 0.987 0.053 0.738 
SB590885 COSMIC 0.283 -0.116 -0.275 0.645 0.853 0.654 
Shikonin COSMIC 0.173 0.224 -0.572 0.781 0.717 0.314 
SL01011 COSMIC 0.240 0.778 0.120 0.697 0.122 0.847 
Sorafenib CCLE -0.434 0.284 0.537 0.466 0.644 0.350 
TAE684 CCLE 0.289 0.378 0.259 0.637 0.531 0.674 
Temsirolimus COSMIC 0.598 0.081 -0.371 0.287 0.897 0.539 
Thapsigargin COSMIC -0.126 0.262 -0.394 0.840 0.670 0.511 
Tipifarnib COSMIC 0.150 0.671 -0.279 0.810 0.215 0.649 
TKI258 CCLE 0.862 -0.932 -0.959 0.060 0.021 0.010 
Topotecan CCLE 0.730 -0.279 -0.292 0.161 0.650 0.634 
TW37 COSMIC 0.326 0.450 0.167 0.592 0.448 0.788 
Vinblastine COSMIC 0.065 0.481 0.456 0.917 0.412 0.440 
Vinorelbine COSMIC -0.045 -0.213 -0.323 0.942 0.730 0.595 
Vorinostat COSMIC -0.751 0.146 0.972 0.143 0.815 0.006 
VX702 COSMIC -0.601 0.892 0.467 0.283 0.042 0.428 
WO2009 
093972 COSMIC 0.508 0.351 0.035 0.382 0.563 0.956 
ZM447439 COSMIC -0.165 0.968 0.041 0.791 0.007 0.948 
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Appendix 9: Estimates and statistical significance of correlations between drug sensitivities and TDP2 protein levels, 
TOP2A/TDP2 protein ratios or TOP2B/TDP2 protein ratios in a panel of lung cancer cell lines  
Drug 
Original 
source 
TDP2 ρ-
value 
TOP2A/ 
TDP2 ρ-
value 
TOP2B/ 
TDP2 ρ-
value 
TDP2 p-
value 
TOP2A/ 
TDP2 p-
value 
TDP2B/ 
TDP2 p-
value 
681640 COSMIC -0.024 0.525 0.108 0.964 0.285 0.838 
17AAG COSMIC 0.177 0.105 0.157 0.737 0.844 0.767 
ABT263 COSMIC 0.491 0.573 -0.248 0.322 0.235 0.636 
ABT888 COSMIC 0.019 -0.440 -0.038 0.972 0.382 0.943 
AG014699 COSMIC -0.860 -0.324 -0.390 0.028 0.531 0.445 
AICAR COSMIC 0.508 0.645 0.353 0.303 0.167 0.492 
AKT inhibitor VIII COSMIC 0.251 0.972 0.213 0.684 0.005 0.731 
AMG706 COSMIC 0.497 0.436 0.177 0.316 0.388 0.737 
AP24534 COSMIC 0.006 0.857 -0.085 0.992 0.064 0.892 
AS601245 COSMIC 0.358 0.607 0.949 0.554 0.277 0.014 
ATRA COSMIC -0.059 -0.531 -0.541 0.912 0.279 0.268 
AUY922 COSMIC 0.448 0.274 0.064 0.449 0.656 0.919 
Axitinib COSMIC -0.689 -0.563 -0.437 0.130 0.244 0.386 
AZD2281 COSMIC 0.369 -0.040 -0.547 0.541 0.949 0.341 
AZD6244 COSMIC -0.808 -0.015 -0.171 0.052 0.977 0.746 
AZD6482 COSMIC 0.134 -0.125 -0.608 0.830 0.841 0.277 
AZD7762 COSMIC 0.158 0.712 0.149 0.765 0.112 0.779 
AZD8055 COSMIC -0.511 0.188 -0.024 0.300 0.721 0.963 
BAY613606 COSMIC -0.844 -0.482 -0.232 0.072 0.411 0.707 
Bexarotene COSMIC 0.534 0.217 0.359 0.354 0.726 0.553 
BIBW2992 COSMIC 0.156 0.097 -0.257 0.768 0.854 0.624 
Bicalutamide COSMIC 0.959 0.539 0.469 0.010 0.349 0.426 
BID1870 COSMIC -0.020 0.546 0.197 0.970 0.262 0.708 
BIRB0796 COSMIC 0.260 0.309 -0.079 0.619 0.552 0.881 
Bleomycin COSMIC 0.351 0.953 0.186 0.563 0.012 0.765 
BMS708163 COSMIC -0.852 -0.486 -0.497 0.031 0.329 0.316 
BMS754807 COSMIC -0.639 -0.239 -0.917 0.245 0.699 0.028 
Bosutinib COSMIC 0.181 0.303 -0.126 0.732 0.560 0.811 
Bryostatin1 COSMIC -0.088 0.666 -0.121 0.888 0.220 0.846 
BX795 COSMIC -0.920 -0.220 -0.272 0.009 0.675 0.602 
Camptothecin COSMIC -0.918 -0.313 -0.403 0.010 0.546 0.428 
CCT007093 COSMIC 0.204 0.566 -0.514 0.699 0.241 0.297 
CCT018159 COSMIC -0.463 -0.235 0.012 0.355 0.653 0.981 
CEP701 COSMIC -0.931 -0.298 -0.327 0.007 0.567 0.527 
CHIR99021 COSMIC 0.440 0.922 0.111 0.458 0.026 0.859 
CI1040 COSMIC -0.939 -0.371 -0.411 0.005 0.469 0.419 
Cisplatin COSMIC 0.061 -0.333 0.404 0.909 0.519 0.427 
Cytarabine COSMIC -0.313 -0.343 -0.509 0.546 0.505 0.302 
DMOG COSMIC 0.361 0.906 0.172 0.550 0.034 0.782 
Docetaxel COSMIC -0.602 -0.785 -0.537 0.282 0.116 0.350 
Doxorubicin COSMIC 0.376 0.679 0.107 0.533 0.208 0.863 
EHT1864 COSMIC -0.264 0.294 0.032 0.613 0.571 0.953 
Elesclomol COSMIC 0.058 -0.319 -0.416 0.913 0.538 0.412 
Embelin COSMIC -0.325 0.259 0.760 0.594 0.674 0.136 
EpothiloneB COSMIC 0.385 0.019 -0.114 0.523 0.976 0.856 
Etoposide COSMIC 0.426 0.871 0.522 0.474 0.054 0.366 
FH535 COSMIC -0.146 0.728 0.686 0.815 0.163 0.201 
FTI277 COSMIC 0.293 0.975 0.561 0.632 0.005 0.326 
GDC0449 COSMIC -0.014 0.123 -0.139 0.979 0.817 0.793 
GDC0941 COSMIC 0.036 0.576 0.220 0.947 0.231 0.676 
Gefitinib COSMIC 0.296 -0.280 -0.541 0.569 0.590 0.268 
Gemcitabine COSMIC 0.442 -0.072 -0.091 0.457 0.909 0.884 
GSK650394 COSMIC 0.156 -0.453 -0.230 0.802 0.444 0.710 
GW441756 COSMIC -0.555 0.370 -0.224 0.253 0.470 0.670 
IPA3 COSMIC -0.375 -0.473 0.290 0.534 0.421 0.636 
JNJ26854165 COSMIC 0.543 0.619 -0.322 0.265 0.191 0.533 
JNK Inhibitor VIII COSMIC 0.512 0.646 -0.028 0.299 0.166 0.958 
JNK9L COSMIC 0.406 0.094 -0.031 0.497 0.881 0.960 
KU55933 COSMIC 0.066 0.362 0.383 0.901 0.481 0.454 
Lenalidomide COSMIC 0.398 0.024 -0.453 0.435 0.964 0.366 
LFMA13 COSMIC 0.809 -0.219 0.251 0.097 0.723 0.684 
Metformin COSMIC -0.100 -0.407 -0.149 0.851 0.423 0.778 
Methotrexate COSMIC 0.707 -0.053 -0.165 0.182 0.933 0.791 
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Midostaurin COSMIC 0.316 0.355 -0.365 0.605 0.558 0.546 
MitomycinC COSMIC 0.460 -0.062 0.303 0.436 0.921 0.620 
MK2206 COSMIC -0.428 0.491 -0.048 0.398 0.323 0.927 
Nilotinib COSMIC 0.310 0.054 -0.836 0.550 0.919 0.038 
NSC87877 COSMIC -0.028 -0.468 0.369 0.965 0.427 0.541 
NU7441 COSMIC -0.055 0.485 0.070 0.918 0.329 0.895 
Nutlin3 COSMIC 0.167 -0.415 -0.097 0.752 0.413 0.855 
NVPBEZ235 COSMIC -0.119 0.498 0.168 0.823 0.315 0.750 
Obatoclax Mesylate COSMIC -0.983 -0.329 -0.418 0.003 0.589 0.484 
OSI906 COSMIC -0.537 -0.454 -0.822 0.351 0.442 0.088 
PAC1 COSMIC 0.491 -0.576 0.032 0.401 0.310 0.959 
Pazopanib COSMIC 0.365 -0.099 0.010 0.546 0.874 0.988 
PD0325901 COSMIC -0.335 0.384 0.083 0.517 0.453 0.875 
PD0332991 COSMIC 0.079 0.578 0.257 0.881 0.229 0.623 
PD173074 COSMIC 0.105 -0.021 0.544 0.842 0.968 0.265 
PF4708671 COSMIC -0.437 -0.706 0.057 0.386 0.117 0.915 
PF562271 COSMIC -0.064 0.918 0.183 0.918 0.028 0.768 
PLX4720 COSMIC 0.184 0.289 0.719 0.726 0.579 0.107 
QS11 COSMIC -0.938 -0.288 -0.442 0.018 0.639 0.456 
RDEA119 COSMIC -0.924 -0.247 -0.292 0.008 0.637 0.575 
RO3306 COSMIC -0.156 -0.378 -0.484 0.768 0.460 0.331 
SB216763 COSMIC -0.430 -0.145 -0.455 0.395 0.784 0.365 
SB590885 COSMIC -0.312 0.094 -0.556 0.547 0.860 0.252 
Shikonin COSMIC -0.068 -0.764 -0.565 0.913 0.132 0.321 
SL01011 COSMIC 0.302 0.943 -0.049 0.561 0.005 0.927 
Temsirolimus COSMIC 0.057 -0.323 -0.416 0.915 0.532 0.412 
Thapsigargin COSMIC -0.994 -0.356 -0.367 0.001 0.556 0.543 
Tipifarnib COSMIC 0.170 0.964 0.205 0.785 0.008 0.741 
TW37 COSMIC -0.873 -0.102 -0.171 0.023 0.848 0.746 
Vinblastine COSMIC -0.889 -0.514 -0.562 0.018 0.297 0.246 
Vinorelbine COSMIC -0.251 -0.110 -0.361 0.684 0.860 0.550 
Vorinostat COSMIC -0.843 -0.102 -0.324 0.073 0.870 0.595 
VX702 COSMIC -0.178 -0.666 -0.300 0.735 0.149 0.564 
WO200 9093972 COSMIC -0.862 -0.203 -0.487 0.027 0.700 0.327 
ZM447439 COSMIC -0.694 -0.431 -0.328 0.126 0.394 0.526 
 
